

(19)



(11)

EP 3 263 596 A1

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:

03.01.2018 Bulletin 2018/01

(51) Int Cl.:

C07K 16/00 ^(2006.01)

A61K 39/395 ^(2006.01)

C12N 15/63 ^(2006.01)

(21) Application number: **17167520.0**

(22) Date of filing: **16.12.2003**

(84) Designated Contracting States:

**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HU IE IT LI LU MC NL PT RO SE SI SK TR**

(30) Priority: **16.12.2002 US 434115 P**

01.12.2003 US 526163 P

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:

10179942.7 / 2 289 936

08005671.6 / 1 944 320

03813759.2 / 1 572 744

(71) Applicant: **Genentech, Inc.**

South San Francisco, CA 94080-4990 (US)

(72) Inventors:

• **ADAMS, Camellia W**
San Jose, CA 95124 (US)

• **CHAN, Andrew C**
Menlo Park, CA 94025 (US)

• **CROWLEY, Craig W**
Del Mar, CA 94014-3618 (US)

• **LOWMAN, Henry B**
El Granada, CA 94018 (US)

• **NAKAMURA, Gerald R**
San Francisco, CA 94127 (US)

• **PRESTA, Leonard G**
San Francisco, CA 91109 (US)

(74) Representative: **Hayes, Emily Anne Luxford et al**
Mewburn Ellis LLP

City Tower
40 Basinghall Street
London EC2V 5DE (GB)

Remarks:

• This application was filed on 21.04.2017 as a
divisional application to the application mentioned
under INID code 62.

• Claims filed after the date of filing of the application
/ after the date of receipt of the divisional application
(Rule 68(4) EPC).

(54) **IMMUNOGLOBULIN VARIANTS AND USES THEREOF**

(57) The invention provides humanized and chimeric anti-CD20 antibodies for treatment of CD20 positive malignancies and autoimmune diseases.

EP 3 263 596 A1

Description**FIELD OF THE INVENTION**

[0001] The invention relates to anti-CD20 antibodies and their use in the treatment of B-cell related diseases.

BACKGROUND OF THE INVENTION

[0002] Lymphocytes are one of several populations of white blood cells; they specifically recognize and respond to foreign antigen. The three major classes of lymphocytes are B lymphocytes (B cells), T lymphocytes (T cells) and natural killer (NK) cells. B lymphocytes are the cells responsible for antibody production and provide humoral immunity. B cells mature within the bone marrow and leave the marrow expressing an antigen-binding antibody on their cell surface. When a naive B cell first encounters the antigen for which its membrane-bound antibody is specific, the cell begins to divide rapidly and its progeny differentiate into memory B cells and effector cells called "plasma cells". Memory B cells have a longer life span and continue to express membrane-bound antibody with the same specificity as the original parent cell. Plasma cells do not produce membrane-bound antibody but instead produce secreted form of the antibody. Secreted antibodies are the major effector molecules of humoral immunity.

[0003] The CD20 antigen (also called human B-lymphocyte-restricted differentiation antigen, Bp35) is a hydrophobic transmembrane protein with a molecular weight of approximately 35 kD located on pre-B and mature B lymphocytes (Valentine et al. J. Biol. Chem. 264(19):11282-11287 (1989); and Einfeld et al. EMBO J. 7(3):711-717 (1988)). The antigen is also expressed on greater than 90% of B cell non-Hodgkin's lymphomas (NHL) (Anderson et al. Blood 63(6):1424-1433 (1984)), but is not found on hematopoietic stem cells, pro-B cells, normal plasma cells or other normal tissues (Tedder et al. J. Immunol. 135(2):973-979 (1985)). CD20 is thought to regulate an early step(s) in the activation process for cell cycle initiation and differentiation (Tedder *et al.*, *supra*) and possibly functions as a calcium ion channel (Tedder et al. J. Cell. Biochem. 14D:195 (1990)).

[0004] Given the expression of CD20 in B cell lymphomas, this antigen has been a useful therapeutic target to treat such lymphomas. There are more than 300,000 people in the United States with B-cell NHL and more than 56,000 new cases are diagnosed each year. For example, the rituximab (RITUXAN®) antibody which is a genetically engineered chimeric murine/human monoclonal antibody directed against human CD20 antigen (commercially available from Genentech, Inc., South San Francisco, California, U.S.) is used for the treatment of patients with relapsed or refractory low-grade or follicular, CD20 positive, B cell non-Hodgkin's lymphoma. Rituximab is the antibody referred to as "C2B8" in US Patent No. 5,736,137 issued April 7, 1998 (Anderson et al.) and in US Pat No. 5,776,456. *In vitro* mechanism of action studies have demonstrated that RITUXAN® binds human complement and lyses lymphoid B cell lines through complement-dependent cytotoxicity (CDC) (Reff et al. Blood 83(2):435-445 (1994)). Additionally, it has significant activity in assays for antibody-dependent cellular cytotoxicity (ADCC). *In vivo* preclinical studies have shown that RITUXAN® depletes B cells from the peripheral blood, lymph nodes, and bone marrow of cynomolgus monkeys, presumably through complement and cell-mediated processes (Reff et al. Blood 83(2):435-445 (1994)). Other anti-CD20 antibodies indicated for the treatment of NHL include the murine antibody Zevalin™ which is linked to the radioisotope, Yttrium-90 (IDEC Pharmaceuticals, San Diego, CA), Bexxar™ which is another fully murine antibody conjugated to I-131 (Corixa, WA).

[0005] A major limitation in the use of murine antibodies in human therapy is the human anti-mouse antibody (HAMA) response (see, e.g., Miller, R.A. et al. "Monoclonal antibody therapeutic trials in seven patients with T-cell lymphoma" Blood, 62:988-995, 1983; and Schroff, R.W., et al. "Human anti-murine immunoglobulin response in patients receiving monoclonal antibody therapy" Cancer Res., 45:879-885, 1985). Even chimeric molecules, where the variable (V) domains of rodent antibodies are fused to human constant (C) regions, are still capable of eliciting a significant immune response (HACA, human anti-chimeric antibody) (Neuberger et al. Nature (Lond.), 314:268-270, 1985). A powerful approach to overcome these limitations in the clinical use of monoclonal antibodies is "humanization" of the murine antibody or antibody from a non-human species (Jones et al. Nature (Lond), 321:522-525, 1986; Riechman et al., Nature (Lond), 332:323-327, 1988).

[0006] Thus, it is beneficial to produce therapeutic antibodies to the CD20 antigen that create minimal or no antigenicity when administered to patients, especially for chronic treatment. The present invention satisfies this and other needs. The present invention provides anti-CD20 antibodies that overcome the limitations of current therapeutic compositions as well as offer additional advantages that will be apparent from the detailed description below.

SUMMARY OF THE INVENTION

[0007] The present invention provides CD20 binding antibodies or functional fragments thereof, and their use in the treatment of B-cell associated diseases. These antibodies are monoclonal antibodies. In specific embodiments, the antibodies that bind CD20 are humanized or chimeric. The humanized 2H7 variants include those that have amino acid

substitutions in the FR and affinity maturation variants with changes in the grafted CDRs. The substituted amino acids in the CDR or FR are not limited to those present in the donor or recipient antibody. In other embodiments, the anti-CD20 antibodies of the invention further comprise changes in amino acid residues in the Fc region that lead to improved effector function including enhanced CDC and/or ADCC function and B-cell killing (also referred to herein as B-cell depletion). Other anti-CD20 antibodies of the invention include those having specific changes that improve stability. In a specific embodiment, the humanized 2H7 variants with increased stability are as described in example 6 below. Fucose deficient variants having improved ADCC function in vivo are also provided. In one embodiment, the chimeric anti-CD20 antibody has murine V regions and human C region. One such specific chimeric anti-CD20 antibody is Rituxan® (Rituximab®; Genentech, Inc.).

[0008] In a preferred embodiment of all of the antibody compositions and methods of use of this invention, the humanized CD20 binding antibody is 2H7.v16 having the light and heavy chain amino acid sequence of SEQ ID NO. 21 and 22, respectively, as shown in FIG. 6 and FIG. 7. When referring to the polypeptide sequences in Figures 6, 7 and 8, it should be understood that the first 19 or so amino acids that form the secretory signal sequence are not present in the mature polypeptide. The V region of all other variants based on version 16 will have the amino acid sequences of v16 except at the positions of amino acid substitutions which are indicated in the disclosure. Unless otherwise indicated, the 2H7 variants will have the same L chain as that of v16.

[0009] The invention provides a humanized antibody that binds human CD20, or an antigen-binding fragment thereof, wherein the antibody is effective to deplete primate B cells in vivo, the antibody comprising in the H chain Variable region (V_H) at least a CDR3 sequence of SEQ ID NO. 12 from an anti-human CD20 antibody and substantially the human consensus framework (FR) residues of human heavy chain subgroup III (V_{HIII}). In one embodiment, the primate B cells are from human and Cynomolgus monkey. In one embodiment, the antibody further comprises the H chain CDR1 sequence of SEQ ID NO. 10 and CDR2 sequence of SEQ ID NO. 11. In another embodiment, the preceding antibody comprises the L chain CDR1 sequence of SEQ ID NO. 4, CDR2 sequence of SEQ ID NO. 5, CDR3 sequence of SEQ ID NO. 6 with substantially the human consensus framework (FR) residues of human light chain κ subgroup I ($V_{\kappa I}$). In a preferred embodiment, the FR region in V_L has a donor antibody residue at position 46; in a specific embodiment, FR2 in V_L has an amino acid substitution of leuL46pro (Leu in the human κI consensus sequence changed to pro which is present in the corresponding position in m2H7).

The V_H region further comprises a donor antibody residue at at least amino acid positions 49, 71 and 73 in the framework. In one embodiment, in the V_H , the following FR positions in the human heavy chain subgroup III are substituted: AlaH49Gly in FR2; ArgH71Val and AsnH73Lys in FR3. In other embodiments, the CDR regions in the humanized antibody further comprise amino acid substitutions where the residues are neither from donor nor recipient antibody.

[0010] The antibody of the preceding embodiments can comprise the V_H sequence of SEQ ID NO.8 of v16, as shown in FIG. 1B. In a further embodiment of the preceding, the antibody further comprises the V_L sequence of SEQ ID NO.2 of v16, as shown in FIG. 1A.

[0011] In other embodiments, the humanized antibody is 2H7.v31 having the light and heavy chain amino acid sequence of SEQ ID NO. 2 and 23, respectively, as shown in FIG. 6 and FIG. 8; 2H7.v31 having the heavy chain amino acid sequence of SEQ ID NO. 23 as shown in FIG. 8; 2H7.v96 with the amino acid substitutions of D56A and N100A in the H chain and S92A in the L chain of v16.

[0012] In separate embodiments, the antibody of any of the preceding embodiments further comprises at least one amino acid substitution in the Fc region that improves ADCC and/or CDC activity over the original or parent antibody from which it was derived, v.16 being the parent antibody being compared to in most cases, and Rituxan in other cases. One such antibody with improved activity comprises the triple Alanine substitution of S298A/E333A/K334A in the Fc region. One antibody having S298A/E333A/K334A substitution is 2H7.v31 having the heavy chain amino acid sequence of SEQ ID NO. 23. Antibody 2H7.v114 and 2H7.v115 show at least 10-fold improved ADCC activity as compared to Rituxan.

[0013] In another embodiment, the antibody further comprises at least one amino acid substitution in the Fc region that decreases CDC activity as compared to the parent antibody from which it was derived which is v16 in most cases. One such antibody with decreased CDC activity as compared to v16 comprises at least the substitution K322A in the H chain. The comparison of ADCC and CDC activity can be assayed as described in the examples.

[0014] In a preferred embodiment, the antibodies of the invention are full length antibodies wherein the V_H region is joined to a human IgG heavy chain constant region. In preferred embodiments, the IgG is human IgG1 or IgG3.

[0015] In one embodiment, the CD20 binding antibody is conjugated to a cytotoxic agent. In preferred embodiments the cytotoxic agent is a toxin or a radioactive isotope.

[0016] In one embodiment, the antibodies of the invention for use in therapeutic or diagnostic purposes are produced in CHO cells.

[0017] Also provided is a composition comprising an antibody of any one of the preceding embodiments, and a carrier. In one embodiment, the carrier is a pharmaceutically acceptable carrier. These compositions can be provided in an article of manufacture or a kit.

[0018] The invention also provided a liquid formulation comprising a humanized 2H7 antibody at 20mg/mL antibody, 10mM histidine sulfate pH5.8, 60mg/ml sucrose (6%), 0.2 mg/ml polysorbate 20 (0.02%).

[0019] The invention also provides an isolated nucleic acid that encodes any of the antibodies disclosed herein, including an expression vector for expressing the antibody.

[0020] Another aspect of the invention are host cells comprising the preceding nucleic acids, and host cells that produce the antibody. In a preferred embodiment of the latter, the host cell is a CHO cell. A method of producing these antibodies is provided, the method comprising culturing the host cell that produces the antibody and recovering the antibody from the cell culture.

[0021] Yet another aspect of the invention is an article of manufacture comprising a container and a composition contained therein, wherein the composition comprises an antibody of any of the preceding embodiments. For use in treating NHL, the article of manufacture further comprises a package insert indicating that the composition is used to treat non-Hodgkin's lymphoma.

[0022] A further aspect of the invention is a method of inducing apoptosis in B cells in vivo, comprising contacting B cells with the antibody of any of the preceding, thereby killing the B cells.

[0023] The invention also provides methods of treating the diseases disclosed herein by administration of a CD20 binding antibody or functional fragment thereof, to a mammal such as a human patient suffering from the disease. In any of the methods for treating an autoimmune disease or a CD20 positive cancer, in one embodiment, the antibody is 2H7.v16 having the light and heavy chain amino acid sequence of SEQ ID NO. 21 and 22, respectively, as shown in FIG. 6 and FIG. 7. Thus, one embodiment is a method of treating a CD20 positive cancer, comprising administering to a patient suffering from the cancer, a therapeutically effective amount of a humanized CD20 binding antibody of the invention. In preferred embodiments, the CD20 positive cancer is a B cell lymphoma or leukemia including non-Hodgkin's lymphoma (NHL) or lymphocyte predominant Hodgkin's disease (LPHD), chronic lymphocytic leukemia (CLL) or SLL. In one embodiment of the method of treating a B cell lymphoma or leukemia, the antibody is administered at a dosage range of about 275-375mg/m². In additional embodiments, the treatment method further comprises administering to the patient at least one chemotherapeutic agent, wherein for non-Hodgkin's lymphoma (NHL), the chemotherapeutic agent is selected from the group consisting of doxorubicin, cyclophosphamide, vincristine and prednisolone.

[0024] Also provided is a method of treating an autoimmune disease, comprising administering to a patient suffering from the autoimmune disease, a therapeutically effective amount of the humanized CD20 binding antibody of any one of the preceding claims. The autoimmune disease is selected from the group consisting of rheumatoid arthritis, juvenile rheumatoid arthritis, systemic lupus erythematosus (SLE), Wegener's disease, inflammatory bowel disease, idiopathic thrombocytopenic purpura (ITP), thrombotic thrombocytopenic purpura (TTP), autoimmune thrombocytopenia, multiple sclerosis, psoriasis, IgA nephropathy, IgM polyneuropathies, myasthenia gravis, vasculitis, diabetes mellitus, Reynaud's syndrome, Sjorgen's syndrome and glomerulonephritis. Where the autoimmune disease is rheumatoid arthritis, the antibody can be administered in conjunction with a second therapeutic agent which is preferably methotrexate.

[0025] In these treatment methods, the CD20 binding antibodies can be administered alone or in conjunction with a second therapeutic agent such as a second antibody, or a chemotherapeutic agent or an immunosuppressive agent. The second antibody can be one that binds CD20 or a different B cell antigen, or a NK or T cell antigen. In one embodiment, the second antibody is a radiolabeled anti-CD20 antibody. In other embodiments, the CD20 binding antibody is conjugated to a cytotoxic agent including a toxin or a radioactive isotope.

[0026] In another aspect, the invention provides a method of treating an autoimmune disease selected from the group consisting of Dermatomyositis, Wegner's granulomatosis, ANCA, Aplastic anemia, Autoimmune hemolytic anemia (AIHA), factor VIII deficiency, hemophilia A, Autoimmune neutropenia, Castleman's syndrome, Goodpasture's syndrome, solid organ transplant rejection, graft versus host disease (GVHD), IgM mediated, thrombotic thrombocytopenic purpura (TTP), Hashimoto's Thyroiditis, autoimmune hepatitis, lymphoid interstitial pneumonitis (HIV), bronchiolitis obliterans (non-transplant) vs. NSIP, Guillain-Barre Syndrome, large vessel vasculitis, giant cell (Takayasu's) arteritis, medium vessel vasculitis, Kawasaki's Disease, polyarteritis nodosa, comprising administering to a patient suffering from the disease, a therapeutically effective amount of a CD20 binding antibody. In one embodiment of this method, the CD20 binding antibody is Rituxan®.

[0027] The invention also provides an isolated nucleic acid comprising the nucleotide sequence of SEQ ID NO.: _ of the Cynomolgus monkey CD20 (shown in FIG. 19), or a degenerate variant of this sequence. One embodiment is an isolated nucleic acid comprising a sequence that encodes a polypeptide with the amino acid sequence of SEQ ID NO._ (shown FIG. 20), or SEQ ID NO._ (FIG. 20) with conservative amino acid substitutions. Another embodiment is a vector comprising the preceding nucleic acid, including an expression vector for expression in a host cell. Included as well is a host cell comprising the vector. Also provided is an isolated polypeptide comprising the amino acid sequence [SEQ ID NO._; FIG. 20] of the Cynomolgus monkey CD20.

BRIEF DESCRIPTION OF THE FIGURES**[0028]**

FIG. 1A is a sequence alignment comparing the amino acid sequences of the light chain variable domain (V_L) of each of murine 2H7 (SEQ ID NO. 1), humanized 2H7.v16 variant (SEQ ID NO.2), and human kappa light chain subgroup I (SEQ ID NO. 3). The CDRs of V_L of 2H7 and hu2H7.v16 are as follows: CDR1 (SEQ ID NO.4), CDR2 (SEQ ID NO.5), and CDR3 (SEQ ID NO.6).

FIG. 1B is a sequence alignment which compares the V_H sequences of murine 2H7 (SEQ ID NO. 7), humanized 2H7.v16 variant (SEQ ID NO. 8), and the human consensus sequence of heavy chain subgroup III (SEQ ID NO. 9). The CDRs of V_H of 2H7 and hu2H7.v16 are as follow: CDR1 (SEQ ID NO. 10), CDR2 (SEQ ID NO. 11), and CDR3 (SEQ ID NO. 12).

In FIG. 1A and FIG. 1B, the CDR1, CDR2 and CDR3 in each chain are enclosed within brackets, flanked by the framework regions, FR1-FR4, as indicated. 2H7 refers to the murine 2H7 antibody. The asterisks in between two rows of sequences indicate the positions that are different between the two sequences. Residue numbering is according to Kabat et al., Sequences of Immunological Interest 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md. (1991), with insertions shown as a, b, c, d, and e.

FIG. 2 shows the sequence of phagemid pVX4 (SEQ ID NO. 13) used for construction of 2H7 Fab plasmids (see Example 1) as well as the amino acid sequences of the L chain (SEQ ID NO. 14) and H chain (SEQ ID NO.15) of the Fab for the CDR-grafted anti-IFN- α humanized antibody.

FIG. 3 shows the sequence of the expression plasmid which encodes the chimeric 2H7.v6.8 Fab (SEQ ID NO.16). The amino acid sequences of the L chain (SEQ ID NO. 17) and H chain (SEQ ID NO.18) are shown.

FIG. 4 shows the sequence of the plasmid pDR1 (SEQ ID NO.19; 5391 bp) for expression of immunoglobulin light chains as described in Example 1. pDR1 contains sequences encoding an irrelevant antibody, the light chain of a humanized anti-CD3 antibody (Shalaby et al., J. Exp. Med. 175: 217-225 (1992)), the start and stop codons for which are indicated in bold and underlined.

FIG. 5 shows the sequence of plasmid pDR2 (SEQ ID NO.20; 6135 bp) for expression of immunoglobulin heavy chains as described in Example 1. pDR2 contains sequences encoding an irrelevant antibody, the heavy chain of a humanized anti-CD3 antibody (Shalaby et al., *supra*), the start and stop codons for which are indicated in bold and underlined.

FIG. 6 shows the amino acid sequence of the 2H7.v16 complete L chain (SEQ ID NO.21). The first 19 amino acids before DIQ are the secretory signal sequence not present in the mature polypeptide chain.

FIG. 7 shows the amino acid sequence of the 2H7.v16 complete H chain (SEQ ID NO.22). The first 19 amino acids before EVQ before are the secretory signal sequence not present in the mature polypeptide chain. Aligning the V_H sequence in FIG. 1B (SEQ ID NO. 8) with the complete H chain sequence, the human $\gamma 1$ constant region is from amino acid position 114-471 in SEQ ID NO. 22.

FIG. 8 shows the amino acid sequence of the 2H7.v31 complete H chain (SEQ ID NO.23). The first 19 amino acids before EVQ before are the secretory signal sequence not present in the mature polypeptide chain. The L chain is the same as for 2H7.v16 (see FIG. 6).

FIG. 9 shows the relative stability of 2H7.v16 and 2H7.v73 IgG variants. Assay results were normalized to the values prior to incubation and reported as percent remaining after incubation.

FIG. 10 is a flow chart summarizing the amino acid changes from the murine 2H7 to a subset of humanized versions up to v75.

FIG. 11 is a summary of mean absolute B-cell count [CD3-/CD40+] in all groups (2H7 study and Rituxan study combined), as described in Example 10.

FIG. 12 shows the results of a representative ADCC assay on fucose deficient 2H7 variants as described in Example 11.

FIG. 13 shows the results of the Annexin V staining plotted as a function of antibody concentration. Ramos cells were treated with an irrelevant IgG1 control antibody (Herceptin®; circles), Rituximab (squares), or rhuMAb 2H7.v16 (triangles) in the presence of a crosslinking secondary antibody and were analyzed by FACS. Figures 13-15 are described in Example 13.

FIG. 14 shows the results of the Annexin V and propidium iodide double-staining are plotted as a function of antibody concentration. Ramos cells were treated with an irrelevant IgG1 control antibody (Herceptin®; circles), Rituximab (squares), or rhuMAb 2H7.v16 (triangles) in the presence of a crosslinking secondary antibody and were analyzed by FACS.

FIG. 15 shows the counts (per 10 s) of live, unstained cells are plotted as a function of antibody concentration. Ramos cells were treated with an irrelevant IgG1 control antibody (Herceptin®; circles), Rituximab (squares), or rhuMAb 2H7.v16 (triangles) in the presence of a crosslinking secondary antibody and were analyzed by FACS.

FIGs. 16,17,18 show inhibition of Raji cell tumor growth in nude mice, as described in Example 14. Animals were treated weekly (as indicated by vertical arrows; n=8 mice per group) for 6 weeks with PBS (control) or with Rituxan® or rhuMAb 2H7.v16 at 5 mg/kg (FIG. 16), 0.5 mg/kg (FIG. 17), or 0.05 mg/kg (FIG. 18).

FIG. 19 shows the nucleotide (SEQ ID NO.) and amino acid (SEQ ID NO.) sequences of Cynomolgus monkey CD20, as described in Example 15.

FIG. 20 shows the amino acid sequence for cynomolgus monkey CD20. Residues that differ from human CD20 are underlined and the human residues are indicated directly below the monkey residue. The putative extracellular domain of the monkey CD20 is in bold type.

FIG. 21 shows the results of Cynomolgus monkey cells expressing CD20 binding to hu2H7.v16, .v31, and Rituxan, as described in Example 15. The antibodies were assayed for the ability to bind and displace FITC-conjugated murine 2H7 binding to cynomolgus CD20.

FIG. 22 shows dose escalation schema for rheumatoid arthritis phase I/II clinical trial.

FIG. 23 shows the vector for expression of 2H7.v16 in CHO cells.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0029] The "CD20" antigen is a non-glycosylated, transmembrane phosphoprotein with a molecular weight of approximately 35 kD that is found on the surface of greater than 90% of B cells from peripheral blood or lymphoid organs. CD20 is expressed during early pre-B cell development and remains until plasma cell differentiation; it is not found on human stem cells, lymphoid progenitor cells or normal plasma cells. CD20 is present on both normal B cells as well as malignant B cells. Other names for CD20 in the literature include "B-lymphocyte-restricted differentiation antigen" and "Bp35". The CD20 antigen is described in, for example, Clark and Ledbetter, Adv. Can. Res. 52:81-149 (1989) and Valentine et al. J. Biol. Chem. 264(19):11282-11287 (1989).

[0030] The term "antibody" is used in the broadest sense and specifically covers monoclonal antibodies (including full length monoclonal antibodies), multispecific antibodies (e.g., bispecific antibodies), and antibody fragments so long as they exhibit the desired biological activity or function.

[0031] The biological activity of the CD20 binding and humanized CD20 binding antibodies of the invention will include at least binding of the antibody to human CD20, more preferably binding to human and other primate CD20 (including cynomolgus monkey, rhesus monkey, chimpanzees). The antibodies would bind CD20 with a K_d value of no higher than 1×10^{-8} , preferably a K_d value no higher than about 1×10^{-9} , and be able to kill or deplete B cells in vivo, preferably by at least 20% when compared to the appropriate negative control which is not treated with such an antibody. B cell depletion can be a result of one or more of ADCC, CDC, apoptosis, or other mechanism. In some embodiments of disease treatment herein, specific effector functions or mechanisms may be desired over others and certain variants of the humanized 2H7 are preferred to achieve those biological functions, such as ADCC.

[0032] "Antibody fragments" comprise a portion of a full length antibody, generally the antigen binding or variable region thereof. Examples of antibody fragments include Fab, Fab', F(ab')₂, and Fv fragments; diabodies; linear antibodies; single-chain antibody molecules; and multispecific antibodies formed from antibody fragments.

[0033] "Fv" is the minimum antibody fragment which contains a complete antigen-recognition and -binding site. This fragment consists of a dimer of one heavy- and one light-chain variable region domain in tight, non-covalent association. From the folding of these two domains emanate six hypervariable loops (3 loops each from the H and L chain) that contribute the amino acid residues for antigen binding and confer antigen binding specificity to the antibody. However, even a single variable domain (or half of an Fv comprising only three CDRs specific for an antigen) has the ability to recognize and bind antigen, although at a lower affinity than the entire binding site.

[0034] The term "monoclonal antibody" as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic site. Furthermore, in contrast to conventional (polyclonal) antibody preparations which typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen. The modifier "monoclonal" indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method. For example, the monoclonal antibodies to be used in accordance with the present invention may be made by the hybridoma method first described by Kohler et al., Nature 256:495 (1975), or may be made by recombinant DNA methods (see, e.g., U.S. Patent No. 4,816,567). The "monoclonal antibodies" may also be isolated from phage antibody libraries using the techniques described in Clackson et al., Nature 352:624-628 (1991) and Marks et al., J. Mol. Biol. 222:581-597 (1991), for example.

[0035] "Functional fragments" of the CD20 binding antibodies of the invention are those fragments that retain binding to CD20 with substantially the same affinity as the intact full length molecule from which they are derived and show biological activity including depleting B cells as measured by in vitro or in vivo assays such as those described herein.

[0036] The term "variable" refers to the fact that certain segments of the variable domains differ extensively in sequence among antibodies. The V domain mediates antigen binding and define specificity of a particular antibody for its particular antigen. However, the variability is not evenly distributed across the 110-amino acid span of the variable domains. Instead, the V regions consist of relatively invariant stretches called framework regions (FRs) of 15-30 amino acids separated by shorter regions of extreme variability called "hypervariable regions" that are each 9-12 amino acids long. The variable domains of native heavy and light chains each comprise four FRs, largely adopting a β -sheet configuration, connected by three hypervariable regions, which form loops connecting, and in some cases forming part of, the β -sheet structure. The hypervariable regions in each chain are held together in close proximity by the FRs and, with the hypervariable regions from the other chain, contribute to the formation of the antigen-binding site of antibodies (see Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD. (1991)). The constant domains are not involved directly in binding an antibody to an antigen, but exhibit various effector functions, such as participation of the antibody in antibody dependent cellular cytotoxicity (ADCC).

[0037] The term "hypervariable region" when used herein refers to the amino acid residues of an antibody which are responsible for antigen-binding. The hypervariable region generally comprises amino acid residues from a "complementarity determining region" or "CDR" (e.g. around about residues 24-34 (L1), 50-56 (L2) and 89-97 (L3) in the V_L , and around about 31-35B (H1), 50-65 (H2) and 95-102 (H3) in the V_H (Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD. (1991)) and/or those residues from a "hypervariable loop" (e.g. residues 26-32 (L1), 50-52 (L2) and 91-96 (L3) in the V_L , and 26-32 (H1), 52A-55 (H2) and 96-101 (H3) in the V_H (Chothia and Lesk J. Mol. Biol. 196:901-917 (1987)).

[0038] As referred to herein, the "consensus sequence" or consensus V domain sequence is an artificial sequence derived from a comparison of the amino acid sequences of known human immunoglobulin variable region sequences. Based on these comparisons, recombinant nucleic acid sequences encoding the V domain amino acids that are a consensus of the sequences derived from the human κ and the human H chain subgroup III V domains were prepared. The consensus V sequence does not have any known antibody binding specificity or affinity.

[0039] "Chimeric" antibodies (immunoglobulins) have a portion of the heavy and/or light chain identical with or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit the desired biological activity (U.S. Patent No. 4,816,567; and Morrison et al., Proc. Natl. Acad. Sci. USA 81:6851-6855 (1984)). Humanized antibody as used herein is a subset of chimeric antibodies.

[0040] "Humanized" forms of non-human (e.g., murine) antibodies are chimeric antibodies which contain minimal sequence derived from non-human immunoglobulin. For the most part, humanized antibodies are human immunoglobulins (recipient or acceptor antibody) in which hypervariable region residues of the recipient are replaced by hypervariable region residues from a non-human species (donor antibody) such as mouse, rat, rabbit or nonhuman primate having the desired specificity, affinity, and capacity. In some instances, Fv framework region (FR) residues of the human immunoglobulin are replaced by corresponding non-human residues. Furthermore, humanized antibodies may comprise residues which are not found in the recipient antibody or in the donor antibody. These modifications are made to further refine antibody performance such as binding affinity. Generally, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the hypervariable loops correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin sequence although the FR regions may include one or more amino acid substitutions that improve binding affinity. The number of these amino acid substitutions in the FR are typically no more than 6 in the H chain, and in the L chain, no more than 3. The humanized antibody optionally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin. For further details, see Jones et al., Nature 321:522-525 (1986); Reichmann et al., Nature 332:323-329 (1988); and Presta, Curr. Op. Struct. Biol. 2:593-596 (1992).

[0041] Antibody "effector functions" refer to those biological activities attributable to the Fc region (a native sequence Fc region or amino acid sequence variant Fc region) of an antibody, and vary with the antibody isotype. Examples of antibody effector functions include: C1q binding and complement dependent cytotoxicity; Fc receptor binding; antibody-dependent cell-mediated cytotoxicity (ADCC); phagocytosis; down regulation of cell surface receptors (e.g. B cell receptor); and B cell activation.

[0042] "Antibody-dependent cell-mediated cytotoxicity" or "ADCC" refers to a form of cytotoxicity in which secreted Ig bound onto Fc receptors (FcRs) present on certain cytotoxic cells (e.g. Natural Killer (NK) cells, neutrophils, and macrophages) enable these cytotoxic effector cells to bind specifically to an antigen-bearing target cell and subsequently kill the target cell with cytotoxins. The antibodies "arm" the cytotoxic cells and are absolutely required for such killing. The primary cells for mediating ADCC, NK cells, express $Fc\gamma RIII$ only, whereas monocytes express $Fc\gamma RI$, $Fc\gamma RII$ and $Fc\gamma RIII$. FcR expression on hematopoietic cells is summarized in Table 3 on page 464 of Ravetch and Kinet, Annu. Rev. Immunol 9:457-92 (1991). To assess ADCC activity of a molecule of interest, an *in vitro* ADCC assay, such as that described in US Patent No. 5,500,362 or 5,821,337 may be performed. Useful effector cells for such assays include

peripheral blood mononuclear cells (PBMC) and Natural Killer (NK) cells. Alternatively, or additionally, ADCC activity of the molecule of interest may be assessed *in vivo*, e.g., in a animal model such as that disclosed in Clynes et al. PNAS (USA) 95:652-656 (1998).

[0043] "Fc receptor" or "FcR" describes a receptor that binds to the Fc region of an antibody. The preferred FcR is a native sequence human FcR. Moreover, a preferred FcR is one which binds an IgG antibody (a gamma receptor) and includes receptors of the FcγRI, FcγRII, and FcγRIII subclasses, including allelic variants and alternatively spliced forms of these receptors. FcγRII receptors include FcγRIIA (an "activating receptor") and FcγRIIB (an "inhibiting receptor"), which have similar amino acid sequences that differ primarily in the cytoplasmic domains thereof. Activating receptor FcγRIIA contains an immunoreceptor tyrosine-based activation motif (ITAM) in its cytoplasmic domain. Inhibiting receptor FcγRIIB contains an immunoreceptor tyrosine-based inhibition motif (ITIM) in its cytoplasmic domain. (see review M. in Daëron, Annu. Rev. Immunol. 15:203-234 (1997)). FcRs are reviewed in Ravetch and Kinet, Annu. Rev. Immunol. 9:457-92 (1991); Capel et al., Immunomethods 4:25-34 (1994); and de Haas et al., J. Lab. Clin. Med. 126:330-41 (1995). Other FcRs, including those to be identified in the future, are encompassed by the term "FcR" herein. The term also includes the neonatal receptor, FcRn, which is responsible for the transfer of maternal IgGs to the fetus (Guyer et al., J. Immunol. 117:587 (1976) and Kim et al., J. Immunol. 24:249 (1994)).

[0044] WO00/42072 (Presta) describes antibody variants with improved or diminished binding to FcRs. The content of that patent publication is specifically incorporated herein by reference. See, also, Shields et al. J. Biol. Chem. 9(2): 6591-6604 (2001).

[0045] "Human effector cells" are leukocytes which express one or more FcRs and perform effector functions. Preferably, the cells express at least FcγRIII and perform ADCC effector function. Examples of human leukocytes which mediate ADCC include peripheral blood mononuclear cells (PBMC), natural killer (NK) cells, monocytes, cytotoxic T cells and neutrophils; with PBMCs and NK cells being preferred. The effector cells may be isolated from a native source, e.g. from blood.

[0046] "Complement dependent cytotoxicity" or "CDC" refers to the lysis of a target cell in the presence of complement. Activation of the classical complement pathway is initiated by the binding of the first component of the complement system (C1q) to antibodies (of the appropriate subclass) which are bound to their cognate antigen. To assess complement activation, a CDC assay, e.g. as described in Gazzano-Santoro et al., J. Immunol. Methods 202:163 (1996), may be performed.

[0047] Polypeptide variants with altered Fc region amino acid sequences and increased or decreased C1q binding capability are described in US patent No. 6,194,551B1 and WO99/51642. The contents of those patent publications are specifically incorporated herein by reference. See, also, Idusogie et al. J. Immunol. 164: 4178-4184 (2000).

[0048] The N-glycosylation site in IgG is at Asn297 in the CH2 domain. The present invention also provides compositions of a CD20-binding, humanized antibody having a Fc region, wherein about 80-100% (and preferably about 90-99%) of the antibody in the composition comprises a mature core carbohydrate structure which lacks fucose, attached to the Fc region of the glycoprotein. Such compositions were demonstrated herein to exhibit a surprising improvement in binding to FcγRIIIA(F158), which is not as effective as FcγRIIIA (V158) in interacting with human IgG. Thus, the compositions herein are anticipated to be superior to previously described anti-CD20 antibody compositions, especially for therapy of human patients who express FcγRIIIA (F158). FcγRIIIA (F158) is more common than FcγRIIIA (V158) in normal, healthy African Americans and Caucasians. See Lehrnbecher et al. Blood 94:4220 (1999). The present application further demonstrates the synergistic increase in FcγRIII binding and/or ADCC function that results from combining the glycosylation variations herein with amino acid sequence modification(s) in the Fc region of the glycoprotein.

[0049] An "isolated" antibody is one which has been identified and separated and/or recovered from a component of its natural environment. Contaminant components of its natural environment are materials which would interfere with diagnostic or therapeutic uses for the antibody, and may include enzymes, hormones, and other proteinaceous or nonproteinaceous solutes. In preferred embodiments, the antibody will be purified (1) to greater than 95% by weight of antibody as determined by the Lowry method, and most preferably more than 99% by weight, (2) to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence by use of a spinning cup sequenator, or (3) to homogeneity by SDS-PAGE under reducing or nonreducing conditions using Coomassie blue or, preferably, silver stain. Isolated antibody includes the antibody *in situ* within recombinant cells since at least one component of the antibody's natural environment will not be present. Ordinarily, however, isolated antibody will be prepared by at least one purification step.

[0050] An "isolated" nucleic acid molecule is a nucleic acid molecule that is identified and separated from at least one contaminant nucleic acid molecule with which it is ordinarily associated in the natural source of the antibody nucleic acid. An isolated nucleic acid molecule is other than in the form or setting in which it is found in nature. Isolated nucleic acid molecules therefore are distinguished from the nucleic acid molecule as it exists in natural cells. However, an isolated nucleic acid molecule includes a nucleic acid molecule contained in cells that ordinarily express the antibody where, for example, the nucleic acid molecule is in a chromosomal location different from that of natural cells.

[0051] The expression "control sequences" refers to DNA sequences necessary for the expression of an operably

linked coding sequence in a particular host organism. The control sequences that are suitable for prokaryotes, for example, include a promoter, optionally an operator sequence, and a ribosome binding site. Eukaryotic cells are known to utilize promoters, polyadenylation signals, and enhancers.

[0052] Nucleic acid is "operably linked" when it is placed into a functional relationship with another nucleic acid sequence. For example, DNA for a presequence or secretory leader is operably linked to DNA for a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide; a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation. Generally, "operably linked" means that the DNA sequences being linked are contiguous, and, in the case of a secretory leader, contiguous and in reading phase. However, enhancers do not have to be contiguous. Linking is accomplished by ligation at convenient restriction sites. If such sites do not exist, the synthetic oligonucleotide adaptors or linkers are used in accordance with conventional practice.

[0053] "Vector" includes shuttle and expression vectors. Typically, the plasmid construct will also include an origin of replication (e.g., the ColE1 origin of replication) and a selectable marker (e.g., ampicillin or tetracycline resistance), for replication and selection, respectively, of the plasmids in bacteria. An "expression vector" refers to a vector that contains the necessary control sequences or regulatory elements for expression of the antibodies including antibody fragment of the invention, in bacterial or eukaryotic cells. Suitable vectors are disclosed below.

[0054] The cell that produces a humanized CD20 binding antibody of the invention will include the bacterial and eukaryotic host cells into which nucleic acid encoding the antibodies have been introduced. Suitable host cells are disclosed below.

[0055] The word "label" when used herein refers to a detectable compound or composition which is conjugated directly or indirectly to the antibody. The label may itself be detectable by itself (e.g., radioisotope labels or fluorescent labels) or, in the case of an enzymatic label, may catalyze chemical alteration of a substrate compound or composition which is detectable.

[0056] An "autoimmune disease" herein is a non-malignant disease or disorder arising from and directed against an individual's own (self) antigens and/or tissues.

As used herein, "B cell depletion" refers to a reduction in B cell levels in an animal or human after drug or antibody treatment, as compared to the B cell level before treatment. B cell levels are measurable using well known assays such as those described in the Experimental Examples. B cell depletion can be complete or partial. In one embodiment, the depletion of CD20 expressing B cells is at least 25%. Not to be limited by any one mechanism, possible mechanisms of B-cell depletion include ADCC, CDC, apoptosis, modulation of calcium flux or a combination of two or more of the preceding.

[0057] The term "cytotoxic agent" as used herein refers to a substance that inhibits or prevents the function of cells and/or causes destruction of cells. The term is intended to include radioactive isotopes (e.g., I^{131} , I^{125} , Y^{90} and Re^{186}), chemotherapeutic agents, and toxins such as enzymatically active toxins of bacterial, fungal, plant or animal origin, or fragments thereof.

[0058] A "chemotherapeutic agent" is a chemical compound useful in the treatment of cancer. Examples of chemotherapeutic agents include alkylating or alkylating agents such as thiotepa and cyclophosphamide (CYTOXANTM); alkyl sulfonates such as busulfan, improsulfan and piposulfan; aziridines such as benzodopa, carboquone, meturedopa, and uredopa; ethylenimines and methylamelamines including altretamine, triethylenemelamine, triethylenephosphoramide, triethylenethiophosphoramide and trimethylolomelamine; nitrogen mustards such as chlorambucil, chlornaphazine, cholophosphamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, novembichin, phenesterine, prednimustine, trofosfamide, uracil mustard; nitrosureas such as carmustine, chlorozotocin, fotemustine, lomustine, nimustine, ranimustine; antibiotics such as aclacinomysins, actinomycin, anthramycin, azaserine, bleomycins, cactinomycin, calicheamicin, carabycin, carminomycin, carzinophilin, chromomycins, dactinomycin, daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine, doxorubicin (Adriamycin), epirubicin, esorubicin, idarubicin, marcellomycin, mitomycins, mycophenolic acid, nogalamycin, olivomycins, peplomycin, potfiromycin, puromycin, quelamycin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, zorubicin; anti-metabolites such as methotrexate and 5-fluorouracil (5-FU); folic acid analogues such as denopterin, methotrexate, pteropterin, trimetrexate; purine analogs such as fludarabine, 6-mercaptopurine, thiamiprine, thioguanine; pyrimidine analogs such as ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine, 5-FU; androgens such as calusterone, dromostanolone propionate, epitostanol, mepitostane, testolactone; anti-adrenals such as aminoglutethimide, mitotane, trilostane; folic acid replenisher such as frolinic acid; aceglatone; aldophosphamide glycoside; aminolevulinic acid; amsacrine; bestrabucil; bisantrene; edatraxate; defofamine; demecolcine; diaziquone; elfornithine; elliptinium acetate; etoglucid; gallium nitrate; hydroxyurea; lentinan; lonidamine; mitoguazone; mitoxantrone; mopidamol; nitracrine; pentostatin; phenamet; pirarubicin; podophyllinic acid; 2-ethylhydrazide; procarbazine; PSK[®]; razoxane; sizofiran; spirogermanium; tenuazonic acid; triaziquone; 2, 2', 2"-trichlorotriethylamine; urethan; vindesine; dacarbazine; mannomustine; mitobronitol; mitolactol; pipobroman; gacytosine; arabinoside ("Ara-C"); thiotepa; taxoids, e.g. paclitaxel (TAXOL[®], Bristol-Myers Squibb Oncology, Princeton, NJ) and doxetaxel (TAXOTERE[®], Rhône-Poulenc Rorer, Antony,

France); chlorambucil; gemcitabine; 6-thioguanine; mercaptopurine; methotrexate; platinum analogs such as cisplatin and carboplatin; platinum; etoposide (VP-16); ifosfamide; mitomycin C; mitoxantrone; vincristine; vinblastine; vinorelbine; navelbine; novantrone; teniposide; daunomycin; aminopterin; xeloda; ibandronate; CPT-11; topoisomerase inhibitor RFS 2000; difluoromethylornithine (DMFO); retinoic acid; esperamicins; capecitabine; and pharmaceutically acceptable salts, acids or derivatives of any of the above. Also included in this definition are anti-hormonal agents that act to regulate or inhibit hormone action on tumors such as anti-estrogens including for example tamoxifen, raloxifene, aromatase inhibiting 4(5)-imidazoles, 4-hydroxytamoxifen, trioxifene, keoxifene, LY117018, onapristone, and toremifene (Fareston); anti-androgens such as flutamide, nilutamide, bicalutamide, leuprolide, and goserelin; other chemotherapeutic agents such as prednisolone. Pharmaceutically acceptable salts, acids or derivatives of any of the above are included.

[0059] "Treating" or "treatment" or "alleviation" refers to both therapeutic treatment and prophylactic or preventative measures, wherein the object is to prevent or slow down (lessen) the targeted pathologic condition or disorder. A subject is successfully "treated" for a CD20 positive cancer or an autoimmune disease if, after receiving a therapeutic amount of a CD20 binding antibody of the invention according to the methods of the present invention, the subject shows observable and/or measurable reduction in or absence of one or more signs and symptoms of the particular disease. For example, for cancer, reduction in the number of cancer cells or absence of the cancer cells; reduction in the tumor size; inhibition (*i.e.*, slow to some extent and preferably stop) of tumor metastasis; inhibition, to some extent, of tumor growth; increase in length of remission, and/or relief to some extent, one or more of the symptoms associated with the specific cancer; reduced morbidity and mortality, and improvement in quality of life issues. Reduction of the signs or symptoms of a disease may also be felt by the patient. Treatment can achieve a complete response, defined as disappearance of all signs of cancer, or a partial response, wherein the size of the tumor is decreased, preferably by more than 50 percent, more preferably by 75%. A patient is also considered treated if the patient experiences stable disease. In a preferred embodiment, the cancer patients are still progression-free in the cancer after one year, preferably after 15 months. These parameters for assessing successful treatment and improvement in the disease are readily measurable by routine procedures familiar to a physician of appropriate skill in the art.

[0060] A "therapeutically effective amount" refers to an amount of an antibody or a drug effective to "treat" a disease or disorder in a subject. In the case of cancer, the therapeutically effective amount of the drug may reduce the number of cancer cells; reduce the tumor size; inhibit (*i.e.*, slow to some extent and preferably stop) cancer cell infiltration into peripheral organs; inhibit (*i.e.*, slow to some extent and preferably stop) tumor metastasis; inhibit, to some extent, tumor growth; and/or relieve to some extent one or more of the symptoms associated with the cancer. See preceding definition of "treating".

[0061] "Chronic" administration refers to administration of the agent(s) in a continuous mode as opposed to an acute mode, so as to maintain the initial therapeutic effect (activity) for an extended period of time. "Intermittent" administration is treatment that is not consecutively done without interruption, but rather is cyclic in nature.

Compositions and Methods of the Invention

[0062] The invention provides humanized antibodies that bind human CD20, and preferably other primate CD20 as well, comprising a H chain having at least one, preferably two or all of the H chain CDRs of a non-human species anti-human CD20 antibody (donor antibody), and substantially all of the framework residues of a human consensus antibody as the recipient antibody. The donor antibody can be from various non-human species including mouse, rat, guinea pig, goat, rabbit, horse, primate but most frequently will be a murine antibody. "Substantially all" in this context is meant that the recipient FR regions in the humanized antibody may include one or more amino acid substitutions not originally present in the human consensus FR sequence. These FR changes may comprise residues not found in the recipient or the donor antibody.

[0063] In one embodiment, the donor antibody is the murine 2H7 antibody, the V region including the CDR and FR sequences of each of the H and L chains of which are shown in FIG. 1A and 1B. In a specific embodiment, the residues for the human Fab framework correspond to the consensus sequence of human V_κ subgroup I and of V_H subgroup III, these consensus sequences are shown in Figure 1A and Figure 1B, respectively. The humanized 2H7 antibody of the invention will have at least one of the CDRs in the H chain of the murine donor antibody. In one embodiment, the humanized 2H7 antibody that binds human CD20 comprises the CDRs of both the H and L chains of the donor antibody.

[0064] In a full length antibody, the humanized CD20 binding antibody of the invention will comprise a humanized V domain joined to a C domain of a human immunoglobulin. In a preferred embodiment, the H chain C region is from human IgG, preferably IgG1 or IgG3. The L chain C domain is preferably from human κ chain.

[0065] Unless indicated otherwise, a humanized 2H7 antibody version herein will have the V and C domain sequences of 2H7.v16 L chain (FIG. 6, SEQ ID NO. 21) and H chain (FIG 7., SEQ ID NO. 22) except at the positions of amino acid substitutions or changes indicated in the experimental examples below.

[0066] The humanized CD20 binding antibodies will bind at least human CD20 and preferably bind other primate CD20 such as that of monkeys including cynomolgus and rhesus monkeys, and chimpanzees. The sequence of the cynomolgus

monkey CD20 is disclosed in Example 15 and Figure 19

[0067] The biological activity of the CD20 binding antibodies and humanized CD20 binding antibodies of the invention will include at least binding of the antibody to human CD20, more preferably binding to human and primate CD20 (including cynomolgus monkey, rhesus monkey, chimpanzees), with a K_d value of no higher than 1×10^{-8} , preferably a K_d value no higher than about 1×10^{-9} , even more preferably a K_d value no higher than about 1×10^{-10} , and be able to kill or deplete B cells in vitro or in vivo, preferably by at least 20% when compared to the baseline level or appropriate negative control which is not treated with such an antibody.

[0068] The desired level of B cell depletion will depend on the disease. For the treatment of a CD20 positive cancer, it may be desirable to maximize the depletion of the B cells which are the target of the anti-CD20 antibodies of the invention. Thus, for the treatment of a CD20 positive B cell neoplasm, it is desirable that the B cell depletion be sufficient to at least prevent progression of the disease which can be assessed by the physician of skill in the art, e.g., by monitoring tumor growth (size), proliferation of the cancerous cell type, metastasis, other signs and symptoms of the particular cancer. Preferably, the B cell depletion is sufficient to prevent progression of disease for at least 2 months, more preferably 3 months, even more preferably 4 months, more preferably 5 months, even more preferably 6 or more months. In even more preferred embodiments, the B cell depletion is sufficient to increase the time in remission by at least 6 months, more preferably 9 months, more preferably one year, more preferably 2 years, more preferably 3 years, even more preferably 5 or more years. In a most preferred embodiment, the B cell depletion is sufficient to cure the disease. In preferred embodiments, the B cell depletion in a cancer patient is at least about 75% and more preferably, 80%, 85%, 90%, 95%, 99% and even 100% of the baseline level before treatment.

[0069] For treatment of an autoimmune disease, it may be desirable to modulate the extent of B cell depletion depending on the disease and/or the severity of the condition in the individual patient, by adjusting the dosage of CD20 binding antibody. Thus, B cell depletion can but does not have to be complete. Or, total B cell depletion may be desired in initial treatment but in subsequent treatments, the dosage may be adjusted to achieve only partial depletion. In one embodiment, the B cell depletion is at least 20%, i.e., 80% or less of CD20 positive B cells remain as compared to the baseline level before treatment. In other embodiments, B cell depletion is 25%, 30%, 40%, 50%, 60%, 70% or greater. Preferably, the B cell depletion is sufficient to halt progression of the disease, more preferably to alleviate the signs and symptoms of the particular disease under treatment, even more preferably to cure the disease.

[0070] The invention also provides bispecific CD20 binding antibodies wherein one arm of the antibody has a humanized H and L chain of the humanized CD20 binding antibody of the invention, and the other arm has V region binding specificity for a second antigen. In specific embodiments, the second antigen is selected from the group consisting of CD3, CD64, CD32A, CD 16, NKG2D or other NK activating ligands.

[0071] In comparison with Rituxan (rituximab), v16 exhibits about 2 to 5 fold increased ADCC potency, ~3-4 fold decreased CDC than Rituxan.

Antibody production

Monoclonal antibodies

[0072] Monoclonal antibodies may be made using the hybridoma method first described by Kohler et al., Nature, 256:495 (1975), or may be made by recombinant DNA methods (U.S. Patent No. 4,816,567).

[0073] In the hybridoma method, a mouse or other appropriate host animal, such as a hamster, is immunized as described above to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the protein used for immunization. Alternatively, lymphocytes may be immunized *in vitro*. After immunization, lymphocytes are isolated and then fused with a myeloma cell line using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell (Goding, Monoclonal Antibodies: Principles and Practice, pp.59-103 (Academic Press, 1986)).

[0074] The hybridoma cells thus prepared are seeded and grown in a suitable culture medium which medium preferably contains one or more substances that inhibit the growth or survival of the unfused, parental myeloma cells (also referred to as fusion partner). For example, if the parental myeloma cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the selective culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine (HAT medium), which substances prevent the growth of HGPRT-deficient cells.

[0075] Preferred fusion partner myeloma cells are those that fuse efficiently, support stable high-level production of antibody by the selected antibody-producing cells, and are sensitive to a selective medium that selects against the unfused parental cells. Preferred myeloma cell lines are murine myeloma lines, such as those derived from MOPC-21 and MPC-11 mouse tumors available from the Salk Institute Cell Distribution Center, San Diego, California USA, and SP-2 and derivatives e.g., X63-Ag8-653 cells available from the American Type Culture Collection, Rockville, Maryland USA. Human myeloma and mouse-human heteromyeloma cell lines also have been described for the production of human monoclonal antibodies (Kozbor, J. Immunol., 133:3001 (1984); and Brodeur et al., Monoclonal Antibody Production Techniques and Applications, pp. 51-63 (Marcel Dekker, Inc., New York, 1987)).

[0076] Culture medium in which hybridoma cells are growing is assayed for production of monoclonal antibodies directed against the antigen. Preferably, the binding specificity of monoclonal antibodies produced by hybridoma cells is determined by immunoprecipitation or by an *in vitro* binding assay, such as radioimmunoassay (RIA) or enzyme-linked immunosorbent assay (ELISA).

[0077] The binding affinity of the monoclonal antibody can, for example, be determined by the Scatchard analysis described in Munson et al., *Anal. Biochem.*, 107:220 (1980).

[0078] Once hybridoma cells that produce antibodies of the desired specificity, affinity, and/or activity are identified, the clones may be subcloned by limiting dilution procedures and grown by standard methods (Goding, *Monoclonal Antibodies: Principles and Practice*, pp.59-103 (Academic Press, 1986)). Suitable culture media for this purpose include, for example, D-MEM or RPMI-1640 medium. In addition, the hybridoma cells may be grown *in vivo* as ascites tumors in an animal e.g., by i.p. injection of the cells into mice.

[0079] The monoclonal antibodies secreted by the subclones are suitably separated from the culture medium, ascites fluid, or serum by conventional antibody purification procedures such as, for example, affinity chromatography (e.g., using protein A or protein G-Sepharose) or ion-exchange chromatography, hydroxylapatite chromatography, gel electrophoresis, dialysis, etc.

[0080] DNA encoding the monoclonal antibodies is readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of murine antibodies). The hybridoma cells serve as a preferred source of such DNA. Once isolated, the DNA may be placed into expression vectors, which are then transfected into host cells such as *E. coli* cells, simian COS cells, Chinese Hamster Ovary (CHO) cells, or myeloma cells that do not otherwise produce antibody protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells. Review articles on recombinant expression in bacteria of DNA encoding the antibody include Skerra et al., *Curr. Opin. in Immunol.*, 5:256-262 (1993) and Pluckthun, *Immunol. Revs.*, 130:151-188 (1992).

[0081] In a further embodiment, monoclonal antibodies or antibody fragments can be isolated from antibody phage libraries generated using the techniques described in McCafferty et al., *Nature*, 348:552-554 (1990). Clackson et al., *Nature*, 352:624-628 (1991) and Marks et al., *J. Mol. Biol.*, 222:581-597 (1991) describe the isolation of murine and human antibodies, respectively, using phage libraries. Subsequent publications describe the production of high affinity (nM range) human antibodies by chain shuffling (Marks et al., *Bio/Technology*, 10:779-783 (1992)), as well as combinatorial infection and *in vivo* recombination as a strategy for constructing very large phage libraries (Waterhouse et al., *Nuc. Acids. Res.*, 21:2265-2266 (1993)). Thus, these techniques are viable alternatives to traditional monoclonal antibody hybridoma techniques for isolation of monoclonal antibodies.

[0082] The DNA that encodes the antibody may be modified to produce chimeric or fusion antibody polypeptides, for example, by substituting human heavy chain and light chain constant domain (C_H and C_L) sequences for the homologous murine sequences (U.S. Patent No. 4,816,567; and Morrison, et al., *Proc. Natl Acad. Sci. USA*, 81:6851 (1984)), or by fusing the immunoglobulin coding sequence with all or part of the coding sequence for a non-immunoglobulin polypeptide (heterologous polypeptide). The non-immunoglobulin polypeptide sequences can substitute for the constant domains of an antibody, or they are substituted for the variable domains of one antigen-combining site of an antibody to create a chimeric bivalent antibody comprising one antigen-combining site having specificity for an antigen and another antigen-combining site having specificity for a different antigen.

Humanized antibodies

[0083] Methods for humanizing non-human antibodies have been described in the art. Preferably, a humanized antibody has one or more amino acid residues introduced into it from a source which is non-human. These non-human amino acid residues are often referred to as "import" residues, which are typically taken from an "import" variable domain. Humanization can be essentially performed following the method of Winter and co-workers (Jones et al., *Nature*, 321:522-525 (1986); Reichmann et al., *Nature*, 332:323-327 (1988); Verhoeyen et al., *Science*, 239:1534-1536 (1988)), by substituting hypervariable region sequences for the corresponding sequences of a human antibody. Accordingly, such "humanized" antibodies are chimeric antibodies (U.S. Patent No. 4,816,567) wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species. In practice, humanized antibodies are typically human antibodies in which some hypervariable region residues and possibly some FR residues are substituted by residues from analogous sites in rodent antibodies.

[0084] The choice of human variable domains, both light and heavy, to be used in making the humanized antibodies is very important to reduce antigenicity and HAMA response (human anti-mouse antibody) when the antibody is intended for human therapeutic use. According to the so-called "best-fit" method, the sequence of the variable domain of a rodent antibody is screened against the entire library of known human variable domain sequences. The human V domain sequence which is closest to that of the rodent is identified and the human framework region (FR) within it accepted for the humanized antibody (Sims et al., *J. Immunol.*, 151:2296 (1993); Chothia et al., *J. Mol. Biol.*, 196:901 (1987)). Another

method uses a particular framework region derived from the consensus sequence of all human antibodies of a particular subgroup of light or heavy chains. The same framework may be used for several different humanized antibodies (Carter et al., Proc. Natl. Acad. Sci. USA, 89:4285 (1992); Presta et al., J. Immunol., 151:2623 (1993)).

[0085] It is further important that antibodies be humanized with retention of high binding affinity for the antigen and other favorable biological properties. To achieve this goal, according to a preferred method, humanized antibodies are prepared by a process of analysis of the parental sequences and various conceptual humanized products using three-dimensional models of the parental and humanized sequences. Three-dimensional immunoglobulin models are commonly available and are familiar to those skilled in the art. Computer programs are available which illustrate and display probable three-dimensional conformational structures of selected candidate immunoglobulin sequences. Inspection of these displays permits analysis of the likely role of the residues in the functioning of the candidate immunoglobulin sequence, i.e., the analysis of residues that influence the ability of the candidate immunoglobulin to bind its antigen. In this way, FR residues can be selected and combined from the recipient and import sequences so that the desired antibody characteristic, such as increased affinity for the target antigen(s), is achieved. In general, the hypervariable region residues are directly and most substantially involved in influencing antigen binding.

[0086] The humanized antibody may be an antibody fragment, such as a Fab, which is optionally conjugated with one or more cytotoxic agent(s) in order to generate an immunoconjugate. Alternatively, the humanized antibody may be an full length antibody, such as an full length IgG1 antibody.

Human antibodies and phage display methodology

[0087] As an alternative to humanization, human antibodies can be generated. For example, it is now possible to produce transgenic animals (e.g., mice) that are capable, upon immunization, of producing a full repertoire of human antibodies in the absence of endogenous immunoglobulin production. For example, it has been described that the homozygous deletion of the antibody heavy-chain joining region (J_H) gene in chimeric and germ-line mutant mice results in complete inhibition of endogenous antibody production. Transfer of the human germ-line immunoglobulin gene array into such germ-line mutant mice will result in the production of human antibodies upon antigen challenge. See, e.g., Jakobovits et al., Proc. Natl. Acad. Sci. USA, 90:2551 (1993); Jakobovits et al., Nature, 362:255-258 (1993); Bruggemann et al., Year in Immuno., 7:33 (1993); U.S. Patent Nos. 5,545,806, 5,569,825, 5,591,669 (all of GenPharm); 5,545,807; and WO 97/17852.

[0088] Alternatively, phage display technology (McCafferty et al., Nature 348:552-553 [1990]) can be used to produce human antibodies and antibody fragments *in vitro*, from immunoglobulin variable (V) domain gene repertoires from unimmunized donors. According to this technique, antibody V domain genes are cloned in-frame into either a major or minor coat protein gene of a filamentous bacteriophage, such as M13 or fd, and displayed as functional antibody fragments on the surface of the phage particle. Because the filamentous particle contains a single-stranded DNA copy of the phage genome, selections based on the functional properties of the antibody also result in selection of the gene encoding the antibody exhibiting those properties. Thus, the phage mimics some of the properties of the B-cell. Phage display can be performed in a variety of formats, reviewed in, e.g., Johnson, Kevin S. and Chiswell, David J., Current Opinion in Structural Biology 3:564-571 (1993). Several sources of V-gene segments can be used for phage display. Clackson et al., Nature, 352:624-628 (1991) isolated a diverse array of anti-oxazolone antibodies from a small random combinatorial library of V genes derived from the spleens of immunized mice. A repertoire of V genes from unimmunized human donors can be constructed and antibodies to a diverse array of antigens (including self-antigens) can be isolated essentially following the techniques described by Marks et al., J. Mol. Biol. 222:581-597 (1991), or Griffith et al., EMBO J. 12:725-734 (1993). See, also, U.S. Patent Nos. 5,565,332 and 5,573,905.

[0089] As discussed above, human antibodies may also be generated by *in vitro* activated B cells (see U.S. Patents 5,567,610 and 5,229,275).

Antibody fragments

[0090] In certain circumstances there are advantages of using antibody fragments, rather than whole antibodies. The smaller size of the fragments allows for rapid clearance, and may lead to improved access to solid tumors.

[0091] Various techniques have been developed for the production of antibody fragments. Traditionally, these fragments were derived via proteolytic digestion of intact antibodies (see, e.g., Morimoto et al., Journal of Biochemical and Biophysical Methods 24:107-117 (1992); and Brennan et al., Science, 229:81 (1985)). However, these fragments can now be produced directly by recombinant host cells. Fab, Fv and ScFv antibody fragments can all be expressed in and secreted from *E. coli*, thus allowing the facile production of large amounts of these fragments. Antibody fragments can be isolated from the antibody phage libraries discussed above. Alternatively, Fab'-SH fragments can be directly recovered from *E. coli* and chemically coupled to form F(ab')₂ fragments (Carter et al., Bio/Technology 10:163-167 (1992)). According to another approach, F(ab')₂ fragments can be isolated directly from recombinant host cell culture. Fab and F(ab')₂

fragment with increased in vivo half-life comprising a salvage receptor binding epitope residues are described in U.S. Patent No. 5,869,046. Other techniques for the production of antibody fragments will be apparent to the skilled practitioner. In other embodiments, the antibody of choice is a single chain Fv fragment (scFv). See WO 93/16185; U.S. Patent No. 5,571,894; and U.S. Patent No. 5,587,458. Fv and sFv are the only species with intact combining sites that are devoid of constant regions; thus, they are suitable for reduced nonspecific binding during in vivo use. sFv fusion proteins may be constructed to yield fusion of an effector protein at either the amino or the carboxy terminus of an sFv. See Antibody Engineering, ed. Borrebaeck supra. The antibody fragment may also be a "linear antibody", e.g., as described in U.S. Patent 5,641,870 for example. Such linear antibody fragments may be monospecific or bispecific.

Bispecific antibodies

[0092] Bispecific antibodies are antibodies that have binding specificities for at least two different epitopes. Exemplary bispecific antibodies may bind to two different epitopes of the CD20 protein. Other such antibodies may combine a CD20 binding site with a binding site for another protein. Alternatively, an anti-CD20 arm may be combined with an arm which binds to a triggering molecule on a leukocyte such as a T-cell receptor molecule (e.g. CD3), or Fc receptors for IgG (FcγR), such as FcγRI (CD64), FcγRII (CD32) and FcγRIII (CD 16), or NKG2D or other NK cell activating ligand, so as to focus and localize cellular defense mechanisms to the CD20-expressing cell. Bispecific antibodies may also be used to localize cytotoxic agents to cells which express CD20. These antibodies possess a CD20-binding arm and an arm which binds the cytotoxic agent (e.g. saporin, anti-interferon-α, vinca alkaloid, ricin A chain, methotrexate or radioactive isotope hapten). Bispecific antibodies can be prepared as full length antibodies or antibody fragments (e.g. F(ab')₂ bispecific antibodies).

[0093] WO 96/16673 describes a bispecific anti-ErbB2/anti-FcγRIII antibody and U.S. Patent No. 5,837,234 discloses a bispecific anti-ErbB2/anti-FcγRI antibody. A bispecific anti-ErbB2/Fcα antibody is shown in WO98/02463. U.S. Patent No. 5,821,337 teaches a bispecific anti-ErbB2/anti-CD3 antibody.

[0094] Methods for making bispecific antibodies are known in the art. Traditional production of full length bispecific antibodies is based on the co-expression of two immunoglobulin heavy chain-light chain pairs, where the two chains have different specificities (Millstein et al., Nature, 305:537-539 (1983)). Because of the random assortment of immunoglobulin heavy and light chains, these hybridomas (quadromas) produce a potential mixture of 10 different antibody molecules, of which only one has the correct bispecific structure. Purification of the correct molecule, which is usually done by affinity chromatography steps, is rather cumbersome, and the product yields are low. Similar procedures are disclosed in WO 93/08829, and in Traunecker et al., EMBO J., 10:3655-3659 (1991).

[0095] According to a different approach, antibody variable domains with the desired binding specificities (antibody-antigen combining sites) are fused to immunoglobulin constant domain sequences. Preferably, the fusion is with an Ig heavy chain constant domain, comprising at least part of the hinge, C_H2, and C_H3 regions. It is preferred to have the first heavy-chain constant region (C_H1) containing the site necessary for light chain bonding, present in at least one of the fusions. DNAs encoding the immunoglobulin heavy chain fusions and, if desired, the immunoglobulin light chain, are inserted into separate expression vectors, and are co-transfected into a suitable host cell. This provides for greater flexibility in adjusting the mutual proportions of the three polypeptide fragments in embodiments when unequal ratios of the three polypeptide chains used in the construction provide the optimum yield of the desired bispecific antibody. It is, however, possible to insert the coding sequences for two or all three polypeptide chains into a single expression vector when the expression of at least two polypeptide chains in equal ratios results in high yields or when the ratios have no significant affect on the yield of the desired chain combination.

[0096] In a preferred embodiment of this approach, the bispecific antibodies are composed of a hybrid immunoglobulin heavy chain with a first binding specificity in one arm, and a hybrid immunoglobulin heavy chain-light chain pair (providing a second binding specificity) in the other arm. It was found that this asymmetric structure facilitates the separation of the desired bispecific compound from unwanted immunoglobulin chain combinations, as the presence of an immunoglobulin light chain in only one half of the bispecific molecule provides for a facile way of separation. This approach is disclosed in WO 94/04690. For further details of generating bispecific antibodies see, for example, Suresh et al., Methods in Enzymology, 121:210 (1986).

[0097] According to another approach described in U.S. Patent No. 5,731,168, the interface between a pair of antibody molecules can be engineered to maximize the percentage of heterodimers which are recovered from recombinant cell culture. The preferred interface comprises at least a part of the C_H3 domain. In this method, one or more small amino acid side chains from the interface of the first antibody molecule are replaced with larger side chains (e.g. tyrosine or tryptophan). Compensatory "cavities" of identical or similar size to the large side chain(s) are created on the interface of the second antibody molecule by replacing large amino acid side chains with smaller ones (e.g. alanine or threonine). This provides a mechanism for increasing the yield of the heterodimer over other unwanted end-products such as homodimers.

[0098] Bispecific antibodies include cross-linked or "heteroconjugate" antibodies. For example, one of the antibodies

in the heteroconjugate can be coupled to avidin, the other to biotin. Such antibodies have, for example, been proposed to target immune system cells to unwanted cells (U.S. Patent No. 4,676,980), and for treatment of HIV infection (WO 91/00360, WO 92/200373, and EP 03089). Heteroconjugate antibodies may be made using any convenient cross-linking methods. Suitable cross-linking agents are well known in the art, and are disclosed in U.S. Patent No. 4,676,980, along with a number of cross-linking techniques.

[0099] Techniques for generating bispecific antibodies from antibody fragments have also been described *in the literature*. For example, bispecific antibodies can be prepared using chemical linkage. Brennan et al., Science, 229: 81 (1985) describe a procedure wherein intact antibodies are proteolytically cleaved to generate F(ab')₂ fragments. These fragments are reduced in the presence of the dithiol complexing agent, sodium arsenite, to stabilize vicinal dithiols and prevent intermolecular disulfide formation. The Fab' fragments generated are then converted to thionitrobenzoate (TNB) derivatives. One of the Fab'-TNB derivatives is then reconverted to the Fab'-thiol by reduction with mercaptoethylamine and is mixed with an equimolar amount of the other Fab'-TNB derivative to form the bispecific antibody. The bispecific antibodies produced can be used as agents for the selective immobilization of enzymes.

[0100] Recent progress has facilitated the direct recovery of Fab'-SH fragments from *E. coli*, which can be chemically coupled to form bispecific antibodies. Shalaby et al., J. Exp. Med., 175: 217-225 (1992) describe the production of a fully humanized bispecific antibody F(ab')₂ molecule. Each Fab' fragment was separately secreted from *E. coli* and subjected to directed chemical coupling *in vitro* to form the bispecific antibody. The bispecific antibody thus formed was able to bind to cells overexpressing the ErbB2 receptor and normal human T cells, as well as trigger the lytic activity of human cytotoxic lymphocytes against human breast tumor targets.

[0101] Various techniques for making and isolating bispecific antibody fragments directly from recombinant cell culture have also been described. For example, bispecific antibodies have been produced using leucine zippers. Kostelny et al., J. Immunol., 148(5):1547-1553 (1992). The leucine zipper peptides from the Fos and Jun proteins were linked to the Fab' portions of two different antibodies by gene fusion. The antibody homodimers were reduced at the hinge region to form monomers and then re-oxidized to form the antibody heterodimers. This method can also be utilized for the production of antibody homodimers. The "diabody" technology described by Hollinger et al., Proc. Natl. Acad. Sci. USA, 90:6444-6448 (1993) has provided an alternative mechanism for making bispecific antibody fragments. The fragments comprise a V_H connected to a V_L by a linker which is too short to allow pairing between the two domains on the same chain. Accordingly, the V_H and V_L domains of one fragment are forced to pair with the complementary V_L and V_H domains of another fragment, thereby forming two antigen-binding sites. Another strategy for making bispecific antibody fragments by the use of single-chain Fv (sFv) dimers has also been reported. See Gruber et al., J. Immunol., 152:5368 (1994).

[0102] Antibodies with more than two valencies are contemplated. For example, trispecific antibodies can be prepared. Tutt et al. J. Immunol. 147: 60 (1991).

Multivalent Antibodies

[0103] A multivalent antibody may be internalized (and/or catabolized) faster than a bivalent antibody by a cell expressing an antigen to which the antibodies bind. The antibodies of the present invention can be multivalent antibodies (which are other than of the IgM class) with three or more antigen binding sites (e.g. tetravalent antibodies), which can be readily produced by recombinant expression of nucleic acid encoding the polypeptide chains of the antibody. The multivalent antibody can comprise a dimerization domain and three or more antigen binding sites. The preferred dimerization domain comprises (or consists of) an Fc region or a hinge region. In this scenario, the antibody will comprise an Fc region and three or more antigen binding sites amino-terminal to the Fc region. The preferred multivalent antibody herein comprises (or consists of) three to about eight, but preferably four, antigen binding sites. The multivalent antibody comprises at least one polypeptide chain (and preferably two polypeptide chains), wherein the polypeptide chain(s) comprise two or more variable domains. For instance, the polypeptide chain(s) may comprise VD 1-(X1)_n-VD2-(X2)_n-Fc, wherein VD1 is a first variable domain, VD2 is a second variable domain, Fc is one polypeptide chain of an Fc region, X1 and X2 represent an amino acid or polypeptide, and n is 0 or 1. For instance, the polypeptide chain(s) may comprise: VH-CH1-flexible linker-VH-CH1-Fc region chain; or VH-CH1-VH-CH1-Fc region chain. The multivalent antibody herein preferably further comprises at least two (and preferably four) light chain variable domain polypeptides. The multivalent antibody herein may, for instance, comprise from about two to about eight light chain variable domain polypeptides. The light chain variable domain polypeptides contemplated here comprise a light chain variable domain and, optionally, further comprise a CL domain.

Other amino acid sequence modifications

[0104] Amino acid sequence modification(s) of the CD20 binding antibodies described herein are contemplated. For example, it may be desirable to improve the binding affinity and/or other biological properties of the antibody. Amino acid sequence variants of the anti-CD20 antibody are prepared by introducing appropriate nucleotide changes into the

anti-CD20 antibody nucleic acid, or by peptide synthesis. Such modifications include, for example, deletions from, and/or insertions into and/or substitutions of, residues within the amino acid sequences of the anti-CD20 antibody. Any combination of deletion, insertion, and substitution is made to arrive at the final construct, provided that the final construct possesses the desired characteristics. The amino acid changes also may alter post-translational processes of the anti-CD20 antibody, such as changing the number or position of glycosylation sites.

[0105] A useful method for identification of certain residues or regions of the anti-CD20 antibody that are preferred locations for mutagenesis is called "alanine scanning mutagenesis" as described by Cunningham and Wells in Science, 244:1081-1085 (1989). Here, a residue or group of target residues are identified (e.g., charged residues such as arg, asp, his, lys, and glu) and replaced by a neutral or negatively charged amino acid (most preferably alanine or polyalanine) to affect the interaction of the amino acids with CD20 antigen. Those amino acid locations demonstrating functional sensitivity to the substitutions then are refined by introducing further or other variants at, or for, the sites of substitution. Thus, while the site for introducing an amino acid sequence variation is predetermined, the nature of the mutation *per se* need not be predetermined. For example, to analyze the performance of a mutation at a given site, ala scanning or random mutagenesis is conducted at the target codon or region and the expressed anti-CD20 antibody variants are screened for the desired activity.

[0106] Amino acid sequence insertions include amino- and/or carboxyl-terminal fusions ranging in length from one residue to polypeptides containing a hundred or more residues, as well as intrasequence insertions of single or multiple amino acid residues. Examples of terminal insertions include an anti-CD20 antibody with an N-terminal methionyl residue or the antibody fused to a cytotoxic polypeptide. Other insertional variants of the anti-CD20 antibody molecule include the fusion to the N- or C-terminus of the anti-CD20 antibody to an enzyme (e.g. for ADEPT) or a polypeptide which increases the serum half-life of the antibody.

[0107] Another type of variant is an amino acid substitution variant. These variants have at least one amino acid residue in the anti-CD20 antibody molecule replaced by a different residue. The sites of greatest interest for substitutional mutagenesis include the hypervariable regions, but FR alterations are also contemplated. Conservative substitutions are shown in the Table below under the heading of "preferred substitutions". If such substitutions result in a change in biological activity, then more substantial changes, denominated "exemplary substitutions" in the Table, or as further described below in reference to amino acid classes, may be introduced and the products screened.

TABLE of Amino Acid Substitutions

Original Residue	Exemplary Substitutions	Preferred Substitutions
Ala (A)	val; leu; ile	val
Arg (R)	lys; gln; asn	lys
Asn (N)	gln; his; asp, lys; arg	gln
Asp (D)	glu; asn	glu
Cys (C)	ser; ala	ser
Gln (Q)	asn; glu	asn
Glu (E)	asp; gln	asp
Gly (G)	ala	ala
His (H)	asn; gln; lys; arg	arg
Ile (I)	leu; val; met; ala; phe; norleucine	leu
Leu (L)	norleucine; ile; val; met; ala; phe	ile
Lys (K)	arg; gln; asn	arg
Met (M)	leu; phe; ile	leu
Phe (F)	leu; val; ile; ala; tyr	tyr
Pro (P)	ala	ala
Ser (S)	thr	thr
Thr (T)	ser	ser
Trp (W)	tyr; phe	tyr
Tyr (Y)	trp; phe; thr; ser	phe

(continued)

Original Residue	Exemplary Substitutions	Preferred Substitutions
Val (V)	ile; leu; met; phe; ala; norleucine	leu

[0108] Substantial modifications in the biological properties of the antibody are accomplished by selecting substitutions that differ significantly in their effect on maintaining (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site, or (c) the bulk of the side chain. Naturally occurring residues are divided into groups based on common side-chain properties:

- (1) hydrophobic: norleucine, met, ala, val, leu, ile;
- (2) neutral hydrophilic: cys, ser, thr;
- (3) acidic: asp, glu;
- (4) basic: asn, gln, his, lys, arg;
- (5) residues that influence chain orientation: gly, pro; and
- (6) aromatic: trp, tyr, phe.

[0109] Non-conservative substitutions will entail exchanging a member of one of these classes for another class.

[0110] Any cysteine residue not involved in maintaining the proper conformation of the anti-CD20 antibody also may be substituted, generally with serine, to improve the oxidative stability of the molecule and prevent aberrant crosslinking. Conversely, cysteine bond(s) may be added to the antibody to improve its stability (particularly where the antibody is an antibody fragment such as an Fv fragment).

[0111] A particularly preferred type of substitutional variant involves substituting one or more hypervariable region residues of a parent antibody (e.g. a humanized or human antibody). Generally, the resulting variant(s) selected for further development will have improved biological properties relative to the parent antibody from which they are generated. A convenient way for generating such substitutional variants involves affinity maturation using phage display. Briefly, several hypervariable region sites (e.g. 6-7 sites) are mutated to generate all possible amino substitutions at each site. The antibody variants thus generated are displayed in a monovalent fashion from filamentous phage particles as fusions to the gene III product of M13 packaged within each particle. The phage-displayed variants are then screened for their biological activity (e.g. binding affinity) as herein disclosed. In order to identify candidate hypervariable region sites for modification, alanine scanning mutagenesis can be performed to identify hypervariable region residues contributing significantly to antigen binding. Alternatively, or additionally, it may be beneficial to analyze a crystal structure of the antigen-antibody complex to identify contact points between the antibody and human CD20. Such contact residues and neighboring residues are candidates for substitution according to the techniques elaborated herein. Once such variants are generated, the panel of variants is subjected to screening as described herein and antibodies with superior properties in one or more relevant assays may be selected for further development.

[0112] Another type of amino acid variant of the antibody alters the original glycosylation pattern of the antibody. By altering is meant deleting one or more carbohydrate moieties found in the antibody, and/or adding one or more glycosylation sites that are not present in the antibody.

[0113] Glycosylation of antibodies is typically either N-linked or O-linked. N-linked refers to the attachment of the carbohydrate moiety to the side chain of an asparagine residue. The tripeptide sequences asparagine-X-serine and asparagine-X-threonine, where X is any amino acid except proline, are the recognition sequences for enzymatic attachment of the carbohydrate moiety to the asparagine side chain. Thus, the presence of either of these tripeptide sequences in a polypeptide creates a potential glycosylation site. O-linked glycosylation refers to the attachment of one of the sugars N-acetylgalactosamine, galactose, or xylose to a hydroxyamino acid, most commonly serine or threonine, although 5-hydroxyproline or 5-hydroxylysine may also be used.

[0114] Addition of glycosylation sites to the antibody is conveniently accomplished by altering the amino acid sequence such that it contains one or more of the above-described tripeptide sequences (for N-linked glycosylation sites). The alteration may also be made by the addition of, or substitution by, one or more serine or threonine residues to the sequence of the original antibody (for O-linked glycosylation sites).

[0115] Nucleic acid molecules encoding amino acid sequence variants of the anti-CD20 antibody are prepared by a variety of methods known in the art. These methods include, but are not limited to, isolation from a natural source (in the case of naturally occurring amino acid sequence variants) or preparation by oligonucleotide-mediated (or site-directed) mutagenesis, PCR mutagenesis, and cassette mutagenesis of an earlier prepared variant or a non-variant version of the anti-CD20 antibody.

[0116] It may be desirable to modify the antibody of the invention with respect to effector function, e.g. so as to enhance

antigen-dependent cell-mediated cytotoxicity (ADCC) and/or complement dependent cytotoxicity (CDC) of the antibody. This may be achieved by introducing one or more amino acid substitutions in an Fc region of the antibody. Alternatively or additionally, cysteine residue(s) may be introduced in the Fc region, thereby allowing interchain disulfide bond formation in this region. The homodimeric antibody thus generated may have improved internalization capability and/or increased complement-mediated cell killing and antibody-dependent cellular cytotoxicity (ADCC). See Caron et al., J. Exp Med. 176:1191-1195 (1992) and Shopes, B. J. Immunol. 148:2918-2922 (1992). Homodimeric antibodies with enhanced anti-tumor activity may also be prepared using heterobifunctional cross-linkers as described in Wolff et al. Cancer Research 53:2560-2565 (1993). Alternatively, an antibody can be engineered which has dual Fc regions and may thereby have enhanced complement mediated lysis and ADCC capabilities. See Stevenson et al. Anti-Cancer Drug Design 3:219-230 (1989).

[0117] To increase the serum half life of the antibody, one may incorporate a salvage receptor binding epitope into the antibody (especially an antibody fragment) as described in U.S. Patent 5,739,277, for example. As used herein, the term "salvage receptor binding epitope" refers to an epitope of the Fc region of an IgG molecule (e.g., IgG₁, IgG₂, IgG₃, or IgG₄) that is responsible for increasing the *in vivo* serum half-life of the IgG molecule.

Other antibody modifications

[0118] Other modifications of the antibody are contemplated herein. For example, the antibody may be linked to one of a variety of nonproteinaceous polymers, e.g., polyethylene glycol, polypropylene glycol, polyoxyalkylenes, or copolymers of polyethylene glycol and polypropylene glycol. The antibody also may be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization (for example, hydroxymethylcellulose or gelatin-microcapsules and poly-(methylmethacrylate) microcapsules, respectively), in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules), or in macroemulsions. Such techniques are disclosed in Remington's Pharmaceutical Sciences, 16th edition, Oslo, A., Ed., (1980).

Screening for antibodies with the desired properties

[0119] Antibodies with certain biological characteristics may be selected as described in the Experimental Examples.

[0120] The growth inhibitory effects of an anti-CD20 antibody of the invention may be assessed by methods known in the art, e.g., using cells which express CD20 either endogenously or following transfection with the CD20 gene. For example, tumor cell lines and CD20-transfected cells may be treated with an anti-CD20 monoclonal antibody of the invention at various concentrations for a few days (e.g., 2-7) days and stained with crystal violet or MTT or analyzed by some other colorimetric assay. Another method of measuring proliferation would be by comparing ³H-thymidine uptake by the cells treated in the presence or absence of an anti-CD20 antibody of the invention. After antibody treatment, the cells are harvested and the amount of radioactivity incorporated into the DNA quantitated in a scintillation counter. Appropriate positive controls include treatment of a selected cell line with a growth inhibitory antibody known to inhibit growth of that cell line.

[0121] To select for antibodies which induce cell death, loss of membrane integrity as indicated by, e.g., propidium iodide (PI), trypan blue or 7AAD uptake may be assessed relative to control. A PI uptake assay can be performed in the absence of complement and immune effector cells. CD20-expressing tumor cells are incubated with medium alone or medium containing of the appropriate monoclonal antibody at e.g., about 10 µg/ml. The cells are incubated for a 3 day time period. Following each treatment, cells are washed and aliquoted into 35 mm strainer-capped 12 x 75 tubes (1ml per tube, 3 tubes per treatment group) for removal of cell clumps. Tubes then receive PI (10 µg/ml). Samples may be analyzed using a FACSCAN™ flow cytometer and FACSCONVERT™ CellQuest software (Becton Dickinson). Those antibodies which induce statistically significant levels of cell death as determined by PI uptake may be selected as cell death-inducing antibodies.

[0122] To screen for antibodies which bind to an epitope on CD20 bound by an antibody of interest, a routine cross-blocking assay such as that described in Antibodies, A Laboratory Manual, Cold Spring Harbor Laboratory, Ed Harlow and David Lane (1988), can be performed. This assay can be used to determine if a test antibody binds the same site or epitope as an anti-CD20 antibody of the invention. Alternatively, or additionally, epitope mapping can be performed by methods known in the art. For example, the antibody sequence can be mutagenized such as by alanine scanning, to identify contact residues. The mutant antibody is initially tested for binding with polyclonal antibody to ensure proper folding. In a different method, peptides corresponding to different regions of CD20 can be used in competition assays with the test antibodies or with a test antibody and an antibody with a characterized or known epitope.

Vectors, Host Cells and Recombinant Methods

[0123] The invention also provides an isolated nucleic acid encoding a humanized CD20 binding antibody, vectors

and host cells comprising the nucleic acid, and recombinant techniques for the production of the antibody.

[0124] For recombinant production of the antibody, the nucleic acid encoding it is isolated and inserted into a replicable vector for further cloning (amplification of the DNA) or for expression. DNA encoding the monoclonal antibody is readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of the antibody). Many vectors are available. The vector components generally include, but are not limited to, one or more of the following: a signal sequence, an origin of replication, one or more marker genes, an enhancer element, a promoter, and a transcription termination sequence.

(i) Signal sequence component

[0125] The CD20 binding antibody of this invention may be produced recombinantly not only directly, but also as a fusion polypeptide with a heterologous polypeptide, which is preferably a signal sequence or other polypeptide having a specific cleavage site at the N-terminus of the mature protein or polypeptide. The heterologous signal sequence selected preferably is one that is recognized and processed (i.e., cleaved by a signal peptidase) by the host cell. For prokaryotic host cells that do not recognize and process the native CD20 binding antibody signal sequence, the signal sequence is substituted by a prokaryotic signal sequence selected, for example, from the group of the alkaline phosphatase, penicillinase, lpp, or heat-stable enterotoxin II leaders. For yeast secretion the native signal sequence may be substituted by, e.g., the yeast invertase leader, α factor leader (including *Saccharomyces* and *Kluyveromyces* α -factor leaders), or acid phosphatase leader, the *C. albicans* glucoamylase leader, or the signal described in WO 90/13646. In mammalian cell expression, mammalian signal sequences as well as viral secretory leaders, for example, the herpes simplex gD signal, are available.

[0126] The DNA for such precursor region is ligated in reading frame to DNA encoding the CD20 binding antibody.

(ii) Origin of replication

[0127] Both expression and cloning vectors contain a nucleic acid sequence that enables the vector to replicate in one or more selected host cells. Generally, in cloning vectors this sequence is one that enables the vector to replicate independently of the host chromosomal DNA, and includes origins of replication or autonomously replicating sequences. Such sequences are well known for a variety of bacteria, yeast, and viruses. The origin of replication from the plasmid pBR322 is suitable for most Gram-negative bacteria, the 2 μ plasmid origin is suitable for yeast, and various viral origins (SV40, polyoma, adenovirus, VSV or BPV) are useful for cloning vectors in mammalian cells. Generally, the origin of replication component is not needed for mammalian expression vectors (the SV40 origin may typically be used only because it contains the early promoter).

(iii) Selection gene component

[0128] Expression and cloning vectors may contain a selection gene, also termed a selectable marker. Typical selection genes encode proteins that (a) confer resistance to antibiotics or other toxins, e.g., ampicillin, neomycin, methotrexate, or tetracycline, (b) complement auxotrophic deficiencies, or (c) supply critical nutrients not available from complex media, e.g., the gene encoding D-alanine racemase for *Bacilli*.

[0129] One example of a selection scheme utilizes a drug to arrest growth of a host cell. Those cells that are successfully transformed with a heterologous gene produce a protein conferring drug resistance and thus survive the selection regimen. Examples of such dominant selection use the drugs neomycin, mycophenolic acid and hygromycin.

[0130] Another example of suitable selectable markers for mammalian cells are those that enable the identification of cells competent to take up the CD20 binding antibody nucleic acid, such as DHFR, thymidine kinase, metallothionein-I and -II, preferably primate metallothionein genes, adenosine deaminase, ornithine decarboxylase, etc.

[0131] For example, cells transformed with the DHFR selection gene are first identified by culturing all of the transformants in a culture medium that contains methotrexate (Mtx), a competitive antagonist of DHFR. An appropriate host cell when wild-type DHFR is employed is the Chinese hamster ovary (CHO) cell line deficient in DHFR activity (e.g., ATCC CRL-9096).

[0132] Alternatively, host cells (particularly wild-type hosts that contain endogenous DHFR) transformed or co-transformed with DNA sequences encoding CD20 binding antibody, wild-type DHFR protein, and another selectable marker such as aminoglycoside 3'-phosphotransferase (APH) can be selected by cell growth in medium containing a selection agent for the selectable marker such as an aminoglycosidic antibiotic, e.g., kanamycin, neomycin, or G418. See U.S. Patent No. 4,965,199.

[0133] A suitable selection gene for use in yeast is the *trp1* gene present in the yeast plasmid YRp7 (Stinchcomb et al., Nature, 282:39 (1979)). The *trp1* gene provides a selection marker for a mutant strain of yeast lacking the ability to grow in tryptophan, for example, ATCC No. 44076 or PEP4-1. Jones, Genetics, 85:12 (1977). The presence of the *trp1*

lesion in the yeast host cell genome then provides an effective environment for detecting transformation by growth in the absence of tryptophan. Similarly, *Leu2*-deficient yeast strains (ATCC 20,622 or 38,626) are complemented by known plasmids bearing the *Leu2* gene.

[0134] In addition, vectors derived from the 1.6 μ m circular plasmid pKD 1 can be used for transformation of *Kluyveromyces* yeasts. Alternatively, an expression system for large-scale production of recombinant calf chymosin was reported for *K. lactis*. Van den Berg, *Bio/Technology*, 8:135 (1990). Stable multi-copy expression vectors for secretion of mature recombinant human serum albumin by industrial strains of *Kluyveromyces* have also been disclosed. Fleer et al., *Bio/Technology*, 9:968-975 (1991).

(iv) Promoter component

[0135] Expression and cloning vectors usually contain a promoter that is recognized by the host organism and is operably linked to the nucleic acid encoding the CD20 binding antibody. Promoters suitable for use with prokaryotic hosts include the *phoA* promoter, β -lactamase and lactose promoter systems, alkaline phosphatase promoter, a tryptophan (*trp*) promoter system, and hybrid promoters such as the *tac* promoter. However, other known bacterial promoters are suitable. Promoters for use in bacterial systems also will contain a Shine-Dalgarno (S.D.) sequence operably linked to the DNA encoding the CD20 binding antibody.

[0136] Promoter sequences are known for eukaryotes. Virtually all eukaryotic genes have an AT-rich region located approximately 25 to 30 bases upstream from the site where transcription is initiated. Another sequence found 70 to 80 bases upstream from the start of transcription of many genes is a CNCAAT region where N may be any nucleotide. At the 3' end of most eukaryotic genes is an AATAAA sequence that may be the signal for addition of the poly A tail to the 3' end of the coding sequence. All of these sequences are suitably inserted into eukaryotic expression vectors.

[0137] Examples of suitable promoter sequences for use with yeast hosts include the promoters for 3-phosphoglycerate kinase or other glycolytic enzymes, such as enolase, glyceraldehyde-3-phosphate dehydrogenase, hexokinase, pyruvate decarboxylase, phosphofructokinase, glucose-6-phosphate isomerase, 3-phosphoglycerate mutase, pyruvate kinase, triosephosphate isomerase, phosphoglucose isomerase, and glucokinase.

[0138] Other yeast promoters, which are inducible promoters having the additional advantage of transcription controlled by growth conditions, are the promoter regions for alcohol dehydrogenase 2, isocytichrome C, acid phosphatase, degradative enzymes associated with nitrogen metabolism, metallothionein, glyceraldehyde-3-phosphate dehydrogenase, and enzymes responsible for maltose and galactose utilization. Suitable vectors and promoters for use in yeast expression are further described in EP 73,657. Yeast enhancers also are advantageously used with yeast promoters.

[0139] CD20 binding antibody transcription from vectors in mammalian host cells is controlled, for example, by promoters obtained from the genomes of viruses such as polyoma virus, fowlpox virus, adenovirus (such as Adenovirus 2), bovine papilloma virus, avian sarcoma virus, cytomegalovirus, a retrovirus, hepatitis-B virus and most preferably Simian Virus 40 (SV40), from heterologous mammalian promoters, e.g., the actin promoter or an immunoglobulin promoter, from heat-shock promoters, provided such promoters are compatible with the host cell systems.

[0140] The early and late promoters of the SV40 virus are conveniently obtained as an SV40 restriction fragment that also contains the SV40 viral origin of replication. The immediate early promoter of the human cytomegalovirus is conveniently obtained as a HindIII E restriction fragment. A system for expressing DNA in mammalian hosts using the bovine papilloma virus as a vector is disclosed in U.S. Patent No. 4,419,446. A modification of this system is described in U.S. Patent No. 4,601,978. See also Reyes et al., *Nature* 297:598-601 (1982) on expression of human β -interferon cDNA in mouse cells under the control of a thymidine kinase promoter from herpes simplex virus. Alternatively, the Rous Sarcoma Virus long terminal repeat can be used as the promoter.

(v) Enhancer element component

[0141] Transcription of a DNA encoding the CD20 binding antibody of this invention by higher eukaryotes is often increased by inserting an enhancer sequence into the vector. Many enhancer sequences are now known from mammalian genes (globin, elastase, albumin, α -fetoprotein, and insulin). Typically, however, one will use an enhancer from a eukaryotic cell virus. Examples include the SV40 enhancer on the late side of the replication origin (bp 100-270), the cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin, and adenovirus enhancers. See also Yaniv, *Nature* 297:17-18 (1982) on enhancing elements for activation of eukaryotic promoters. The enhancer may be spliced into the vector at a position 5' or 3' to the CD20 binding antibody-encoding sequence, but is preferably located at a site 5' from the promoter.

(vi) Transcription termination component

[0142] Expression vectors used in eukaryotic host cells (yeast, fungi, insect, plant, animal, human, or nucleated cells

from other multicellular organisms) will also contain sequences necessary for the termination of transcription and for stabilizing the mRNA. Such sequences are commonly available from the 5' and, occasionally 3', untranslated regions of eukaryotic or viral DNAs or cDNAs. These regions contain nucleotide segments transcribed as polyadenylated fragments in the untranslated portion of the mRNA encoding CD20 binding antibody. One useful transcription termination component is the bovine growth hormone polyadenylation region. See WO94/11026 and the expression vector disclosed therein.

(vii) Selection and transformation of host cells

[0143] Suitable host cells for cloning or expressing the DNA in the vectors herein are the prokaryote, yeast, or higher eukaryote cells described above. Suitable prokaryotes for this purpose include eubacteria, such as Gram-negative or Gram-positive organisms, for example, Enterobacteriaceae such as *Escherichia*, e.g., *E. coli*, *Enterobacter*, *Erwinia*, *Klebsiella*, *Proteus*, *Salmonella*, e.g., *Salmonella typhimurium*, *Serratia*, e.g., *Serratia marcescans*, and *Shigella*, as well as *Bacilli* such as *B. subtilis* and *B. licheniformis* (e.g., *B. licheniformis* 41P disclosed in DD 266,710 published 12 April 1989), *Pseudomonas* such as *P. aeruginosa*, and *Streptomyces*. One preferred *E. coli* cloning host is *E. coli* 294 (ATCC 31,446), although other strains such as *E. coli* B, *E. coli* X1776 (ATCC 31,537), and *E. coli* W3110 (ATCC 27,325) are suitable. These examples are illustrative rather than limiting.

[0144] Full length antibody, antibody fragments, and antibody fusion proteins can be produced in bacteria, in particular when glycosylation and Fc effector function are not needed, such as when the therapeutic antibody is conjugated to a cytotoxic agent (e.g., a toxin) and the immunoconjugate by itself shows effectiveness in tumor cell destruction. Full length antibodies have greater half life in circulation. Production in *E. coli* is faster and more cost efficient. For expression of antibody fragments and polypeptides in bacteria, see, e.g., U.S. 5,648,237 (Carter et. al.), U.S. 5,789,199 (Joly et al.), and U.S. 5,840,523 (Simmons et al.) which describes translation initiation region (TIR) and signal sequences for optimizing expression and secretion, these patents incorporated herein by reference. After expression, the antibody is isolated from the *E. coli* cell paste in a soluble fraction and can be purified through, e.g., a protein A or G column depending on the isotype. Final purification can be carried out similar to the process for purifying antibody expressed e.g., in CHO cells.

[0145] In addition to prokaryotes, eukaryotic microbes such as filamentous fungi or yeast are suitable cloning or expression hosts for CD20 binding antibody-encoding vectors. *Saccharomyces cerevisiae*, or common baker's yeast, is the most commonly used among lower eukaryotic host microorganisms. However, a number of other genera, species, and strains are commonly available and useful herein, such as *Schizosaccharomyces pombe*; *Kluyveromyces* hosts such as, e.g., *K. lactis*, *K. fragilis* (ATCC 12,424), *K. bulgaricus* (ATCC 16,045), *K. wickerhamii* (ATCC 24,178), *K. waltii* (ATCC 56,500), *K. drosophilae* (ATCC 36,906), *K. thermotolerans*, and *K. marxianus*; *Yarrowia* (EP 402,226); *Pichia pastoris* (EP 183,070); *Candida*; *Trichoderma reesia* (EP 244,234); *Neurospora crassa*; *Schwanniomyces* such as *Schwanniomyces occidentalis*; and filamentous fungi such as, e.g., *Neurospora*, *Penicillium*, *Tolypocladium*, and *Aspergillus* hosts such as *A. nidulans* and *A. niger*.

[0146] Suitable host cells for the expression of glycosylated CD20 binding antibody are derived from multicellular organisms. Examples of invertebrate cells include plant and insect cells. Numerous baculoviral strains and variants and corresponding permissive insect host cells from hosts such as *Spodoptera frugiperda* (caterpillar), *Aedes aegypti* (mosquito), *Aedes albopictus* (mosquito), *Drosophila melanogaster* (fruitfly), and *Bombyx mori* have been identified. A variety of viral strains for transfection are publicly available, e.g., the L-1 variant of *Autographa californica* NPV and the Bm-5 strain of *Bombyx mori* NPV, and such viruses may be used as the virus herein according to the present invention, particularly for transfection of *Spodoptera frugiperda* cells.

[0147] Plant cell cultures of cotton, corn, potato, soybean, petunia, tomato, and tobacco can also be utilized as hosts.

[0148] However, interest has been greatest in vertebrate cells, and propagation of vertebrate cells in culture (tissue culture) has become a routine procedure. Examples of useful mammalian host cell lines are monkey kidney CV1 line transformed by SV40 (COS-7, ATCC CRL 1651); human embryonic kidney line (293 or 293 cells subcloned for growth in suspension culture, Graham et al., J. Gen Virol. 36:59 (1977)); baby hamster kidney cells (BHK, ATCC CCL 10); Chinese hamster ovary cells/DHFR (CHO, Urlaub et al., Proc. Natl. Acad. Sci. USA 77:4216 (1980)); mouse sertoli cells (TM4, Mather, Biol. Reprod. 23:243-251 (1980)); monkey kidney cells (CV1 ATCC CCL 70); African green monkey kidney cells (VERO-76, ATCC CRL-1587); human cervical carcinoma cells (HELA, ATCC CCL 2); canine kidney cells (MDCK, ATCC CCL 34); buffalo rat liver cells (BRL 3A, ATCC CRL 1442); human lung cells (W138, ATCC CCL 75); human liver cells (Hep G2, HB 8065); mouse mammary tumor (MMT 060562, ATCC CCL51); TRI cells (Mather et al., Annals N.Y. Acad. Sci. 383:44-68 (1982)); MRC 5 cells; FS4 cells; and a human hepatoma line (Hep G2).

[0149] Host cells are transformed with the above-described expression or cloning vectors for CD20 binding antibody production and cultured in conventional nutrient media modified as appropriate for inducing promoters, selecting transformants, or amplifying the genes encoding the desired sequences.

(viii) Culturing the host cells

[0150] The host cells used to produce the CD20 binding antibody of this invention maybe cultured in a variety of media. Commercially available media such as Ham's F10 (Sigma), Minimal Essential Medium ((MEM), (Sigma), RPMI-1640 (Sigma), and Dulbecco's Modified Eagle's Medium ((DMEM), Sigma) are suitable for culturing the host cells. In addition, any of the media described in Ham et al., Meth. Enz. 58:44 (1979), Barnes et al., Anal. Biochem. 102:255 (1980), U.S. Pat. Nos. 4,767,704; 4,657,866; 4,927,762; 4,560,655; or 5,122,469; WO 90/03430; WO 87/00195; or U.S. Patent Re. 30,985 may be used as culture media for the host cells. Any of these media may be supplemented as necessary with hormones and/or other growth factors (such as insulin, transferrin, or epidermal growth factor), salts (such as sodium chloride, calcium, magnesium, and phosphate), buffers (such as HEPES), nucleotides (such as adenosine and thymidine), antibiotics (such as GENTAMYCIN™ drug), trace elements (defined as inorganic compounds usually present at final concentrations in the micromolar range), and glucose or an equivalent energy source. Any other necessary supplements may also be included at appropriate concentrations that would be known to those skilled in the art. The culture conditions, such as temperature, pH, and the like, are those previously used with the host cell selected for expression, and will be apparent to the ordinarily skilled artisan.

(ix) Purification of antibody

[0151] When using recombinant techniques, the antibody can be produced intracellularly, in the periplasmic space, or directly secreted into the medium. If the antibody is produced intracellularly, as a first step, the particulate debris, either host cells or lysed fragments, are removed, for example, by centrifugation or ultrafiltration. Carter et al., Bio/Technology 10:163-167 (1992) describe a procedure for isolating antibodies which are secreted to the periplasmic space of *E. coli*. Briefly, cell paste is thawed in the presence of sodium acetate (pH 3.5), EDTA, and phenylmethylsulfonylfluoride (PMSF) over about 30 min. Cell debris can be removed by centrifugation. Where the antibody is secreted into the medium, supernatants from such expression systems are generally first concentrated using a commercially available protein concentration filter, for example, an Amicon or Millipore Pellicon ultrafiltration unit. A protease inhibitor such as PMSF may be included in any of the foregoing steps to inhibit proteolysis and antibiotics may be included to prevent the growth of adventitious contaminants.

[0152] The antibody composition prepared from the cells can be purified using, for example, hydroxylapatite chromatography, gel electrophoresis, dialysis, and affinity chromatography, with affinity chromatography being the preferred purification technique. The suitability of protein A as an affinity ligand depends on the species and isotype of any immunoglobulin Fc domain that is present in the antibody. Protein A can be used to purify antibodies that are based on human $\gamma 1$, $\gamma 2$, or $\gamma 4$ heavy chains (Lindmark et al., J. Immunol. Meth. 62:1-13 (1983)). Protein G is recommended for all mouse isotypes and for human $\gamma 3$ (Guss et al., EMBO J. 5:15671575 (1986)). The matrix to which the affinity ligand is attached is most often agarose, but other matrices are available. Mechanically stable matrices such as controlled pore glass or poly(styrenedivinyl)benzene allow for faster flow rates and shorter processing times than can be achieved with agarose. Where the antibody comprises a C_H3 domain, the Bakerbond ABX™ resin (J. T. Baker, Phillipsburg, NJ) is useful for purification. Other techniques for protein purification such as fractionation on an ion-exchange column, ethanol precipitation, Reverse Phase HPLC, chromatography on silica, chromatography on heparin SEPHAROSE™ chromatography on an anion or cation exchange resin (such as a polyaspartic acid column), chromatofocusing, SDS-PAGE, and ammonium sulfate precipitation are also available depending on the antibody to be recovered.

[0153] Following any preliminary purification step(s), the mixture comprising the antibody of interest and contaminants may be subjected to low pH hydrophobic interaction chromatography using an elution buffer at a pH between about 2.5-4.5, preferably performed at low salt concentrations (e.g., from about 0-0.25M salt).

Antibody conjugates

[0154] The antibody may be conjugated to a cytotoxic agent such as a toxin or a radioactive isotope. In certain embodiments, the toxin is calicheamicin, a maytansinoid, a dolastatin, auristatin E and analogs or derivatives thereof, are preferable.

[0155] Preferred drugs/toxins include DNA damaging agents, inhibitors of microtubule polymerization or depolymerization and antimetabolites. Preferred classes of cytotoxic agents include, for example, the enzyme inhibitors such as dihydrofolate reductase inhibitors, and thymidylate synthase inhibitors, DNA intercalators, DNA cleavers, topoisomerase inhibitors, the anthracycline family of drugs, the vinca drugs, the mitomycins, the bleomycins, the cytotoxic nucleosides, the pteridine family of drugs, diynenes, the podophyllotoxins and differentiation inducers. Particularly useful members of those classes include, for example, methotrexate, methopterin, dichloromethotrexate, 5-fluorouracil, 6-mercaptopurine, cytosine arabinoside, melphalan, leurosine, leurosideine, actinomycin, daunorubicin, doxorubicin, N-(5,5-diacetoxypentyl)doxorubicin, morpholino-doxorubicin, 1-(2-chloroethyl)-1,2-dimethanesulfonyl hydrazide, N⁸-acetyl spermidine,

aminopterin methopterin, esperamicin, mitomycin C, mitomycin A, actinomycin, bleomycin, carminomycin, aminopterin, tallysomycin, podophyllotoxin and podophyllotoxin derivatives such as etoposide or etoposide phosphate, vinblastine, vincristine, vindesine, taxol, taxotere, retinoic acid, butyric acid, N⁸-acetyl spermidine, camptothecin, calicheamicin, bryostatins, cephalostatins, ansamitocin, actosin, maytansinoids such as DM-1, maytansine, maytansinol, N-desmethyl-4,5-desepoxymaytansinol, C-19-dechloromaytansinol, C-20-hydroxymaytansinol, C-20-demethoxymaytansinol, C-9-SH maytansinol, C-14-alkoxymethylmaytansinol, C-14-hydroxy or acetyloxymethylmaytansinol, C-15-hydroxy/acetyloxy-maytansinol, C-15-methoxymaytansinol, C-18-N-demethylmaytansinol and 4,5-deoxymaytansinol, auristatins such as auristatin E, M, PHE and PE; dolostatins such as dolostatin A, dolostatin B, dolostatin C, dolostatin D, dolostatin E (20-epi and 11-epi), dolostatin G, dolostatin H, dolostatin I, dolostatin 1, dolostatin 2, dolostatin 3, dolostatin 4, dolostatin 5, dolostatin 6, dolostatin 7, dolostatin 8, dolostatin 9, dolostatin 10, deo-dolostatin 10, dolostatin 11, dolostatin 12, dolostatin 13, dolostatin 14, dolostatin 15, dolostatin 16, dolostatin 17, and dolostatin 18; cephalostatins such as cephalostatin 1, cephalostatin 2, cephalostatin 3, cephalostatin 4, cephalostatin 5, cephalostatin 6, cephalostatin 7, 25'-epi-cephalostatin 7, 20-epi-cephalostatin 7, cephalostatin 8, cephalostatin 9, cephalostatin 10, cephalostatin 11, cephalostatin 12, cephalostatin 13, cephalostatin 14, cephalostatin 15, cephalostatin 16, cephalostatin 17, cephalostatin 18, and cephalostatin 19..

[0156] Maytansinoids are mitototic inhibitors which act by inhibiting tubulin polymerization. Maytansine was first isolated from the east African shrub *Maytenus serrata* (U.S. Patent No. 3,896,111). Subsequently, it was discovered that certain microbes also produce maytansinoids, such as maytansinol and C-3 maytansinol esters (U.S. Patent No. 4,151,042). Synthetic maytansinol and derivatives and analogues thereof are disclosed, for example, in U.S. Patent Nos. 4,137,230; 4,248,870; 4,256,746; 4,260,608; 4,265,814; 4,294,757; 4,307,016; 4,308,268; 4,308,269; 4,309,428; 4,313,946; 4,315,929; 4,317,821; 4,322,348; 4,331,598; 4,361,650; 4,364,866; 4,424,219; 4,450,254; 4,362,663; and 4,371,533, the disclosures of which are hereby expressly incorporated by reference.

[0157] Maytansine and maytansinoids have been conjugated to antibodies specifically binding to tumor cell antigens. Immunoconjugates containing maytansinoids and their therapeutic use are disclosed, for example, in U.S. Patent Nos. 5,208,020, 5,416,064 and European Patent EP 0 425 235 B1, the disclosures of which are hereby expressly incorporated by reference. Liu et al., Proc. Natl. Acad. Sci. USA 93:8618-8623 (1996) described immunoconjugates comprising a maytansinoid designated DM1 linked to the monoclonal antibody C242 directed against human colorectal cancer. The conjugate was found to be highly cytotoxic towards cultured colon cancer cells, and showed antitumor activity in an *in vivo* tumor growth assay. Chari et al. Cancer Research 52:127-131 (1992) describe immunoconjugates in which a maytansinoid was conjugated via a disulfide linker to the murine antibody A7 binding to an antigen on human colon cancer cell lines, or to another murine monoclonal antibody TA.1 that binds the *HER-2/neu* oncogene.

[0158] There are many linking groups known in the art for making antibody-maytansinoid conjugates, including, for example, those disclosed in U.S. Patent No. 5,208,020 or EP Patent 0 425 235 B1, and Chari et al. Cancer Research 52: 127-131 (1992). The linking groups include disulfide groups, thioether groups, acid labile groups, photolabile groups, peptidase labile groups, or esterase labile groups, as disclosed in the above-identified patents, disulfide and thioether groups being preferred.

[0159] Conjugates of the antibody and maytansinoid may be made using a variety of bifunctional protein coupling agents such as N-succinimidyl-3-(2-pyridyldithio) propionate (SPDP), succinimidyl-4-(N-maleimidomethyl) cyclohexanecarboxylate, iminothiolane (IT), bifunctional derivatives of imidoesters (such as dimethyl adipimidate HCL), active esters (such as disuccinimidyl suberate), aldehydes (such as glutaraldehyde), bis-azido compounds (such as bis (p-azidobenzoyl) hexanediamine), bis-diazonium derivatives (such as bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (such as toluene 2,6-diisocyanate), and bis-active fluorine compounds (such as 1,5-difluoro-2,4-dinitrobenzene). Particularly preferred coupling agents include N-succinimidyl-3-(2-pyridyldithio) propionate (SPDP) (Carlsson et al., Biochem. J. 173:723-737 [1978]) and N-succinimidyl-4-(2-pyridyldithio)pentanoate (SPP) to provide for a disulfide linkage.

[0160] The linker may be attached to the maytansinoid molecule at various positions, depending on the type of the link. For example, an ester linkage may be formed by reaction with a hydroxyl group using conventional coupling techniques. The reaction may occur at the C-3 position having a hydroxyl group, the C-14 position modified with hydroxymethyl, the C-15 position modified with a hydroxyl group, and the C-20 position having a hydroxyl group. In a preferred embodiment, the linkage is formed at the C-3 position of maytansinol or a maytansinol analogue.

Calicheamicin

[0161] Another immunoconjugate of interest comprises an CD20 binding antibody conjugated to one or more calicheamicin molecules. The calicheamicin family of antibiotics are capable of producing doublestranded DNA breaks at sub-picomolar concentrations. For the preparation of conjugates of the calicheamicin family, see U.S. patents 5,712,374, 5,714,586, 5,739,116, 5,767,285, 5,770,701, 5,770,710, 5,773,001, 5,877,296 (all to American Cyanamid Company). Structural analogues of calicheamicin which may be used include, but are not limited to, γ_1^I , α_2^I , α_3^I , N-acetyl- γ_1^I , PSAG and θ_1^I (Hinman et al. Cancer Research 53: 3336-3342 (1993), Lode et al. Cancer Research 58: 2925-2928 (1998) and

the aforementioned U.S. patents to American Cyanamid). Another anti-tumor drug that the antibody can be conjugated is QFA which is an antifolate. Both calicheamicin and QFA have intracellular sites of action and do not readily cross the plasma membrane. Therefore, cellular uptake of these agents through antibody mediated internalization greatly enhances their cytotoxic effects.

Radioactive isotopes

[0162] For selective destruction of the tumor, the antibody may comprise a highly radioactive atom. A variety of radioactive isotopes are available for the production of radioconjugated anti-CD20 antibodies. Examples include At²¹¹, I¹³¹, I¹²⁵, Y⁹⁰, Re¹⁸⁶, Re¹⁸⁸, Sm¹⁵³, Bi²¹², P³², Pb²¹² and radioactive isotopes of Lu. When the conjugate is used for diagnosis, it may comprise a radioactive atom for scintigraphic studies, for example tc^{99m} or I¹²³, or a spin label for nuclear magnetic resonance (NMR) imaging (also known as magnetic resonance imaging, mri), such as iodine-123 again, iodine-131, indium-111, fluorine-19, carbon-13, nitrogen-15, oxygen-17, gadolinium, manganese or iron.

[0163] The radio- or other labels may be incorporated in the conjugate in known ways. For example, the peptide may be biosynthesized or may be synthesized by chemical amino acid synthesis using suitable amino acid precursors involving, for example, fluorine-19 in place of hydrogen. Labels such as tc^{99m} or I¹²³, Re¹⁸⁶, Re¹⁸⁸ and In¹¹¹ can be attached via a cysteine residue in the peptide. Yttrium-90 can be attached via a lysine residue. The IODOGEN method (Fraker et al (1978) Biochem. Biophys. Res. Commun. 80: 49-57 can be used to incorporate iodine-123. "Monoclonal Antibodies in Immunoscintigraphy" (Chatal, CRC Press 1989) describes other methods in detail.

[0164] Conjugates of the antibody and cytotoxic agent may be made using a variety of bifunctional protein coupling agents such as N-succinimidyl-3-(2-pyridyldithio) propionate (SPDP), succinimidyl-4-(N-maleimidomethyl) cyclohexane-1-carboxylate, iminothiolane (IT), bifunctional derivatives of imidoesters (such as dimethyl adipimidate HCL), active esters (such as disuccinimidyl suberate), aldehydes (such as glutaraldehyde), bis-azido compounds (such as bis (p-azidobenzoyl) hexanediamine), bis-diazonium derivatives (such as bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (such as tolyene 2,6-diisocyanate), and bis-active fluorine compounds (such as 1,5-difluoro-2,4-dinitrobenzene). For example, a ricin immunotoxin can be prepared as described in Vitetta et al. Science 238: 1098 (1987). Carbon-14-labeled 1-isothiocyanatobenzyl-3-methyldiethylene triaminepentaacetic acid (MX-DTPA) is an exemplary chelating agent for conjugation of radionucleotide to the antibody. See WO94/11026. The linker may be a "cleavable linker" facilitating release of the cytotoxic drug in the cell. For example, an acid-labile linker, peptidase-sensitive linker, photolabile linker, dimethyl linker or disulfide-containing linker (Chari et al. Cancer Research 52: 127-131 (1992); U.S. Patent No. 5,208,020) may be used.

Therapeutic Uses of the CD20 binding Antibodies

[0165] The CD20 binding antibodies of the invention are useful to treat a number of malignant and non-malignant diseases including autoimmune diseases and related conditions, and CD20 positive cancers including B cell lymphomas and leukemias. Stem cells (B-cell progenitors) in bone marrow lack the CD20 antigen, allowing healthy B-cells to regenerate after treatment and return to normal levels within several months.

[0166] Autoimmune diseases or autoimmune related conditions include arthritis (rheumatoid arthritis, juvenile rheumatoid arthritis, osteoarthritis, psoriatic arthritis), psoriasis, dermatitis including atopic dermatitis; chronic autoimmune urticaria, polymyositis/dermatomyositis, toxic epidermal necrolysis, systemic scleroderma and sclerosis, responses associated with inflammatory bowel disease (IBD) (Crohn's disease, ulcerative colitis), respiratory distress syndrome, adult respiratory distress syndrome (ARDS), meningitis, allergic rhinitis, encephalitis, uveitis, colitis, glomerulonephritis, allergic conditions, eczema, asthma, conditions involving infiltration of T cells and chronic inflammatory responses, atherosclerosis, autoimmune myocarditis, leukocyte adhesion deficiency, systemic lupus erythematosus (SLE), lupus (including nephritis, non-renal, discoid, alopecia), juvenile onset diabetes, multiple sclerosis, allergic encephalomyelitis, immune responses associated with acute and delayed hypersensitivity mediated by cytokines and T-lymphocytes, tuberculosis, sarcoidosis, granulomatosis including Wegener's granulomatosis, agranulocytosis, vasculitis (including ANCA), aplastic anemia, Coombs positive anemia, Diamond Blackfan anemia, immune hemolytic anemia including autoimmune hemolytic anemia (AIHA), pernicious anemia, pure red cell aplasia (PRCA), Factor VIII deficiency, hemophilia A, autoimmune neutropenia, pancytopenia, leukopenia, diseases involving leukocyte diapedesis, CNS inflammatory disorders, multiple organ injury syndrome, myasthenia gravis, antigen-antibody complex mediated diseases, anti-glomerular basement membrane disease, anti-phospholipid antibody syndrome, allergic neuritis, Bechet disease, Castelman's syndrome, Goodpasture's Syndrome, Lambert-Eaton Myasthenic Syndrome, Reynaud's syndrome, Sjorgen's syndrome, Stevens-Johnson syndrome, solid organ transplant rejection (including pretreatment for high panel reactive antibody titers, IgA deposit in tissues, etc), graft versus host disease (GVHD), pemphigoid bullous, pemphigus (all including vulgaris, foliatis), autoimmune polyendocrinopathies, Reiter's disease, stiff-man syndrome, giant cell arteritis, immune complex nephritis, IgA nephropathy, IgM polyneuropathies or IgM mediated neuropathy, idiopathic thrombocytopenic purpura (ITP), throm-

botic thrombocytopenic purpura (TTP), autoimmune thrombocytopenia, autoimmune disease of the testis and ovary including autoimmune orchitis and oophoritis, primary hypothyroidism; autoimmune endocrine diseases including autoimmune thyroiditis, chronic thyroiditis (Hashimoto's Thyroiditis), subacute thyroiditis, idiopathic hypothyroidism, Addison's disease, Grave's disease, autoimmune polyglandular syndromes (or polyglandular endocrinopathy syndromes), Type I diabetes also referred to as insulindependent diabetes mellitus (IDDM) and Sheehan's syndrome; autoimmune hepatitis, Lymphoid interstitial pneumonitis (HIV), bronchiolitis obliterans (non-transplant) vs NSIP, Guillain-Barre' Syndrome, Large Vessel Vasculitis (including Polymyalgia Rheumatica and Giant Cell (Takayasu's) Arteritis), Medium Vessel Vasculitis (including Kawasaki's Disease and Polyarteritis Nodosa), ankylosing spondylitis, Berger's Disease (IgA nephropathy), Rapidly Progressive Glomerulonephritis, Primary biliary cirrhosis, Celiac sprue (gluten enteropathy), Cryoglobulinemia, ALS, coronary artery disease.

[0167] CD20 positive cancers are those comprising abnormal proliferation of cells that express CD20 on the cell surface. The CD20 positive B cell neoplasms include CD20-positive Hodgkin's disease including lymphocyte predominant Hodgkin's disease (LPHD); non-Hodgkin's lymphoma (NHL); follicular center cell (FCC) lymphomas; acute lymphocytic leukemia (ALL); chronic lymphocytic leukemia (CLL); Hairy cell leukemia. The non-Hodgkins lymphoma include low grade/follicular non-Hodgkin's lymphoma (NHL), small lymphocytic lymphoma (SLL), intermediate grade/follicular NHL, intermediate grade diffuse NHL, high grade immunoblastic NHL, high grade lymphoblastic NHL, high grade small non-cleaved cell NHL, bulky disease NHL, plasmacytoid lymphocytic lymphoma, mantle cell lymphoma, AIDS-related lymphoma and Waldenstrom's macroglobulinemia. Treatment of relapses of these cancers are also contemplated. LPHD is a type of Hodgkin's disease that tends to relapse frequently despite radiation or chemotherapy treatment and is characterized by CD20-positive malignant cells. CLL is one of four major types of leukemia. A cancer of mature B-cells called lymphocytes, CLL is manifested by progressive accumulation of cells in blood, bone marrow and lymphatic tissues.

[0168] In specific embodiments, the humanized CD20 binding antibodies and functional fragments thereof are used to treat non-Hodgkin's lymphoma (NHL), lymphocyte predominant Hodgkin's disease (LPHD), small lymphocytic lymphoma (SLL), chronic lymphocytic leukemia, rheumatoid arthritis and juvenile rheumatoid arthritis, systemic lupus erythematosus (SLE) including lupus nephritis, Wegener's disease, inflammatory bowel disease, idiopathic thrombocytopenic purpura (ITP), thrombotic thrombocytopenic purpura (TTP), autoimmune thrombocytopenia, multiple sclerosis, psoriasis, IgA nephropathy, IgM polyneuropathies, myasthenia gravis, vasculitis, diabetes mellitus, Reynaud's syndrome, Sjorgen's syndrome and glomerulonephritis.

[0169] The humanized CD20 binding antibodies or functional fragments thereof are useful as a single-agent treatment in, e.g., for relapsed or refractory low-grade or follicular, CD20-positive, B-cell NHL, or can be administered to patients in conjunction with other drugs in a multi drug regimen.

[0170] Indolent lymphoma is a slow-growing, incurable disease in which the average patient survives between six and 10 years following numerous periods of remission and relapse. In one embodiment, the humanized CD20 binding antibodies or functional fragments thereof are used to treat indolent NHL.

[0171] The parameters for assessing efficacy or success of treatment of the neoplasm will be known to the physician of skill in the appropriate disease. Generally, the physician of skill will look for reduction in the signs and symptoms of the specific disease. Parameters can include median time to disease progression, time in remission, stable disease.

[0172] The following references describe lymphomas and CLL, their diagnoses, treatment and standard medical procedures for measuring treatment efficacy.

[0173] The following references describe lymphomas and CLL, their diagnoses, treatment and standard medical procedures for measuring treatment efficacy. Canellos GP, Lister, TA, Sklar JL: The Lymphomas. W.B.Saunders Company, Philadelphia, 1998; van Besien K and Cabanillas, F: Clinical Manifestations, Staging and Treatment of Non-Hodgkin's Lymphoma, Chap. 70, pp 1293-1338, in: Hematology, Basic Principles and Practice, 3rd ed. Hoffman et al. (editors). Churchill Livingstone, Philadelphia, 2000; and Rai, K and Patel, D: Chronic Lymphocytic Leukemia, Chap. 72, pp 1350-1362, in: Hematology, Basic Principles and Practice, 3rd ed. Hoffman et al. (editors). Churchill Livingstone, Philadelphia, 2000.

[0174] The parameters for assessing efficacy or success of treatment of an autoimmune or autoimmune related disease will be known to the physician of skill in the appropriate disease. Generally, the physician of skill will look for reduction in the signs and symptoms of the specific disease. The following are by way of examples.

[0175] In one embodiment, the antibodies of the invention are useful to treat rheumatoid arthritis. RA is characterized by inflammation of multiple joints, cartilage loss and bone erosion that leads to joint destruction and ultimately reduced joint function. Additionally, since RA is a systemic disease, it can have effects in other tissues such as the lungs, eyes and bone marrow. Fewer than 50 percent of patients who have had RA for more than 10 years can continue to work or function normally on a day-to-day basis.

[0176] The antibodies can be used as first-line therapy in patients with early RA (i.e., methotrexate (MTX) naive) and as monotherapy, or in combination with, e.g., MTX or cyclophosphamide. Or, the antibodies can be used in treatment as second-line therapy for patients who were DMARD and/or MTX refractory, and as monotherapy or in combination with, e.g., MTX. The humanized CD20 binding antibodies are useful to prevent and control joint damage, delay structural

damage, decrease pain associated with inflammation in RA, and generally reduce the signs and symptoms in moderate to severe RA. The RA patient can be treated with the humanized CD20 antibody prior to, after or together with treatment with other drugs used in treating RA (see combination therapy below). In one embodiment, patients who had previously failed disease-modifying antirheumatic drugs and/or had an inadequate response to methotrexate alone are treated with

a humanized CD20 binding antibody of the invention. In one embodiment of this treatment, the patients are in a 17-day treatment regimen receiving humanized CD20 binding antibody alone (1g iv infusions on days 1 and 15); CD20 binding antibody plus cyclophosphamide (750mg iv infusion days 3 and 17); or CD20 binding antibody plus methotrexate.

[0177] One method of evaluating treatment efficacy in RA is based on American College of Rheumatology (ACR) criteria, which measures the percentage of improvement in tender and swollen joints, among other things. The RA patient can be scored at for example, ACR 20 (20 percent improvement) compared with no antibody treatment (e.g., baseline before treatment) or treatment with placebo. Other ways of evaluating the efficacy of antibody treatment include X-ray scoring such as the Sharp X-ray score used to score structural damage such as bone erosion and joint space narrowing. Patients can also be evaluated for the prevention of or improvement in disability based on Health Assessment Questionnaire [HAQ] score, AIMS score, SF-36 at time periods during or after treatment. The ACR 20 criteria may include 20% improvement in both tender (painful) joint count and swollen joint count plus a 20% improvement in at least 3 of 5 additional measures:

1. patient's pain assessment by visual analog scale (VAS),
2. patient's global assessment of disease activity (VAS),
3. physician's global assessment of disease activity (VAS),
4. patient's self-assessed disability measured by the Health Assessment Questionnaire, and
5. acute phase reactants, CRP or ESR.

The ACR 50 and 70 are defined analogously. Preferably, the patient is administered an amount of a CD20 binding antibody of the invention effective to achieve at least a score of ACR 20, preferably at least ACR 30, more preferably at least ACR50, even more preferably at least ACR70, most preferably at least ACR 75 and higher.

[0178] Psoriatic arthritis has unique and distinct radiographic features. For psoriatic arthritis, joint erosion and joint space narrowing can be evaluated by the Sharp score as well. The humanized CD20 binding antibodies of the invention can be used to prevent the joint damage as well as reduce disease signs and symptoms of the disorder.

[0179] Yet another aspect of the invention is a method of treating Lupus or SLE by administering to the patient suffering from SLE, a therapeutically effective amount of a humanized CD20 binding antibody of the invention. SLEDAI scores provide a numerical quantitation of disease activity. The SLEDAI is a weighted index of 24 clinical and laboratory parameters known to correlate with disease activity, with a numerical range of 0-103. see Bryan Gescuk & John Davis, "Novel therapeutic agent for systemic lupus erythematosus" in Current Opinion in Rheumatology 2002, 14:515-521.

Antibodies to double-stranded DNA are believed to cause renal flares and other manifestations of lupus. Patients undergoing antibody treatment can be monitored for time to renal flare, which is defined as a significant, reproducible increase in serum creatinine, urine protein or blood in the urine. Alternatively or in addition, patients can be monitored for levels of antinuclear antibodies and antibodies to double-stranded DNA. Treatments for SLE include high-dose corticosteroids and/or cyclophosphamide (HDCC).

[0180] Spondyloarthropathies are a group of disorders of the joints, including ankylosing spondylitis, psoriatic arthritis and Crohn's disease. Treatment success can be determined by validated patient and physician global assessment measuring tools.

[0181] Various medications are used to treat psoriasis; treatment differs directly in relation to disease severity. Patients with a more mild form of psoriasis typically utilize topical treatments, such as topical steroids, anthralin, calcipotriene, clobetasol, and tazarotene, to manage the disease while patients with moderate and severe psoriasis are more likely to employ systemic (methotrexate, retinoids, cyclosporine, PUVA and UVB) therapies. Tars are also used. These therapies have a combination of safety concerns, time consuming regimens, or inconvenient processes of treatment. Furthermore, some require expensive equipment and dedicated space in the office setting. Systemic medications can produce serious side effects, including hypertension, hyperlipidemia, bone marrow suppression, liver disease, kidney disease and gastrointestinal upset. Also, the use of phototherapy can increase the incidence of skin cancers. In addition to the inconvenience and discomfort associated with the use of topical therapies, phototherapy and systemic treatments require cycling patients on and off therapy and monitoring lifetime exposure due to their side effects.

[0182] Treatment efficacy for psoriasis is assessed by monitoring changes in clinical signs and symptoms of the disease including Physician's Global Assessment (PGA) changes and Psoriasis Area and Severity Index (PASI) scores, Psoriasis Symptom Assessment (PSA), compared with the baseline condition. The patient can be measured periodically throughout treatment on the Visual analog scale used to indicate the degree of itching experienced at specific time points.

[0183] Patients may experience an infusion reaction or infusion-related symptoms with their first infusion of a therapeutic antibody. These symptoms vary in severity and generally are reversible with medical intervention. These symptoms

include but are not limited to, flu-like fever, chills/rigors, nausea, urticaria, headache, bronchospasm, angioedema. It would be desirable for the disease treatment methods of the present invention to minimize infusion reactions. Thus, another aspect of the invention is a method of treating the diseases disclosed by administering a humanized CD20 binding antibody wherein the antibody has reduced or no complement dependent cytotoxicity and results in reduced infusion related symptoms as compared to treatment with Rituxan®. In one embodiment, the humanized CD20 binding antibody is 2H7.v116.

Dosage

[0184] Depending on the indication to be treated and factors relevant to the dosing that a physician of skill in the field would be familiar with, the antibodies of the invention will be administered at a dosage that is efficacious for the treatment of that indication while minimizing toxicity and side effects. For the treatment of a CD20 positive cancer or an autoimmune disease, the therapeutically effective dosage will be in the range of about 250mg/m² to about 400 mg/m² or 500 mg/m², preferably about 250-375mg/m². In one embodiment, the dosage range is 275-375 mg/m². In one embodiment of the treatment of a CD20 positive B cell neoplasm, the antibody is administered at a range of 300-375 mg/m². For the treatment of patients suffering from B-cell lymphoma such as non-Hodgkins lymphoma, in a specific embodiment, the anti-CD20 antibodies and humanized anti-CD20 antibodies of the invention will be administered to a human patient at a dosage of 10mg/kg or 375mg/m². For treating NHL, one dosing regimen would be to administer one dose of the antibody composition a dosage of 10mg/kg in the first week of treatment, followed by a 2 week interval, then a second dose of the same amount of antibody is administered. Generally, NHL patients receive such treatment once during a year but upon recurrence of the lymphoma, such treatment can be repeated. In another dosing regimen, patients treated with low-grade NHL receive four weeks of a version of humanized 2H7, preferably v16 (375 mg/m² weekly) followed at week five by three additional courses of the antibody plus standard CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) or CVP (cyclophosphamide, vincristine, prednisone) chemotherapy, which was given every three weeks for three cycles.

[0185] For treating rheumatoid arthritis, in one embodiment, the dosage range for the humanized antibody is 125mg/m² (equivalent to about 200mg/dose) to 600mg/m², given in two doses, e.g., the first dose of 200mg is administered on day one followed by a second dose of 200mg on day 15. In different embodiments, the dosage is 250mg/dose, 275mg, 300mg, 325mg, 350mg, 375mg, 400mg, 425mg, 450mg, 475mg, 500mg, 525mg, 550mg, 575mg, 600mg.

[0186] In treating disease, the CD20 binding antibodies of the invention can be administered to the patient chronically or intermittently, as determined by the physician of skill in the disease.

[0187] A patient administered a drug by intravenous infusion or subcutaneously may experience adverse events such as fever, chills, burning sensation, asthenia and headache. To alleviate or minimize such adverse events, the patient may receive an initial conditioning dose(s) of the antibody followed by a therapeutic dose. The conditioning dose(s) will be lower than the therapeutic dose to condition the patient to tolerate higher dosages.

Route of administration

[0188] The CD20 binding antibodies are administered to a human patient in accord with known methods, such as by intravenous administration, e.g., as a bolus or by continuous infusion over a period of time, by subcutaneous, intramuscular, intraperitoneal, intracerebrospinal, intra-articular, intrasynovial, intrathecal, or inhalation routes, generally by intravenous or subcutaneous administration.

[0189] In one embodiment, the humanized 2H7 antibody is administered by intravenous infusion with 0.9% sodium chloride solution as an infusion vehicle.

Combination Therapy

[0190] In treating the B cell neoplasms described above, the patient can be treated with the CD20 binding antibodies of the present invention in conjunction with one or more therapeutic agents such as a chemotherapeutic agent in a multidrug regimen. The CD20 binding antibody can be administered concurrently, sequentially, or alternating with the chemotherapeutic agent, or after non-responsiveness with other therapy. Standard chemotherapy for lymphoma treatment may include cyclophosphamide, cytarabine, melphalan and mitoxantrone plus melphalan. CHOP is one of the most common chemotherapy regimens for treating Non-Hodgkin's lymphoma. The following are the drugs used in the CHOP regimen: cyclophosphamide (brand names cytoxan, neosar); adriamycin (doxorubicin / hydroxydoxorubicin); vincristine (Oncovin); and prednisolone (sometimes called Deltasone or Orasone). In particular embodiments, the CD20 binding antibody is administered to a patient in need thereof in combination with one or more of the following chemotherapeutic agents of doxorubicin, cyclophosphamide, vincristine and prednisolone. In a specific embodiment, a patient suffering from a lymphoma (such as a non-Hodgkin's lymphoma) is treated with an anti-CD20 antibody of the present

invention in conjunction with CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) therapy. In another embodiment, the cancer patient can be treated with a humanized CD20 binding antibody of the invention in combination with CVP (cyclophosphamide, vincristine, and prednisone) chemotherapy. In a specific embodiment, the patient suffering from CD20-positive NHL is treated with humanized 2H7.v16 in conjunction with CVP. In a specific embodiment of the treatment of CLL, the CD20 binding antibody is administered in conjunction with chemotherapy with one or both of fludarabine and cytoxan.

[0191] In treating the autoimmune diseases or autoimmune related conditions described above, the patient can be treated with the CD20 binding antibodies of the present invention in conjunction with a second therapeutic agent, such as an immunosuppressive agent, such as in a multi drug regimen. The CD20 binding antibody can be administered concurrently, sequentially or alternating with the immunosuppressive agent or upon non-responsiveness with other therapy. The immunosuppressive agent can be administered at the same or lesser dosages than as set forth in the art. The preferred adjunct immunosuppressive agent will depend on many factors, including the type of disorder being treated as well as the patient's history.

[0192] "Immunosuppressive agent" as used herein for adjunct therapy refers to substances that act to suppress or mask the immune system of a patient. Such agents would include substances that suppress cytokine production, down regulate or suppress self-antigen expression, or mask the MHC antigens. Examples of such agents include steroids such as glucocorticosteroids, e.g., prednisone, methylprednisolone, and dexamethasone; 2-amino-6-aryl-5-substituted pyrimidines (see U.S. Pat. No. 4,665,077), azathioprine (or cyclophosphamide, if there is an adverse reaction to azathioprine); bromocryptine; glutaraldehyde (which masks the MHC antigens, as described in U.S. Pat. No. 4,120,649); anti-idiotypic antibodies for MHC antigens and MHC fragments; cyclosporin A; cytokine or cytokine receptor antagonists including anti-interferon- γ , - β , or - α antibodies; anti-tumor necrosis factor- α antibodies; anti-tumor necrosis factor- β antibodies; anti-interleukin-2 antibodies and anti-IL-2 receptor antibodies; anti-L3T4 antibodies; heterologous anti-lymphocyte globulin; pan-T antibodies, preferably anti-CD3 or anti-CD4/CD4a antibodies; soluble peptide containing a LFA-3 binding domain (WO 90/08187 published 7/26/90); streptokinase; TGF- β ; streptodornase; RNA or DNA from the host; FK506; RS-61443; deoxyspergualin; rapamycin; T-cell receptor (U.S. Pat. No. 5,114,721); T-cell receptor fragments (Offner et al., Science 251:430-432 (1991); WO 90/11294; and WO 91/01133); and T cell receptor antibodies (EP 340,109) such as T10B9.

[0193] For the treatment of rheumatoid arthritis, the patient can be treated with a CD20 antibody of the invention in conjunction with any one or more of the following drugs: DMARDs (disease-modifying antirheumatic drugs (e.g., methotrexate), NSAID or NSAID (non-steroidal anti-inflammatory drugs), HUMIRATM (adalimumab; Abbott Laboratories), AR-AVA[®] (leflunomide), REMICADE[®] (infliximab; Centocor Inc., of Malvern, Pa), ENBREL (etanercept; Immunex, WA), COX-2 inhibitors. DMARDs commonly used in RA are hydroxycycloquine, sulfasalazine, methotrexate, leflunomide, etanercept, infliximab, azathioprine, D-penicillamine, Gold (oral), Gold (intramuscular), minocycline, cyclosporine, Staphylococcal protein A immunoadsorption. Adalimumab is a human monoclonal antibody that binds to TNF α . Infliximab is a chimeric monoclonal antibody that binds to TNF α . Etanercept is an "immunoadhesin" fusion protein consisting of the extracellular ligand binding portion of the human 75 kD (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of a human IgG1. For conventional treatment of RA, see, e.g., "Guidelines for the management of rheumatoid arthritis" Arthritis & Rheumatism 46(2): 328-346 (February, 2002). In a specific embodiment, the RA patient is treated with a CD20 antibody of the invention in conjunction with methotrexate (MTX). An exemplary dosage of MTX is about 7.5-25 mg/kg/wk. MTX can be administered orally and subcutaneously.

[0194] For the treatment of ankylosing spondylitis, psoriatic arthritis and Crohn's disease, the patient can be treated with a CD20 binding antibody of the invention in conjunction with, for example, Remicade[®] (infliximab; from Centocor Inc., of Malvern, Pa.), ENBREL (etanercept; Immunex, WA).

[0195] Treatments for SLE include high-dose corticosteroids and/or cyclophosphamide (HDCC).

[0196] For the treatment of psoriasis, patients can be administered a CD20 binding antibody in conjunction with topical treatments, such as topical steroids, anthralin, calcipotriene, clobetasol, and tazarotene, or with methotrexate, retinoids, cyclosporine, PUVA and UVB therapies. In one embodiment, the psoriasis patient is treated with the CD20 binding antibody sequentially or concurrently with cyclosporine.

Pharmaceutical Formulations

[0197] Therapeutic formulations of the CD20-binding antibodies used in accordance with the present invention are prepared for storage by mixing an antibody having the desired degree of purity with optional pharmaceutically acceptable carriers, excipients or stabilizers (Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980)), in the form of lyophilized formulations or aqueous solutions. Acceptable carriers, excipients, or stabilizers are nontoxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride, benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl

parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrans; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose or sorbitol; salt-forming counter-ions such as sodium; metal complexes (e.g. Zn-protein complexes); and/or non-ionic surfactants such as TWEEN™, PLURONICS™ or polyethylene glycol (PEG).

[0198] Exemplary anti-CD20 antibody formulations are described in WO98/56418, expressly incorporated herein by reference. Another formulation is a liquid multidose formulation comprising the anti-CD20 antibody at 40 mg/mL, 25 mM acetate, 150 mM trehalose, 0.9% benzyl alcohol, 0.02% polysorbate 20 at pH 5.0 that has a minimum shelf life of two years storage at 2-8°C. Another anti-CD20 formulation of interest comprises 10mg/mL antibody in 9.0 mg/mL sodium chloride, 7.35 mg/mL sodium citrate dihydrate, 0.7mg/mL polysorbate 80, and Sterile Water for Injection, pH 6.5. Yet another aqueous pharmaceutical formulation comprises 10-30 mM sodium acetate from about pH 4.8 to about pH 5.5, preferably at pH5.5, polysorbate as a surfactant in an amount of about 0.01-0.1% v/v, trehalose at an amount of about 2-10% w/v, and benzyl alcohol as a preservative (U.S. 6,171,586). Lyophilized formulations adapted for subcutaneous administration are described in WO97/04801. Such lyophilized formulations may be reconstituted with a suitable diluent to a high protein concentration and the reconstituted formulation may be administered subcutaneously to the mammal to be treated herein.

[0199] One formulation for the humanized 2H7 variants is antibody at 12-14 mg/mL in 10 mM histidine, 6% sucrose, 0.02% polysorbate 20, pH 5.8.

[0200] In a specific embodiment, 2H7 variants and in particular 2H7.v16 is formulated at 20mg/mL antibody in 10mM histidine sulfate, 60mg/ml sucrose., 0.2 mg/ml polysorbate 20, and Sterile Water for Injection, at pH5.8.

[0201] The formulation herein may also contain more than one active compound as necessary for the particular indication being treated, preferably those with complementary activities that do not adversely affect each other. For example, it may be desirable to further provide a cytotoxic agent, chemotherapeutic agent, cytokine or immunosuppressive agent (e.g. one which acts on T cells, such as cyclosporin or an antibody that binds T cells, e.g. one which binds LFA-1). The effective amount of such other agents depends on the amount of antibody present in the formulation, the type of disease or disorder or treatment, and other factors discussed above. These are generally used in the same dosages and with administration routes as described herein or about from 1 to 99% of the heretofore employed dosages.

[0202] The active ingredients may also be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsules and poly-(methylmethacrylate) microcapsules, respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules) or in macroemulsions. Such techniques are disclosed in Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980).

[0203] Sustained-release preparations may be prepared. Suitable examples of sustained-release preparations include semi-permeable matrices of solid hydrophobic polymers containing the antagonist, which matrices are in the form of shaped articles, e.g. films, or microcapsules. Examples of sustained-release matrices include polyesters, hydrogels (for example, poly(2-hydroxyethyl-methacrylate), or poly(vinylalcohol)), polylactides (U.S. Pat. No. 3,773,919), copolymers of L-glutamic acid and ethyl-L-glutamate, non-degradable ethylene-vinyl acetate, degradable lactic acid-glycolic acid copolymers such as the LUPRON DEPOT™ (injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate), and poly-D-(-)-3-hydroxybutyric acid.

[0204] The formulations to be used for *in vivo* administration must be sterile. This is readily accomplished by filtration through sterile filtration membranes.

Articles of Manufacture and Kits

[0205] Another embodiment of the invention is an article of manufacture containing materials useful for the treatment of autoimmune diseases and related conditions and CD20 positive cancers such as non-Hodgkin's lymphoma. The article of manufacture comprises a container and a label or package insert on or associated with the container. Suitable containers include, for example, bottles, vials, syringes, etc. The containers may be formed from a variety of materials such as glass or plastic. The container holds a composition which is effective for treating the condition and may have a sterile access port (for example the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle). At least one active agent in the composition is a CD20 binding antibody of the invention. The label or package insert indicates that the composition is used for treating the particular condition. The label or package insert will further comprise instructions for administering the antibody composition to the patient. Package insert refers to instructions customarily included in commercial packages of therapeutic products, that contain information about the indications, usage, dosage, administration, contraindications and/or warnings concerning the use of such therapeutic products. In one embodiment, the package insert indicates that the composition is used for treating non-

Hodgkins' lymphoma.

[0206] Additionally, the article of manufacture may further comprise a second container comprising a pharmaceutically-acceptable buffer, such as bacteriostatic water for injection (BWI), phosphate-buffered saline, Ringer's solution and dextrose solution. It may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, and syringes.

[0207] Kits are also provided that are useful for various purposes, e.g., for B-cell killing assays, as a positive control for apoptosis assays, for purification or immunoprecipitation of CD20 from cells. For isolation and purification of CD20, the kit can contain an anti-CD20 antibody coupled to beads (e.g., sepharose beads). Kits can be provided which contain the antibodies for detection and quantitation of CD20 *in vitro*, e.g. in an ELISA or a Western blot. As with the article of manufacture, the kit comprises a container and a label or package insert on or associated with the container. The container holds a composition comprising at least one anti-CD20 antibody of the invention. Additional containers may be included that contain, e.g., diluents and buffers, control antibodies. The label or package insert may provide a description of the composition as well as instructions for the intended *in vitro* or diagnostic use.

Cynomolgus monkey CD20

[0208] The invention also provides an isolated nucleic acid comprising the nucleotide sequence of SEQ ID NO.:_ of the Cynomolgus monkey CD20 as shown in FIG. 19. In one embodiment, the nucleic acid is a cDNA. In one embodiment, the nucleic acid encoding the monkey CD20 is in an expression vector for expression in a host cell. The nucleotide sequence of SEQ ID NO.:_ in the expression vector is operably linked to an expression control sequence such as a promoter or promoter and enhancer. The expression control sequence can be the native sequence normally associated with the Cynomolgus CD20 gene, or heterologous to the gene. Also provided is an isolated polypeptide comprising the amino acid sequence [SEQ ID NO. _; FIG. 19 & 20] of the Cynomolgus monkey CD20, as well as host cells containing the Cynomolgus CD20 nucleic acid. In one aspect the host cells are eukaryotic cells, e.g., CHO cells. Fusion proteins comprising the Cynomolgus CD20 amino acid sequence or fragments of the sequence are also contemplated.

Experimental Examples

Example 1

Humanization of 2H7 anti-CD20 murine monoclonal antibody

[0209] Humanization of the murine anti-human CD20 antibody, 2H7 (also referred to herein as m2H7, m for murine), was carried out in a series of site-directed mutagenesis steps. The murine 2H7 antibody variable region sequences and the chimeric 2H7 with the mouse V and human C have been described, see, e.g., U.S. patents 5,846,818 and 6,204,023. The CDR residues of 2H7 were identified by comparing the amino acid sequence of the murine 2H7 variable domains (disclosed in U.S. 5,846,818) with the sequences of known antibodies (Kabat et al., Sequences of proteins of immunological interest, Ed. 5. Public Health Service, National Institutes of Health, Bethesda, MD (1991)). The CDR regions for the light and heavy chains were defined based on sequence hypervariability (Kabat et al., *supra*) and are shown in Fig. 1A and Fig. 1B, respectively. Using synthetic oligonucleotides (Table 1), site-directed mutagenesis (Kunkel, Proc. Natl. Acad. Sci. 82:488-492 (1985)) was used to introduce all six of the murine 2H7 CDR regions into a complete human Fab framework corresponding to a consensus sequence V_κI, V_HIII (V_L kappa subgroup I, V_H subgroup III) contained on plasmid pVX4 (Fig. 2).

[0210] The phagemid pVX4 (Fig. 2) was used for mutagenesis as well as for expression of F(ab)s in *E. coli*. Based on the phagemid pb0720, a derivative of pB0475 (Cunningham et al., Science 243: 1330-1336 (1989)), pVX4 contains a DNA fragment encoding a humanized consensus κ -subgroup I light chain (V_L κ I-C_L) and a humanized consensus subgroup III heavy chain (V_HIII-C_H1) anti-IFN- α (interferon α) antibody. pVX4 also has an alkaline phosphatase promoter and Shine-Dalgarno sequence both derived from another previously described pUC119-based plasmid, pAK2 (Carter et al., Proc. Natl. Acad. Sci. USA 89: 4285 (1992)). A unique *Spe*I restriction site was introduced between the DNA encoding for the F(ab) light and heavy chains. The first 23 amino acids in both anti-IFN- α heavy and light chains are the *Sfi*I secretion signal sequence (Chang et al., Gene 55: 189-196 (1987)).

[0211] To construct the CDR-swap version of 2H7 (2H7.v2), site-directed mutagenesis was performed on a deoxyuridine-containing template of pVX4; all six CDRs of anti-IFN- α were changed to the murine 2H7 CDRs. The resulting molecule is referred to as humanized 2H7 version 2 (2H7.v2), or the "CDR-swap version" of 2H7; it has the m2H7 CDR residues with the consensus human FR residues shown in Figures 1A and 1B. Humanized 2H7.v2 was used for further humanization.

[0212] Table 1 shows the oligonucleotide sequence used to create each of the murine 2H7 (m2H7) CDRs in the H

and L chain. For example, the CDR-H1 oligonucleotide was used to recreate the m2H7 H chain CDR1. CDR-H1, CDR-H2 and CDR-H3 refers to the H chain CDR1, CDR2 and CDR3, respectively; similarly, CDR-L1, CDR-L2 and CDR-L3 refers to each of the L chain CDRs. The substitutions in CDR-H2 were done in two steps with two oligonucleotides, CDR-H2A and CDR-H2B.

Table 1. Oligonucleotide sequences used for construction of the CDR-swap of murine 2H7 CDRs into a human framework in pVX4. Residues changed by each oligonucleotide are underlined.

Substitution	Oligonucleotide sequence
CDR-H1	C TAC ACC TTC ACG <u>AGC</u> TAT <u>AAC</u> <u>ATG</u> CAC TGG GTC CG (SEQ ID NO.)
CDR-H2A	G ATT AAT CCT GAC <u>AAC</u> <u>GGC</u> <u>GAC</u> ACG <u>AGC</u> TAT AAC CAG <u>AAG</u> TTC AAG GGC CG (SEQ ID NO.)
CDR-H2B	GAA TGG GTT GCA <u>GCG</u> ATC TAT CCT <u>GGC</u> AAC GGC GAC AC (SEQ ID NO.)
CDR-H3	AT TAT TGT GCT CGA GTG <u>GTC</u> <u>TAC</u> TAT <u>AGC</u> <u>AAC</u> <u>AGC</u> <u>TAC</u> <u>TGG</u> <u>TAC</u> <u>TTC</u> GAC <u>GTC</u> TGG GGT CAA GGA (SEQ ID NO.)
CDR-L1	C TGC ACA GCC AGC <u>TCT</u> TCT <u>GTC</u> AGC TAT ATG CAT TG (SEQ ID NO.)
CDR-L2	AA CTA CTG ATT TAC <u>GCT</u> <u>CCA</u> <u>TGC</u> AAC CTC <u>GCG</u> CT GGA GTC C (SEQ ID NO.)
CDR-L3	TAT TAC TGT CAA CAG <u>TGG</u> <u>AGC</u> <u>TTC</u> <u>AAT</u> CCG <u>CCC</u> ACA TTT GGA <u>CAG</u> (SEQ ID NO.)

[0213] For comparison with humanized constructs, a plasmid expressing a chimeric 2H7 Fab (containing murine V_L and V_H domains, and human C_L and CH_1 domains) was constructed by site-directed mutagenesis (Kunkel, *supra*) using synthetic oligonucleotides to introduce the murine framework residues into 2H7.v2. The sequence of the resulting plasmid construct for expression of the chimeric Fab known as 2H7.v6.8, is shown in Fig. 3. Each encoded chain of the Fab has a 23 amino acid Sfil secretion signal sequence as described for pVX4 (Fig.2) above.

[0214] Based on a sequence comparison of the murine 2H7 framework residues with the human V_{κ} , V_{μ} consensus framework (Figures 1A and 1B) and previously humanized antibodies (Carter et al., Proc. Natl. Acad. Sci. USA 89:4285-4289 (1992)), several framework mutations were introduced into the 2H7.v2 Fab construct by site-directed mutagenesis. These mutations result in a change of certain human consensus framework residues to those found in the murine 2H7 framework, at sites that might affect CDR conformations or antigen contacts. Version 3 contained V_H (R71V, N73K), version 4 contained V_H (R71V), version 5 contained V_H (R71V, N73K) and V_L (L46P), and version 6 contained V_H (R71V, N73K) and V_L (L46P, L47W).

[0215] Humanized and chimeric Fab versions of m2H7 antibody were expressed in E. coli and purified as follows. Plasmids were transformed into E. coli strain XL-1 Blue (Stratagene, San Diego, CA) for preparation of double- and single-stranded DNA. For each variant, both light and heavy chains were completely sequenced using the dideoxynucleotide method (Sequenase, U.S. Biochemical Corp.). Plasmids were transformed into E. coli strain 16C9, a derivative of MM294, plated onto LB plates containing 5 μ g/ml carbenicillin, and a single colony selected for protein expression. The single colony was grown in 5 ml LB-100 μ g/ml carbenicillin for 5-8 h at 37° C. The 5 ml culture was added to 500 ml AP5-100 μ g/ml carbenicillin and allowed to grow for 16 h in a 4 L baffled shake flask at 37° C. AP5 media consists of: 1.5g glucose, 11.0 Hycase SF, 0.6g yeast extract (certified), 0.19g anhydrous $MgSO_4$, 1.07g NH_4Cl , 3.73g KCl, 1.2g NaCl, 120 ml 1 M triethanolamine, pH 7.4, to 1 L water and then sterile filtered through 0.1 μ m Sealkeen filter.

[0216] Cells were harvested by centrifugation in a 1 L centrifuge bottle (Nalgene) at 3000xg and the supernatant removed. After freezing for 1 h, the pellet was resuspended in 25 ml cold 10 mM MES-10 mM EDTA, pH 5.0 (buffer A). 250 μ l of 0.1M PMSF (Sigma) was added to inhibit proteolysis and 3.5 ml of stock 10 mg/ml hen egg white lysozyme (Sigma) was added to aid lysis of the bacterial cell wall. After gentle shaking on ice for 1 h, the sample was centrifuged at 40,000xg for 15 min. The supernatant was brought to 50 ml with buffer A and loaded onto a 2 ml DEAE column equilibrated with buffer A. The flow-through was then applied to a protein G-Sepharose CL-4B (Pharmacia) column (0.5 ml bed volume) equilibrated with buffer A. The column was washed with 10 ml buffer A and eluted with 3 ml 0.3 M glycine, pH 3.0, into 1.25 ml 1 M Tris, pH 8.0. The F(ab) was then buffer exchanged into PBS using a Centricon-30 (Amicon) and concentrated to a final volume of 0.5 ml. SDS-PAGE gels of all F(ab)s were run to ascertain purity and the molecular weight of each variant was verified by electrospray mass spectrometry.

[0217] In cell-based ELISA binding assays (described below), the binding of Fabs, including chimeric 2H7 Fab, to CD20 was difficult to detect. Therefore, the 2H7 Fab versions were reformatted as full-length IgG1 antibodies for assays

and further mutagenesis.

[0218] Plasmids for expression of full-length IgG's were constructed by subcloning the V_L and V_H domains of chimeric 2H7 (v6.8) Fab as well as humanized Fab versions 2 to 6 into previously described pRK vectors for mammalian cell expression (Gorman et al., DNA Prot. Eng. Tech. 2:3-10 (1990)). Briefly, each Fab construct was digested with *EcoRV* and *BlnI* to excise a V_L fragment, which was cloned into the *EcoRV/BlnI* sites of plasmid pDR1 (Fig. 4) for expression of the complete light chain (V_L - C_L domains). Additionally, each Fab construct was digested with *PvuII* and *Apal* to excise a V_H fragment, which was cloned into the *PvuII/Apal* sites of plasmid pDR2 (Fig. 5) for expression of the complete heavy chain (V_H -CH₁-hinge-CH₂-CH₃ domains). For each IgG variant, transient transfections were performed by cotransfecting a light-chain expressing plasmid and a heavy-chain expressing plasmid into an adenovirus-transformed human embryonic kidney cell line, 293 (Graham et al., J. Gen. Virol., 36:59-74, (1977)). Briefly, 293 cells were split on the day prior to transfection, and plated in serum-containing medium. On the following day, double-stranded DNA prepared as a calcium phosphate precipitate was added, followed by pAdVantage™ DNA (Promega, Madison, WI), and cells were incubated overnight at 37°C. Cells were cultured in serum-free medium and harvested after 4 days. Antibodies were purified from culture supernatants using protein A-Sepharose CL-4B, then buffer exchanged into 10 mM sodium succinate, 140 mM NaCl, pH 6.0, and concentrated using a Centricon-10 (Amicon). Protein concentrations were determined by quantitative amino acid analysis.

[0219] To measure relative binding affinities to the CD20 antigen, a cell-based ELISA assay was developed. Human B-lymphoblastoid WIL2-S cells (ATCC CRL 8885, American Type Culture Collection, Rockville, MD) were grown in RPMI 1640 supplemented with 2 mM L-glutamine, 20 mM HEPES, pH 7.2 and 10% heat-inactivated fetal bovine serum in a humidified 5% CO₂ incubator. The cells were washed with PBS containing 1% FBS (assay buffer) and seeded at 250-300,000 cell/well in 96-well round bottom plates (Nunc, Roskilde, Denmark). Two-fold serially diluted standard (15.6-1000 ng/ml of 2H7 v6.8 chimeric IgG) and threefold serially diluted samples (2.7-2000 ng/ml) in assay buffer were added to the plates. The plates were buried in ice and incubated for 45 min. To remove the unbound antibody, 0.1 mL assay buffer were added to the wells. Plates were centrifuged and supernatants were removed. Cells were washed two more times with 0.2 mL assay buffer. Antibody bound to the plates was detected by adding peroxidase conjugated goat anti-human Fc antibody (Jackson ImmunoResearch, West Grove, PA) to the plates. After a 45 min incubation, cells were washed as described before. TMB substrate (3,3',5,5'-tetramethyl benzidine; Kirkegaard & Perry Laboratories, Gaithersburg, MD) was added to the plates. The reaction was stopped by adding 1 M phosphoric acid. Titration curves were fit with a four-parameter nonlinear regression curve-fitting program (KaleidaGraph, Synergy software, Reading, PA). The absorbance at the midpoint of the titration curve (mid-OD) and its corresponding concentration of the standard were determined. Then the concentration of each variant at this mid-OD was determined, and the concentration of the standard was divided by that of each variant. Hence the values are a ratio of the binding of each variant relative to the standard. Standard deviations in relative affinity (equivalent concentration) were generally +/- 10% between experiments.

[0220] As shown in Table 2, binding of the CDR-swap variant (v.2) was extremely reduced compared to chimeric 2H7 (v.6.8). However, versions 3 to 6 showed improved binding. To determine the minimum number of mutations that might be required to restore binding affinity to that of chimeric 2H7, additional mutations and combinations of mutations were constructed by site-direct mutagenesis to produce variants 7 to 17 as indicated in Table 3. In particular, these included V_H mutations A49G, F67A, I69L, N73K, and L78A; and V_L mutations M4L, M33I, and F71Y. Versions 16 and 17 showed the best relative binding affinities, within 2-fold of that of the chimeric version, with no significant difference (s.d. = +/- 10%) between the two. To minimize the number of mutations, version 16, having only 4 mutations of human framework residues to murine framework residues (Table 3), was therefore chosen as the humanized form for additional characterization.

Table 2. Relative binding affinity of humanized 2H7 IgG variants to CD20 compared to chimeric 2H7 using cell-based ELISA. The relative binding is expressed as the concentration of the chimeric 2H7 over the concentration of the variant required for equivalent binding; hence a ratio <1 indicates weaker affinity for the variant. Standard deviation in relative affinity determination averaged +/- 10%. Framework substitutions in the variable domains are relative to the CDR-swap version according to the numbering system of Kabat (Kabat et al., *supra*).

2H7 version	Heavy chain (V_H) substitutions	Light Chain (V_L) substitutions	Relative binding
6.8	(Chimera)	(Chimera)	-1-
2	(CDR swap)	(CDR swap)	0.01
3	R71V, N73K	(CDR swap)	0.21
4	R71V	(CDR swap)	0.21
5	R71V, N73K	L46P	0.50

(continued)

2H7 version	Heavy chain (V _H) substitutions	Light Chain (V _L) substitutions	Relative binding
6	R71V, N73K	L46P, L47W	0.58
7	R71V	L46P	0.33
8	R71V, L78A	L46P	0.19
9	R71V, F67A	L46P	0.07
10	R71V, F67A, I69L	L46P	0.12
11	R71V, F67A, L78A	L46P	0.19
12	R71V	L46P, M4L	0.32
13	R71V	L46P, M33I	0.31
14	R71V	L46P, F71Y	0.25
15	R71V	L46P, M4L, M33I	0.26
16	R71V, N73K, A49G	L46P	0.65
17	R71V, N73K, A49G	L46P, L47W	0.67

Table 3 Oligonucleotide sequences used for construction of mutations V_H(A49G, R71V, N73K) and V_L(L46P) in humanized 2H7 version 16 (2H7.v16). Underlined codons encode the indicated amino acid substitutions. For V_H (R71V, N73K) and V_L (L46P), the oligos are shown as the sense strand since these were used for mutagenesis on the Fab template, while for V_H (A49G), the oligo is shown as the anti-sense strand, since this was used with the pRK (IgG heavy chain) template. The protein sequence of version 16 is shown in Fig. 6 and Fig. 7.

Substitution	Oligonucleotide sequence
V _H (R71V, N73K)	GT TTC ACT ATA AGT <u>GTC</u> GAC <u>AAG</u> TCC AAA AAC ACA TT (SEQ ID NO. _)
V _H (A49G)	GCCAGGATAGATGGCGCCAACCCATTCCAGGCC (SEQ ID NO. _)
V _L (L46P)	AAGCTCCGAAACCACTGATTTACGCT (SEQ ID NO. _)

Example 2

Antigen-binding determinants (paratope) of 2H7

[0221] Alanine substitutions (Cunningham & Wells, Science 244: 1081-1085 (1989) were made in 2H7.v16 or 2H7.v17 in order to test the contributions of individual side chains of the antibody in binding to CD20. IgG variants were expressed in 293 cells from pDR1 and pDR2 vectors, purified, and assayed for relative binding affinity as described above. Several alanine substitutions resulted in significant decreases in relative binding to CD20 on WIL-2S cells (Table 4).

Table 4. Effects of alanine substitutions in the CDR regions of humanized 2H7.v16 measured using cell-based ELISA (WIL2-S cells). The relative binding is expressed as the concentration of the 2H7.v16 parent over the concentration of the variant required for equivalent binding; hence a ratio <1 indicates weaker affinity for the variant; a ratio >1 indicates higher affinity for the variant. Standard deviation in relative affinity determination averaged +/-10%. Framework substitutions in the variable domains are relative to 2H7.v16 according to the numbering system of Kabat (Kabat et al., *supra*). NBD means no detectable binding. The two numbers for version 45 are from separate experiments.

2H7 version	CDR location	Heavy chain substitutions	Light chain substitutions	Relative binding
16	-	-	-	-1-

EP 3 263 596 A1

(continued)

	2H7	CDR	Heavy chain	Light chain	Relative binding
	version	location	substitutions	substitutions	
5	140	H1	G26A	-	0.63
	141	H1	Y27A	-	0.47
	34	H1	T28A	-	0.86
10	35	H1	F29A	-	0.07
	36	H1	T30A	-	0.81
	37	H1	S31A	-	0.97
15	142	H1	Y32A	-	0.63
	143	H1	N33A	-	NDB
	144	H1	M34A	-	1.2
	145	H1	H35A	-	<0.25
20					
	146	H2	A50G	-	0.31
	147	H2	I51A	-	0.65
25	38	H2	Y52A	-	0.01
	148	H2	P52aA	-	0.66
	39	H2	G53A	-	0.89
	57	H2	N54A	-	1.4
30	40	H2	G55A	-	0.79
	41	H2	D56A	-	2.0
	89	H2	T57A	-	0.61
35	90	H2	S58A	-	0.92
	91	H2	Y59A	-	0.74
	92	H2	N60A	-	0.80
	93	H2	Q61A	-	0.83
40	94	H2	K62A	-	0.44
	95	H2	F63A	-	0.51
	83	H2	V71A	-	0.96
45	149	H2	K64A	-	0.82
	150	H2	G65A	-	1.2
	153	H3	V95A	-	0.89
50	42	H3	V96A	-	0.98
	43	H3	Y97A	-	0.63
	44	H3	Y98A	-	0.40
55	45	H3	S99A	-	0.84; 0.92
	46	H3	N100A	-	0.81
	47	H3	S100aA	-	0.85

EP 3 263 596 A1

(continued)

	2H7	CDR	Heavy chain	Light chain	Relative binding
	version	location	substitutions	substitutions	
5	48	H3	Y100bA	-	0.78
	49	H3	W100cA	-	0.02
	59	H3	Y100dA	-	0.98
10	50	H3	F100eA	-	NDB
	61	H3	D101A	-	0.31
	151	H3	V102A	-	1.1
15					
	117	L1	-	R24A	0.85
	118	L1	-	A25G	0.86
	119	L1	-	S26A	0.98
20	120	L1	-	S27A	0.98
	121	L1	-	S28A	1.0
	122	L1	-	V29A	0.41
25	50	L1	-	S30A	0.96
	51	L1	-	Y32A	1.0
	123	L1	-	M33A	1.0
	124	L1	-	H34A	0.21
30					
	125	L2	-	A50G	0.92
	126	L2	-	P51A	0.88
35	52	L2	-	S52A	0.80
	53	L2	-	N53A	0.76
	54	L2	-	L54A	0.60
	127	L2	-	A55G	1.1
40	128	L2	-	S56A	1.1
	129	L3	-	Q89A	0.46
	130	L3	-	Q90A	<0.22
45	55	L2	-	W91A	0.88
	56	L3	-	S92A	1.1
	57	L3	-	F93A	0.36
	58	L3	-	N94A	0.61
50	131	L3	-	P95A	NDB
	132	L3	-	P96A	0.18
	133	L3	-	T97A	<0.22
55					

Example 3**Additional mutations within 2H7 CDR regions**

[0222] Substitutions of additional residues and combinations of substitutions at CDR positions that were identified as important by Ala-scanning were also tested. Several combination variants, particularly v.96 appeared to bind more tightly than v.16.

Table 5. Effects of combinations of mutations and non-alanine substitutions in the CDR regions of humanized 2H7.v16 measured using cell-based ELISA (WIL2-S cells). The relative binding to CD20 is expressed as the concentration of the 2H7.v16 parent over the concentration of the variant required for equivalent binding; hence a ratio <1 indicates weaker affinity for the variant; a ratio >1 indicates higher affinity for the variant. Standard deviation in relative affinity determination averaged +/- 10%. Framework substitutions in the variable domains are relative to 2H7.v16 according to the numbering system of Kabat (Kabat et al., *supra*).

2H7 version	Heavy chain substitutions	Light chain substitutions	Relative binding
16	-	-	-1-
96	D56A, N100A	S92A	3.5
97	S99T, N100G, Y100bl	-	0.99
98	S99G, N100S, Y100bl	-	1.6
99	N100G, Y100bl	-	0.80
101	N54S, D56A	-	1.7
102	N54K, D56A	-	0.48
103	D56A, N100A	-	2.1
104	S99T, N100G	-	0.81
105	S99G, N100S	-	1.1
106	N100G	-	~1
167	S100aG, Y100bS	-	
136	D56A, N100A	S56A, S92A	2.6
137	D56A, N100A	A55G, S92A	2.1
156	D56A, N100A	S26A, S56A, S92A	2.1
107	D56A, N100A, Y100bl	S92A	not expressed
182	Y27W	-	
183	Y27F	-	
184	F29Y	-	
185	F29W	-	
186	Y32F	-	
187	Y32W	-	
188	N33Q	-	
189	N33D	-	
190	N33Y	-	
191	N33S	-	
208	H35S	-	

EP 3 263 596 A1

(continued)

	2H7 version	Heavy chain substitutions	Light chain substitutions	Relative binding
5				
	209	A50S	-	
	210	A50R	-	
	211	A50V	-	
10	212	A50L	-	
	168	Y52W	-	
	169	Y52F	-	0.75
15	170	N54D	-	0.25
	171	N54S	-	1.2
	172	D56K	-	1
	173	D56R	-	
20	174	D56H	-	1.5
	175	D56E	-	1.2
	213	D56S	-	
25	214	D56G	-	
	215	D56N	-	
	216	D56Y	-	
	176	Y59W	-	
30	177	Y59F	-	
	180	K62R	-	
	181	K62D	-	
35	178	F63W	-	
	179	F63Y	-	
	157	Y97W	-	0.64
40	158	Y97F	-	1.2
	159	Y98W	-	0.64
	160	Y98F	-	0.88
45	106	N100G	-	
	161	W100cY	-	0.05
	162	W100cF	-	0.27
	163	E100eY	-	0.59
50	164	P100eW	-	0.71
	165	D101N	-	0.64
	166	S99G, N100G, S100aD, Y100b deleted	-	0.99
55	217	V102Y	-	1.0

(continued)

2H7 version	Heavy chain substitutions	Light chain substitutions	Relative binding
207	-	H34Y	
192	-	Q89E	
193	-	Q89N	
194	-	Q90E	
195	-	Q90N	
196	-	W91Y	
197	-	W91F	
205	-	S92N	
206	-	S92G	
198	-	F93Y	
199	-	F93W	
204	-	F93S, N94Y	
200	-	P96L	
201	-	P96Y	
202	-	P96W	
203	-	P96R	

Example 4**Mutations at sites of framework humanization substitutions**

[0223] Substitutions of additional residues at framework positions that were changed during humanization were also tested in the 2H7.v16 background. In particular, alternative framework substitutions that were neither found in the murine 2H7 parent nor the human consensus framework were made at V_L(P46) and V_H(G49, V71, and K73).

[0224] These substitutions generally led to little change in relative binding (Table 6), indicating that there is some flexibility in framework residues at these positions.

Table 6. Relative binding in a cell-based (WIL2-S) assay of framework substitutions. IgG variants are shown with mutations with respect to the 2H7.v16 background. The relative binding is expressed as the concentration of the 2H7.v6.8 chimera over the concentration of the variant required for equivalent binding; hence a ratio <1 indicates weaker affinity for the variant; a ratio >1 indicates higher affinity for the variant. Standard deviation in relative affinity determination averaged +/-10%. Framework substitutions in the variable domains are relative to 2H7.v16 according to the numbering system of Kabat (Kabat et al., *supra*). (*) Variants that were assayed with 2H7.v16 as the standard comparator; relative values are normalized to that of the chimera.

2H7 version	Heavy chain substitutions	Light chain substitutions	Relative binding
6.8	(chimera)	(chimera)	-1-
16	-	-	0.64
78	K73R	-	0.72
79	K73H	-	0.49
80	K73Q	-	0.58
31	V71I	-	0.42

(continued)

2H7 version	Heavy chain substitutions	Light chain substitutions	Relative binding
82	V71T	-	0.58
83	V71A	-	
84	G49S	-	0.32
85	G49L	-	
86	-	P46E	0.22
87	-	P46V	0.51
88	-	P46T	
108	G49A, V71T, K73R	S92A, M32L, P46T	0.026*
109	G49A, A49G, V71T, K73R	S92A, M32L, P46T	0.026*
110	K73R, D56A, N100A	S92A, M32L	Not expressed
111	G49A, V71T, K73R	-	0.46*
112	G49A, A50G, V71T, K73R	-	0.12*
(*) Variants that were assayed with 2H7.v16 as the standard comparator; relative values are normalized to that of the chimera.			

Example 5**Humanized 2H7 variants with enhanced effector functions**

[0225] Because 2H7 can mediate lysis of B-cells through both complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC), we sought to produce variants of humanized 2H7.v16 with improved CDC and ADCC activity. Mutations of certain residues within the Fc regions of other antibodies have been described (Idusogie et al., J. Immunol. 166:2571-2575 (2001)) for improving CDC through enhanced binding to the complement component C1q. Mutations have also been described (Shields et al., J. Biol. Chem. 276:6591-6604 (2001); Presta et al., Biochem. Soc. Trans. 30:487-490 (2002)) for improving ADCC through enhanced IgG binding to activating Fc γ receptors and reduced IgG binding to inhibitory Fc γ receptors. In particular, three mutations have been identified for improving CDC and ADCC activity: S298A/E333A/K334A (also referred to herein as a triple Ala mutant or variant; numbering in the Fc region is according to the EU numbering system; Kabat et al., *supra*) as described (Idusogie et al., *supra* (2001); Shields et al., *supra*).

[0226] In order to enhance CDC and ADCC activity of 2H7, a triple Ala mutant of the 2H7 Fc was constructed. A humanized variant of the anti-HER2 antibody 4d5 has been produced with mutations S298A/E333A/K334A and is known as 4D5Fc110 (*i.e.*, anti-p¹⁸⁵HER2 IgG1 (S298A/E333A/K334A); Shields et al., *supra*). A plasmid, p4D5Fc110 encoding antibody 4D5Fc110 (Shields et al., *supra*) was digested with *Apal* and *HindIII*, and the Fc-fragment (containing mutations S298A/E333A/K334A) was ligated into the *Apal/HindIII* sites of the 2H7 heavy-chain vector pDR2-v16, to produce pDR2-v31. The amino acid sequence of the version 31 complete H chain is shown in Fig. 8. The L chain is the same as that of v16.

[0227] Although the constant domains of the Fc region of IgG1 antibodies are relatively conserved within a given species, allelic variations exist (reviewed by Lefranc and Lefranc, in *The human IgG subclasses: molecular analysis of structure, function, and regulation*, pp. 43-78, F. Shakib (ed.), Pergamon Press, Oxford (1990)).

Table 7. Effects of substitutions in the Fc region on CD20 binding. Relative binding to CD20 was measured in a cell-based (WIL2-S) assay of framework substitutions. Fc mutations (*) are indicated by EU numbering (Kabat, *supra*) and are relative to the 2H7.v16 parent. The combination of three Ala changes in the Fc region of v.31 is described as "Fc110." IgG variants are shown with mutations with respect to the 2H7.v16 background. The relative binding is expressed as the concentration of the 2H7.v6.8 chimera over the concentration of the variant required for equivalent binding; hence a ratio <1 indicates weaker affinity for the variant. Standard deviation in relative affinity determination averaged +/- 10%.

2H7 version	Fc Substitutions*	Relative binding
6.8	-	-1-

(continued)

2H7 version	Fc Substitutions*	Relative binding
16	-	0.65
31	S298A, E333A, K334A	0.62

Example 6**Humanized 2H7 variants with enhanced stability**

[0228] For development as therapeutic proteins, it is desirable to choose variants that remain stable with respect to oxidation, deamidation, or other processes that may affect product quality, in a suitable formulation buffer. In 2H7.v16, several residues were identified as possible sources of instability: VL (M32) and VH (M34, N100). Therefore, mutations were introduced at these sites for comparison with v16.

Table 8. Relative binding of 2H7 variants designed for enhanced stability and/or effector function, to CD20 in a cell-based (WIL2-S) assay. IgG variants are shown with mutations with respect to the 2H7.v16 background. The relative binding is expressed as the concentration of the 2H7.v6.8 chimera over the concentration of the variant required for equivalent binding; hence a ratio <1 indicates weaker affinity for the variant. Standard deviation in relative affinity determination averaged +/- 10%. Framework substitutions in the variable domains are relative to 2H7.v16 according to the numbering system of Kabat and Fc mutations (*) are indicated by EU numbering (Kabat et al., *supra*). (**) Variants that were measured with 2H7.v16 as the standard comparator; relative values are normalized to that of the chimera.

Additional Fc mutations were combined with stability or affinity-enhancing mutations to alter or enhance effector functions based on previously reported mutations (Idusogie et al. (2000); Idusogie et al. (2001); Shields et al. (2001)). These changes include S298, E333A, K334A as described in Example 5; K322A to reduced CDC activity; D265A to reduce ADCC activity; K326A or K326W to enhance CDC activity; and E356D/M358L to test the effects of allotypic changes in the Fc region. None of these mutations caused significant differences in CD20 binding affinity.

2H7 version	Heavy chain (V _H) changes	Light chain (V _L) changes	Fc changes *	Relative binding
6.8	(chimera)	(chimera)	-	-1-
16	-	-	-	0.65
52	-	M32I	-	0.46
63	M34I	-	-	0.49
64	N100A	-	-	
5	N100A	L47W	-	0.74
66	S99A	L47W	-	0.62
67	N54A	-	-	
68	-	M32I	-	0.48
69	-	M32L	-	0.52
70	N100A	-	S298A, E333A, K334A	0.80
71	N100D	-	S298A, E333A, K334A	0.44
72	N100A	M32I	-	0.58
73	N100A	M32L	-	0.53

(continued)

2H7 version	Heavy chain (V _H) changes	Light chain (V _L) changes	Fc changes *	Relative binding
74	N100A	M321	S298A, E333A, K334A	0.61
75	N100A	M32L	S298A, E333A, K334A	0.60
113	-	-	E356D, M358L	0.60**
114	D56A, N100A	M32L, S92A	S298A, E333A, K334A	1.2**
115	D56A, N100A	M32L, S92A	P298A, E333A, K334A, E356D, M358L	1.4**
116	D56A, N100A	M32L, S92A	S298A, K334A, K322A	1.2**
134	D56A, N100A	M32L, S92A	E356D, M358L, D265A	1.5**
135	D56A, N100A	M32L, S92A	E356D, M358L, D265A, K326W	0.95**
138	D56A, N100A	M32L, S92A	S298A, E333A, K334A, K326A	1.2**
139	D56A, N100A	M32L, S92A	S298A, E333A, K334A, K326A, E356N, M358L	1.1**
154	-	-	D265A	0.70**
155	-	-	S298A, K322A, K334A	0.70**
(**) Variants that were measured with 2H7.v16 as comparator; relative binding values are normalized to that of the chimera.				

[0229] To test the effects of stability mutations on the rate of protein degradation, 2H7.v16 and 2H7.v73 were formulated at 12-14 mg/mL, in 10 mM histidine, 6% sucrose, 0.02% polysorbate 20, pH 5.8 and incubated at 40°C for 16 days. The incubated samples were then assayed for changes in charge variants by ion exchange chromatography, aggregation and fragmentation by size exclusion chromatography, and relative binding by testing in a cell-based (WIL2-S) assay.

[0230] The results (Fig. 9) show that 2H7 v.73 has greater stability compared to 2H7 v.16 with respect to losses in the fraction of main peak by ion exchange chromatography under accelerated stability conditions. No significant differences were seen with respect to aggregation, fragmentation, or binding affinity.

Example 7

Scatchard analysis of antibody binding to CD20 on WIL2-S cells

[0231] Equilibrium dissociation constants (K_d) were determined for 2H7 IgG variants binding to WIL2-S cells using radiolabeled 2H7 IgG. IgG variants were produced in CHO cells. Rituxan® (source for all experiments is Genentech, S. San Francisco, CA) and murine 2H7 (BD PharMingen, San Diego, CA) were used for comparison with humanized variants. The murine 2H7 antibody is also available from other sources, e.g., eBioscience, and Calbiochem (both of San Diego, CA), Accurate Chemical & Scientific Corp., (Westbury, NY), Ancell (Bayport, MN), and Vinci-Biochem (Vinci, Italy). All dilutions were performed in binding assay buffer (DMEM media containing 1% bovine serum albumin, 25 mM HEPES pH 7.2, and 0.01% sodium azide). Aliquots (0.025 mL) of ¹²⁵I-2H7.v16 (iodinated with lactoperoxidase) at a concentration of 0.8 nM were dispensed into wells of a V-bottom 96-well microassay plate, and serial dilutions (0.05 mL) of cold antibody were added and mixed. WIL2-S cells (60,000 cells in 0.025 mL) were then added. The plate was sealed

and incubated at room temperature for 24h, then centrifuged for 15 min at 3,500 RPM. The supernatant was then aspirated and the cell pellet was washed and centrifuged. The supernatant was again aspirated, and the pellets were dissolved in 1N NaOH and transferred to tubes for gamma counting. The data were used for Scatchard analysis (Munson and Rodbard, Anal. Biochem. 107:220-239 (1980)) using the program Ligand (McPherson, Comput. Programs Biomed. 17: 107-114 (1983)). The results, shown in Table 9, indicate that humanized 2H7 variants had similar CD20 binding affinity as compared to murine 2H7, and similar binding affinity to Rituxan®. It is expected that 2H7.v31 will have very similar K_d to v.16 on the basis of the binding shown in Table 7 above.

Table 9. Equilibrium binding affinity of 2H7 variants from Scatchard analysis

Antibody variant	K_d (nM)	n
Rituxan	0.99 ± 0.49	3
2H7 (murine)	1.23 ± 0.29	3
2H7.v16	0.84 ± 0.37	4
2H7.v73	1.22 ± 0.39	4
2H7.v75	1.09 ± 0.17	4

Example 8

Complement Dependent Cytotoxicity (CDC) Assays

[0232] 2H7 IgG variants were assayed for their ability to mediate complement-dependent lysis of WIL2-S cells, a CD20 expressing lymphoblastoid B-cell line, essentially as described (Idusogie et al., J. Immunol. 164:4178-4184 (2000); Idusogie et al., J. Immunol. 166:2571-2575 (2001)). Antibodies were serially diluted 1:3 from a 0.1 mg/mL stock solution. A 0.05 mL aliquot of each dilution was added to a 96-well tissue culture plate that contained 0.05 mL of a solution of normal human complement (Quidel, San Diego, CA). To this mixture, 50,000 WIL2-S cells were added in a 0.05 mL volume. After incubation for 2h at 37°C, 0.05 mL of a solution of Alamar blue (Accumed International, Westlake, OH) was added, and incubation was continued for an additional 18h at 37°C. Covers were then removed from the plates, and they were shaken for 15 min at room temperature on an orbital shaker. Relative fluorescent units (RFU) were read using a 530 nm excitation filter and a 590 nm emission filter. An EC_{50} was calculated by fitting RFU as a function of concentration for each antibody using KaleidaGraph software.

[0233] The results (Table 10) show surprising improvement in CDC by humanized 2H7 antibodies, with relative potency similar to Rituxan® for v.73, 3-fold more potent than Rituxan® for v.75, and 3-fold weaker than Rituxan® for v.16.

Table 10. CDC activity of 2H7 antibodies compared to Rituxan. Numbers >1 indicate less potent CDC activity than Rituxan® and numbers <1 indicate more potent activity than Rituxan®. Antibodies were produced from stable CHO lines, except that those indicated by (*) were produced transiently.

Antibody variant	n	$EC_{50}(\text{variant})/EC_{50}(\text{Rituxan})$
Rituxan®	4	-1-
2H7.v16	4	3.72; 4.08
2H7.v31*	4	2.21
2H7.v73	4	1.05
2H7.v75	4	0.33
2H7.v96*	4	0.956
2H7.v114*	4	0.378
2H7.v115*	4	0.475
2H7.v116*	1	>100
2H7.v135*	2	0.42

Example 9**Antibody Dependent Cellular Cytotoxicity (ADCC) Assays**

[0234] 2H7 IgG variants were assayed for their ability to mediate Natural-Killer cell (NK cell) lysis of WIL2-S cells, a CD20 expressing lymphoblastoid B-cell line, essentially as described (Shields et al., J. Biol. Chem. 276:6591-6604 (2001)) using a lactate dehydrogenase (LDH) readout. NK cells were prepared from 100 mL of heparinized blood, diluted with 100 mL of PBS (phosphate buffered saline), obtained from normal human donors who had been isotypized for Fc γ RIII, also known as CD16 (Koene et al., Blood 90:1109-1114 (1997)). In this experiment, the NK cells were from human donors heterozygous for CD16 (F158/V158). The diluted blood was layered over 15 mL of lymphocyte separation medium (ICN Biochemical, Aurora, Ohio) and centrifuged for 20 min at 2000 RPM. White cells at the interface between layers were dispensed to 4 clean 50-mL tubes, which were filled with RPMI medium containing 15% fetal calf serum. Tubes were centrifuged for 5 min at 1400 RPM and the supernatant discarded. Pellets were resuspended in MACS buffer (0.5% BSA, 2mM EDTA), and NK cells were purified using beads (NK Cell Isolation Kit, 130-046-502) according to the manufacturer's protocol (Miltenyi Biotech,). NK cells were diluted in MACS buffer to 2×10^6 cells/mL.

[0235] Serial dilutions of antibody (0.05 mL) in assay medium (F12/DMEM 50:50 without glycine, 1 mM HEPES buffer pH 7.2, Penicillin/Streptomycin (100 units/mL; Gibco), glutamine, and 1% heat-inactivated fetal bovine serum) were added to a 96-well round-bottom tissue culture plate. WIL2-S cells were diluted in assay buffer to a concentration of 4×10^5 /mL. WIL2-S cells (0.05 mL per well) were mixed with diluted antibody in the 96-well plate and incubated for 30 min at room temperature to allow binding of antibody to CD20 (opsonization).

[0236] The ADCC reaction was initiated by adding 0.1 mL of NK cells to each well. In control wells, 2% Triton X-100 was added. The plate was then incubated for 4h at 37°C. Levels of LDH released were measured using a cytotoxicity (LDH) detection kit (Kit#1644793, Roche Diagnostics, Indianapolis, Indiana.) following the manufacturers instructions. 0.1 mL of LDH developer was added to each well, followed by mixing for 10s. The plate was then covered with aluminum foil and incubated in the dark at room temperature for 15 min. Optical density at 490 nm was then read and use to calculate % lysis by dividing by the total LDH measured in control wells. Lysis was plotted as a function of antibody concentration, and a 4-parameter curve fit (KaleidaGraph) was used to determine EC₅₀ concentrations.

[0237] The results showed that humanized 2H7 antibodies were active in ADCC, with relative potency 20-fold higher than Rituxan® for v.31 and v.75, 5-fold more potent than Rituxan® for v.16, and almost 4-fold higher than Rituxan® for v.73.

Table 11. ADCC activity of 2H7 antibodies on WIL2-S cells compared to 2H7.v16, based on n experiments. (Values >1 indicate lower potency than 2H7.v16, and values <1 indicate greater potency.)

Antibody variant	n	EC ₅₀ (variant)/EC ₅₀ (2H7.v16)
Rituxan®	4	5.3
2H7.v16	5	1
2H7.v31	1	0.24
2H7.v73	5	1.4
2H7.v75	4	0.25

[0238] Additional ADCC assays were carried out to compare combination-variants of 2H7 with Rituxan®. The results of these assays indicated that 2H7.v114 and 2H7.v115 have >10-fold improved ADCC potency as compared to Rituxan® (Table 12).

Table 12. ADCC activity of 2H7 antibodies on WIL2-S cells compared to Rituxan®, based on n experiments (Values >1 indicate lower potency than Rituxan®, and values <1 indicate greater potency).

Antibody variant		EC50(variant)/EC50(Rituxan)
Rituxan®	2	-1-
2H7 v.16	2	0.52
ZH7 v.96	2	0.58
ZH7.v114	2	0.093

(continued)

Antibody variant		EC50(variant)/EC50(Rituxan)
2H7.v115	2	0.083
2H7.v116	2	0.30

Example 10**In vivo effects of 2H7 variants in a pilot study in cynomolgus monkeys**

[0239] 2H7 variants, produced by transient transfection of CHO cells, were tested in normal male cynomolgus (*Macaca fascicularis*) monkeys in order to evaluate their *in vivo* activities. Other anti-CD20 antibodies, such as C2B8 (Rituxan®) have demonstrated an ability to deplete B-cells in normal primates (Reff et al., Blood 83: 435-445 (1994)).

[0240] In one study, humanized 2H7 variants were compared. In a parallel study, Rituxan® was also tested in cynomolgus monkeys. Four monkeys were used in each of five dose groups: (1) vehicle, (2) 0.05 mg/kg hu2H7.v16, (3) 10 mg/kg hu2H7.v16, (4) 0.05 mg/kg hu2H7.v31, and (5) 10 mg/kg hu2H7.v31. Antibodies were administered intravenously at a concentration of 0, 0.2, or 20 mg/mL, for a total of two doses, one on day 1 of the study, and another on day 8. The first day of dosing is designated day 1 and the previous day is designated day -1; the first day of recovery (for 2 animals in each group) is designated as day 11. Blood samples were collected on days -19, -12, 1 (prior to dosing), and at 6h, 24h, and 72h following the first dose. Additional samples were taken on day 8 (prior to dosing), day 10 (prior to sacrifice of 2 animals/group), and on days 36 and 67 (for recovery animals).

[0241] Peripheral B-cell concentrations were determined by a FACS method that counted CD3-/CD40+ cells. The percent of CD3-CD40+ B cells of total lymphocytes in monkey samples were obtained by the following gating strategy. The lymphocyte population was marked on the forward scatter/ side scatter scattergram to define Region 1 (R1). Using events in R1, fluorescence intensity dot plots were displayed for CD40 and CD3 markers. Fluorescently labeled isotype controls were used to determine respective cutoff points for CD40 and CD3 positivity.

[0242] The results indicated that both 2H7.v16 and 2H7.v31 were capable of producing full peripheral B-cell depletion at the 10 mg/kg dose and partial peripheral B-cell depletion at the 0.05 mg/kg dose (Fig. 11). The time course and extent of B-cell depletion measured during the first 72h of dosing were similar for the two antibodies. Subsequent analysis of the recovery animals indicated that animals treated with 2H7.v31 showed a prolonged depletion of B-cells as compared to those dosed with 2H7.v16. In particular, recovery animals treated with 10 mg/kg 2H7.v16, B-cells showed substantial B-cell recovery at some time between sampling on Day 10 and on Day 36. However, for recovery animals treated with 10 mg/kg 2H7.v31, B-cells did not show recovery until some time between Day 36 and Day 67 (Fig. 11). This suggests a greater duration of full depletion by about one month for 2H7.v31 compared to 2H7.v16.

[0243] No toxicity was observed in the monkey study at low or high dose and the gross pathology was normal. In other studies, v16 was well tolerated up to the highest dose evaluated of (100mg/kgx2 = 1200 mg/m² x2) following i.v. administration of 2 doses given 2 weeks apart in these monkeys.

[0244] Data in Cynomolgus monkeys with 2H7.v16 versus Rituxan® suggests that a 5-fold reduction in CDC activity does not adversely affect potency. An antibody with potent ADCC activity but reduced CDC activity may have more favorable safety profile with regard to first infusion reactions than one with greater CDC activity.

Example 11**Fucose deficient 2H7 variant antibodies with enhanced effector function**

[0245] Normal CHO and HEK293 cells add fucose to IgG oligosaccharide to a high degree (97-98%). IgG from sera are also highly fucosylated.

[0246] DP12, a dihydrofolate reductase minus (DHFR⁻) CHO cell line that is fucosylation competent, and Lec13, a cell line that is deficient in protein fucosylation were used to produce antibodies for this study. The CHO cell line Pro-Lec13.6a (Lec13), was obtained from Professor Pamela Stanley of Albert Einstein College of Medicine of Yeshiva University. Parental lines are Pro- (proline auxotroph) and Gat- (glycine, adenosine, thymidine auxotroph). The CHO-DP12 cell line is a derivative of the CHO-K1 cell line (ATCC #CCL-61), which is dihydrofolate reductase deficient, and has a reduced requirement for insulin. Cell lines were transfected with cDNA using the Superfect method (Qiagen, Valencia, CA). Selection of the Lec13 cells expressing transfected antibodies was performed using puromycin dihydrochloride (Calbiochem, San Diego, CA) at 10 µg/ml in growth medium containing: MEM Alpha Medium with L-glutamine, ribonucleosides and deoxyribonucleosides (GIBCO-BRL, Gaithersburg, MD), supplemented with 10% inactivated FBS (GIBCO), 10 mM

HEPES, and 1X penicillin/streptomycin (GIBCO). The CHO cells were similarly selected in growth medium containing Ham's F12 without GHT: Low Glucose DMEM without Glycine with NaHCO₃ supplemented with 5% FBS (GIBCO), 10 mM HEPES, 2 mM L-glutamine, 1X GHT(glycine, hypoxanthine,thymidine), and 1X penicillin/streptomycin.

[0247] Colonies formed within two to three weeks and were pooled for expansion and protein expression. The cell pools were seeded initially at 3×10^6 cells/10 cm plate for small batch protein expression. The cells were converted to serum-free media once they grew to 90-95% confluency and after 3-5 days cell supernatants were collected and tested in an Fc IgG- and intact IgG-ELISA to estimate protein expression levels. Lec13 and CHO cells were seeded at approximately 8×10^6 cells/15 cm plate one day prior to converting to PS24 production medium, supplemented with 10 mg/L recombinant human insulin and 1 mg/L trace elements.

[0248] Lec13 cells and DP12 cells remained in serum-free production medium for 3-5 days. Supernatants were collected and clarified by centrifugation in 150 ml conical tubes to remove cells and debris. The protease inhibitors PMSF and aprotinin (Sigma, St. Louis, MO) were added and the supernatants were concentrated 5-fold on stirred cells using MWCO30 filters (Amicon, Beverly, MA) prior to immediate purification using protein G chromatography (Amersham Pharmacia Biotech, Piscataway, NJ)). All proteins were buffer exchanged into phosphate-buffered saline (PBS) using Centriprep-30 concentrators (Amicon) and analyzed by SDS-polyacrylamide gel electrophoresis. Protein concentrations were determined using A280 and verified using amino acid composition analysis.

[0249] The CHO cells were transfected with vectors expressing humanized 2H7v16, 2H7v.31 and selected as described. The 2H7v.16 antibody retains the wild type Fc region while v.31 (see Example 5, Table 7 above) has an Fc region wherein 3 amino acid changes were made (S298A, E333A, K334A) which results in higher affinity for the Fc γ R1IIa receptor (Shields et al. J. Biol. Chem. 276 (9):6591-6604 (2001)). Following transfection and selection, individual colonies of cells were isolated and evaluated for protein expression level and the highest producers were subjected to methotrexate selection to select for cells that had amplified the plasmid copy number and which therefore produced higher levels of antibody. Cells were grown, transferred to serum free medium for a period of 7 days, then the medium was collected, loaded onto a protein A column and the antibody was eluted using standard techniques. The final concentration of the antibody was determined using an Elisa that measures intact antibody. All proteins were buffer exchanged into phosphate-buffered saline (PBS) using Centriprep-30 concentrators. (Amicon) and analyzed by SDS-polyacrylamide gel electrophoresis.

[0250] *Matrix-Assisted Laser Desorption/Ionization Time-of-flight (MALDI-TOF) Mass Spectral Analysis of Asparagine-Linked Oligosaccharides:* N-linked oligosaccharides were released from recombinant glycoproteins using the procedure of Papac et al., Glycobiology 8, 445-454 (1998). Briefly, the wells of a 96 well PVDF-lined microtitre plate (Millipore, Bedford, MA) were conditioned with 100 μ l methanol that was drawn through the PDVF membranes by applying vacuum to the Millipore Multiscreen vacuum manifold. The conditioned PVDF membranes were washed with 3 X 250 μ l water. Between all wash steps the wells were drained completely by applying gentle vacuum to the manifold. The membranes were washed with reduction and carboxymethylation buffer (RCM) consisting of 6 M guanidine hydrochloride, 360 mM Tris, 2 mM EDTA, pH 8.6. Glycoprotein samples (50 μ g) were applied to individual wells, again drawn through the PVDF membranes by gentle vacuum and the wells were washed with 2 X 50 μ l of RCM buffer. The immobilized samples were reduced by adding 50 μ l of a 0.1 M dithiothreitol (DTT) solution to each well and incubating the microtitre plate at 37°C for 1 hr. DTT was removed by vacuum and the wells were washed 4 x 250 μ l water. Cysteine residues were carboxyl-methylated by the addition of 50 μ l of a 0.1 M iodoacetic acid (IAA) solution which was freshly prepared in 1 M NaOH and diluted to 0.1 M with RCM buffer. Carboxymethylation was accomplished by incubation for 30 min in the dark at ambient temperature. Vacuum was applied to the plate to remove the IAA solution and the wells were washed with 4 x 250 μ l purified water. The PVDF membranes were blocked by the addition of 100 μ l of 1% PVP360 (polyvinylpyrrolidone 360,000 MW) (Sigma) solution and incubation for 1 hr at ambient temperature. The PVP-360 solution was removed by gentle vacuum and the wells were washed 4 x 250 μ l water. The PNGase F (New England Biolabs, Beverly, MA) digest solution, 25 μ l of a 25 Unit/ml solution in 10 mM Tris acetate, pH 8.4, was added to each well and the digest proceeded for 3 hr at 37°C. After digestion, the samples were transferred to 500 μ l Eppendorf tubes and 2.5 μ l of a 1.5 M acetic acid solution was added to each sample. The acidified samples were incubated for 3 hr at ambient temperature to convert the oligosaccharides from glycosylamines to the hydroxyl form. Prior to MALDI-TOF mass spectral analysis, the released oligosaccharides were desalted using a 0.7-ml bed of cation exchange resin (AG50W-X8 resin in the hydrogen form) (Bio-Rad, Hercules, CA) slurried packed into compact reaction tubes (US Biochemical, Cleveland, OH).

[0251] For MALDI-TOF mass spectral analysis of the samples in the positive mode, the desalted oligosaccharides (0.5 μ l aliquots) were applied to the stainless target with 0.5 μ l of the 2,5 dihydroxybenzoic acid matrix (sDHB) that was prepared by dissolving 2 mg 2,5 dihydroxybenzoic acid with 0.1 mg of 5-methoxysilylic acid in 1 ml of ethanol/10 mM sodium chloride 1:1 (v/v). The sample/matrix mixture was dried by vacuum. For analysis in the negative mode, the desalted N-linked oligosaccharides (0.5 μ l aliquots) were applied to the stainless target along with 0.5 μ l 2',4',6'-trihydroxyacetophenone matrix (THAP) prepared in 1:3 (v/v) acetonitrile/13.3 mM ammonium citrate buffer. The sample/matrix mixture was vacuum dried and then allowed to absorb atmospheric moisture prior to analysis. Released oligosaccharides were analyzed by MALDI-TOF on a PerSeptive BioSystems Voyager-DE mass spectrometer. The mass spectrometer

was operated at 20 kV either in the positive or negative mode with the linear configuration and utilizing delayed extraction. Data were acquired using a laser power of 1300 and in the data summation mode (240 scans) to improve the signal to noise. The instrument was calibrated with a mixture of standard oligosaccharides and the data was smoothed using a 19 point Savitsky-Golay algorithm before the masses were assigned. Integration of the mass spectral data was achieved using Caesar 7.0 data analysis software package (SciBridge Software).

Natural killer (NK) cell antibody dependent cytotoxicity assays.

[0252] ADCC assays were performed as described in Example 9. NK to target cell (WIL2-S) ratio was 4 to 1, assays were run for 4 hours, and toxicity was measured as before using lactose dehydrogenase assay. Target cells were opsonized with the concentrations of antibody indicated for 30 min prior to addition of NK cells. The Rituxan® antibody used was from Genentech (S. San Francisco, CA). Figure 12 shows the results of a representative ADCC assay.

[0253] The results show that underfucosylated antibodies mediate NK cell target cell killing more efficiently than do antibodies with a full complement of fucose. The underfucosylated antibody, 2H7v.31, is most efficient at mediating target cell killing. This antibody is effective at lower concentrations and is capable of mediating killing of a greater percentage of target cells at higher concentrations than are the other antibodies. The activity of the antibodies is as follows: Lec13-derived 2H7 v31 > Lec 13 derived 2H7v16 > Dp12 derived 2H7v31 > Dp12 derived 2H7v16 > or = to Rituxan. The protein and carbohydrate alterations are additive. Comparison of the carbohydrate found on native IgG from the Lec13-produced and CHO-produced IgG showed no appreciable differences in the extent of galactosylation and hence the results can be attributed solely to the presence/absence of fucose.

Example 12

Fucose-deficient 2H7 variant antibodies with enhanced ADCC in vivo

[0254] This example describes ADCC activity in vivo of the fucose-deficient humanized 2H7 variants including v.16 and v.31 produced in Lec13 compared to normal fucosylated counterparts produced in DP 12, in mice expressing human CD16 [FcRγIII] and human CD20.

Generation of huCD20Tg⁺ huCD16Tg⁺ mCD16^{-/-} mice

[0255] Human CD20 transgenic mice were generated from human CD20 BAC DNA (Invitrogen, Carlsbad, CA). Mice were screened based on the FACS analysis of human CD20 expression. HuCD20 Tg⁺ mice were then crossed with huCD16Tg⁺mCD16^{-/-} mice to generate huCD20Tg⁺huCD16Tg⁺mCD16^{-/-} mice.

In vivo treatment,

[0256] Ten to 100 μg of each of the 2H7 variants or Rituxan® is administered to huCD20Tg⁺huCD16Tg⁺mCD16^{-/-} mice via intraperitoneal injections. Equal amount of isotype-matched antibodies will be applied similarly to the negative control group of animals.

Mouse lymphocytes preparation

[0257] Mouse lymphocytes from whole blood, spleen, lymph nodes and bone marrow are prepared according to standard protocol described in "Current Protocols in Immunology, edited by John Coligan, Ada Kruisbeek, David Margulies, Ethan Shevach and Warren Strober, 1994".

FACS analysis

[0258] Half million cells are washed and resuspended in 100 μl of FACS buffer, which is phosphate buffered saline with 1% BSA, containing 5 μl of staining or control antibody. All the staining antibodies, including isotype controls, are obtained from PharMingen, San Diego, CA. Human CD20 expression is assessed by staining with Rituxan® along with FITC-conjugated anti-human IgG1 secondary antibody. FACS analysis is conducted using FACScan and Cell Quest (Becton Dickinson Immunocytometry Systems, San Jose, CA). All the lymphocytes are defined in the forward and side light scatterings, while all the B lymphocytes are defined with the expression of B220 on the cell surface.

[0259] B cell depletion and recovery are assessed by analyzing peripheral B cell counts and analysis of hCD20⁺ B cells by FACS in the spleen, lymph node and bone marrow on a daily basis for the first week after injection and thereafter on a weekly basis. Serum levels of the injected 2H7 variant antibody are monitored.

[0260] The results of this *in vivo* assay confirms the *in vitro* findings on the increased ADCC activity and greater B cell depletion of fucose-deficient 2H7 variants over wild-type (with respect to fucosylation) glycosylation counterparts.

Example 13

Apoptosis Activity

[0261] Anti-CD20 antibodies including Rituxan® have been shown to induce *apoptosis in vitro* when crosslinked by a secondary antibody or by chemical means (Shan et al., Blood 9:1644-1652 (1998); Byrd et al., Blood 99:1038-43 (2002); Pederson et al., Blood 99:1314-19 (2002)). When chemically crosslinked, murine 2H7 dimers induced apoptosis of Daudi cells (Ghetie et al., Proc Natl Acad Sci USA 94:7509-14 (1997)). Crosslinking with a secondary antibody also induced apoptosis with the murine 2H7 antibody (Shan et al., 1998). These activities are believed to be physiologically relevant because a variety of mechanisms could lead to crosslinking of anti-CD20 antibodies bound to cell-surface CD20 *in vivo*.

[0262] RhuMAb 2H7.v16 [humanized 2H7 v16; RhuMAb stands for recombinant human monoclonal antibody] and Rituxan® were compared in apoptosis assays *in vitro* using a secondary crosslinking antibody. Ramos cells (CRL-1596, ATCC, Manassas, VA), a CD20-expressing, human B lymphocyte cell line, were used to measure the ability of the anti-CD20 monoclonal antibodies rhuMAb 2H7.v16 and Rituximab versus a negative-control antibody, Trastuzumab (Herceptin®, Genentech, South San Francisco, CA), to induce apoptosis as measured through Annexin V staining and propidium iodide dye exclusion (Vybrant® Apoptosis Assay Kit, Molecular Probes, Seattle, WA). The Ramos cells were cultured in RPMI-1640 medium (Gibco, Rockville, MD) containing 10% fetal bovine serum (Biosource International, Camarillo, CA) and 2 mM L-glutamine (Gibco). Prior to being assayed, the cells were washed twice in fresh media and then adjusted to a cell concentration of 2×10^6 per mL. Cells (150 μ L) were added to 96-well assay plates (Becton Dickinson, Palo Alto, CA) which contained 150 μ L of a predetermined amount of control IgG1, rhuMAb 2H7.v16, or Rituximab, along with F(ab)'2 goat anti-human Fc (Pierce Biotechnology, Rockford, IL). The final IgG concentrations were 100, 10, 1.0, 0.1, 0.01 and 0.001 nM, and the F(ab)'2 goat anti-human Fc antibody concentration was set at twice the respective sample antibody concentration. Each dilution was set up in triplicate. After a 24-hour incubation at 37° C, the cells were washed twice with PBS and then stained with Annexin V and propidium iodide according to the manufacturer's recommendations. The staining patterns of the Ramos cells were analyzed by flow cytometry using a FACscan Flow Cytometer (Becton Dickinson, San Jose, CA), and data were collected for 10 s-periods. The data were reduced using the Cellquest Pro software (Becton Dickinson). Ramos cells that were positive for (1) Annexin V staining, (2) Annexin V and propidium iodide double-staining, and (3) the number of unstained live cells, were counted and plotted using KaleidaGraph software (Synergy Software, Reading, PA).

[0263] Both rhuMAb 2H7.v16 and Rituximab induced apoptosis of Ramos cells when crosslinked with anti-human Fc and as compared to an irrelevant IgG1 control antibody (Figures 13-15). The apoptotic activity of (rhuMAb 2H7) was slightly lower than that of Rituximab. At 10 nM concentrations of crosslinked rhuMAb 2H7, Rituximab, and control IgG1 antibody, fractions of Annexin V stained cells were 18.5, 16.5, 2.5%, respectively, fractions of doubly labeled cells were 29, 38, and 16%, and numbers of live cells counted per 10 s were 5200, 3100, and 8600.

[0264] These *in vitro* data demonstrate that apoptosis is one potential mechanism for *in vivo* B cell depletion. *In vivo* crosslinking of rhuMAb 2H7 or Rituximab bound to cell-surface CD20 may occur through Fc γ R on the surfaces of immune effector cells.

Example 14

In Vivo Suppression of Tumor Growth

[0265] The ability of rhuMAb 2H7.v16 to inhibit the growth of the Raji human B-cells, a lymphoma cell line (ATCC CCL 86), was evaluated in Balb/c nude (athymic) mice. The Raji cells express CD20 and have been reported to grow in nude mice, producing metastatic disease; tumor growth is inhibited by Rituxan® (Clynes et al., Nature Medicine 6, 443-446 (2000)). Fifty-six 8-10 week old, Balb/c nude mice were divided into 7 groups (A-G) with each group consisting of 8 mice. On day 0, each mouse received a subcutaneous injection of 5×10^6 Raji B-lymphoma cells in the flank. Beginning at day 0, each mouse received either 100 μ L of the negative-control solution (PBS; phosphate-buffered saline), Rituxan® or 2H7.v16. Dosage was dependent on weight and drug delivery was intravenously via the tail vein. Group A mice received PBS. Groups B-D received Rituxan® at 5.0, mg/kg, 0.5 mg/kg, and 0.05 mg/kg respectively. Groups E-G mice received 2H7.v16 at 5.0 mg/kg, 0.5 mg/kg, and 0.05 mg/kg respectively. The injections were repeated every week for 6 weeks. At weekly intervals during treatment, each mouse was inspected for the presence of palpable tumors at the site of injection, and the volume of the tumors if present were measured and recorded. A final inspection was made at week 8 (after a two-week interval of no treatments).

[0266] The results of this study showed that both rhuMAb 2H7.v16 and Rituxan® and were effective at inhibiting

subcutaneous Raji-cell tumor growth in nude mice (FIGs. 16-18). Tumor growth was observed in the PBS control group beginning at 4 weeks. However, no tumor growth was observed in groups treated with Rituxan® or 2H7.v16 at 5 mg/kg or 0.5 mg/kg for the 8-week duration of the study. In the low-dose 0.05 mg/kg treatment groups, tumors were observed in one animal in the 2H7 group and in one animal in the Rituxan® group (FIG. 18).

Example 15

Cloning of Cynomolgus monkey CD20 and antibody binding

[0267] The CD20 DNA sequence for cynomolgus monkey (*Macaca fascicularis*) was determined upon the isolation of cDNA encoding CD20 from a cynomolgus spleen cDNA library. A SUPERScript™ Plasmid System for cDNA Synthesis and Plasmid Cloning (Cat#18248-013, Invitrogen, Carlsbad, CA) was used with slight modifications to construct the library. The cDNA library was ligated into a pRK5E vector using restriction sites Xho I and Not I. mRNA was isolated from spleen tissue ((California Regional Research Primate Center, Davis, CA). Primers to amplify cDNA encoding CD20 were designed based on non-coding sequences of human CD20. N-terminal region primer 5'-AGTTTGGAGAG-CAAAATG-3' and C-terminal region primer 5'-AAGCTATGAACACTAATG-3' were used to clone by polymerase chain reaction (PCR) the cDNA encoding cynomolgus monkey CD20. The PCR reaction was carried out using Platinum Taq DNA Polymerase High Fidelity according to the manufacturers recommendation (Gibco, Rockville, MD). The PCR product was subcloned into pCR®2.1-TOPO®Vector (Invitrogen) and transformed into XL-1 blue E. coli (Stratagene, La Jolla, CA). Plasmid DNA containing ligated PCR products was isolated from individual clones and sequenced.

[0268] The amino acid sequence for cynomolgus monkey CD20 is shown in Figure 19. Figure 20 shows a comparison of cynomolgus and human CD20. The cynomolgus monkey CD20 is 97.3% similar to human CD20 with 8 differences. The extracellular domain contains one change at V157A, while the remaining 7 residues can be found in the cytoplasmic or transmembrane regions.

[0269] Antibodies directed against human CD20 were assayed for the ability to bind and displace FITC-conjugated murine 2H7 binding to cynomolgus monkey cells expressing CD20. Twenty milliliters of blood were drawn from 2 cynomolgus monkeys (California Regional Research Primate Center, Davis, CA) into sodium heparin and shipped directly to Genentech Inc.. On the same day, the blood samples were pooled and diluted 1:1 by the addition of 40 ml of phosphate buffered saline (PBS). 20 ml of diluted blood was layered on 4 x 20 ml of Ficoll-Paque™ Plus (Amersham Biosciences, Uppsala, Sweden) in 50 ml conical tubes (Cat#352098, Falcon, Franklin Lakes, NJ) and centrifuged at 1300 rpm for 30 minutes R.T. in a Sorval 7 centrifuge. (Dupont, Newtown, CT). The PBMC layer was isolated and washed in PBS. Red blood cells were lysed in a 0.2% NaCl solution, restored to isotonicity with an equivalent volume of a 1.6% NaCl solution, and centrifuged for 10 minutes at 1000 RPM. The PBMC pellet was resuspended in RPMI 1640 (Gibco, Rockville, MD) containing 5% fetal bovine serum (FBS) and dispensed into a 10 cm tissue culture dish for 1 hour at 37° C. The non-adherent B and T cell populations were removed by aspiration, centrifuged and counted. A total of 2.4×10^7 cells were recovered. The resuspended PBMC were distributed into twenty 12 x 75 mm culture tubes (Cat#352053, Falcon), with each tube containing 1×10^6 cells in a volume of 0.25 ml. Tubes were divided into four sets of five tubes. To each set was added either media (RPMI1640, 5% FBS), titrated amounts of control human IgG₁ antibody, Rituxan®, 2H7.v16, or 2H7.v31. The final concentration of each antibody was 30, 10, 3.3 and 1.1 nM. In addition, each tube also received 20 ul of Fluorescein Isothiocyanate (FITC)-conjugated anti-human CD20 (Cat#555622, BD Biosciences, San Diego, CA). The cells were gently mixed, incubated for 1 hour on ice and then washed twice in cold PBS. The cell surface staining was analyzed on a Epic XL-MCL (Coulter, Miami, FL), the geometric means derived, plotted (KaleidaGraph™, Synergy Software, Reading, PA) versus antibody concentrations.

[0270] Data in Figure 21 showed that 2H7 v.16 and 2H7 v.31 competitively displaced FITC-murine 2H7 binding to cynomolgus monkey cells. Furthermore, Rituxan® also displaced FITC-murine 2H7 binding thus demonstrating that both 2H7 and Rituxan® bind to an overlapping epitope on CD20. In addition, the data show that the IC₅₀ value for 2H7 v.16, 2H7 v.31 and Rituxan are similar and fall in the 4-6 nM range.

Example 16

Phase I/II study of rhuMAb 2H7 (2H7.v16) in moderate to severe rheumatoid arthritis

Protocol Synopsis

[0271] A randomized, placebo-controlled, multicenter, blinded phase I/II study of the safety of escalating doses of PRO70769 (rhuMAb 2H7) in subjects with moderate to severe rheumatoid arthritis receiving stable doses of concomitant methotrexate.

Objectives

[0272] The primary objective of this study is to evaluate the safety and tolerability of escalating intravenous (IV) doses of PRO70769 (rhuMAb 2H7) in subjects with moderate to severe rheumatoid arthritis (RA).

Study Design

[0273] This is a randomized, placebo-controlled, multicenter, blinded Phase I/II, investigator- and subject-blinded study of the safety of escalating doses of PRO70769 in combination with MTX in subjects with moderate to severe RA. The study consists of a dose escalation phase and a second phase with enrollment of a larger number of subjects. The Sponsor will remain unblinded to treatment assignment.

[0274] Subjects with moderate to severe RA who have failed one to five disease-modifying antirheumatic drugs or biologics who currently have unsatisfactory clinical responses to treatment with MTX will be enrolled.

[0275] Subjects will be required to receive MTX in the range of 10-25 mg weekly for at least 12 weeks prior to study entry and to be on a stable dose for at least 4 weeks before receiving their initial dose of study drug (PRO70769 or placebo). Subjects may also receive stable doses of oral corticosteroids (up to 10 mg daily or prednisone equivalent) and stable doses of nonsteroidal anti-inflammatory drugs (NSAIDs). Subjects will receive two IV infusions of PRO70769 or placebo equivalent at the indicated dose on Days 1 and 15 according to the following dose escalation plan (see Figure 22).

[0276] Dose escalation will occur according to specific criteria (see Dose Escalation Rules) and after review of safety data by an internal safety data review committee and assessment of acute toxicity 72 hours following the second infusion in the last subject treated in each cohort. After the dose escalation phase, 40 additional subjects (32 active and 8 placebo) will be randomized to each of the following dose levels: 2x50 mg, 2x200 mg, 2x500 mg, and 2x1000 mg, if the dose levels have been demonstrated to be tolerable during the dose escalation phase. Approximately 205 subjects will be enrolled in the study.

[0277] B-cell counts will be obtained and recorded (for study assessments, see Section 4.5 and Appendix A-1). B-cell counts will be evaluated using flow cytometry in a 48-week follow-up period beyond the 6-month efficacy evaluation. B-cell depletion will not be considered a dose-limiting toxicity (DLT), but rather the expected pharmacodynamic outcome of PRO70769 treatment.

[0278] In an optional substudy, blood for serum and RNA analyses, as well as urine samples will be obtained from subjects at various timepoints (see Section 3.3.3). These samples may be used to identify biomarkers that may be predictive of response to PRO70769 treatment in subjects with moderate to severe RA.

Outcome Measures

[0279] The primary outcome measure for this study is the safety and tolerability of PRO70769 in subjects with moderate to severe RA.

Study Treatment

[0280] Cohorts of subjects will receive two IV infusions of PRO70769 or placebo equivalent at the indicated dose on Days 1 and 15 according to the following escalation plan:

- 10 mg PRO70769 or placebo equivalent: 4 subjects active drug, 1 control
- 50 mg PRO70769 or placebo equivalent: 8 subjects active drug, 2 control
- 200 mg PRO70769 or placebo equivalent: 8 subjects active drug, 2 control
- 500 mg PRO70769 or placebo equivalent: 8 subjects active drug, 2 control
- 1000 mg PRO70769 or placebo equivalent: 8 subjects active drug, 2 control

Efficacy

[0281] The efficacy of PRO70769 will be measured by ACR responses. The percentage of subjects who achieve an ACR20, ACR50, and ACR70 response will be summarized by treatment group and 95% confidence intervals will be generated for each group. The components of these response and their change from baseline will be summarized by treatment and visit.

Conclusion

[0282] The data above demonstrated the success in producing humanized CD20 binding antibodies, in particular humanized 2H7 antibody variants, that maintained and even enhanced their biological properties. The humanized 2H7 antibodies of the invention bound to CD20 at affinities similar to the murine donor and chimeric 2H7 antibodies and were effective at B cell killing in a primate, leading to B cell depletion. Certain variants showed enhanced ADCC over a chimeric anti-CD20 antibody currently used to treat NHL, favoring the use of lower doses of the therapeutic antibody in patients. Additional, whereas it may be necessary for a chimeric antibody that has murine FR residues to be administered at a dose effective to achieve complete B cell depletion to obviate an antibody response against it, the present humanized antibodies can be administered at dosages that achieve partial or complete B cell depletion, and for different durations of time, as desired for the particular disease and patient. In addition, these antibodies demonstrated stability in solution. These properties of the humanized 2H7 antibodies make them ideal for use as immunotherapeutic agent in the treatment of CD20 positive cancers and autoimmune diseases; these antibodies are not expected to be immunogenic or will at least be less immunogenic than fully murine or chimeric anti-CD20 antibodies in human patients.

References

[0283] References cited within this application, including patents, published applications and other publications, are hereby incorporated by reference.

[0284] The practice of the present invention will employ, unless otherwise indicated, conventional techniques of molecular biology and the like, which are within the skill of the art. Such techniques are explained fully in the literature. See e.g., Molecular Cloning: A Laboratory Manual, (J. Sambrook et al., Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y., 1989); Current Protocols in Molecular Biology (F. Ausubel et al., eds., 1987 updated); Essential Molecular Biology (T. Brown ed., IRL Press 1991); Gene Expression Technology (Goeddel ed., Academic Press 1991); Methods for Cloning and Analysis of Eukaryotic Genes (A. Bothwell et al. eds., Bartlett Publ. 1990); Gene Transfer and Expression (M. Kriegler, Stockton Press 1990); Recombinant DNA Methodology II (R Wu et al. eds., Academic Press 1995); PCR: A Practical Approach (M. McPherson et al., IRL Press at Oxford University Press 1991); Oligonucleotide Synthesis (M. Gait ed., 1984); Cell Culture for Biochemists (R. Adams ed., Elsevier Science Publishers 1990); Gene Transfer Vectors for Mammalian Cells (J. Miller & M. Calos eds., 1987); Mammalian Cell Biotechnology (M. Butler ed., 1991); Animal Cell Culture (J. Pollard et al. eds., Humana Press 1990); Culture of Animal Cells, 2nd Ed. (R. Freshney et al. eds., Alan R. Liss 1987); Flow Cytometry and Sorting (M. Melamed et al. eds., Wiley-Liss 1990); the series Methods in Enzymology (Academic Press, Inc.); Wirth M. and Hauser H. (1993); Immunochemistry in Practice, 3rd edition, A. Johnstone & R. Thorpe, Blackwell Science, Cambridge, MA, 1996; Techniques in Immunocytochemistry, (G. Bullock & P. Petrusz eds., Academic Press 1982, 1983, 1985, 1989); Handbook of Experimental Immunology, (D. Weir & C. Blackwell, eds.); Current Protocols in Immunology (J. Coligan et al. eds. 1991); Immunoassay (E. P. Diamandis & T.K. Christopoulos, eds., Academic Press, Inc., 1996); Goding (1986) Monoclonal Antibodies: Principles and Practice (2d ed) Academic Press, New York; Ed Harlow and David Lane, Antibodies A laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 1988; Antibody Engineering, 2nd edition (C. Borrebaeck, ed., Oxford University Press, 1995); and the series Annual Review of Immunology; the series Advances in Immunology.

[0285] The following numbered clauses, describing aspects of the invention, are part of the description

1. A humanized antibody that binds human CD20, or an antigen-binding fragment thereof, wherein the antibody is effective to deplete primate B cells in vivo, the antibody comprising in the H chain Variable region (V_H) at least a CDR3 sequence of SEQ ID NO. 12 from an anti-human CD20 antibody and substantially the human consensus framework (FR) residues of human heavy chain subgroup III (V_{HIII}).
2. The antibody of clause 1, further comprising the H chain CDR1 sequence of SEQ ID NO. 10 and CDR2 sequence of SEQ ID NO. 11.
3. The antibody of clause 2, further comprising the L chain CDR1 sequence of SEQ ID NO. 4, CDR2 sequence of SEQ ID NO. 5, CDR3 sequence of SEQ ID NO. 6 and substantially the human consensus framework (FR) residues of human light chain κ subgroup I ($V_{\kappa I}$).
4. The antibody of the preceding clause comprising the V_H sequence of SEQ ID NO.8 (v16, as shown in FIG. 1B).
5. The antibody of clause 4, further comprising the V_L sequence of SEQ ID NO.2 (v16, as shown in FIG. 1A).
6. The antibody of clause 3, wherein the V_H region is joined to a human IgG chain constant region.
7. The antibody of clause 6, wherein the human IgG is IgG1 or IgG3.
8. The antibody of clause 1, wherein the antibody is 2H7.v16, having the light and heavy chain amino acid sequence of SEQ ID NO. 21 and 22, respectively, [as shown in FIG. 6 and FIG. 7]
9. The antibody of clause 1, wherein the antibody is 2H7.v31 having the light and heavy chain amino acid sequence of SEQ ID NO. 2 and 23, respectively, [as shown in FIG. 6 and FIG. 8].

10. The antibody of clause 5, but with the amino acid substitutions of D56A and N100A in the H chain and S92A in the L chain. [v.96]
11. The antibody of any of the preceding clause further comprising at least one amino acid substitution in the Fc region that improves ADCC and/or CDC activity.
- 5 12. The antibody of clause 11, wherein the amino acid substitutions are S298A/E333A/K334A.
13. The antibody of clause 12, wherein the antibody is 2H7.v31 having the heavy chain amino acid sequence of SEQ ID NO. 23 [as shown in FIG. 8].
14. The antibody of any of clause 1-10, further comprising at least one amino acid substitution in the Fc region that decreases CDC activity.
- 10 15. The antibody of any of clause 14, comprising at least the substitution K322A.
16. The antibody of clause 1-10 wherein the antibody is 2H7.v114 or 2H7.v115 having at least 10-fold improved ADCC activity as compared to Rituxan.
17. The antibody of clause 1 wherein the primate B cells are from human and Cynomolgus monkey.
18. The antibody of any of the preceding clause conjugated to a cytotoxic agent.
- 15 19. The antibody of clause 18 wherein the cytotoxic agent is a radioactive isotope or a toxin.
20. The antibody of any of the preceding clause which antibody is produced in CHO cells.
21. An isolated nucleic acid that encodes the antibody of any one of the preceding clause
22. An expression vector encoding the antibody of any of the preceding clause
23. A host cell comprising a nucleic acid of clause 21.
- 20 24. The host cell of clause 23 that produces the antibody of any one of preceding clause
25. The host cell of clause 24 which is a CHO cell.
26. A method of producing the antibody of any one of the preceding clause comprising culturing the cell that produces the antibody of clause 24 and recovering the antibody from the cell culture.
27. A composition comprising the antibody of clause 1 and a carrier.
- 25 28. The composition of clause 27 wherein the antibody is 2H7.v16 and the carrier is a pharmaceutically acceptable carrier.
29. An article of manufacture comprising a container and a composition contained therein, wherein the composition comprises an antibody of any of the preceding clause
30. The article of manufacture of clause 29, further comprising a package insert indicating that the composition can be used to treat non-Hodgkin's lymphoma.
- 30 31. A method of inducing apoptosis in B cells in vivo, comprising contacting B cells with the antibody of any of the preceding clause thereby killing the B cells.
32. A method of treating a CD20 positive cancer, comprising administering to a patient suffering from the cancer, a therapeutically effective amount of the humanized CD20 binding antibody of any of the preceding clause
- 35 33. The method of clause 32 wherein the CD20 positive cancer is a B cell lymphoma or leukemia.
34. The method of clause 33 wherein CD20 positive cancer is non-Hodgkin's lymphoma (NHL) or lymphocyte predominant Hodgkin's disease (LPHD).
35. The method of clause 32 wherein the cancer is chronic lymphocytic leukemia or SLL.
36. The method of clause 34 or 35 wherein the antibody is selected from the group consisting of 2H7.v16, v31.v96, v114, v115 having the respective amino acid sequences as shown in the figures and tables.
- 40 37. The method of clause 34 or 35 wherein the antibody is 2H7.v16 having the light and heavy chain amino acid sequence of SEQ ID NO. 21 and 22, respectively, as shown in FIG. 6 and FIG. 7.
38. The method of clause 33, wherein the antibody is administered at a dosage range of about 275-375mg/m².
39. The method of clause 32, further comprising administering to the patient at least one chemotherapeutic agent.
- 45 40. The method of clause 39, wherein the cancer is non-Hodgkin's lymphoma (NHL) and the chemotherapeutic agent is selected from the group consisting of doxorubicin, cyclophosphamide, vincristine and prednisolone.
41. A method of treating an autoimmune disease, comprising administering to a patient suffering from the autoimmune disease, a therapeutically effective amount of the humanized CD20 binding antibody of any one of the preceding clause
- 50 42. The method of clause 41, wherein the autoimmune disease is selected from the group consisting of rheumatoid arthritis, juvenile rheumatoid arthritis, systemic lupus erythematosus (SLE), Wegener's disease, inflammatory bowel disease, idiopathic thrombocytopenic purpura (ITP), thrombotic thrombocytopenic purpura (TTP), autoimmune thrombocytopenia, multiple sclerosis, psoriasis, IgA nephropathy, IgM polyneuropathies, myasthenia gravis, vasculitis, diabetes mellitus, Reynaud's syndrome, Sjorgen's syndrome and glomerulonephritis.
- 55 43. The method of clause 42, wherein the autoimmune disease is rheumatoid arthritis.
44. The method of clause 43, further comprising administering to the patient a second therapeutic agent.
45. The method of clause 44, wherein the second therapeutic agent is an immunosuppressive agent.
46. The method of clause 45, wherein the immunosuppressive agent is methotrexate.

47. A method of treating an autoimmune disease selected from the group consisting of Dermatomyositis, Wegner's granulomatosis, ANCA (included under vasculitis), Aplastic anemia, Autoimmune hemolytic anemia (AIHA), factor VIII deficiency, hemophilia A, Autoimmune neutropenia, Castleman's syndrome, Goodpasture's syndrome, solid organ transplant rejection, graft versus host disease (GVHD), IgM mediated, thrombotic thrombocytopenic purpura (TTP), Hashimoto's Thyroiditis, autoimmune hepatitis, lymphoid interstitial pneumonitis (HIV), bronchiolitis obliterans (non-transplant) vs. NSIP, Guillain-Barre Syndrome, large vessel vasculitis, giant cell (Takayasu's) arteritis, medium vessel vasculitis, Kawasaki's Disease, and polyarteritis nodosa, comprising administering to a patient suffering from the disease, a therapeutically effective amount of a CD20 binding antibody or functional fragment thereof

48. The method of clause 47 wherein the CD20 binding antibody is Rituxan®.

49. An isolated nucleic acid comprising the nucleotide sequence of SEQ ID NO.: _ of the Cynomolgus monkey CD20 (shown in FIG. 19), or a degenerate variant of this sequence.

50. An isolated nucleic acid comprising a sequence that encodes a polypeptide with the amino acid sequence of SEQ ID NO. _ (shown FIG. 20), or SEQ ID NO. _ (FIG. 20) with conservative amino acid substitutions.

51. A vector comprising the nucleic acid of clause 50.

52. The vector of clause 51 which is an expression vector comprising the nucleic acid of clause 49 operably lined to an expression control sequence.

53. A host cell comprising the nucleic acid of clause 50.

54. An isolated polypeptide comprising the amino acid sequence [SEQ ID NO. _ ; FIG. 20] of the Cynomolgus monkey CD20.

55. A liquid formulation comprising a humanized 2H7 antibody at 20mg/mL, 10mM histidine sulfate at pH5.8, 60mg/ml sucrose, 0.2 mg/ml polysorbate 20.

Sequence Listing

<110> GENENTECH, INC.

<120> Immunoglobulin Variants and Uses Thereof

<130> EAH/FP7272883

<140> EP

<141> 2003-12-16

<150> EP10179942.7

<151> 2003-12-16

<150> EP 08005671.6

<151> 2003-12-16

<150> EP 03813759.2

<151> 2003-12-16

<150> PCT/US03/40426

<151> 2003-12-16

<150> US 60/434,115

<151> 2002-12-16

<150> US 60/526,163

<151> 2003-12-01

<160> 38

<210> 1

<211> 107

<212> PRT

<213> Mus musculus

<400> 1

Gln	Ile	Val	Leu	Ser	Gln	Ser	Pro	Ala	Ile	Leu	Ser	Ala	Ser	Pro
1				5					10					15

Gly	Glu	Lys	Val	Thr	Met	Thr	Cys	Arg	Ala	Ser	Ser	Ser	Val	Ser
				20					25					30

Tyr	Met	His	Trp	Tyr	Gln	Gln	Lys	Pro	Gly	Ser	Ser	Pro	Lys	Pro
				35					40					45

Trp	Ile	Tyr	Ala	Pro	Ser	Asn	Leu	Ala	Ser	Gly	Val	Pro	Ala	Arg
				50					55					60

Phe	Ser	Gly	Ser	Gly	Ser	Gly	Thr	Ser	Tyr	Ser	Leu	Thr	Ile	Ser
				65					70					75

Arg	Val	Glu	Ala	Glu	Asp	Ala	Ala	Thr	Tyr	Tyr	Cys	Gln	Gln	Trp
				80					85					90

Ser	Phe	Asn	Pro	Pro	Thr	Phe	Gly	Ala	Gly	Thr	Lys	Leu	Glu	Leu
				95					100					105

Lys Arg

<210> 2

<211> 107

<212> PRT

<213> Artificial sequence

<220>

<223> Sequence is synthesized

<400> 2

Asp	Ile	Gln	Met	Thr	Gln	Ser	Pro	Ser	Ser	Leu	Ser	Ala	Ser	Val
1				5					10					15

Gly	Asp	Arg	Val	Thr	Ile	Thr	Cys	Arg	Ala	Ser	Ser	Ser	Val	Ser
				20					25					30

Tyr	Met	His	Trp	Tyr	Gln	Gln	Lys	Pro	Gly	Lys	Ala	Pro	Lys	Pro
				35					40					45

Leu	Ile	Tyr	Ala	Pro	Ser	Asn	Leu	Ala	Ser	Gly	Val	Pro	Ser	Arg
				50					55					60

Phe	Ser	Gly	Ser	Gly	Ser	Gly	Thr	Asp	Phe	Thr	Leu	Thr	Ile	Ser
				65					70					75

Ser	Leu	Gln	Pro	Glu	Asp	Phe	Ala	Thr	Tyr	Tyr	Cys	Gln	Gln	Trp
				80					85					90

Ser	Phe	Asn	Pro	Pro	Thr	Phe	Gly	Gln	Gly	Thr	Lys	Val	Glu	Ile
				95					100					105

Lys Arg

<210> 3

<211> 108

<212> PRT

<213> Artificial Sequence

<220>

<223> Sequence is synthesized

<400> 3

Asp	Ile	Gln	Met	Thr	Gln	Ser	Pro	Ser	Ser	Leu	Ser	Ala	Ser	Val
1				5					10					15

Gly	Asp	Arg	Val	Thr	Ile	Thr	Cys	Arg	Ala	Ser	Gln	Ser	Ile	Ser
				20					25					30

Asn	Tyr	Leu	Ala	Trp	Tyr	Gln	Gln	Lys	Pro	Gly	Lys	Ala	Pro	Lys
				35					40					45

Leu	Leu	Ile	Tyr	Ala	Ala	Ser	Ser	Leu	Glu	Ser	Gly	Val	Pro	Ser
				50					55					60

Arg	Phe	Ser	Gly	Ser	Gly	Ser	Gly	Thr	Asp	Phe	Thr	Leu	Thr	Ile
				65					70					75

Ser	Ser	Leu	Gln	Pro	Glu	Asp	Phe	Ala	Thr	Tyr	Tyr	Cys	Gln	Gln
				80					85					90

Tyr	Asn	Ser	Leu	Pro	Trp	Thr	Phe	Gly	Gln	Gly	Thr	Lys	Val	Glu
				95					100					105

Ile Lys Arg

EP 3 263 596 A1

<210> 4
 <211> 10
 <212> PRT
 <213> Mus musculus
 5
 <400> 4
 Arg Ala Ser Ser Ser Val Ser Tyr Met His
 1 5 10
 10
 <210> 5
 <211> 7
 <212> PRT
 <213> Mus musculus
 <400> 5
 15 Ala Pro Ser Asn Leu Ala Ser
 1 5
 <210> 6
 <211> 9
 <212> PRT
 20 <213> Mus musculus
 <400> 6
 Gln Gln Trp Ser Phe Asn Pro Pro Thr
 1 5
 25
 <210> 7
 <211> 122
 <212> PRT
 <213> Mus musculus
 30
 <400> 7
 Gln Ala Tyr Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly
 1 5 10 15
 Ala Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr
 20 25 30
 35 Ser Tyr Asn Met His Trp Val Lys Gln Thr Pro Arg Gln Gly Leu
 35 40 45
 Glu Trp Ile Gly Ala Ile Tyr Pro Gly Asn Gly Asp Thr Ser Tyr
 40 50 55 60
 Asn Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser
 65 70 75
 45 Ser Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp
 80 85 90
 Ser Ala Val Tyr Phe Cys Ala Arg Val Val Tyr Tyr Ser Asn Ser
 95 100 105
 50 Tyr Trp Tyr Phe Asp Val Trp Gly Thr Gly Thr Thr Val Thr Val
 110 115 120
 Ser Ser
 55
 <210> 8
 <211> 122

<212> PRT

<213> Artificial sequence

<220>

<223> Sequence is synthesized

<400> 8

Glu	Val	Gln	Leu	Val	Glu	Ser	Gly	Gly	Gly	Leu	Val	Gln	Pro	Gly
1				5					10					15

Gly	Ser	Leu	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Tyr	Thr	Phe	Thr
				20					25					30

Ser	Tyr	Asn	Met	His	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu
				35					40					45

Glu	Trp	Val	Gly	Ala	Ile	Tyr	Pro	Gly	Asn	Gly	Asp	Thr	Ser	Tyr
				50					55					60

Asn	Gln	Lys	Phe	Lys	Gly	Arg	Phe	Thr	Ile	Ser	Val	Asp	Lys	Ser
				65					70					75

Lys	Asn	Thr	Leu	Tyr	Leu	Gln	Met	Asn	Ser	Leu	Arg	Ala	Glu	Asp
				80					85					90

Thr	Ala	Val	Tyr	Tyr	Cys	Ala	Arg	Val	Val	Tyr	Tyr	Ser	Asn	Ser
				95					100					105

Tyr	Trp	Tyr	Phe	Asp	Val	Trp	Gly	Gln	Gly	Thr	Leu	Val	Thr	Val
				110					115					120

Ser Ser

<210> 9

<211> 119

<212> PRT

<213> Artificial Sequence

<220>

<223> Sequence is synthesized

<400> 9

Glu	Val	Gln	Leu	Val	Glu	Ser	Gly	Gly	Gly	Leu	Val	Gln	Pro	Gly
1				5					10					15

Gly	Ser	Leu	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Phe	Thr	Phe	Ser
				20					25					30

Ser	Tyr	Ala	Met	Ser	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu
				35					40					45

Glu	Trp	Val	Ala	Val	Ile	Ser	Gly	Asp	Gly	Gly	Ser	Thr	Tyr	Tyr
				50					55					60

Ala	Asp	Ser	Val	Lys	Gly	Arg	Phe	Thr	Ile	Ser	Arg	Asp	Asn	Ser
				65					70					75

Lys	Asn	Thr	Leu	Tyr	Leu	Gln	Met	Asn	Ser	Leu	Arg	Ala	Glu	Asp
				80					85					90

Thr	Ala	Val	Tyr	Tyr	Cys	Ala	Arg	Gly	Arg	Val	Gly	Tyr	Ser	Leu
				95					100					105

EP 3 263 596 A1

Tyr Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
110 115

<210> 10
<211> 10
<212> PRT
<213> Mus musculus

<400> 10
Gly Tyr Thr Phe Thr Ser Tyr Asn Met His
1 5 10

<210> 11
<211> 17
<212> PRT
<213> Mus musculus

<400> 11
Ala Ile Tyr Pro Gly Asn Gly Asp Thr Ser Tyr Asn Gln Lys Phe
1 5 10 15

Lys Gly

<210> 12
<211> 13
<212> PRT
<213> Mus musculus

<400> 12
Val Val Tyr Tyr Ser Asn Ser Tyr Trp Tyr Phe Asp Val
1 5 10

<210> 13
<211> 5679
<212> DNA
<213> Artificial Sequence

<220>
<223> Sequence is synthesized

<400> 13
gaattcaact tctccatact ttggataagg aaatacagac atgaaaaatc 50
tcattgctga gttgttattt aagcttgccc aaaaagaaga agagtcgaat 100
gaactgtgtg cgcaggtaga agctttggag attatcgtca ctgcaatgct 150
tcgcaatatg gcgcaaaatg accaacagcg gttgattgat caggtagagg 200
gggcgctgta cgaggtaaag cccgatgccg gcattcctga cgacgatacg 250
gagctgctgc gcgattacgt aaagaagtta ttgaagcatc ctcgtcagta 300
aaaagttaat cttttcaaca gctgtcataa agttgtcacg gccgagactt 350
atagtcgctt tgttttttatt ttttaatgta tttgtaacta gaattcgagc 400
tcgggtaccg gggatcctct agagggtgag gtgatttt atg aaa 444
Met Lys
1

EP 3 263 596 A1

	aag aat atc gca ttt ctt ctt gca tct atg ttc gtt ttt	483
	Lys Asn Ile Ala Phe Leu Leu Ala Ser Met Phe Val Phe	
	5 10 15	
5	tct att gct aca aac gcg tac gct gat atc cag atg acc	522
	Ser Ile Ala Thr Asn Ala Tyr Ala Asp Ile Gln Met Thr	
	20 25	
10	cag tcc ccg agc tcc ctg tcc gcc tct gtg ggc gat agg	561
	Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg	
	30 35 40	
	gtc acc atc acc tgc aga gcc agt cag agc gtg tcg act	600
	Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Val Ser Thr	
	45 50	
15	agc tct tat agc tat atg cac tgg tat caa cag aaa cca	639
	Ser Ser Tyr Ser Tyr Met His Trp Tyr Gln Gln Lys Pro	
	55 60 65	
20	gga aaa gct ccg aaa cta ctg att tac tat gct agc aac	678
	Gly Lys Ala Pro Lys Leu Leu Ile Tyr Tyr Ala Ser Asn	
	70 75 80	
	ctc gag tct gga gtc cct tct cgc ttc tct gga tcc ggt	717
	Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly	
	85 90	
25	tct ggg acg gat ttc act ctg acc atc agc agt ctg cag	756
	Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln	
	95 100 105	
30	cca gaa gac ttc gca act tat tac tgt caa cac tct tgg	795
	Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln His Ser Trp	
	110 115	
35	ggt att ccg cgc aca ttt gga cag ggt acc aag gtg gag	834
	Gly Ile Pro Arg Thr Phe Gly Gln Gly Thr Lys Val Glu	
	120 125 130	
	atc aaa cga act gtg gct gca cca tct gtc ttc atc ttc	873
	Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe	
	135 140 145	
40	ccg cca tct gat gag cag ttg aaa tct gga act gct tct	912
	Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser	
	150 155	
45	gtt gtg tgc ctg ctg aat aac ttc tat ccc aga gag gcc	951
	Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala	
	160 165 170	
	aaa gta cag tgg aag gtg gat aac gcc ctc caa tcg ggt	990
	Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly	
	175 180	
50	aac tcc cag gag agt gtc aca gag cag gac agc aag gac	1029
	Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp	
	185 190 195	
55	agc acc tac agc ctc agc agc acc ctg acg ctg agc aaa	1068
	Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys	
	200 205 210	

EP 3 263 596 A1

gca gac tac gag aaa cac aaa gtc tac gcc tgc gaa gtc 1107
Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val
215 220

5 acc cat cag ggc ctg agc tcg ccc gtc aca aag agc ttc 1146
Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe
225 230 235

10 aac agg gga gag tgt t aagctgat cctctacgcc ggacgcatcg 1190
Asn Arg Gly Glu Cys
240 241

tgggccctagt acgcaagttc acgtaaaaag ggtatctaga gggtgaggtg 1240

15 atttt atg aaa aag aat atc gca ttt ctt ctt gca tct 1278
Met Lys Lys Asn Ile Ala Phe Leu Leu Ala Ser
1 5 10

20 atg ttc gtt ttt tct att gct aca aac gcg tac gct gag 1317
Met Phe Val Phe Ser Ile Ala Thr Asn Ala Tyr Ala Glu
15 20

25 gtt cag ctg gtg gag tct ggc ggt ggc ctg gtg cag cca 1356
Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro
25 30 35

30 ggg ggc tca ctc cgt ttg tcc tgt gca gct tct ggc tac 1395
Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr
40 45 50

35 acc ttc acc gaa tat atc atc cac tgg gtc cgt cag gcc 1434
Thr Phe Thr Glu Tyr Ile Ile His Trp Val Arg Gln Ala
55 60

40 ccg ggt aag ggc ctg gaa tgg gtt gca tcg att aat cct 1473
Pro Gly Lys Gly Leu Glu Trp Val Ala Ser Ile Asn Pro
65 70 75

45 gac tac gac atc acg aac tat aac cag cgc ttc aag ggc 1512
Asp Tyr Asp Ile Thr Asn Tyr Asn Gln Arg Phe Lys Gly
80 85

50 cgt ttc act ata agt cgc gac gat tcc aaa aac aca tta 1551
Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu
90 95 100

55 tac ctg cag atg aac agc ctg cgt gct gag gac act gcc 1590
Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala
105 110 115

60 gtc tat tat tgt gct cga tgg atc agc gat ttc ttc gac 1629
Val Tyr Tyr Cys Ala Arg Trp Ile Ser Asp Phe Phe Asp
120 125

65 tac tgg ggt caa gga acc ctg gtc acc gtc tcc tcg gcc 1668
Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala
130 135 140

70 tcc acc aag ggc cca tcg gtc ttc ccc ctg gca ccc tcc 1707
Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser
145 150

EP 3 263 596 A1

tcc aag agc acc tct ggg ggc aca gcg gcc ctg ggc tgc 1746
 Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys
 155 160 165

5 ctg gtc aag gac tac ttc ccc gaa ccg gtg acg gtg tgc 1785
 Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser
 170 175 180

tgg aac tca ggc gcc ctg acc agc ggc gtg cac acc ttc 1824
 10 Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
 185 190

ccg gct gtc cta cag tcc tca gga ctc tac tcc ctc agc 1863
 Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser
 195 200 205

15 agc gtg gtg acc gtg ccc tcc agc agc ttg ggc acc cag 1902
 Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln
 210 215

acc tac atc tgc aac gtg aat cac aag ccc agc aac acc 1941
 20 Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr
 220 225 230

aag gtg gac aag aaa gtt gag ccc aaa tct tgt gac aaa 1980
 Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys
 235 240 245

25 act cac aca t gaccaccgca tgcaccagta tcgtccattc 2020
 Thr His Thr
 248

30 cgacagcatc gccagtcact atggcgtgct gctagcgccg ccctataacct 2070

tgtctgcctc cccgcgttgc gtcgcggtgc atggagcccg gccacctcga 2120

cctgaatgga agccggcggc acctcgctaa cggattcacc actccaagaa 2170

35 ttggagccaa tcaattcttg cggagaactg tgaatgcgca aaccaaccct 2220

tggcagaaca tatccatcgc gtccgccatc tccagcagcc gcacgcggcg 2270

catctcgggc agcgttgggt cctggccacg ggtgcgcatg atcgtgctcc 2320

40 tgtcgttgag gacccggcta ggctggcggg gttgccttac tggttagcag 2370

aatgaatcac cgatacgca gogaacgtga agcgactgct gctgcaaaac 2420

gtctgcgacc tgagcaacaa catgaatggt cttcggtttc cgtgtttcgt 2470

45 aaagtctgga aacgcggaag tcagcgccct gcaccattat gttccggatc 2520

tgcacgcgag gatgctgctg gctaccctgt ggaacaccta catctgtatt 2570

aacgaagcgc tggcattgac cctgagtgat ttttctctgg tcccgcgca 2620

50 tccataccgc cagttgttta ccctcacaac gttccagtaa ccgggcatgt 2670

tcatcatcag taaccctgat cgtgagcatc ctctctcgtt tcatcggtat 2720

cattaccccc atgaacagaa attccccctt acacggaggc atcaagtgac 2770

55 caaacaggaa aaaaccgccc ttaacatggc ccgctttatc agaagccaga 2820

EP 3 263 596 A1

cattaacgct tctggagaaa ctcaacgagc tggacgcgga tgaacaggca 2870
 gacatctgtg aatcgcttca cgaccacgct gatgagcttt accgcagcat 2920
 5 ccggaattg taaacgttaa tattttgtta aaattcgcgt taaatttttg 2970
 ttaaatacagc tcatttttta accaataggc cgaaatcggc aaaatccctt 3020
 ataaatcaaa agaatagacc gagatagggt tgagtgttgt tccagtttgg 3070
 10 aacaagagtc cactattaaa gaacgtggac tccaacgtca aagggcgaaa 3120
 aaccgtctat cagggctatg gccactacg tgaaccatca ccctaataca 3170
 gttttttggg gtcgaggtgc cgtaaagcac taaatcggaa ccctaaaggg 3220
 15 agccccgat ttagagcttg acggggaaaag ccggcgaacg tggcgagaaa 3270
 ggaagggaaag aaagcgaaaag gagcggggcgc tagggcgctg gcaagtgtag 3320
 20 cggtcacgct gcgcgtaacc accacacccg ccgcgcttaa tgcgccgcta 3370
 cagggcgctg ccgcatacctg cctcgcgcgt ttcggtgatg acggtgaaaa 3420
 cctctgacac atgcagctcc cggagacggt cacagcttgt ctgtaagcgg 3470
 25 atgccgggag cagacaagcc cgtcagggcg cgtcagcggg tgttggcggg 3520
 tgtcggggcg cagccatgac ccagtcacgt agcgatagcg gagtgtatac 3570
 tggcttaact atgcggcatc agagcagatt gtactgagag tgcaccatat 3620
 30 gcggtgtgaa ataccgcaca gatgcgtaag gagaaaatac cgcatacaggc 3670
 gctcttccgc ttccctcgctc actgactcgc tgcgctcggg cgttcggctg 3720
 cggcgagcgg tatcagctca ctcaaaggcg gtaatacggg tatccacaga 3770
 35 atcaggggat aacgcaggaa agaacatgtg agcaaaaggc cagcaaaagg 3820
 ccaggaaccg taaaaaggcc gcgttgctgg cgtttttcca taggctccgc 3870
 40 cccctgacg agcatcacia aaatcgacgc tcaagtcaga ggtggcgaaa 3920
 cccgacagga ctataaagat accaggcgtt tccccctgga agctccctcg 3970
 tgcgctctcc tgttccgacc ctgccgctta ccggatacct gtccgccttt 4020
 45 ctcccttcgg gaagcgtggc gctttctcat agctcacgct gtaggtatct 4070
 cagttcgggt taggtcgttc gctccaagct gggctgtgtg cacgaacccc 4120
 ccgttcagcc cgaccgctgc gccttatccg gtaactatcg tcttgagtcc 4170
 50 aaccggtaaa gacacgactt atcgccactg gcagcagcca ctggtaacag 4220
 gattagcaga gcgaggtatg taggcggtgc tacagagttc ttgaagtgg 4270
 55 ggcctaacta cggctacact agaaggacag tatttggtat ctgcgctctg 4320
 ctgaagccag ttaccttcgg aaaaagagtt ggtagctctt gatccggcaa 4370

EP 3 263 596 A1

acaaaccacc gctggtagcg gtggtttttt tgtttgcaag cagcagatta 4420
 cgcgagaaaa aaaaggatct caagaagatc ctttgatctt ttctacgggg 4470
 5 tctgacgctc agtggaaacga aaactcacgt taagggattt tggatcatgag 4520
 attatcaaaa aggatcttca cctagatcct tttaaattaa aaatgaagtt 4570
 ttaaataaat ctaaagtata tatgagtaaa cttggtctga cagttaccaa 4620
 10 tgcttaatac gtgaggcacc tatctcagcg atctgtctat ttcgttcac 4670
 catagttgcc tgactccccg tcgtgtagat aactacgata cgggagggct 4720
 taccatctgg cccagtgct gcaatgatac cgcgagaccc acgctcaccg 4770
 15 gctccagatt tatcagcaat aaaccagcca gccggaaggg ccgagcgag 4820
 aagtggctc gcaactttat ccgcctccat ccagtctatt aattgttgcc 4870
 gggaagctag agtaagtagt tcgccagtta atagtttgcg caacgttggt 4920
 20 gccattgctg caggcatcgt ggtgtcacgc tcgtcgtttg gtatggcttc 4970
 attcagctcc ggttcccaac gatcaaggcg agttacatga tccccatgt 5020
 tgtgcaaaaa agcgggttagc tccttcgggc ctccgatcgt tgtcagaagt 5070
 25 aagttggccg cagtgttacc actcatgggt atggcagcac tgcataattc 5120
 tcttactgtc atgccatccg taagatgctt ttctgtgact ggtgagtact 5170
 caaccaagtc attctgagaa tagtgtatgc ggcgaccgag ttgctcttgc 5220
 30 ccggcgctca caggggataa taccgcgcca catagcagaa ctttaaaagt 5270
 gctcatcatt ggaaaacgtt ctccggggcg aaaactctca aggatcttac 5320
 35 cgctgttgag atccagttcg atgtaacca ctctgacacc caactgatct 5370
 tcagcatctt ttactttcac cagcgtttct gggtagcaca aaacaggaag 5420
 gcaaaatgcc gcaaaaaagg gaataagggc gacacggaaa tgttgaatac 5470
 40 tcatactctt cctttttcaa tattattgaa gcatttatca gggttattgt 5520
 ctcatgagcg gatacatatt tgaatgtatt tagaaaaata aacaaatagg 5570
 gggtccgcgc acatttcccc gaaaagtgcc acctgacgtc taagaaacca 5620
 45 ttattatcat gacattaacc tataaaaaata ggcgtatcac gagggccctt 5670
 cgtcttcaa 5679
 50 <210> 14
 <211> 241
 <212> PRT
 <213> Artificial Sequence
 <220>
 55 <223> Sequence is synthesized
 <400> 14

EP 3 263 596 A1

	Met	Lys	Lys	Asn	Ile	Ala	Phe	Leu	Leu	Ala	Ser	Met	Phe	Val	Phe	
	1				5					10					15	
5	Ser	Ile	Ala	Thr	Asn	Ala	Tyr	Ala	Asp	Ile	Gln	Met	Thr	Gln	Ser	
					20					25					30	
	Pro	Ser	Ser	Leu	Ser	Ala	Ser	Val	Gly	Asp	Arg	Val	Thr	Ile	Thr	
					35					40					45	
10	Cys	Arg	Ala	Ser	Gln	Ser	Val	Ser	Thr	Ser	Ser	Tyr	Ser	Tyr	Met	
					50					55					60	
	His	Trp	Tyr	Gln	Gln	Lys	Pro	Gly	Lys	Ala	Pro	Lys	Leu	Leu	Ile	
					65					70					75	
15	Tyr	Tyr	Ala	Ser	Asn	Leu	Glu	Ser	Gly	Val	Pro	Ser	Arg	Phe	Ser	
					80					85					90	
	Gly	Ser	Gly	Ser	Gly	Thr	Asp	Phe	Thr	Leu	Thr	Ile	Ser	Ser	Leu	
					95					100					105	
20	Gln	Pro	Glu	Asp	Phe	Ala	Thr	Tyr	Tyr	Cys	Gln	His	Ser	Trp	Gly	
					110					115					120	
	Ile	Pro	Arg	Thr	Phe	Gly	Gln	Gly	Thr	Lys	Val	Glu	Ile	Lys	Arg	
					125					130					135	
25	Thr	Val	Ala	Ala	Pro	Ser	Val	Phe	Ile	Phe	Pro	Pro	Ser	Asp	Glu	
					140					145					150	
	Gln	Leu	Lys	Ser	Gly	Thr	Ala	Ser	Val	Val	Cys	Leu	Leu	Asn	Asn	
30					155					160					165	
	Phe	Tyr	Pro	Arg	Glu	Ala	Lys	Val	Gln	Trp	Lys	Val	Asp	Asn	Ala	
					170					175					180	
	Leu	Gln	Ser	Gly	Asn	Ser	Gln	Glu	Ser	Val	Thr	Glu	Gln	Asp	Ser	
35					185					190					195	
	Lys	Asp	Ser	Thr	Tyr	Ser	Leu	Ser	Ser	Thr	Leu	Thr	Leu	Ser	Lys	
					200					205					210	
	Ala	Asp	Tyr	Glu	Lys	His	Lys	Val	Tyr	Ala	Cys	Glu	Val	Thr	His	
40					215					220					225	
	Gln	Gly	Leu	Ser	Ser	Pro	Val	Thr	Lys	Ser	Phe	Asn	Arg	Gly	Glu	
					230					235					240	
45	Cys															
	<210>	15														
	<211>	248														
	<212>	PRT														
50	<213>	Artificial Sequence														
	<220>															
	<223>	Sequence is synthesized														
55	<400>	15														
	Met	Lys	Lys	Asn	Ile	Ala	Phe	Leu	Leu	Ala	Ser	Met	Phe	Val	Phe	
	1				5					10					15	

EP 3 263 596 A1

	Ser	Ile	Ala	Thr	Asn	Ala	Tyr	Ala	Glu	Val	Gln	Leu	Val	Glu	Ser	
					20					25					30	
5	Gly	Gly	Gly	Leu	Val	Gln	Pro	Gly	Gly	Ser	Leu	Arg	Leu	Ser	Cys	
					35					40					45	
	Ala	Ala	Ser	Gly	Tyr	Thr	Phe	Thr	Glu	Tyr	Ile	Ile	His	Trp	Val	
					50					55					60	
10	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu	Glu	Trp	Val	Ala	Ser	Ile	Asn	
					65					70					75	
	Pro	Asp	Tyr	Asp	Ile	Thr	Asn	Tyr	Asn	Gln	Arg	Phe	Lys	Gly	Arg	
					80					85					90	
15	Phe	Thr	Ile	Ser	Arg	Asp	Asp	Ser	Lys	Asn	Thr	Leu	Tyr	Leu	Gln	
					95					100					105	
	Met	Asn	Ser	Leu	Arg	Ala	Glu	Asp	Thr	Ala	Val	Tyr	Tyr	Cys	Ala	
					110					115					120	
20	Arg	Trp	Ile	Ser	Asp	Phe	Phe	Asp	Tyr	Trp	Gly	Gln	Gly	Thr	Leu	
					125					130					135	
	Val	Thr	Val	Ser	Ser	Ala	Ser	Thr	Lys	Gly	Pro	Ser	Val	Phe	Pro	
					140					145					150	
25	Leu	Ala	Pro	Ser	Ser	Lys	Ser	Thr	Ser	Gly	Gly	Thr	Ala	Ala	Leu	
					155					160					165	
	Gly	Cys	Leu	Val	Lys	Asp	Tyr	Phe	Pro	Glu	Pro	Val	Thr	Val	Ser	
30					170					175					180	
	Trp	Asn	Ser	Gly	Ala	Leu	Thr	Ser	Gly	Val	His	Thr	Phe	Pro	Ala	
					185					190					195	
	Val	Leu	Gln	Ser	Ser	Gly	Leu	Tyr	Ser	Leu	Ser	Ser	Val	Val	Thr	
35					200					205					210	
	Val	Pro	Ser	Ser	Ser	Leu	Gly	Thr	Gln	Thr	Tyr	Ile	Cys	Asn	Val	
					215					220					225	
40	Asn	His	Lys	Pro	Ser	Asn	Thr	Lys	Val	Asp	Lys	Lys	Val	Glu	Pro	
					230					235					240	
	Lys	Ser	Cys	Asp	Lys	Thr	His	Thr								
					245											
45	<210> 16															
	<211> 5678															
	<212> DNA															
	<213> Artificial Sequence															
	<220>															
50	<223> Sequence is chimeric															
	<400> 16															
	gaattcaact tctccatact ttggataagg aaatacagac atgaaaaatc 50															
55	tcattgctga gttgttattt aagcttgccc aaaaagaaga agagtcgaat 100															
	gaactgtgtg cgcaggtaga agctttggag attatcgtca ctgcaatgct 150															

EP 3 263 596 A1

tcgcaatatg gcgcaaaatg accaacagcg gttgattgat caggtagagg 200
 gggcgctgta cgaggtaaag cccgatgccg gcattcctga cgacgatacg 250
 5 gagctgctgc gcgattacgt aaagaagtta ttgaagcatc ctcgtcagta 300
 aaaagttaat cttttcaaca gctgtcataa agttgtcacg gccgagactt 350
 atagtcgctt tgtttttatt ttttaatgta tttgtaacta gaattcgagc 400
 10 tcggtacccg gggatcctct agaggttgag gtgattt atg aaa 443
 Met Lys
 1
 aag aat atc gca ttt ctt ctt gca tct atg ttc gtt ttt 482
 15 Lys Asn Ile Ala Phe Leu Leu Ala Ser Met Phe Val Phe
 5 10 15
 tct att gct aca aac gcg tac gct cag ata gta ctg tcc 521
 Ser Ile Ala Thr Asn Ala Tyr Ala Gln Ile Val Leu Ser
 20 20 25
 cag tcc ccg gct atc ctg tcc gcc tct cct ggc gag aag 560
 Gln Ser Pro Ala Ile Leu Ser Ala Ser Pro Gly Glu Lys
 30 35 40
 gtc act atg acc tgc aga gcc agc tct tct gtg agc tat 599
 25 Val Thr Met Thr Cys Arg Ala Ser Ser Ser Val Ser Tyr
 45 50
 atg cat tgg tat caa cag aaa cca gga agc tct ccg aaa 638
 30 Met His Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Lys
 55 60 65
 cca tgg att tac gct cca tcg aac ctc gcg tct gga gtc 677
 Pro Trp Ile Tyr Ala Pro Ser Asn Leu Ala Ser Gly Val
 70 75 80
 cct gcg cgc ttc tct gga tcc ggt tct ggg act agt tac 716
 35 Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr
 85 90
 tct ctg acc atc agc aga gtg gag gca gaa gac gcc gca 755
 40 Ser Leu Thr Ile Ser Arg Val Glu Ala Glu Asp Ala Ala
 95 100 105
 act tat tac tgt caa cag tgg agc ttc aat ccg ccc aca 794
 Thr Tyr Tyr Cys Gln Gln Trp Ser Phe Asn Pro Pro Thr
 110 115
 45 ttt gga gcc ggc acc aag ctg gag ctc aaa cga act gtg 833
 Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys Arg Thr Val
 120 125 130
 gct gca cca tct gtc ttc atc ttc ccg cca tct gat gag 872
 50 Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu
 135 140 145
 cag ttg aaa tct gga act gct tct gtt gtg tgc ctg ctg 911
 Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu
 150 155
 55 aat aac ttc tat ccc aga gag gcc aaa gta cag tgg aag 950

EP 3 263 596 A1

	Asn	Asn	Phe	Tyr	Pro	Arg	Glu	Ala	Lys	Val	Gln	Trp	Lys	
	160						165					170		
5	gtg	gat	aac	gcc	ctc	caa	tcg	ggt	aac	tcc	cag	gag	agt	989
	Val	Asp	Asn	Ala	Leu	Gln	Ser	Gly	Asn	Ser	Gln	Glu	Ser	
			175						180					
10	gtc	aca	gag	cag	gac	agc	aag	gac	agc	acc	tac	agc	ctc	1028
	Val	Thr	Glu	Gln	Asp	Ser	Lys	Asp	Ser	Thr	Tyr	Ser	Leu	
	185					190					195			
15	agc	agc	acc	ctg	acg	ctg	agc	aaa	gca	gac	tac	gag	aaa	1067
	Ser	Ser	Thr	Leu	Thr	Leu	Ser	Lys	Ala	Asp	Tyr	Glu	Lys	
			200					205					210	
20	cac	aaa	gtc	tac	gcc	tgc	gaa	gtc	acc	cat	cag	ggc	ctg	1106
	His	Lys	Val	Tyr	Ala	Cys	Glu	Val	Thr	His	Gln	Gly	Leu	
					215					220				
25	agc	tcg	ccc	gtc	aca	aag	agc	ttc	aac	agg	gga	gag	tgt	1145
	Ser	Ser	Pro	Val	Thr	Lys	Ser	Phe	Asn	Arg	Gly	Glu	Cys	
			225				230					235	236	
30	t	aagc	tgatcctcta	cgccggacgc	atcgtggccc	tagtacgcaa	1190							
35	gttcacgtaa	aaaggggtatc	tagaggttga	ggtgatttt	atg	aaa	1235							
					Met	Lys								
					1									
40	aag	aat	atc	gca	ttt	ctt	ctt	gca	tct	atg	ttc	gtt	ttt	1274
	Lys	Asn	Ile	Ala	Phe	Leu	Leu	Ala	Ser	Met	Phe	Val	Phe	
			5					10					15	
45	tct	att	gct	aca	aac	gcg	tac	gct	cag	gct	tat	ctg	cag	1313
	Ser	Ile	Ala	Thr	Asn	Ala	Tyr	Ala	Gln	Ala	Tyr	Leu	Gln	
					20					25				
50	cag	tct	ggc	gcc	gag	ctg	gtg	cgg	cca	gga	gct	agc	gtc	1352
	Gln	Ser	Gly	Ala	Glu	Leu	Val	Arg	Pro	Gly	Ala	Ser	Val	
			30				35					40		
55	aag	atg	tcc	tgt	aaa	gct	tct	ggc	tac	acc	ttc	acc	agc	1391
	Lys	Met	Ser	Cys	Lys	Ala	Ser	Gly	Tyr	Thr	Phe	Thr	Ser	
				45					50					
60	tat	aac	atg	cat	tgg	gtc	aag	cag	aca	ccg	agg	caa	ggc	1430
	Tyr	Asn	Met	His	Trp	Val	Lys	Gln	Thr	Pro	Arg	Gln	Gly	
		55				60					65			
65	ctg	gaa	tgg	att	gga	gcg	atc	tat	cct	ggc	aac	ggc	gac	1469
	Leu	Glu	Trp	Ile	Gly	Ala	Ile	Tyr	Pro	Gly	Asn	Gly	Asp	
			70					75					80	
70	acg	agc	tat	aac	cag	aag	ttc	aag	ggc	aag	gcc	act	ctg	1508
	Thr	Ser	Tyr	Asn	Gln	Lys	Phe	Lys	Gly	Lys	Ala	Thr	Leu	
					85					90				
75	act	gtg	gac	aag	tcc	agc	agt	act	gcc	tac	atg	caa	ctg	1547
	Thr	Val	Asp	Lys	Ser	Ser	Ser	Thr	Ala	Tyr	Met	Gln	Leu	
			95				100					105		
80	agc	agc	ctg	act	tct	gag	gac	agc	gct	gtc	tac	ttt	tgt	1586
	Ser	Ser	Leu	Thr	Ser	Glu	Asp	Ser	Ala	Val	Tyr	Phe	Cys	

EP 3 263 596 A1

	110	115	
5	gct cgc gtg gtc tac tat agc aac agc tac tgg tac ttc 1625 Ala Arg Val Val Tyr Tyr Ser Asn Ser Tyr Trp Tyr Phe 120 125 130		
	gac gtc tgg ggt acc gga acc aca gtc acc gtc tcc tcg 1664 Asp Val Trp Gly Thr Gly Thr Thr Val Thr Val Ser Ser 135 140 145		
10	gcc tcc acc aag ggc cca tcg gtc ttc ccc ctg gca ccc 1703 Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro 150 155		
15	tcc tcc aag agc acc tct ggg ggc aca gcg gcc ctg ggc 1742 Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly 160 165 170		
20	tgc ctg gtc aag gac tac ttc ccc gaa ccg gtg acg gtg 1781 Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val 175 180		
	tcg tgg aac tca ggc gcc ctg acc agc ggc gtg cac acc 1820 Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr 185 190 195		
25	ttc ccg gct gtc cta cag tcc tca gga ctc tac tcc ctc 1859 Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu 200 205 210		
30	agc agc gtg gtg acc gtg ccc tcc agc agc ttg ggc acc 1898 Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr 215 220		
	cag acc tac atc tgc aac gtg aat cac aag ccc agc aac 1937 Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn 225 230 235		
35	acc aag gtg gac aag aaa gtt gag ccc aaa tct tgt gac 1976 Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp 240 245		
40	aaa act cac aca t g accaccgcat gcaccagtat cgtccattcc 2020 Lys Thr His Thr 250 253		
45	gacagcatcg ccagtcacta tggcgtgctg ctagcgccgc cctatacctt 2070 gtctgcctcc ccgcgttgcg tcgcggtgca tggagccggg ccacctcgac 2120 ctgaatggaa gccggcgga cctcgctaac ggattcacca ctccaagaat 2170 tggagccaat caattcttgc ggagaactgt gaatgcgcaa accaaccctt 2220		
50	ggcagaacat atccatcgcg tccgccatct ccagcagccg cagcgggcgc 2270 atctcgggca gcgttgggtc ctggccacgg gtgcgcatga tcgtgctcct 2320 gtcgttgagg acccggttag gctggcgggg ttgccttact ggtagcaga 2370		
55	atgaatcacc gatacgcgag cgaacgtgaa gcgactgctg ctgcaaaacg 2420 tctgcgacct gagcaacaac atgaatggtc ttcggtttcc gtgtttcgta 2470		

EP 3 263 596 A1

aagtctggaa acgcggaagt cagcgccctg caccattatg ttccggatct 2520
 gcatcgcagg atgctgctgg ctaccctgtg gaacacctac atctgtatta 2570
 5 acgaagcgct ggcattgacc ctgagtgatt tttctctggt cccgccgcat 2620
 ccataccgcc agttgtttac cctcacaacg ttccagtaac cgggcatgtt 2670
 catcatcagt aaccctgtatc gtgagcatcc tctctcggtt catcgggtatc 2720
 10 attaccccca tgaacagaaa ttccccctta cacggaggca tcaagtgacc 2770
 aaacaggaaa aaaccgccct taacatggcc cgctttatca gaagccagac 2820
 attaacgctt ctggagaaac tcaacgagct ggacgcggat gaacaggcag 2870
 15 acatctgtga atcgcttcac gaccacgctg atgagcttta ccgcagcatc 2920
 cggaaattgt aaacgttaat attttgttaa aattcgcgtt aaatttttgt 2970
 taaatcagct cattttttta ccaataggcc gaaatcggca aaatccctta 3020
 20 taaatcaaaa gaatagaccg agatagggtt gagtgttggt ccagtttgga 3070
 acaagagtcc actattaaag aacgtggact ccaacgtcaa agggcgaaaa 3120
 25 accgtctatc agggctatgg ccactacgt gaaccatcac cctaatacag 3170
 ttttttgggg tcgaggtgcc gttaaagcact aaatcggaac cctaaaggga 3220
 gcccccgatt tagagcttga cggggaaagc cggcgaacgt ggcgagaaag 3270
 30 gaaggggaaga aagcgaaagg agcgggcgct agggcgctgg caagtgtagc 3320
 ggtcacgctg cgcgtaacca ccacaccgc cgcgcttaat gcgccgtac 3370
 agggcgcgctc cgcacctctgc ctgcgcgctt tcggtgatga cggtgaaaac 3420
 35 ctctgacaca tgcagctccc ggagacggtc acagcttgct tgtaagcggga 3470
 tgccgggagc agacaagccc gtcagggcgc gtcagcgggt gttggcgggt 3520
 40 gtcggggcgc agccatgacc cagtcacgta gcgatagcgg agtgtatact 3570
 ggcttaacta tgcggcatca gagcagattg tactgagagt gcaccatatg 3620
 cgggtgtgaaa taccgcacag atgcgtaagg agaaaatacc gcatcaggcg 3670
 45 ctcttccgct tcctcgctca ctgactcgtc gcgctcggtc gttcggctgc 3720
 ggcgagcgggt atcagctcac tcaaaggcgg taatacgggt atccacagaa 3770
 tcaggggata acgcaggaaa gaacatgtga gcaaaaggcc agcaaaaggc 3820
 50 caggaaccgt aaaaaggccg cgttgctggc gtttttccat aggctccgcc 3870
 cccctgacga gcatcacaaa aatcgacgct caagtcagag gtggcgaaac 3920
 ccgacaggac tataaagata ccaggcgttt cccctggaa gctccctcgt 3970
 55 gcgctctcct gttccgaccc tgccgcttac cggatacctg tccgcctttc 4020

EP 3 263 596 A1

tcccttcggg aagcgtggcg ctttctcata gctcacgctg taggtatctc 4070
 agttcgggtgt aggtcgttcg ctccaagctg ggctgtgtgc acgaaccccc 4120
 5 cgttcagccc gaccgctgcg ccttatccgg taactatcgt cttgagtcca 4170
 acccggttaag acacgactta tcgccactgg cagcagccac tggtaacagg 4220
 attagcagag cgaggtatgt aggcgggtgct acagagttct tgaagtgggtg 4270
 10 gcctaactac ggctacacta gaaggacagt atttggtatc tgcgctctgc 4320
 tgaagccagt taccttcgga aaaagagttg gtagctcttg atccggcaaa 4370
 caaacaccog ctggtagcgg tgggtttttt gtttgcaagc agcagattac 4420
 15 gcgcagaaaa aaagatctc aagaagatcc tttgatcttt tctacgggggt 4470
 ctgacgctca gtggaacgaa aactcacgtt aagggatttt ggtcatgaga 4520
 ttatcaaaaa ggatcttcac ctagatcctt ttaaattaaa aatgaagttt 4570
 20 taaatcaatc taaagtatat atgagtaaac ttggtctgac agttaccaat 4620
 gcttaatcag tgaggcacct atctcagcga tctgtctatt tcgttcatcc 4670
 atagttgcct gactccccgt cgtgtagata actacgatac gggagggctt 4720
 25 accatctggc ccagtgctg caatgatacc gcgagacca cgctcaccgg 4770
 ctccagattt atcagcaata aaccagccag ccggaagggc cgagcgcaga 4820
 agtggtcctg caactttatc cgcctccatc cagtctatta attggtgccg 4870
 30 ggaagctaga gtaagtagtt cgccagttaa tagtttgccg aacgttggtg 4920
 ccattgctgc aggcacgtg gtgtcacgct cgtcgtttgg tatggcttca 4970
 35 ttcagctcog gttcccaacg atcaaggcga gttacatgat ccccatgtt 5020
 gtgcaaaaaa gcggttagct ccttcggtcc tccgatcgtt gtcagaagta 5070
 agttggccgc agtgttatca ctcatggta tggcagcact gcataattct 5120
 40 cttactgtca tgccatccgt aagatgcttt tctgtgactg gtgagtactc 5170
 aaccaagtca ttctgagaat agtgtatgcg gcgaccgagt tgctcttgcc 5220
 cggcgtcaac acgggataat accgcgccac atagcagaac tttaaaagtg 5270
 45 ctcatcattg gaaaacgttc ttcggggcga aaactctcaa ggatcttacc 5320
 gctgttgaga tccagttcga tgtaaccac tcgtgcaccc aactgatctt 5370
 cagcatcttt tactttcacc agcgtttctg ggtgagcaaa aacaggaagg 5420
 50 caaatgccg caaaaaaggg aataagggcg acacggaaat gttgaatact 5470
 catactcttc ctttttcaat attattgaag catttatcag ggttattgtc 5520
 55 tcatgagcgg atacatattt gaatgtattt agaaaaataa acaaataggg 5570
 gttccgcgca catttccccg aaaagtgcc cctgacgtct aagaaaccat 5620

tattatcatg acattaacct ataaaaatag gcgtatcacg aggccctttc 5670

gtcttcaa 5678

<210> 17
 <211> 236
 <212> PRT
 <213> Artificial sequence

<220>
 <223> Sequence is chimeric

<400> 17
 Met Lys Lys Asn Ile Ala Phe Leu Leu Ala Ser Met Phe Val Phe
 1 5 10 15
 Ser Ile Ala Thr Asn Ala Tyr Ala Gln Ile Val Leu Ser Gln Ser
 20 25 30
 Pro Ala Ile Leu Ser Ala Ser Pro Gly Glu Lys Val Thr Met Thr
 35 40 45
 Cys Arg Ala Ser Ser Ser Val Ser Tyr Met His Trp Tyr Gln Gln
 50 55 60
 Lys Pro Gly Ser Ser Pro Lys Pro Trp Ile Tyr Ala Pro Ser Asn
 65 70 75
 Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly
 80 85 90
 Thr Ser Tyr Ser Leu Thr Ile Ser Arg Val Glu Ala Glu Asp Ala
 95 100 105
 Ala Thr Tyr Tyr Cys Gln Gln Trp Ser Phe Asn Pro Pro Thr Phe
 110 115 120
 Gly Ala Gly Thr Lys Leu Glu Leu Lys Arg Thr Val Ala Ala Pro
 125 130 135
 Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
 140 145 150
 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu
 155 160 165
 Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn
 170 175 180
 Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr
 185 190 195
 Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys
 200 205 210
 His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser
 215 220 225
 Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
 230 235

<210> 18

EP 3 263 596 A1

```
<211> 253
<212> PRT
<213> Artificial sequence
```

```
<220>
<223> Sequence is chimeric
```

<400> 18

Met Lys Lys Asn Ile Ala Phe Leu Leu Ala Ser Met Phe Val Phe
1 5 10 15

Ser Ile Ala Thr Asn Ala Tyr Ala Gln Ala Tyr Leu Gln Gln Ser
20 25 30

Gly Ala Glu Leu Val Arg Pro Gly Ala Ser Val Lys Met Ser Cys
35 40 45

Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Asn Met His Trp Val
50 55 60

Lys Gln Thr Pro Arg Gln Gly Leu Glu Trp Ile Gly Ala Ile Tyr
65 70 75

Pro Gly Asn Gly Asp Thr Ser Tyr Asn Gln Lys Phe Lys Gly Lys
80 85 90

Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met Gln
95 100 105

Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys Ala
110 115 120

Arg Val Val Tyr Tyr Ser Asn Ser Tyr Trp Tyr Phe Asp Val Trp
125 130 135

Gly Thr Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly
140 145 150

Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly
155 160 165

Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu
170 175 180

Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val
185 190 195

His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu
200 205 210

Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr
215 220 225

Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp
230 235 240

Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr
245 250

<210> 19

<211> 5391

<212> DNA

<213> Artificial sequence

<220>

<223> Sequence is synthesized

<400> 19

5 ttcgagctcg cccgacattg attattgact agttattaat agtaatcaat 50
 tacgggggtca ttagttcata gcccatatat ggagttccgc gttacataac 100
 ttacggtaaa tggcccgccct ggctgaccgc ccaacgaccc ccgcccattg 150
 10 acgtcaataa tgacgtatgt tcccatagta acgccaatag ggactttcca 200
 ttgacgtcaa tgggtggagt atttacggta aactgccac ttggcagtac 250
 atcaagtgt tcatatgcc agtacgcccc ctattgacgt caatgacggg 300
 15 aaatggcccg cctggcatta tgcccagtac atgaccttat gggactttcc 350
 tacttggcag tacatctacg tattagtcac cgctattacc atgggtgatgc 400
 20 ggttttggca gtacatcaat gggcgtggat agcggtttga ctcacgggga 450
 tttccaagtc tccaccccat tgacgtcaat gggagtttgt tttggcacca 500
 aaatcaacgg gactttccaa aatgtcgtaa caactccgcc ccattgacgc 550
 25 aaatgggagg taggcgtgta cgggtggagg tctatataag cagagctcgt 600
 ttagtgaacc gtcagatcgc ctggagacgc catccacgct gttttgacct 650
 ccatagaaga caccgggacc gatccagcct ccgcgcccg gaacgggtgca 700
 30 ttggaacgcg gattccccgt gccaaagagt acgtaagtac cgcctataga 750
 gtctataggc ccacccctt ggcttcgtta gaacgcggct acaattaata 800
 cataacctta tgtatcatal acatacgatt taggtgacac tatagaataa 850
 35 catccacttt gcctttctct ccacaggtgt cactcccag gtccaactgc 900
 acctcggttc tatcgattga attccacat gggatggta tgtatcatcc 950
 40 tttttctagt agcaactgca actggagtac attcagatat ccagatgacc 1000
 cagtccccga gctccctgtc cgcctctgtg ggcgataggg tcaccatcac 1050
 ctgccgtgcc agtcaggaca tccgtaatta tttgaactgg tatcaacaga 1100
 45 aaccaggaaa agctccgaaa ctactgattt actatactc ccgcctggag 1150
 tctggagtcc cttctcgctt ctctggttct ggttctggga cggattacac 1200
 tctgaccatc agtagtctgc aaccggagga cttcgcaact tattactgtc 1250
 50 agcaaggtaa tactctgccg tggacgttcg gacagggcac caaggtggag 1300
 atcaaacgaa ctgtggctgc accatctgtc ttcactctcc cgccatctga 1350
 55 tgagcagttg aaatctggaa ctgcctctgt tgtgtgcctg ctgaataact 1400
 tctatcccag agaggccaaa gtacagtgga aggtggataa cgccctccaa 1450

EP 3 263 596 A1

tcgggtaact cccaggagag tgtcacagag caggacagca aggacagcac 1500
 ctacagcctc agcagcacc cagcgtgag caaagcagac tacgagaaac 1550
 5 acaaagtcta cgcctgcgaa gtcacccatc agggcctgag ctgcccgtc 1600
 acaaagagct tcaacagggg agagtgttaa gcttggccgc catggcccaa 1650
 cttgtttatt gcagcttata atggttacaa ataaagcaat agcatcacia 1700
 10 atttcacaaa taaagcattt ttttactgc attctagttg tggtttgtcc 1750
 aaactcatca atgtatctta tcatgtctgg atcgatcggg aattaattcg 1800
 ggcgagcacc atggcctgaa ataacctctg aaagaggaac ttggttaggt 1850
 15 accttctgag gcggaagaa ccagctgtgg aatgtgtgtc agttaggggtg 1900
 tggaaagtcc ccaggctccc cagcaggcag aagtatgcaa agcatgcatc 1950
 tcaattagtc agcaaccagg tgtggaaagt cccaggctc cccaggcaggc 2000
 20 agaagtatgc aaagcatgca tctcaattag tcagcaacca tagtcccgcc 2050
 cctaactccg cccatccgc ccctaactcc gccagttcc gccattctc 2100
 cgccccatgg ctgactaatt ttttttattt atgcagaggc cgaggccgcc 2150
 25 tcggcctctg agctattcca gaagtagtga ggaggctttt ttggaggcct 2200
 aggcttttgc aaaaagctgt taacagcttg gcactggccg tcgttttaca 2250
 acgtcgtgac tgggaaaacc ctggcggttac ccaacttaat cgccttgag 2300
 30 cacatcccc cttcgccagc tggcgtaata gcgaagaggc ccgcaccgat 2350
 cgcccttccc aacagttgcg tagcctgaat ggcaatggc gcctgatgcg 2400
 35 gtattttctc cttacgcac tgtgcggtat ttcacaccgc atacgtcaaa 2450
 gcaaccatag tacgcgccct gtagcggcgc attaaagcgc gcgggtgtgg 2500
 tggttacgcg cagcgtgacc gctacacttg ccagcggcct agcggccgct 2550
 40 cctttcgctt tcttccctc ctttctcgcc acgttcgccc gctttccccc 2600
 tcaagctcta aatcgggggc tccctttagg gttccgattt agtgctttac 2650
 ggcacctcga ccccaaaaaa cttgatttgg gtgatgggtc acgtagtggg 2700
 45 ccatcgccct gatagacggt ttttcgccct ttgacgttgg agtccacgtt 2750
 ctttaatagt ggactcttgt tccaaactgg aacaacactc aaccctatct 2800
 cgggctattc ttttgattta taagggtatt tgccgatttc ggctatttgg 2850
 50 ttaaaaaatg agctgattta aaaaaattt aacgcgaatt ttaacaaaat 2900
 attaacgttt acaattttat ggtgactctc cagtacaatc tgctctgatg 2950
 55 ccgcatagtt aagccaactc cgctatcgct acgtgactgg gtcattggctg 3000
 cgccccgaca ccgcgaaca ccgctgacg cgccctgacg ggcttgtctg 3050

EP 3 263 596 A1

ctcccggcat ccgcttacag acaagctgtg accgtctccg ggagctgcat 3100
 gtgtcagagg ttttcaccgt catcaccgaa acgcgcgagg cagtattctt 3150
 5 gaagacgaaa gggcctcgtg atacgcctat ttttataggt taatgtcatg 3200
 ataataatgg tttcttagac gtcagggtggc acttttcggg gaaatgtgcg 3250
 cggaaccctt atttgtttat ttttctaaat acattcaa atgtatccgc 3300
 10 tcatgagaca ataaccctga taaatgcttc aataatattg aaaaaggaag 3350
 agtatgagta ttcaacatth ccgtgtcgcc cttattccct tttttgcggc 3400
 attttgcctt cctgtttttg ctcaccaga aacgctggtg aaagtaaaag 3450
 15 atgctgaaga tcagttgggt gcacgagtgg gttacatoga actggatctc 3500
 aacagcggta agatccttga gagttttcgc ccgaagaac gttttccaat 3550
 gatgagcact tttaaagttc tgctatgtgg cgcggtatta tcccgtgatg 3600
 20 acgccgggca agagcaactc ggtcgccgca tacactattc tcagaatgac 3650
 ttggttgagt actcaccagt cacagaaaag catcttacgg atggcatgac 3700
 25 agtaagagaa ttatgcagtg ctgccataac catgagtgat aacactgcgg 3750
 ccaacttact tctgacaacg atcggaggac cgaaggagct aaccgctttt 3800
 ttgcacaaca tgggggatca tgtaactcgc cttgatcgtt gggaaccgga 3850
 30 gctgaatgaa gccataccaa acgacgagcg tgacaccacg atgccagcag 3900
 caatggcaac aacgttgccg aaactattaa ctggcgaaact acttactcta 3950
 gcttcccggc aacaattaat agactggatg gaggcggata aagttgcagg 4000
 35 accacttctg cgctcggccc ttccggctgg ctggtttatt gctgataaat 4050
 ctggagccgg tgagcgtggg tctcgcggta tcattgcagc actggggcca 4100
 gatggtaagc cctcccgat atcgtagttatc tacacgacgg ggagtcaggc 4150
 aactatggat gaacgaaata gacagatcgc tgagataggt gcctcactga 4200
 ttaagcattg gtaactgtca gaccaagttt actcatatat actttagatt 4250
 45 gattttaaac ttcatthttt atttaaaagg atctaggtga agatcctttt 4300
 tgataatctc atgacaaaaa tcccttaacg tgagtthttc ttccactgag 4350
 cgtcagaccc cgtagaaaag atcaaaggat cttcttgaga tcctthtttt 4400
 50 ctgcgcgtaa tctgctgctt gcaaacaaaa aaaccaccgc taccagcggg 4450
 ggthttgttg ccggatcaag agctaccaac tctthttccg aaggtaactg 4500
 gcttcagcag agcgcagata ccaaatactg tccttctagt gtagccgtag 4550
 ttaggccacc acttcaagaa ctctgtagca ccgcctacat acctcgtctt 4600

EP 3 263 596 A1

gctaatacctg ttaccagtgg ctgctgccag tggcgataag tcgtgtctta 4650
 ccgggttgga ctcaagacga tagttaccgg ataaggcgca gcggtcgggc 4700
 5 tgaacggggg gttcgtgcac acagcccagc ttggagcgaa cgacctacac 4750
 cgaactgaga tacctacagc gtgagcattg agaaagcgcc acgcttcccg 4800
 aagggagaaa ggcggacagg tatccggtaa gcggcagggc cggaacagga 4850
 10 gagcgcacga gggagcttcc agggggaaac gcctggatc tttatagtcc 4900
 tgtcgggttt cgccacctct gacttgagcg tcgatttttg tgatgctcgt 4950
 caggggggag gagcctatgg aaaaacgcca gcaacgcggc ctttttacgg 5000
 15 ttcctggcct tttgctggcc ttttgcac atgttctttc ctgcgttatc 5050
 ccctgattct gtggataacc gtattaccgc ctttgagtga gctgataccg 5100
 ctgccgcag ccgaacgacc gagcgcagcg agtcagtga cgaggaagcg 5150
 20 gaagagcgcc caatacgcaa accgcctctc ccgcgcgtt ggccgattca 5200
 ttaatccagc tggcacgaca ggtttccga ctggaaagcg ggcagtgaac 5250
 gcaacgcaat taatgtgagt tacctcactc attaggcacc ccaggcttta 5300
 25 cactttatgc ttccggctcg tatgttgtgt ggaattgtga gcggataaca 5350
 atttcacaca ggaaacagct atgaccatga ttacgaatta a 5391
 30 <210> 20
 <211> 6135
 <212> DNA
 <213> Artificial sequence
 35 <220>
 <223> Sequence is synthesized
 <400> 20
 attcgagctc gcccgacatt gattattgac tagttattaa tagtaatcaa 50
 40 ttacggggtc attagttcat agccatata tggagttccg cgttacataa 100
 cttacggtaa atggcccgcc tggctgaccg cccaacgacc ccgcccatt 150
 gacgtcaata atgacgtatg ttcccatagt aacgccaata gggactttcc 200
 45 attgacgtca atgggtggag tatttacggc aaactgcca cttggcagta 250
 catcaagtgt atcatatgcc aagtacgcc cctattgacg tcaatgacgg 300
 taaatggccc gcctggcatt atgcccagta catgacctta tgggactttc 350
 50 ctacttgga gtacatctac gtattagtca tcgctattac catggtgatg 400
 cggttttggc agtacatcaa tgggcgtgga tagcggtttg actcacgggg 450
 atttccaagt ctccacccca ttgacgtcaa tgggagtttg ttttggcacc 500
 55 aaaatcaacg ggactttcca aaatgtcgta acaactccgc ccattgacg 550

EP 3 263 596 A1

caaatgggag gtaggcgtgt acgggtgggag gtctatataa gcagagctcg 600
 tttagtgaac cgtcagatcg cctggagacg ccatccacgc tgttttgacc 650
 5 tccatagaag acaccgggac cgatccagcc tccgcgggccg ggaacgggtgc 700
 attggaacgc ggattccccg tgccaagagt gacgtaagta ccgcctatag 750
 agtctatagg cccaccccct tggcttcggt agaacgcggc tacaattaat 800
 10 acataacctt atgtatcata cacatacgat ttaggtgaca ctatagaata 850
 acatccactt tgcctttctc tccacaggtg tccactccca ggtccaactg 900
 cacctcggtt ctatcgattg aattccacca tgggatggtc atgtatcatc 950
 15 ctttttctag tagcaactgc aactggagta cattcagaag ttcagctggt 1000
 ggagtctggc ggtggcctgg tgcagccagg gggctcactc cgtttgtcct 1050
 gtgcagcttc tggctactcc tttaccggct acactatgaa ctgggtgcgt 1100
 20 caggccccag gtaagggcct ggaatgggtt gcaactgatta atccttataa 1150
 aggtgttact acctatgccg atagcgtcaa gggccgtttc actataagcg 1200
 tagataaatc caaaaacaca gcctacctgc aaatgaacag cctgcgtgct 1250
 25 gaggacactg ccgtctatta ttgtgctaga agcggatact acggcgatag 1300
 cgactggtat tttgacgtct ggggtcaagg aacctgggtc accgtctcct 1350
 30 cggcctccac caagggccca tcggtcttcc ccctggcacc ctccctcaaag 1400
 agcacctctg ggggcacagc ggccctgggc tgcctgggtca aggactactt 1450
 ccccgaaacg gtgacggtgt cgtggaactc aggcgcctcg accagcggcg 1500
 35 tgcacacctt cccggctgtc ctacagtcct caggactcta ctccctcagc 1550
 agcgtggtga ctgtgccctc tagcagcttg ggcacccaga cctacatctg 1600
 caacgtgaat cacaagccca gcaacaccaa ggtggacaag aaagttgagc 1650
 40 ccaaactctg tgacaaaact cacacatgcc caccgtgcc agcacctgaa 1700
 ctccctggggg gaccgtcagt cttcctcttc cccccaaaac ccaaggacac 1750
 cctcatgata tcccggaccc ctgaggtcac atgcgtggtg gtggacgtga 1800
 45 gccacgaaga ccctgaggtc aagttcaact ggtacgtgga cggcgtggag 1850
 gtgcataatg ccaagacaaa gccgcgggag gagcagtaca acagcacgta 1900
 ccgtgtggtc agcgtcctca ccgtcctgca ccaggactgg ctgaatggca 1950
 50 aggagtacaa gtgcaaggtc tccaacaaag ccctcccagc ccccatcgag 2000
 aaaaccatct ccaaagccaa agggcagccc cgagaaccac aggtgtacac 2050
 55 cctgccccca tcccgggaag agatgaccaa gaaccaggtc agcctgacct 2100
 gcctggtcaa aggcttctat ccagcgaca tcgccgtgga gtgggagagc 2150

EP 3 263 596 A1

aatgggcagc cggagaacaa ctacaagacc acgcctcccg tgctggactc 2200
cgacggctcc ttcttcctct acagcaagct caccgtggac aagagcaggt 2250
5 ggcagcaggg gaacgtcttc tcatgctccg tgatgcatga ggctctgcac 2300
aaccactaca cgcagaagag cctctccctg tctccgggta aatgagtgcg 2350
acggccctag agtcgacctg cagaagcttg gccgccatgg cccaacttgt 2400
10 ttattgcagc ttataatggg tacaaataaa gcaatagcat cacaaatttc 2450
acaaataaag catttttttc actgcattct agttgtgggt tgtccaaact 2500
catcaatgta tcttatcatg tctggatcga tcgggaatta attcggcgca 2550
15 gcacatggc ctgaaataac ctctgaaaga ggaacttggg taggtacctt 2600
ctgaggcgga aagaaccatc tgtggaatgt gtgtcagtta ggggtgtgga 2650
agtccccagg ctccccagca ggcagaagta tgcaaagcat gcatctcaat 2700
20 tagtcagcaa ccagggtgtg aaagtcccca ggctccccag caggcagaag 2750
tatgcaaagc atgcatctca attagtcagc aaccatagtc ccgcccctaa 2800
ctccgcccac cccgccccta actccgcca gttccgcca ttctccgcc 2850
catggctgac taattttttt tatttatgca gaggcgagg ccgcctcggc 2900
ctctgagcta ttccagaagt agtgaggagg cttttttgga ggcctaggct 2950
30 tttgcaaaaa gctgttaaca gcttggcact ggccgtcgtt ttacaacgtc 3000
gtgactggga aaaccctggc gttaccaac ttaatcgct tgcagcacat 3050
cccccttcg ccagttggcg taatagcgaa gaggcccgca ccgatcgccc 3100
35 ttcccaacag ttgcgtagcc tgaatggcga atggcgctg atgcggtatt 3150
ttctccttac gcatctgtgc ggtatttcac accgcatacg tcaaagcaac 3200
catagtacgc gccctgtagc ggcgcattaa gcgcggcggtg tgtggtgggt 3250
40 acgcgcagcg tgaccgctac acttgccagc gccctagcgc ccgctccttt 3300
cgctttcttc ccttcctttc tcgccacgtt cgccggcttt ccccgtaag 3350
45 ctctaaatcg ggggtccct ttagggttcc gathtagtgc ttacggcac 3400
ctcgacccca aaaaacttga tttgggtgat gggtcacgta gtgggccatc 3450
gccctgatag acgggttttc gccctttgac gttggagtcc acgttcttta 3500
50 atagtggact cttgttccaa actggaacaa cactcaacc tatctcgggc 3550
tattcttttg atttataagg gatattgccc atttcggcct attggttaaa 3600
aatgagctg atttaacaaa aatttaacgc gaattttaac aaaatattaa 3650
55 cgtttacaat tttatggtgc actctcagta caatctgctc tgatgccgca 3700

EP 3 263 596 A1

tagttaagcc aactccgcta tcgctacgtg actgggtcat ggctgcgccc 3750
 cgacacccgc caacacccgc tgacgcgccc tgacgggctt gtctgctccc 3800
 5 ggcatccgct tacagacaag ctgtgaccgt ctccgggagc tgcattgtgtc 3850
 agaggttttc accgtcatca ccgaaacgcg cgaggcagta ttcttgaaga 3900
 cgaaagggcc tcgtgatacg cctatTTTTA taggttaatg tcatgataat 3950
 10 aatggtttct tagacgtcag gtggcacttt tcggggaaat gtgcgcggaa 4000
 cccctatttg tttatTTTTc taaatacatt caaatatgta tccgctcatg 4050
 agacaataac cctgataaat gcttcaataa tattgaaaaa ggaagagtat 4100
 15 gagtattcaa catttccgtg tcgcccttat tccctTTTTt gcggcatttt 4150
 gccttcctgt ttttgctcac ccagaaacgc tggtgaaagt aaaagatgct 4200
 gaagatcagt tgggtgcacg agtgggttac atcgaactgg atctcaacag 4250
 20 cggtaagatc cttgagagtt ttgcgcccgga agaacgtttt ccaatgatga 4300
 gcacttttaa agttctgcta tgtggcgcggt tattatcccg tgatgacgcc 4350
 gggcaagagc aactcggtcg ccgcatacac tattctcaga atgacttgggt 4400
 25 tgagtactca ccagtcacag aaaagcatct tacggatggc atgacagtaa 4450
 gagaattatg cagtgctgcc ataaccatga gtgataacac tgcggccaac 4500
 ttacttctga caacgatcgg aggaccgaag gagctaaccg cttttttgca 4550
 caacatgggg gatcatgtaa ctgccttga tcgttgggaa ccggagctga 4600
 atgaagccat accaaacgac gagcgtgaca ccacgatgcc agcagcaatg 4650
 35 gcaacaacgt tgcgcaaaact attaaactggc gaactactta ctctagcttc 4700
 ccggcaacaa ttaatagact ggatggaggc ggataaagtt gcaggaccac 4750
 ttctgcgctc ggcccttccg gctggctgggt ttattgctga taaatctgga 4800
 40 gccggtgagc gtgggtctcg cggtatcatt gcagcactgg ggccagatgg 4850
 taagccctcc cgtatcgtag ttatctacac gacggggagt caggcaacta 4900
 tggatgaacg aaatagacag atcgctgaga taggtgcctc actgattaag 4950
 45 cattggtaac tgtcagacca agtttactca tatatacttt agattgattt 5000
 aaaacttcat ttttaattta aaaggatcta ggtgaagatc ctttttgata 5050
 atctcatgac caaaatccct taacgtgagt ttctgttcca ctgagcgtca 5100
 50 gaccccgtag aaaagatcaa aggatcttct tgagatcctt tttttctgcg 5150
 cgtaatctgc tgcttgcaaa caaaaaaacc accgctacca gcggtgggtt 5200
 gtttgccgga tcaagagcta ccaactcttt ttccgaagggt aactggcttc 5250
 55 agcagagcgc agataccaaa tactgtcctt ctagtgtagc cgtagttagg 5300

EP 3 263 596 A1

ccaccacttc aagaactctg tagcaccgcc tacatacctc gctctgctaa 5350
 tcctgttacc agtggctgct gccagtggcg ataagtcgtg tcttaccggg 5400
 5 ttggactcaa gacgatagtt accggataag gcgcagcggg cgggctgaac 5450
 ggggggttcg tgcacacagc ccagcttggg gcgaacgacc tacaccgaac 5500
 tgagatacct acagcgtgag cattgagaaa gcgccacgct tcccgaaggg 5550
 10 agaaaggcgg acaggtatcc ggtaagcggc agggtcggaa caggagagcg 5600
 cacgagggag cttccagggg gaaacgcctg gtatctttat agtcctgtcg 5650
 ggtttcgcca cctctgactt gagcgtcgat ttttgtgatg ctcgtcaggg 5700
 15 gggcggagcc tatggaaaaa cgccagcaac gcggcctttt tacggttcct 5750
 ggccttttgc tggccttttg ctcacatggt ctttcctgcg ttatcccctg 5800
 attctgtgga taaccgtatt accgcctttg agtgagctga taccgctcgc 5850
 20 cgcagccgaa cgaccgagcg cagcgagtca gtgagcgagg aagcggaaga 5900
 gcgccaata cgcaaaccgc ctctccccgc gcgttggccg attcattaat 5950
 25 ccaactggca cgacaggttt cccgactgga aagcgggcag tgagcgcaac 6000
 gcaattaatg tgagttacct cactcattag gcaccccagg ctttacactt 6050
 tatgcttccg gctcgtatgt tgtgtggaat tgtgagcgga taacaatttc 6100
 30 acacaggaaa cagctatgac catgattacg aatta 6135

<210> 21

<211> 232

<212> PRT

<213> Artificial sequence

<220>

<223> Sequence is synthesized

<400> 21

Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala Thr
 1 5 10 15

Gly Val His Ser Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu
 20 25 30

Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser
 35 40 45

Ser Ser Val Ser Tyr Met His Trp Tyr Gln Gln Lys Pro Gly Lys
 50 55 60

Ala Pro Lys Pro Leu Ile Tyr Ala Pro Ser Asn Leu Ala Ser Gly
 65 70 75

Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr
 80 85 90

Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr

EP 3 263 596 A1

					95					100				105					
					Cys	Gln	Gln	Trp	Ser	Phe	Asn	Pro	Pro	Thr	Phe	Gly	Gln	Gly	Thr
					110									115					120
5					Lys	Val	Glu	Ile	Lys	Arg	Thr	Val	Ala	Ala	Pro	Ser	Val	Phe	Ile
					125									130					135
					Phe	Pro	Pro	Ser	Asp	Glu	Gln	Leu	Lys	Ser	Gly	Thr	Ala	Ser	Val
10					140									145					150
					Val	Cys	Leu	Leu	Asn	Asn	Phe	Tyr	Pro	Arg	Glu	Ala	Lys	Val	Gln
					155									160					165
					Trp	Lys	Val	Asp	Asn	Ala	Leu	Gln	Ser	Gly	Asn	Ser	Gln	Glu	Ser
15					170									175					180
					Val	Thr	Glu	Gln	Asp	Ser	Lys	Asp	Ser	Thr	Tyr	Ser	Leu	Ser	Ser
					185									190					195
					Thr	Leu	Thr	Leu	Ser	Lys	Ala	Asp	Tyr	Glu	Lys	His	Lys	Val	Tyr
20					200									205					210
					Ala	Cys	Glu	Val	Thr	His	Gln	Gly	Leu	Ser	Ser	Pro	Val	Thr	Lys
					215									220					225
					Ser	Phe	Asn	Arg	Gly	Glu	Cys								
25					230														
					<210>	22													
					<211>	471													
					<212>	PRT													
30					<213>	Artificial sequence													
					<220>														
					<223>	Sequence is synthesized													
					<400>	22													
35					Met	Gly	Trp	Ser	Cys	Ile	Ile	Leu	Phe	Leu	Val	Ala	Thr	Ala	Thr
					1				5					10					15
					Gly	Val	His	Ser	Glu	Val	Gln	Leu	Val	Glu	Ser	Gly	Gly	Gly	Leu
									20					25					30
40					Val	Gln	Pro	Gly	Gly	Ser	Leu	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Gly
									35					40					45
					Tyr	Thr	Phe	Thr	Ser	Tyr	Asn	Met	His	Trp	Val	Arg	Gln	Ala	Pro
									50					55					60
45					Gly	Lys	Gly	Leu	Glu	Trp	Val	Gly	Ala	Ile	Tyr	Pro	Gly	Asn	Gly
									65					70					75
					Asp	Thr	Ser	Tyr	Asn	Gln	Lys	Phe	Lys	Gly	Arg	Phe	Thr	Ile	Ser
									80					85					90
50					Val	Asp	Lys	Ser	Lys	Asn	Thr	Leu	Tyr	Leu	Gln	Met	Asn	Ser	Leu
									95					100					105
					Arg	Ala	Glu	Asp	Thr	Ala	Val	Tyr	Tyr	Cys	Ala	Arg	Val	Val	Tyr
55									110					115					120
					Tyr	Ser	Asn	Ser	Tyr	Trp	Tyr	Phe	Asp	Val	Trp	Gly	Gln	Gly	Thr

EP 3 263 596 A1

					125					130					135	
		Leu	Val	Thr	Val	Ser	Ser	Ala	Ser	Thr	Lys	Gly	Pro	Ser	Val	Phe
						140					145					150
5		Pro	Leu	Ala	Pro	Ser	Ser	Lys	Ser	Thr	Ser	Gly	Gly	Thr	Ala	Ala
						155					160					165
		Leu	Gly	Cys	Leu	Val	Lys	Asp	Tyr	Phe	Pro	Glu	Pro	Val	Thr	Val
10						170					175					180
		Ser	Trp	Asn	Ser	Gly	Ala	Leu	Thr	Ser	Gly	Val	His	Thr	Phe	Pro
						185					190					195
		Ala	Val	Leu	Gln	Ser	Ser	Gly	Leu	Tyr	Ser	Leu	Ser	Ser	Val	Val
15						200					205					210
		Thr	Val	Pro	Ser	Ser	Ser	Leu	Gly	Thr	Gln	Thr	Tyr	Ile	Cys	Asn
						215					220					225
		Val	Asn	His	Lys	Pro	Ser	Asn	Thr	Lys	Val	Asp	Lys	Lys	Val	Glu
20						230					235					240
		Pro	Lys	Ser	Cys	Asp	Lys	Thr	His	Thr	Cys	Pro	Pro	Cys	Pro	Ala
						245					250					255
		Pro	Glu	Leu	Leu	Gly	Gly	Pro	Ser	Val	Phe	Leu	Phe	Pro	Pro	Lys
25						260					265					270
		Pro	Lys	Asp	Thr	Leu	Met	Ile	Ser	Arg	Thr	Pro	Glu	Val	Thr	Cys
						275					280					285
		Val	Val	Val	Asp	Val	Ser	His	Glu	Asp	Pro	Glu	Val	Lys	Phe	Asn
30						290					295					300
		Trp	Tyr	Val	Asp	Gly	Val	Glu	Val	His	Asn	Ala	Lys	Thr	Lys	Pro
						305					310					315
35		Arg	Glu	Glu	Gln	Tyr	Asn	Ser	Thr	Tyr	Arg	Val	Val	Ser	Val	Leu
						320					325					330
		Thr	Val	Leu	His	Gln	Asp	Trp	Leu	Asn	Gly	Lys	Glu	Tyr	Lys	Cys
						335					340					345
40		Lys	Val	Ser	Asn	Lys	Ala	Leu	Pro	Ala	Pro	Ile	Glu	Lys	Thr	Ile
						350					355					360
		Ser	Lys	Ala	Lys	Gly	Gln	Pro	Arg	Glu	Pro	Gln	Val	Tyr	Thr	Leu
						365					370					375
45		Pro	Pro	Ser	Arg	Glu	Glu	Met	Thr	Lys	Asn	Gln	Val	Ser	Leu	Thr
						380					385					390
		Cys	Leu	Val	Lys	Gly	Phe	Tyr	Pro	Ser	Asp	Ile	Ala	Val	Glu	Trp
						395					400					405
50		Glu	Ser	Asn	Gly	Gln	Pro	Glu	Asn	Asn	Tyr	Lys	Thr	Thr	Pro	Pro
						410					415					420
		Val	Leu	Asp	Ser	Asp	Gly	Ser	Phe	Phe	Leu	Tyr	Ser	Lys	Leu	Thr
						425					430					435
55		Val	Asp	Lys	Ser	Arg	Trp	Gln	Gln	Gly	Asn	Val	Phe	Ser	Cys	Ser

EP 3 263 596 A1

	440		445		450
	Val Met His Glu Ala Leu His Asn His	Tyr Thr Gln Lys Ser Leu			
	455	460	465		
5	Ser Leu Ser Pro Gly Lys				
	470				
	<210> 23				
	<211> 471				
10	<212> PRT				
	<213> Artificial sequence				
	<220>				
	<223> Sequence is synthesized				
15	<400> 23				
	Met Gly Trp Ser Cys Ile Ile Leu Phe	Leu Val Ala Thr Ala Thr			
	1	5	10	15	
	Gly Val His Ser Glu Val Gln Leu Val	Glu Ser Gly Gly Gly Leu			
20	20	25	30		
	Val Gln Pro Gly Gly Ser Leu Arg Leu	Ser Cys Ala Ala Ser Gly			
	35	40	45		
	Tyr Thr Phe Thr Ser Tyr Asn Met His	Trp Val Arg Gln Ala Pro			
25	50	55	60		
	Gly Lys Gly Leu Glu Trp Val Gly Ala	Ile Tyr Pro Gly Asn Gly			
	65	70	75		
	Asp Thr Ser Tyr Asn Gln Lys Phe Lys	Gly Arg Phe Thr Ile Ser			
30	80	85	90		
	Val Asp Lys Ser Lys Asn Thr Leu Tyr	Leu Gln Met Asn Ser Leu			
	95	100	105		
	Arg Ala Glu Asp Thr Ala Val Tyr Tyr	Cys Ala Arg Val Val Tyr			
35	110	115	120		
	Tyr Ser Asn Ser Tyr Trp Tyr Phe Asp	Val Trp Gly Gln Gly Thr			
	125	130	135		
40	Leu Val Thr Val Ser Ser Ala Ser Thr	Lys Gly Pro Ser Val Phe			
	140	145	150		
	Pro Leu Ala Pro Ser Ser Lys Ser Thr	Ser Gly Gly Thr Ala Ala			
	155	160	165		
45	Leu Gly Cys Leu Val Lys Asp Tyr Phe	Pro Glu Pro Val Thr Val			
	170	175	180		
	Ser Trp Asn Ser Gly Ala Leu Thr Ser	Gly Val His Thr Phe Pro			
	185	190	195		
50	Ala Val Leu Gln Ser Ser Gly Leu Tyr	Ser Leu Ser Ser Val Val			
	200	205	210		
	Thr Val Pro Ser Ser Ser Leu Gly Thr	Gln Thr Tyr Ile Cys Asn			
55	215	220	225		
	Val Asn His Lys Pro Ser Asn Thr Lys	Val Asp Lys Lys Val Glu			

EP 3 263 596 A1

	230	235	240
	Pro Lys Ser Cys Asp Lys Thr His Thr	Cys Pro Pro Cys Pro	Ala
	245	250	255
5	Pro Glu Leu Leu Gly Gly Pro Ser Val	Phe Leu Phe Pro Pro	Lys
	260	265	270
	Pro Lys Asp Thr Leu Met Ile Ser Arg	Thr Pro Glu Val Thr	Cys
	275	280	285
10	Val Val Val Asp Val Ser His Glu Asp	Pro Glu Val Lys Phe	Asn
	290	295	300
	Trp Tyr Val Asp Gly Val Glu Val His	Asn Ala Lys Thr Lys	Pro
	305	310	315
15	Arg Glu Glu Gln Tyr Asn Ala Thr Tyr	Arg Val Val Ser Val	Leu
	320	325	330
	Thr Val Leu His Gln Asp Trp Leu Asn	Gly Lys Glu Tyr Lys	Cys
	335	340	345
20	Lys Val Ser Asn Lys Ala Leu Pro Ala	Pro Ile Ala Ala Thr	Ile
	350	355	360
	Ser Lys Ala Lys Gly Gln Pro Arg Glu	Pro Gln Val Tyr Thr	Leu
	365	370	375
25	Pro Pro Ser Arg Glu Glu Met Thr Lys	Asn Gln Val Ser Leu	Thr
	380	385	390
30	Cys Leu Val Lys Gly Phe Tyr Pro Ser	Asp Ile Ala Val Glu	Trp
	395	400	405
	Glu Ser Asn Gly Gln Pro Glu Asn Asn	Tyr Lys Thr Thr Pro	Pro
	410	415	420
35	Val Leu Asp Ser Asp Gly Ser Phe Phe	Leu Tyr Ser Lys Leu	Thr
	425	430	435
	Val Asp Lys Ser Arg Trp Gln Gln Gly	Asn Val Phe Ser Cys	Ser
	440	445	450
40	Val Met His Glu Ala Leu His Asn His	Tyr Thr Gln Lys Ser	Leu
	455	460	465
	Ser Leu Ser Pro Gly Lys		
	470		
45	<210> 24		
	<211> 891		
	<212> DNA		
	<213> Macaca fascicularis		
50	<400> 24		
	atg aca aca ccc aga aat tca gta aat ggg act ttc	36	
	Met Thr Thr Pro Arg Asn Ser Val Asn Gly Thr Phe		
	1 5 10		
55	cca gca gag cca atg aaa ggc cct att gct atg caa cct	75	
	Pro Ala Glu Pro Met Lys Gly Pro Ile Ala Met Gln Pro		
	15 20 25		

EP 3 263 596 A1

	ggt cca aaa cca ctc ctc agg agg atg tct tca ctg gtg	114
	Gly Pro Lys Pro Leu Leu Arg Arg Met Ser Ser Leu Val	
		30 35
5	ggt ccc acg caa agc ttc ttc atg agg gaa tct aag gct	153
	Gly Pro Thr Gln Ser Phe Phe Met Arg Glu Ser Lys Ala	
		40 45 50
10	ttg ggg gct gtc cag att atg aat ggg ctc ttc cac att	192
	Leu Gly Ala Val Gln Ile Met Asn Gly Leu Phe His Ile	
		55 60
15	gcc ctg ggg ggt ctt ctg atg atc cca gca ggg atc tat	231
	Ala Leu Gly Gly Leu Leu Met Ile Pro Ala Gly Ile Tyr	
		65 70 75
20	gca ccc atc tgt gtg act gtg tgg tac cct ctg tgg gga	270
	Ala Pro Ile Cys Val Thr Val Trp Tyr Pro Leu Trp Gly	
		80 85 90
25	ggc att atg tat att att tcc gga tca ctc ctg gca gca	309
	Gly Ile Met Tyr Ile Ile Ser Gly Ser Leu Leu Ala Ala	
		95 100
30	acg gag aaa aac tcc agg aag tgt ttg gtc aaa gga aaa	348
	Thr Glu Lys Asn Ser Arg Lys Cys Leu Val Lys Gly Lys	
		105 110 115
35	atg ata atg aat tca ttg agc ctc ttt gct gcc att tct	387
	Met Ile Met Asn Ser Leu Ser Leu Phe Ala Ala Ile Ser	
		120 125
40	gga atg att ctt tca atc atg gac ata ctt aat att aaa	426
	Gly Met Ile Leu Ser Ile Met Asp Ile Leu Asn Ile Lys	
		130 135 140
45	att tcc cat ttt tta aaa atg gag agt ctg aat ttt atc	465
	Ile Ser His Phe Leu Lys Met Glu Ser Leu Asn Phe Ile	
		145 150 155
50	aga gtt cac aca cca tat att aac ata tac aac tgt gaa	504
	Arg Val His Thr Pro Tyr Ile Asn Ile Tyr Asn Cys Glu	
		160 165
55	cca gct aat ccc tct gag aaa aac tct cca tct act caa	543
	Pro Ala Asn Pro Ser Glu Lys Asn Ser Pro Ser Thr Gln	
		170 175 180
60	tac tgt tac agc ata caa tct ctg ttc ctg ggc att ttg	582
	Tyr Cys Tyr Ser Ile Gln Ser Leu Phe Leu Gly Ile Leu	
		185 190
65	tca gtg atg ctg atc ttt gcc ttc ttc cag gaa ctt gta	621
	Ser Val Met Leu Ile Phe Ala Phe Phe Gln Glu Leu Val	
		195 200 205
70	ata gct ggc atc gtt gag aat gaa tgg aga aga aca tgc	660
	Ile Ala Gly Ile Val Glu Asn Glu Trp Arg Arg Thr Cys	
		210 215 220
75	tcc aga ccc aaa tct agc gta gtt ctc ctg tca gct gaa	699
	Ser Arg Pro Lys Ser Ser Val Val Leu Leu Ser Ala Glu	

EP 3 263 596 A1

	225	230	
	gaa aaa aaa gaa caa gtc att gaa ata aaa gaa gaa gtg		738
5	Glu Lys Lys Glu Gln Val Ile Glu Ile Lys Glu Glu Val		
	235	240	245
	ggt ggg cta act gaa aca tct tcc caa cca aag aat gaa		777
	Val Gly Leu Thr Glu Thr Ser Ser Gln Pro Lys Asn Glu		
	250	255	
10	gaa gcc att gaa att att cca atc caa gaa gag gaa gaa		816
	Glu Ala Ile Glu Ile Ile Pro Ile Gln Glu Glu Glu		
	260	265	270
	gaa gaa aca gag aca aac ttt cca gaa cct ccc caa gat		855
15	Glu Glu Thr Glu Thr Asn Phe Pro Glu Pro Pro Gln Asp		
	275	280	285
	cag gaa tct tca cca ata gaa aat gac agc tct cct		891
	Gln Glu Ser Ser Pro Ile Glu Asn Asp Ser Ser Pro		
	290	295	297
20			
	<210> 25		
	<211> 297		
	<212> PRT		
	<213> Macaca fascicularis		
25	<400> 25		
	Met Thr Thr Pro Arg Asn Ser Val Asn Gly Thr Phe Pro Ala Glu		
	1	5	10 15
	Pro Met Lys Gly Pro Ile Ala Met Gln Pro Gly Pro Lys Pro Leu		
30		20	25 30
	Leu Arg Arg Met Ser Ser Leu Val Gly Pro Thr Gln Ser Phe Phe		
		35	40 45
	Met Arg Glu Ser Lys Ala Leu Gly Ala Val Gln Ile Met Asn Gly		
35		50	55 60
	Leu Phe His Ile Ala Leu Gly Gly Leu Leu Met Ile Pro Ala Gly		
		65	70 75
40	Ile Tyr Ala Pro Ile Cys Val Thr Val Trp Tyr Pro Leu Trp Gly		
		80	85 90
	Gly Ile Met Tyr Ile Ile Ser Gly Ser Leu Leu Ala Ala Thr Glu		
		95	100 105
45	Lys Asn Ser Arg Lys Cys Leu Val Lys Gly Lys Met Ile Met Asn		
		110	115 120
	Ser Leu Ser Leu Phe Ala Ala Ile Ser Gly Met Ile Leu Ser Ile		
		125	130 135
50	Met Asp Ile Leu Asn Ile Lys Ile Ser His Phe Leu Lys Met Glu		
		140	145 150
	Ser Leu Asn Phe Ile Arg Val His Thr Pro Tyr Ile Asn Ile Tyr		
		155	160 165
55	Asn Cys Glu Pro Ala Asn Pro Ser Glu Lys Asn Ser Pro Ser Thr		
		170	175 180

EP 3 263 596 A1

	Gln Tyr Cys Tyr Ser Ile Gln Ser Leu Phe Leu Gly Ile Leu Ser	185	190	195
5	Val Met Leu Ile Phe Ala Phe Phe Gln Glu Leu Val Ile Ala Gly	200	205	210
	Ile Val Glu Asn Glu Trp Arg Arg Thr Cys Ser Arg Pro Lys Ser	215	220	225
10	Ser Val Val Leu Leu Ser Ala Glu Glu Lys Lys Glu Gln Val Ile	230	235	240
	Glu Ile Lys Glu Glu Val Val Gly Leu Thr Glu Thr Ser Ser Gln	245	250	255
15	Pro Lys Asn Glu Glu Ala Ile Glu Ile Ile Pro Ile Gln Glu Glu	260	265	270
	Glu Glu Glu Glu Thr Glu Thr Asn Phe Pro Glu Pro Pro Gln Asp	275	280	285
20	Gln Glu Ser Ser Pro Ile Glu Asn Asp Ser Ser Pro	290	295	
	<210> 26			
	<211> 297			
25	<212> PRT			
	<213> Homo sapiens			
	<400> 26			
30	Met Thr Thr Pro Arg Asn Ser Val Asn Gly Thr Phe Pro Ala Glu	1	5	10
	Pro Met Lys Gly Pro Ile Ala Met Gln Ser Gly Pro Lys Pro Leu	20	25	30
35	Phe Arg Arg Met Ser Ser Leu Val Gly Pro Thr Gln Ser Phe Phe	35	40	45
	Met Arg Glu Ser Lys Ala Leu Gly Ala Val Gln Ile Met Asn Gly	50	55	60
40	Leu Phe His Ile Ala Leu Gly Gly Leu Leu Met Ile Pro Ala Gly	65	70	75
	Ile Tyr Ala Pro Ile Cys Val Thr Val Trp Tyr Pro Leu Trp Gly	80	85	90
45	Gly Ile Met Tyr Ile Ile Ser Gly Ser Leu Leu Ala Ala Thr Glu	95	100	105
	Lys Asn Ser Arg Lys Cys Leu Val Lys Gly Lys Met Ile Met Asn	110	115	120
50	Ser Leu Ser Leu Phe Ala Ala Ile Ser Gly Met Ile Leu Ser Ile	125	130	135
	Met Asp Ile Leu Asn Ile Lys Ile Ser His Phe Leu Lys Met Glu	140	145	150
55	Ser Leu Asn Phe Ile Arg Ala His Thr Pro Tyr Ile Asn Ile Tyr	155	160	165

EP 3 263 596 A1

	Asn Cys Glu Pro	Ala Asn Pro Ser Glu Lys Asn Ser Pro Ser Thr	170	175	180
5	Gln Tyr Cys Tyr	Ser Ile Gln Ser Leu Phe Leu Gly Ile Leu Ser	185	190	195
	Val Met Leu Ile	Phe Ala Phe Phe Gln Glu Leu Val Ile Ala Gly	200	205	210
10	Ile Val Glu Asn	Glu Trp Lys Arg Thr Cys Ser Arg Pro Lys Ser	215	220	225
	Asn Ile Val Leu	Leu Ser Ala Glu Glu Lys Lys Glu Gln Thr Ile	230	235	240
15	Glu Ile Lys Glu	Glu Val Val Gly Leu Thr Glu Thr Ser Ser Gln	245	250	255
	Pro Lys Asn Glu	Glu Asp Ile Glu Ile Ile Pro Ile Gln Glu Glu	260	265	270
20	Glu Glu Glu Glu	Thr Glu Thr Asn Phe Pro Glu Pro Pro Gln Asp	275	280	285
	Gln Glu Ser Ser	Pro Ile Glu Asn Asp Ser Ser Pro	290	295	
25					
	<210> 27				
	<211> 36				
	<212> DNA				
	<213> Artificial sequence				
30					
	<220>				
	<223> Sequence is synthesized				
	<400> 27				
35	ctacaccttc acgagctata acatgcactg ggtccg 36				
	<210> 28				
	<211> 51				
	<212> DNA				
	<213> Artificial sequence				
40					
	<220>				
	<223> Sequence is synthesized				
	<400> 28				
45	gattaatcct gacaacggcg acacgagcta taaccagaag ttcaagggcc 50				
	g 51				
	<210> 29				
	<211> 38				
50	<212> DNA				
	<213> Artificial sequence				
	<220>				
	<223> Sequence is synthesized				
55					
	<400> 29				
	gaatgggttg cagcgatcta tcctggcaac ggcgacac 38				

<210> 30
 <211> 65
 <212> DNA
 <213> Artificial sequence
 5
 <220>
 <223> Sequence is synthesized
 <400> 30
 10 attattgtgc tcgagtggtc tactatagca acagctactg gtacttcgac 50
 gtctgggggc aagga 65
 <210> 31
 <211> 36
 <212> DNA
 15 <213> Artificial sequence
 <220>
 <223> Sequence is synthesized
 <400> 31
 20 ctgcacagcc agctcttctg tcagctatat gcattg 36
 <210> 32
 <211> 42
 <212> DNA
 25 <213> Artificial sequence
 <220>
 <223> Sequence is synthesized
 <400> 32
 30 aactactgat ttacgtccca tcgaacctcg cgtctggagt cc 42
 <210> 33
 <211> 45
 <212> DNA
 35 <213> Artificial sequence
 <220>
 <223> Sequence is synthesized
 <400> 33
 40 tattactgtc aacagtggag cttcaatccg cccacatttg gacag 45
 <210> 34
 <211> 37
 <212> DNA
 45 <213> Artificial sequence
 <220>
 <223> Sequence is synthesized
 <400> 34
 50 gtttcactat aagtgtcgac aagtccaaaa acacatt 37
 <210> 35
 <211> 33
 <212> DNA
 55 <213> Artificial sequence
 <220>

<223> Sequence is synthesized

<400> 35

gccaggatag atggcgccaa cccattccag gcc 33

<210> 36

<211> 26

<212> DNA

<213> Artificial sequence

<220>

<223> Sequence is synthesized

<400> 36

aagctccgaa accactgatt tacgct 26

<210> 37

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> Sequence is synthesized

<400> 37

agttttgaga gcaaaatg 18

<210> 38

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> Sequence is synthesized

<400> 38

aagctatgaa cactaatg 18

1

1

1

5

1

10

Claims

1. An antibody that binds to human CD20, or an antigen-binding fragment thereof, wherein the antibody heavy chain variable region comprises the amino acid sequence of SEQ ID NO:8 with amino acid substitutions D56A and N100A and the antibody light chain variable region comprises the amino acid sequence of SEQ ID NO:2 with amino acid substitution M32L and S92A based on the Kabat numbering system.
2. The antibody or antigen-binding fragment of claim 1, wherein the V_H region is joined to a human IgG chain constant region, optionally wherein the human IgG is IgG1 or IgG3.
3. The antibody or antigen-binding fragment of claim 2, wherein the Fc region of the IgG chain constant region comprises at least one amino acid substitution in the Fc region that improves ADCC and/or CDC activity, optionally wherein the amino acid substitutions are S298A, E333A and K334A based on the Kabat numbering system; or the Fc region of the IgG chain constant region comprises at least one amino acid substitution in the Fc region that decreases CDC activity, optionally comprising at least the substitution K322A based on the Kabat numbering system.
4. The antibody or antigen-binding fragment of any of the preceding claims conjugated to a cytotoxic agent, optionally wherein the cytotoxic agent is a radioactive isotope or toxin.
5. An isolated nucleic acid or an expression vector that encodes the antibody or antigen-binding fragment of any one of the preceding claims.
6. A host cell comprising a nucleic acid of claim 5 or expression vectors encoding the antibody or antigen-binding fragment, optionally wherein the host cell produces the antibody or antigen-binding fragment, and optionally wherein the host cell is a CHO cell.
7. A method of producing the antibody or antigen-binding fragment of any one of claims 1 to 4, comprising culturing the host cell that produces the antibody or antigen-binding fragment of claim 6 and recovering the antibody or antigen-binding fragment.
8. The antibody or antigen-binding fragment of any one of claims 1 to 4 for use in a method of treating an autoimmune disease, the method comprising administering to a patient suffering from the autoimmune disease, a therapeutically effective amount of the antibody or antigen-binding fragment, optionally wherein the autoimmune disease is selected from the group consisting of multiple sclerosis, rheumatoid arthritis, juvenile rheumatoid arthritis, systemic lupus erythematosus (SLE), Wegener's disease, inflammatory bowel disease, idiopathic thrombocytopenic purpura (ITP), thrombotic thrombocytopenic purpura (TTP), autoimmune thrombocytopenia, psoriasis, IgA nephropathy, IgM polyneuropathies, myasthenia gravis, vasculitis, diabetes mellitus, Raynaud's syndrome, Sjögren's syndrome and glomerulonephritis.
9. The antibody for use according to claim 8, wherein autoimmune disease is multiple sclerosis.
10. The use of the antibody or antigen-binding fragment of any one of claims 1 to 4 in the manufacture of a medicament for use in a method of treating an autoimmune disease, the method comprising administering to a patient suffering from the autoimmune disease, a therapeutically effective amount of the antibody or antigen-binding fragment, optionally wherein the autoimmune disease is selected from the group consisting of multiple sclerosis, rheumatoid arthritis, juvenile rheumatoid arthritis, systemic lupus erythematosus (SLE), Wegener's disease, inflammatory bowel disease, idiopathic thrombocytopenic purpura (ITP), thrombotic thrombocytopenic purpura (TTP), autoimmune thrombocytopenia, psoriasis, IgA nephropathy, IgM polyneuropathies, myasthenia gravis, vasculitis, diabetes mel-

litis, Raynaud's syndrome, Sjögren's syndrome and glomerulonephritis.

11. The use according to claim 10, wherein autoimmune disease is multiple sclerosis.

5

10

15

20

25

30

35

40

45

50

55

FIG. 1A

Sequence alignment of variable light-chain domain

	FR1	CDR1	
	10	20	30 40
2H7	QIVLSQSPAILSASPGEKVTMTC	[RASSSVS-YMH]	WYQQKP
	* * * *	* * * *	
hu2H7.v16	DIQMTQSPSSLSASVGDRVTITC	[RASSSVS-YMH]	WYQQKP
		* * * *	
hum KI	DIQMTQSPSSLSASVGDRVTITC	[RASQISNYLA]	WYQQKP
	FR2	CDR2	FR3
	50	60	70 80
2H7	GSSPKPWIY	[APSNLAS]	GVPARFSGSGSGTSYSLTISRVEA
	** *	*	*** ****
hu2H7.v16	GKAPKPLIY	[APSNLAS]	GVPSRFSGSGSGTDFTLTISSLQP
	*	* * *	
hum KI	GKAPKLLIY	[AASSLES]	GVPSRFSGSGSGTDFTLTISSLQP
		CDR3	FR4
	90	100	
2H7	EDAATYYC	[QQWSFNPPT]	FGAGTKLELKR
	*		* * *
hu2H7.v16	EDFATYYC	[QQWSFNPPT]	FGQGTKVEIKR
		**** *	
hum KI	EDFATYYC	[QQYNSLPWT]	FGQGTKVEIKR

FIG. 1B

Sequence alignment of variable heavy-chain domain




FIG. 2-1
PX4

1 GAATTCAACT TCTCCATACT TTGGATAAGG AAATACAGAC ATGAAAATC TCATTGCTGA GTTGTATT TTTCAGCGG TTTTCTTCT TCTCAGCTTA
 CTTAAGTTGA AGAGGTATGA AACCTATTCC TTTAATGCTG TACTTTTGTAG AGTAACGACT CAACATATAA TTTCAGCGG TTTTCTTCT TCTCAGCTTA
 101 GAACTGTGTG CGCAGGTAGA AGCTTTGGAG ATTATGCTCA CTGCAATGCT TCGCATATATG GCGCAAAATG ACCAACAGCG GTTGATTGAT CAGGTAGAGG
 CTTGACACAC GCGTCCATCT TCGAACCTC TAATAGCAGT GACGTACGA AGCGTTATAC GCGTTTATC TGGTTGTGCG CAACATACTA GTCCATCTCC
 201 GGGCGCTGTA CGAGGTAAG CCCGATGCCA GCATTCCTGA CGACGATACG GAGTGTCTGC GCGATTACGT AAAGAGTTA TTGAAGCATC CTCGTCACTA
 CCGCGACAT GCTCCATTTT GGGCTACGGT CGTAAGGACT GCTGCTATGC CTCGACGACG CGCTAATGCA TTTCITCAAT AACCTCGTAG GAGCAGTCAT
 301 AAAAGTTAAT CTTTTCACA GCTGTCAATA AGTTGTACG GCGGAGACTT ATAGTCGCTT TGTTTTATT TTTTAAATGA TTGTAACTA GAATTCGAGC
 TTTTCAATTA GAAAGTTTGT CGACAGTATT TCAACAGTGC CCGCTCTGAA TATCAGCGAA ACRAAATAA AAAATTACAT AACATTGAT CTTAAGCTCG
 401 TCGGTACCGG GGGATCCTCT AGAGGTTGAG GTGATTTTAT GAAAGAAT ATCGCATTTT TCTTGCATC TATGTTGCTT TTTTCTATTG CTACAAAGC
 AGCCATGGGC CCTAGGAGA TCTCCAACTC CACTAAAATA CTTTCTTTA TAGGTAAG AGAACGCTAG ATACAGCAA AAAAGATAAC GATGTTGCG
 501 GTACGCTGAT ATCCAGATGA CCGAGTCCCTG GAGTCCCTG TCGGCTCTG TGGCGATAG GGTCAACATC ACCTGCAGG CCAGTCAGAG CGTGTGACT
 CATGCGACTA TAGGTCTACT GGTTCAGGG CTGAGGAGGAC AGCGCTATC CCACTGCTAG TGGACGCTC GGTCACTCTC GCACAGCTGA
 22 Y A D I Q M T Q S P S S L S A S V G D R V T I T C R A S Q S V S T
 601 AGCTCTTATA GCTATATGCA CTGTATACAA CAGAACCAG GAAAGCTCC GAACTACTG ATTTACTATG CTAGCAACCT CGAGTCTGGA GTCCCTTCTC
 TCGAGATAT CGATATACGT GACCATAGTT GTCTTTGGT CTTTTCGAGG CTTTGTATGAC TAAATGATAC GATGCTTGA GCTCAGACCT CAGGGAAGAG
 55 S S Y S Y M H W Y Q Q K P G K A P K L L I Y Y A S N L E S G 'V P S R
 701 GCTTCTCTGG ATCCGGTTCT GGGACGGATT TCACTCTGAC CATCAGCAGT CTGACGCCAG AAGACTTCG AACTTATTAC TGTCACACT CTTGGGGTAT
 CGAAGAGACC TAGGCCAAGA CCTGCGCTAA AGTGAGACTG GTACTCTGTC GACTCGGTC TTCTGAAGCG TTGAATAATG ACAGTTGTGA GAACCCCAT
 89 F S G S G S G T D F T L T I S S L Q P E D F A T Y Y C Q H S W G I
 801 TCCGCGCACA TTTGGACAGG GTACCAAGGT GAGATCTCAA CCACTGTGG CTGACCATC TGTCTTCACT TTCCGCCAT CTGATGAGCA GTTGAATCT
 AGCGCGGTGT AAACCTGTCC CATGGTTCCA CCTCTAGTT GCTTGACACC GACTGGTAG ACAGAAGTAG AAGGCGGTA GACTACTCGT CAACTTAGA
 122 P R T F G Q G T K V E I K R T V A A P S V F I F P P S D E Q L K S
 901 GGAAGTCTT CTGTTGTGTG CCTGCTGAT AACTTCTAT CCAGAGGC CAAGTACAG TGGAGGTG ATRACGCCCT CCAATCGGT AACTCCAGG
 CCTTGACGAA GACAACACAC GGACGACTA TTGAAGATAG GGTCTCTCG GTTTCATGTC ACCTTCCACC TATTCGGGA GTTAGCCCA TTGAGGTCC
 155 G T A S V V C L L N F Y P R E A K V Q W K V D N A L Q S G N S Q E
 1001 AGAGTGTAC AGAGCAGGAC AGCAAGGACA GCACCTACAG CCTCAGCAGC ACCTGACG TGAACAAAG AGACTACGAG AAACACAAAG TCTACGCTG
 TCTCAGAGT TCTGTCCTG TCGTTCCTGT CGTGGATGTC GAGTCTGTC TGGACTGCG ACTGTTTCG TCTGATGCTC TTTGTGTTTC AGATCGGAC
 189 S V T E Q D S K D S T Y S L S S T L T L S K A D Y E K H K V Y A C

FIG. 2-2
PVX4

1101 CGAAGTCACC CATCAGGGCC TGAGCTCGCC CBTACAAAG AGCTTCAACA GGGGAGAGTG TTAAGCTGAT CCTCTAGGCC GGACGATCG TGGCCCTAGT
 GCTTCAGTGG GTAGTCCCGG ACTCGAGCGG GCGTGTTC TCGAGTTGT CCTCTCAC AATCGACTA GGAGATCGG CCTGCGTAGC ACCGGGATCA
 222 E V T H Q G L S S P V T K S F N R G E C O
 1201 ACGCAAGTTC ACGTAAAG GGTATCTAGA GGTGAGGTG ATTTIAGA AAGAATATC GAATTTCTC TTGATCTAT GTTCGTTTT TCTATTGCTA
 TGGCTTCAAG TGCATTTTTC CCATAGTCT CCACTCCAC TAAATACIT TTTCTTATAG CGTAAAGAG AACGTAGATA CAAGCAAAA AGATAACGAT
 1 M K K N I A F L L A S M F V F S I A T
 1301 CAAACGGCTA CGCTGAGGT CAGTGTGG AGTCTGCGG TGGCTGGTG CAGCCAGGG GGTCACTCGG TTGTCTCTGT GCAGTCTCTG GCTACACCTT
 GTTGGCGCAT GCGACTCCAA GTCGACCACC TCAGACGGCC ACCGACCAC GTCGGTCCCG CGAGTGAGGC AAACAGGACA CGTGAAGAC CGATGTGGAA
 20 N A Y A E V Q L V E S G G L V Q P G G S L R L S C A A S G Y T F
 1401 CACCGAATAT ATCATCCACT GGTCCGTCA GGCCTGGGT AAGGCTGG ATCGATTAT CCTGACTAGC ACATCAAGAA CTATAACGAG
 GTGGCTTATA TAGTAGGTGA CCCAGGAGT CCGGGGCCA TTCCCGGACC TTACCCAGC TAGCTAATTA GGAATGATGC TGTAGTGTCT GATATTGGTC
 53 T E Y I I H W V R Q A P G K G L E W V A S I N P D Y D I T N Y N Q
 1501 CGCTTCAAGG GCGTTTCAC TATAAGTCG GACGTTCCA ABAACACAT ATACCTGCG ATGACAGCC TCGTGTCTGA GGACACTGCC GTCTATTATT
 GCGAAGTTC CCGCAAGTG ATATTACGCG CTGCTAAGGT TTTGTGTAA TATGAGCTC TACTTGTGG ACGCAGACT CCTGTGACGG CAGATAATAA
 86 R F K G R F T I S R D D S K N T L Y L Q M N S L R A E D T A V Y Y C
 1601 GTGCTCGATG GATCAGCAT TTCTTCGACT ACTGGGTCA AGGAACCTG GTACCTCTCT CCTGSCCTC CACCAAGGC CCATCGGTCT TCCCCCTGGC
 CACGAGTAC CTAGTCGCTA AAGAAGCTGA TGACCCAGT TCCTGGGAC CAGTGGCAGA GGAGCCGAG GTGTTCCCG GGTAGCCAGA AGSGGACCG
 120 A R W I S D F F D Y W G Q G T L V T V S S A S T K G P S V F P L A
 1701 AOCCTCCTCC AAGAGCACCT CTGGGGCAC AGCGGCTG GGTGCTG TCAAGGACTA CTTCOCGAA CCGTGTGAGG TGTGTGAA CTGAGGGCC
 TGGGAGGAG TTCTCGTGA GACCCCGTG TCGCCGGGAC CCGAGGAC AGTTCCTGAT GAAGGCTT GGCCACTGCC ACAGCACCTT GAGTCCGCGG
 153 P S S K S T S G G T A A L G C L V K D Y F P E P V T V S W N S G A
 1801 CTGACGAGG GGTGCACAC CTTCOCGGCT GTCCTACAT CCTCAGACT CTACTCCTC AGCAGGTGG TGACCGTGC CTCCAGGAGC TTGGGCACCC
 GACTGTGCG CACAGGTG GAAGGCGCA CAGGATGCA GGAGTCTCA GATAGGAG TCGTGCACC ACTGACCG GAGTCTGCG AACCCGTGGG
 186 L T S G V H T F P A V L Q S S G L Y S L S S V V T V P S S S L G T Q
 1901 AGACCTACAT CTGACAGTG AATCAAGC CACGACAC CAGGTGAC AAGAAGTTG AGCCCAATC TTGTGACAAA ACTCACACAT GACCACCGCA
 TCTGGATGTA GACGTTGCAC TTAGTGTG GGTGCTTGG GTTCCACCTG TTCTTTCAAC TCGGTTTAG AACACTGTT TGAATGTGTA CTGGTGGCT
 220 T Y I C N V N H K P S N T K V D K K V E P K S C D K T H T O
 2001 TGCACAGTA TCGTCCATTC CGACAGATC GCCAGTCACT ATGCGGTGCT GTAGGCGCG CCCTATACCT TGTCTGCTC CCGCGTTC GTGCGGTGC
 ACGTGTCTAT AGCAGTAAG GCTGTCTAG CCGTCACTA TACCGACGA CAGTCCGCG GGTATGGA ACAGACGGAG GGCGGCAAG CAGCGCCACG
 2101 ATGAGCGCG GCCACCTCGA CCTGAATGGA AGCGGCGCG ACCTCGCTAA CCGATTACCC ACTCAAGAA TTGAGGCCAA TCAATTCTTG CGGAGAACTG
 TACCTCGGCG CCGTGGAGCT GGACTTACCT TCGGCGCGCG TGGAGCGATT GCGTATGAG TGAGTTCTT AACCTGGTT AGTTAGAAC GCCTCTTGAC
 2201 TGAATCGCA AACCAACCT TGGCAGAACA TATCATGCG GTCCGCCATC TCCAGACCC GCACGCGCG CATCTCGGC AGGTTGGGT CTGCGCCACG
 ACTTACCGGT TTGTTGGGA ACCGTCTTGT ATAGTAGCG CAGCGGCTAG AGTCTCTCG CGTGGCGCG GTAGAGCCCG TCGCAACCCA GGACCGGTGC

FIG. 2-3
PVX4

2301 GGTGGCATG ATCGTGCTCC TGTGTTGAG GACCCGGCTA GGTGGGGG GTTGCTTAC TGGTTAGCAG AATGAATCAC CGATACGGA GCGAACGTGA
 CCACGCGTAC TAGCACGAGG ACAGCACTC CTGGGCGCAT CCGACCGCC CACGGAATG ACCAATCGTC TTACTTAGTG GCTATGCGT CGCTTGCACT
 2401 ACCGACTGCT GCTGCAAAAC GTCTGGACC TGAGCAACA CATGAATGGT CTTCGGTTTC CGTGTTCGT AAAGCTGGA AACGCGGAAG TCAGCGCCCT
 TCGCTGACGA CGACGTTTTG CAGACGCTGG ACTCGTTGTT GTACTTACCA GAAGCAAAG GCACAAAGCA TTTTCAGACCT TTGCGCCCTTC AGTCGCGGGA
 2501 GCACCATTA GTTCCGGATC TGCAATCGAG GATGTGCTG CTAACGCTGT GGAACACCTA CATCTGTATT AACGAAGCGC TGGCATTTGAC CCTGAGTGAT
 CGTGSTAATA CAAGGCGTAG ACGTAGCGTC CTACGACGAC CGATGGGACA CCTGTGGAT GTACACATAA TTGCTTCGG ACCGTAACTG GGAATCACTA
 2601 TTTTCTCTGG TCCGCGCGCA TCCATACCGC CAGTTGTTA CCTCACAAC GTTCCAGTAA CCGGGCATGT TCATCATCAG TAACCCGAT CBTGAGCATC
 AAAAGAGACC AGGGCGCGT AGGTATGGG GTCAACAAAT GGAATGTTG CAAGTCAAT GGCCCGTACA AGTAGTAGTC ATTGGGCATA GCACTCGTAG
 2701 CTCTCTCGTT TCATCGGTAT CATTACCCCC ATGAACAGAA ATTCCGCCCT ACAGGAGGC ATCAAGTGAC CAAACAGGAA AAAACCGCCC TTAACATGGC
 GAGAGAGCAA AGTAGCCATA GTAAATGGGG TACTTGCTTT TAAGGGGAA TGTGCTCTCG TAGTTCACTG GTTGTCTCTT TTTTGGCGGG AATGTACCG
 2801 CCGCTTTATC AGAAGCCAGA CATTAAAGCT TCTGGAGAAA CTCACGAGC TGAACGCGGA TGAATCTGTG AATCGCTTCA CGACCAACGCT
 GCGGAAATAG TCTTCGGTCT GTRATGCGA AGACCTCTTT GAGTTGCTCG ACCTGGCGCT ACTGTCCGT CTGTAGACAC TTAGCGAAGT GCTGGTGCGA
 2901 GATGAGCTTT ACCGAGCAT CCGGAAATG TAAAGTTAA TATTTGTTA AAATTCGGT TAAATTTTG TTAATCAGC TCATTTTAA ACCAATAGGC
 CTACTCGAAA TGGCGTCGTA GGCTTTTAC ATTGCAAT ATAAACAAI TTTAAGCGCA ATTTAGTTCG AGTAAAAAT TGGTTATCCG
 3001 CGRAATCGC AAATCCCTT ATAAATCAA AGAATAGACC GAGTAGGGT TGAGTGTGTG TCCAGTTTGG AACAGAGTC CACTATTAAA GAACGTGGAC
 GCTTAGCCG TTTTAGGAA TATTTAGTT TCTTATCTG CTCTATCCA ACTCACAAAC AGTCAAAAC TTGTTCTCAG GTGATAATTT CTTCACCTG
 3101 TCCBACGTCA AAGGCGAAA AACCGTCTAT CAGGCTATG GCGCACTAG TGAACCATCA CCTAATCAA GTTTTTTGG GTGAGGTGC CBTAAAGCAC
 AGGTTGCAGT TTCCCGCTTT TTGGCAGATA GTCCCGATAC CCGGTGATGC ACTTGTAGT GGAATAGCT CAAAAAACCC CAGCTCCACG GCATTTCTGT
 3201 TAAATCGGAA CCTTAAAGG AGCCCGCGAT TTAGAGCTTG ACGGGGAAG CCGGCGAAG TGCGGAGAAA GGAAGGGAAG AAAGCGAAAG GAGCGGGCGC
 ATTTAGCCTT GGGATTTCCC TCGGGGGCTA AATCTGAAAC TGCCCTTTT GCGGCTTTC CCTTCCCTTC TTTGCTTTC CTGCGCCCGG
 3301 TAGGCGGCTG GCAAGCTAG CCGTCAAGCT GCGCTAAACC ACCACACCG CCGGCTTAA TGCGCCGCTA CAGGCGCGT CCGCATCCTG CCTCGCGGT
 ATCCCGCGAC CGTTCACATC GCGCATTTG TGGTGTGGC GCGCGAAT ACAGGCGCAT GTCCCGCGCA GCGTAGGAC GCGTAGGCA GAGCGCGCA
 3401 TTCGGTGATG ACGGTGAAA CCTCTGACAC ATGAGCTCC CCGAGACGGT CACAGCTGT CTGTAGCGG ATGCGGGAG CAGACAAGCC CBTAGCGCG
 AAGCCACTAC TGCCACTTTT GCGACTGTG TACGTGAGG GCTCTGCA GATCTGCA GACATTCGCC TACGCGCTC GTCTGTTGG GCGTCCCGC
 3501 CGTCAGCGG TGTGGGGG TGTCGGGG CAGCATGAC CCGATCAGT AGCATAGG GAGTGTATAC TGGCTTAACT ATGCGGCATC AGAGCAGATT
 GCACTCGCC ACACCGCC ACAGCCCGC GTCCGTACTG GGTCAGTGCA TCGTATGCG CTCACATATG ACCGAATGA TACGCCGTAG TCTCGTCTAA
 3601 GTACTGAGAG TGCACCATAT GCGGTGTGAA ATACGACACA GATCGTTRAG GAGAAATAC CGCATCAGG GCTCTTCGC TCCCTCGCTC ACTGACTCGC
 CATGACTCTC ACGTGGTATA CGCCACACTT TATGCGGTGT CTAGCATTC CTCTTTATG GGTAGTCCG CGAGAAGCG AAGAGCGAG TGACTGAGCG
 3701 TGGCTCGGT CGTTCGGCTG CCGCGAGCGG TATCAGCTCA CTCAAAGCG GTAATACGT TATCCACAGA ATCAGGGAAT AACGAGGAA AGAATATGT
 ACGGAGCCA GCAAGCCGAC GCGCTCGCC ATAGTCGAGT GAGTTTCCG CATTATGCCA ATAGTGTCT TAGTCCCTA TTGCTCTCTT TCTGTATAC

FIG. 2-4
PVX4

3801 AGCAAAAGGC CAGCRAAAGG CCAGGAAAGG TAAAAAGGC GCGTTGCTGG CTTTTTCCA TAGGTCGCG CCCCTGAGC AGCATCACAA AAATCGAGCG
 TCGTTTTCCG GTCGTTTTCC GCTCCITGGC ATTTTTCCG CGCAACGACC GCAAAAAGT ATCCGAGGCG GGGGAGTGC TCGTAGTGT TTTAGCTGCG
 3901 TCAAGTCAGA GGTGGCGAAA CCCGACAGGA CTATAAGAT ACCAAGCGTT TCCCCCTGGA AGTCCCTCC TGGCTCTCC TGTTCGACC CTGCCGCTTA
 AGTTCAGTCT CCACCGCTTT GGGCTGCTCT GATATTCTA TGGTCCGCA AAGGGGACCT TCGAGGGAGC ACAGGAGG ACAAAGGCTGG GACGGCGAAT
 4001 CCGGATACCT GTCCGCTCTT CTCCCTTCGG GAAGCGTGGC GCTTTCTCAT AGCTCAGCT GTAGTATCT CAGTTGGTG TAGGTGCTTC GCTCCAGCT
 GGCTATGGA CAGGCGGAAA GAGGGAAGCC CTTCGCAUG CGAAAGAGTA TCGAGTCCGA CATCCATAGA GTCAAGCCAC ATCCAGCAAG CGAGGTTGGA
 4101 GGGCTGTGT CACGAACCC CCGTTCAGCC CGACGCTGC GCCTTATCG GTRACTATCG TCTTGAGTCC AACCCGGTAA GACACGACTT ATCGCCACTG
 CCCGACACAC GTGCTTGGGG GCAAGTCCG GCTGGCGAGC CGGAATAGGC CATTGATAGC AGAACTCAGG TTGGGCCATT CTGTGTGAAA TAGCGGTGAC
 4201 GCAGCAGCCA CTGGTAACAG GATTAGCAGA GCGAGGTATG TAGGCGGTGC TACAGATTTC TTGAAGTGGT GGCCTRACTA CGGTACACT AGRAGGACAG
 CGTCGTCGGT GACCATGTGC CTATCGTCT CGTCCATAC ATCCGCCAGC AIGTCTCAG AACTTCACCA CCGGATTGAT GCCGATGGA TCTTCTGTC
 4301 TATTTGGTAT CTGGCTCTG CTGAAGCCAG TTACTTCCG AAAAGAGTT GGTAGTCTT GATCCGGCAA ACAPACCACC GCTGGTAGOG GTGGTTTTT
 ATAPACCATA GACGCGAGAC GACTTCGGTC RATGGRAGCC TTTTCTCAA CCATCGAGAA CTAGGCCGTT TGTTTGGTGG CGACCATCGC CACCAAAAA
 4401 TGTTTGCAAG CAGCAGATTA GCGCGAGAAA ABAAGGATCT CAAGAGATC CTTCGATCTT TTCTACGGGG TCTGACGCTC AGTGGAACGA AAACCTCACCT
 ACAACGCTC GTGCTCTAAT GCGGCTCTT TTTTCTCTAG GTTCTCTAG GAACTAGAAA AGATGCCCC AGACTGCGAG TCACCTTGCT TTTGAGTGCA
 4501 TAAGGGATTT TGGTCATGAG ATTATCAAAA AGGATCTTCA CCTAGATCTT TTAAATTAA AATGAGATT TTAPATCAT CTAAAGTATA TATGATATA
 ATTCCCTAAA ACCAGTACTC TATAGTTTTC TCCTAGAGT GGAATCTAGGA AATTTAATT TTTACTTCAA AATTTAGTTA GATTTCATAT ATACTCATTT
 4601 CTTGGTCTGA CAGTTACCPA TGCTTAATCA GTGAGGACCC TATCTCAGC ATCTGTCTAT TTGCTTATC CATAGTTGCC TGACTCCCC TCGGTAGAT
 GAACCAAGCT GTCAATGGTT ACGAATTAGT CACTCCGTTG ATAGGTGTCG TACACAGATA AGCAAGTAG GTATCAGCG ACTGAGGGGC AGCACAICTA
 4701 AACTACGATA CGGGAGGGCT TACCATCTGG CCCAGTGGT GCAATGATAC GCGAGACCC CCGCTCACCG GCTCCAGATT TATCAGCAAT'AAACCAGCCA
 TTGATGCTAT GCCCTCCGA ATGCTAGACC GGGCTCACGA CGTTACTATG GCGCTCTGGG TGGAGTGGC CGAGGTCTAA ATAGTCGTTA TTTGGTCGGT
 4801 GCGGGAAGG CCGAGCGCAG AAGTGGTCTT GCACTTTAT CCGCTCCAT CCACTTATT AATTGTTGCC GGAAGCTAG AGTAAGTAGT TCGCCAGTTA
 CGGCCCTTCCC GGTCCGCTC TTACCCAGGA CGTTGAAATA GCGGAGGTA GGTCAAGATA TTAACAACGG CCTTTCGATC TCATTTCATCA AGCGTCAAT
 4901 ATAGTTTGGC CAACGTTGTT GCCATGCTG CAGCATCTGT GGTCTCAGC TCGTCTTTG GTATGGTTC ATTCAAGTCC GGTTCCTAAC GATCAAGGGC
 TATCAACGC GTTGCAACAA CCGTAACGAC GTCCGTAGCA CCACAGTGGC AGCACAAC CATACCGAG TAAGTCGAGG CCAAGGTTG CTAGTTCGCG
 5001 AGTTACATGA TCCCCATGT TGTGCAAAA AGCGTTAGC TCGTTCGGTC CTCCGATCTG TGTCAAGAT AGTTGGCGC CAGTCTTATC ACTCATGGTT
 TCAATGTACT AGGGGTGACA ACACGTTTTT TCGCCAATCG AGGAAGCCAG GAGGTAGCA ACAGTCTTCA TTCAACGGC GTCAATAG TGAGTACCAA
 5101 ATGGCAGCAC TGCATAATTC TCTTACTGTC ATGCCATCG TAAGATGCTT TCTGTGACT GGTGAGTACT CAACCAAGTC ATTCTGAGAA TAGTGTATGC
 TACCGTGGTG ACGTATTAG AGAATGACAG TACGGTAGGC ATTCTAGCA AAGACACTGA CCACCTCAGA GTTGGTTTCG TAAGACTCTT ATCACATAGC
 5201 GCGCAGCGAG TTGCTCTTGC CCGGCTCAA CAGGGATAA TACCGGCCCA CATAGCAGAA CTTTAAAGT GCTCATCATT GGAACACGTT CTTGCGGGCG
 CCGCTGGCTC AACGAGAAG GCGCCAGTT GTGCCCTATT ATGGCGGGT GTATGCTCTT GAAATTTCA CGAGTAGTAA CCTTTTGCAA GAAGCCCCCG

FIG. 2-5
PVX4

```

5301 AAAACTCTCA AGGATCTTAC CGTGTGTGAG ATCCAGTTTCG ATGTAACCCA CTCGTGCACC CAACTGATCT TCAGCATCTT TTACTTTTCC CAGCGTTTCT
      TTTTGAGAGT TCCTAGAATG GCGACAACTC TAGGTCAAGC TACATTGGGT GAGCACGTGG GTTGACTAGA AGTCGTAGAA AATGAAAGTG GTCGCAAGA
5401 GGGTGAGCAA AACAGGAAG GCRAAATGCC GCRAAAGAGG GAATAAGGC GACACGGAAA TGTTGAATAC TCATACTCTT CCTTTTTCAA TATTATTGAA
      CCCACTCGTT TTTGTCCCTC CGTTTACGG CGTTTTCCTT CTTATTCCCG CTGTGCCCTT ACAACTTATG AGTATGAGAA GGAAGAAAGT ATAATAACTT
5501 GCATTTATCA GGGTTATTGT CTCATGAGCG GATACATATT TGAATGTATT TAGAAAAATA AACAAATAGG GGTCCCGCGC ACATTTCCCC GAAAAGTGCC
      CGTAAATAGT CCCAATAACA GAGTACTCGC CTATGTATAA ACTTACATTA ATCTTTTAT TTGTTTATCC CCAAGGCGCG TGTAAAGGGG CTTTTCACGG
5601 ACCTGACGC TAAGAAACCA TTATTATCAT GACATTAAAC TATAAAATA GGCGTATCAC GAGGCCCTTT CGTCTTCAA
      TGGACTGCAG ATTCTTTGGT AATAATAGTA CTGTAATTGG ATATTTTAT CCGCATAGTG CTCCGGGAAA GCAGAAATT

```

FIG 3-1

P2H7.chim6.8

1 GAATTCACCT TCCTCATACT TTGGATAAGG AATACAGAC ATGAATAATC TCATTGCTGA GTTGTATATT AAGCTTGCCC AAAAGAAGA AGAGTCGAAT
 CTTAAGTTGA AGAGGTATGA AACCTATTCC TTATGCTG TACTTTTAG AGTAACGACT CAACAATAAA TTGGAACGGG TTTTCTCTCT TCTCAGCTTA
 101 GAACTGTGTG CGCAGGTAGA AGCTTTGGAG ATTATGCTCA CTGCAATGCT TCGCAATATG GCGCAAAATG ACCAACACGG GTTGATTGAT CAGGTAGAGG
 CTTGACACAC GGTCCATCT TCGAAACCTC TAATAGCAGT GACGTTACGA AGCGTTATAC CGCGTTTAC TGTTGTGCG CAACTAACTA GTCCATCTCC
 201 GGGCGCTGTA CGAGGTAAAG CCCGATGCCA GCATTCTCTGA CGACGATACG GAGCTGCTGC GCGATTACGT AAAGAAGTTA TTGAAGCATC CTCGTCAGTA
 CCCGCGACAT GCTCCATTTC GGGCTACGGT CGTAAGGACT GCTGCTATGC CTCGACGACG CGCTAATGCA TTCTTCAAT AACTTCGTAG GAGCAGTCAT
 301 AAAAGTTAAT CTTTTCACA GCTGTCTATA AGTGTCAAG GCCGAGACTT ATAGTCGCTT TGTTTTATT TTTTAATGTA TTTGTAACCTA GAATTCGAGC
 TTTTCAATTA GAAAAGTTGT CGACAGTATT TCAACAGTGC CGGCTCTGAA TATACCGAA ACAAATAA AAAATTACAT AAACATTGAT CTTAAGCTCG
 401 TGGTACCG GGGATCCTCT AGAGTTGAG GTGATTTATG AAAAGAATA TCGCATTTCT TCTTGCATCT ATGTTGCTTT TTTCTATTGC TACAAACGGC
 AGCCATGGGC CCTAGGAGA TCTCCAACTC CACTAATATC TTTTCTTAT AGCGTAAGA AGAACGTAGA TACRAGCAAA AAGATAACG ATGTTGCGC
 1 M K K N I A F L L A S M F V F S I A T N A
 501 TACGCTCAGA TAGTACTGTC CGAGTCCCG GCTATCCTGT CGGCTCTCTC TGGGAGAAG GTCACATAGA CCTGCAGAC CAGCTCTTCT GTGAGCTATA
 ATGCGAGTCT ATCATGACAG GGTGAGGGC CGATAGGACA GCGGAGAGG ACCGCTCTTC CAGTGATACT GAGCTCTCG GTGAGAGA CACTCGATAT
 22 Y A Q I V L S Q S P A I L S A S P G E K V T M T C R A S S S V S Y M
 601 TGCATTGGTA TCAACAGAAA CCAGGAGGT CTCGAAAAC ATGGATTATC GTCOCATGA ACCTCGGTC TGGAGTCCT GCGGCTTCT CTGATCCGG
 ACGTAACCAT AGTTGTCTTT GGTCTTCGA GAGGTTTGG TACCTAAATG CGAGTAGCT TGGAGGCGAG ACCTCAGGA CCGCGAAGA GACCTAGGCC
 56 H W Y Q Q K P G S S P K P W I Y A P S N L A S G V P A R F S , G S G
 701 TTCTGGGACT AGTTACTCTC TGACCATCAG CAGAGTGGAG GCAGAGAAG CCGCAACTTA TTACTGCAA CAGTGGAGCT TCAATCCGCC CACATTGGA
 AAGACCTGA TCAATGAGAG ACTGTAGTC GTCTCACCTC GGTCTCTGTC GCGTTGAAT AATGACAGTT GTCACCTGA AGTAGGCGG GTGTAACCT
 89 S G T S Y S L T I S R V E A E D A A T Y Y C Q Q W S F N P P T F G
 801 GCGGCRACA AGCTGGAGCT CAAACGAAT GTGGTGCAC CATCTGTCTT CATCTCCCG CCATCTGATG AGCAGTTGAA ATCTGGAAT GCTTCTGTTG
 CGGCCGTGGT TCGACCTCGA GTTGTCTTGA CACGACGTG GTAGACAGAA GTAGAGGGC GGTAGACTAC TCGTCAACTT TAGACCTTGA CGAAGACAAC
 122 A G T K L E L K R T V A A P S V F I F P P S D E Q L K S G T A S V V
 901 TGTGCTGCT GAATACCTC TATCCAGAG AGGCCAAAGT ACAGTGGAG GTGGTAAG CCCTCAATC GGTAACTCC CAGGAGAGTG TCACAGAGCA
 ACAOGGACA CTATTGAAG ATAGGCTC TCAGCTTCA TGTCACTTC CACCTATG CAGCTATG GAGGAGTAG CCATTTAGG GTCTCTCAC AGTCTCTGT
 156 C L L N N F Y P R E A K V Q W K V D N A L Q S G N S Q E S V T E Q
 1001 GGACAGCAAG GACAGCACT ACAGCCTCAG CAGCACCTG ACAGTGAACA AAGCAGACTA CGAGAACAAC AAAGTCTACG COTGCGAAGT CACCATCAG
 CCTGTCGTT CTTGCTGGA TGTGAGGATC GTGCTGGAC TGGCACTCGT TTGCTGTGAT GCTCTTGTG TTTCAATGC GACGCTTCA GTGGGTAGTC
 189 D S K D S T Y S L S S T L T L S K A D Y E K H K V Y A C E V T H Q

FIG. 3-2
P2H7.chim6.8

1101 GGCTGAGCT CGCCGCTCAC AAGAGAGCTTC AACAGGGGAG AGTGTAAAGC TGAATCTCTTA CGCCGGACGC ATCTGTGGCC TAGTACGCAA GTTACAGTAA
 CCGGACTCGA GCGGGCAGTG TTCTCTGAAG TTGTCCCTTC TCACAAATCG ACTAGAGAT GCGGCCGTGG TAGCACGGG ATCATGCGTT CAAGTGCATT
 222 G L S S P V T K S F N R G E C O

1201 AAAGGTATC TAGAGTTGA GGTCAATTTA TGAAGAAGA TATCGCAATT CTCTTGCAAT CTATGTTGCT TTTTCTATT GTTACAAACG CGTACGCTCA
 TTTCCTCATG ATCTCCAACT CCACTAAAT ACTTTTCTT ATAGCGTAAA GAGAACGTA GATACAGCA AAAAGATAA CGATGTTGC GCATCGGAGT
 1 M K K N I A F L L A S M F V F S I A T N A Y A Q

1301 GGCTTATCTG CAGCACTCG GCGCCGAGCT GGTGCGGCA GAGACTAGCG TCAAGATGTC CTGTAAGCT TCTGGCTACA CTTTACACG CTATAACATG
 CCGAATAGAC GTCGTCAGAC CCGCGCTCGA CCACCGCGT CCTCGATCG AGTCTACAG GACATTGCA AGACCGATGT GGAAGTGTG GATATGTAC
 25 A Y L Q Q S G A E L V R P G A S V K M S C K A S G Y T F T S Y N M

1401 CATTGGTCA AGCAGACAC GAGGCAAGGC CTGGAATGGA TTGGAGGAT CTATCCTGGC AACGGGACA CGAGCTATAA CCAGAGTTC AAGGCAAGG
 GTAACCAAGT TCGTCTGAG CTTCCGTTCCG GACCTTACTT AACCTCGCTA GATAGGACCG TTGCGCTGT GTCGATATT GCTCTTCAAG TTCCCGTTCC
 58 H W V K Q T P R Q G L E W I G A I Y P G N G D T S Y N Q K F K G K A

1501 CCACTCTGAC TGTGACAGTA TCCAGCAGTA CTGCTACAT GCACTGAGC AGCTGACTT CTGAGGACAG CGCTGTCTAC TTTTGTGCT GCGTGTCTA
 GGTGAGACTG ACACCTGTT AGGTCTGTCAT GACGATGTA CTTGACTCG TCGGACTGAA GACTCTGTC GGCACAGATG AAAACACAG CGCACAGAT
 92 T L T V D K S S S T A Y M Q L S S L T S E D S A V Y F C A R V V Y

1601 CTATAGCAC AGCTACTGCT ACTTCGAGT CTGGGTACC GGAACACAG TCACTGCTC CTCGGCTCC ACCAAGGCC CATCGTCTT CCCCCTGGCA
 GATATGTTG TCGATGACCA TGAAGTGCA GACCCCATG CTTGTGTC AGTGGACAG GAGCCGAGG TGTTTCCCG GTAGCCAGAA GGGGACCGT
 125 Y S N S Y W Y F D V W G T G T V T V S S A S T K G F S V F P L A

1701 CCCTCTCCA AGACACCTC TGGGGGACA GCGGCCCTG GTCGCTGCT CAGGACTAC TTCCCGAAC CGGTGACGCT GTCGTGGAAC TCAGGCGCCC
 GGGAGAGGT TCTGTGGAG ACCCCGCTGT CCGCGGACC CAGCGACCA GTTCTGATG AAGGGCTTG GCCACTGCA CASCACCTTG AGTCGCGGG
 158 P S S K S T S G G T A A L G C L V K D Y F P E P V T V S W N S G A L

1801 TGACCAAGCG CGTGCACACC TTCCCGGCTG TCCTACATC CTCAGACTC TACTCCCTCA GCAGCTGCT GACCGTGGCT TCCAGGAGCT TGGGACCCCA
 ACTGTGCGC GCAGTGTGG AAGGGCGAC AGGATGTGAG GAGTCTGAG ATGAGGAGT GTCGCACCA CTGGCACGGG AGTCTGTCGA ACCCGTGGT
 192 T S G V H T P P A V L Q S S G L Y S L S S V V T V P S S L G T Q

1901 GACCTACATC TGCACAGTGA ATCACAAGCC CAGCAACACC AAGGTGACA AGAAGTTGA GCCCAATCT TGTGACAAA CTCACACATG ACCACCGAT
 CTGGAATAG ACCTTGCACT TAGTGTGCG GTCTGTGCG TTCCACTGT TCTTCACT CCGGTTTGA ACCTGTTT GAGTGTGAT TGGTGGCGTA
 225 T Y I C N V N H K P S N T K V D K K V E P K S C D K T H T O

2001 GCACCAATAT GTCCATTCC GACAGCATCG CCACTACATA TGGGTGCTG CTAGCGCGC CCACTACCTT GTCTGCTCC CCGCTTGG TCAGCGTGCA
 CGTGTGATA GCAGTAAGG CTGTGTAGC GGTCAGTGAT ACCGACGAC GATCGCGCG GATATGGA CAGACGGAGG GCGCAACGC AGCGCCAGT

2101 TGGAGCCGG CCACCTCGAC CTGAATGGA GCGCGGSCA CCTCGCTAC GATTCACA CTCACAGAT TGGAGCGCAT CAATCTTGC GGAGACTGT
 ACCTCGGCC GGTGGAGCTG GACTTACCTT CCGCGCGCT GAGCGATTG CTAAGTGTG GAGTCTTGA ACCTCGTTA GTTAAGAAG CCTCTTGACA

2201 GAATGCGCAA ACCAACCCTT GGCAGAACAT ATCATCGCG TCCGCCATCT CCAGCAGCG CACGCGGCG ATCTCGGCA CGCTTGGTCT CTGCCCCAGG
 CTTACGCGT TGGTTGGAA CCGTCTTGA TAGGTAGCG AGCGGTAGA GGTCTGGC GTGCGCGCG TAGAGCCGT CGCAACCCAG GACCGGTGCC

FIG. 3-3
p2H7.chim6.8

2301 GTGGCGATGA TCGTGTCTCT GTGCTTGAGG ACCGGCTAG GTGGGGGG TTGCTTACT GTTACGAGA ATGAATACCC GATACGGAG CGAAGCTGAA
CACGCTACT AGCAGGAGGA CAGCACTCC TGGGCGGATC CGACGGCCC AACGAATGA CCAATGCTCT TACTAGTGG CTATGGCTC GCTTGCACTT

2401 GCGACTGCTG CTGCAAAACG TCTGCGACCT GAGCAACAAC ATGAATGTC TTGCTTTCC GTGTTTCGTA AAGTCTGGA AGCGGAGT CAGCGCCCTG
CGCTGACGAC GACGTTTTGC AGACGCTGGA CTGTTGTTG TACTTACCAG AAGCCAAAG CACAAGCAT TTCAAGCTT TCGGCTTCA GTCGGGGAC

2501 CACCATATG TTCCGGATCT GCATGCGAGG ATGCTGCTG CTACCTGTG GACCACTTAC ATCTGATTA ACGAAGGCT GGCATTGACC CTGAGTGATT
GTGTTAATAC AAGGCTTAGA CGTAGCTCC TACGAGACC GATGGGACAC CTGTGGATG TAGACATAAT TGCTTGGGA CCGTAATGG GACTCATAA

2601 TTTCTCTGGT CCGCGCGCAT CCATACGCG AGTTGTTTAC CCTCAACAAG TTCAGTAAC CCGGATGTT CATCATCAGT AACCGTATC GTGAGCATCC
AAGAGACCA GGGCGGCGTA GGTATGGCG TCAACATG GAGTGTG AGGTCTATT GCCGTACA GTAGTAGTCA TTGGGCATAG CACTGTAGG

2701 TCTCTGTTT CATCGGTATC ATTACCCCCA TGAACAGAA TTCCCTTTA CAGGAGGA TCAAGTACC AAACGGCCCT TAACATGGCC
AGAGACAAA GTAGCCATAG TAATGGGGT ACTGTCTTT AAGGGGAAT GTGCTCTGT AGTCACTGG TTTGTCTTT TTGGCGGGA ATTGTACCGG

2801 CGCTTTATCA GAAGCCAGAC ATTAACGCTT CTGAGAAAC TCAACGAGT GGACGGGAT GAACAGGAG ACATCTGTGA ATGCTTTCAC GACCACGCTG
GCGAATAGT CTTGCGTCTG TAATTGCGAA GACCTCTTG AGTTGCTGA CTTGGGCTA CTGTCCGTC TGTAGACACT TAGCGAAGTG CTGTGCGAC

2901 ATGAGCTTTA CCGCAGCATC CGAATATTG AAGCTTAA ATTTGTTA AATTCGGT AAATTTTGT TAAATCAGT CATTTTAA CCAATAGGCC
TACTCGAAT GCGTCTGAG GCCTTTAACA TTGCAATTA TAAACAAT TTAAGCGCA ATTAGTGA GTAAAAAT GGTATCCGG

3001 GAATCGGCA AATCCCTTA TAAATCAAA GAATAGACG AGATAGGTT GAGTGTGTT CCAGTTTGA ACAAGATCC ACTATTAAAG AACGTGACT
CTTAGCCGT TTAGGGAT ATTAGTTTT CTATCTGCT TCTATCCCA CTCACAAA GGTCAACCT TGTCTCAGG TGATATTTT TTGACACTGA

3101 CCAAGTCAA AGGCGAATA ACCGTCTATC AGGCTATGG CCCACTAGT GAACATCAC CTAATCAAG TTTTGTGGG TCGAGGTGC GTAAAGCACT
GGTTCAGT TCCGCTTTT TGGCAGTAG TCCGCTACC GGTGATGA CTTGCTAGT GATTAGTTC AAAAAACCC AGCTCAACG CATTTCGTGA

3201 AATCGGAAC CTTAAAGGA GCGCCGAT TAGAGCTTGA GGGGAAAG CCGCGAAGT GCGGAAAG GAAGGGAAGA AAGCGAAAG AGCGGGCGCT
TTTAGCCTG GATTTCCCT CCGGGCTAA ATCTGAACT GCGCTTTG CCGCTTGA CCGCTCTTC TTCCCTTCT TTCCCTTCC TCGCCCGGA

3301 AGGGGCTGG CAGTGTAGC GGTACGCTG CGGTAAAC CCACACCG CCGCTTAAT GCGCGCTAC AGGCGGCTC GCATCTCTC CTCGGCGGT
TCCCGCGCC GTTACATCG CCAGTCCGAC GCGCATTGT GGTGTGGG GCGGAATTA CCGCGGATG TCCCGGCGAG CGTAGGAC GAGCGCGCAA

3401 TCGGTATGA CGGTAAAC CTCTGACACA TGCAGCTCC GAGACGGTC ACAGCTGTC TGTAGCGGA TGCCGGGAGC AGACAGCCC GTGAGGGCC
AGCACTACT GCCACTTTG GAGACTGTGT ACGTCGAGG CCTCTGCCAG TGTGGAACAG ACATTCGCC CTGCGCTCCG TCTGTTCGG CAGTCCCGG

3501 GTCAGCGGT GTTGGCGGT GTCGGGGGC AGCATGACC CAGTCACTA GCGATGAGT AGTGTATCT GCGTTACTA TGGGCACTA GAGCAGATTG
CAGTGGCCA CAACCGCCA CAGCCCGCG TCGGTACTG GTCACTGCT CCGTATGCC TCACATATGA CCGAATGAT ACGCGTAGT CTGCTTAC

3601 TACTGAGAGT GCACATATG CCGTGTGAA TACGACAG ATGCTTAG AGAATATACC GCATCAGGG CTCTTCGCT TCCTCGCTCA CTGACTCGCT
ATGACTCTCA CGTGTATATC GCCACACTTT ATGCGGTCT TACGATTC CTTTTATGG CGTAGTCCG GAGAAGGGA AGAGCGAGT GACTGAGCGA

3701 GCGCTCGTC GTTCGGTGC GCGAGCGGT ATCAGTCAAC TCAAGCGG TAATCGGT ATCCACAGAA TCAGGGGATA ACGCAGGAA GAACTGTGA
CGCAGGCCAG CAAGCCGAC GCGCTCGCA TATCGAGT AGTTCCGC ATATGCCAA TAGTGTCTT AGTCCCTAT TCGCTCTTT CTGTACTACT

FIG. 3-4
P2H7.chim6.8

3801 GCAAGAGCC AGCAAGAGC CAGGAACCGT AAAAGGCCG CGTTGCTGGC GTTTTCCAT AGGCTCGCC CCCCTGACGA GCATCABAA AATCGACGCT
CGTTTCCG TGTTTTCCG GTCTTGGCA TTTTTCGGC GCAAGGACG CAAAAAGTA TCCAGGCGG GGGGACTGCT CGTAGTGT TTAGTSCGA

3901 CRAAGTCAGG GTGGGAAAC CCGACAGAC TATAAGATA CAGGCGGTT CCCCTGGAA GCTCCCTCGT GCGCTCTCT GTTCCGACC TCCGCTTAC
GTTCACTC CACCGCTTG GCGTGTCTG ATATTCTAT GTTCCGAAA GGGGACCTT CAGGAGACA CCGGAGAGA CRAAGCTGG ACGGCGAATG

4001 CGGATACCTG TCCGCTTTC TCCCTTCGG AAGCGTGGG CTTCTCAT GCTCAGCTG TAGGTATCT AGTTCGGT AGTTCGGT CTTCAAGCTG
GCCTATGAC AGGCGAAG AGGAGGCC TTGCAACGC GAAAGATAT CGAGTCGAC ATCCATAGAG TCAAGCCACA TCCAGCAAGC GAGGTTCCGAC

4101 GCGTGTGTC ACGAACCCC CGTTAGCCC GACCGTGGC CTTATCCG TAACTATCT TTGAGTCCA ACCCGTAG ACACGACTTA TCGCCACTGG
CCGACACAG TGCTTGGGG GCAAGTCGG CTGGGACGC GGNATAGCC ATTATAGCA GAATCAGGT TGGGCCATTC TGTGCTGAAT AGCGGTGACC

4201 CAGCAGCCAC TGGTAACAG ATTAGCAGC CAGGTATGT AGCGGTGCT ACAGATTCT TGAAGTGGT GCCTAATCTAC GGTACACTA GAAGACAGT
GTCTGGTG ACCATTGTCT TATCTCTC TCCGACGA TGTCTCAAGA ACTTCACCAC CGGATTGAT CCGATGTAT CTTCCTGTCA

4301 ATTGCTATC TCGCTCTGC TGAAGCCAGT TACCTTCGA AAAAGCTTG GTAGCTTG ATCCGCAAA CAAACACACG CTGTAGCGG TGTGTTTTT
TAAACATAG ACGCAGAGC ACTTCGTCA ACGGAGCCT TTTTCTAAC CATCGAGAC TAGGCCGTTT GTTTGTTGGC GACCATCGCC ACCAAAAA

4401 GTTTCGAGC AGCAGATTAC GCGCAGAAA AAGGATCTC AAGAGTCC TTTGATCTTT TCTACGGGT CTGACGCTCA GTGGAACGA AACTCAGTT
CAACGTTG TCGTCTAAT CGGCTCTTT TTTCTAGG TTTCTTAGG AAATAGAAA AGATGCCCA GACTCGAGT CACCTTGCT TTGAGTCAA

4501 AAGGATTTT GGTATGAGA TTATCAAAA GGAATCTAC CTAGATCTT TTAATTAAT AATGATTT TAAATCAATC TAAATATAT ATGATTAAC
TTCCCTAATA CCAGTACTCT AATAGTTTT CTTAGAGTG GATCTAGAA AATTAAAT TTACTTCAA ATTTAGTTAG ATTATATA TACTCATTTG

4601 TTGCTCTGAC AGTTACCAAT GCTTATCAG TGAACACCT ATCTACGA TCTGTCTAT TCGTTCATCC ATAGTTGCT GACTCCCGT CGTGTAGATA
AACCAGACTG TCAATGGTTA CGAATTAGTC ACTCCGTGGA TAGAGTCTGT AGACAGATAA AGCAATAGG TATCAACGGA CTGAGGGGCA GCATCTAT

4701 ACTACGATAC GGGAGGCTT ACCATCTGC CCCAGTCTG CAATGATAC CCGTACCCG CCGTACCCG CTCCAGATT ATCAGCAATA AACCAGCCAG
TGATGCTATG CCTCCCGAA TGGTAGACG GGTACAGAC GTTACTATGG CGCTCTGGT GCGAGTGGC GAGTCTAAA TAGTCTAT TTGTCGGTC

4801 CCGAAGGC CGAGCCAGA AGTGTCTG CAATTTATC CGCTTCATC GAGTCTATTA ATTGTTCCG GGAAGTAGA GTAAGTAGT CGCCAGTTAA
GGCTTCCG GCTCGGTCT TCACCAAGC GTTGAATAG GCGAGTAG GTCHGATAT TAACACGGC CCTTCGATCT CATTCATCAA GGGTCAATT

4901 TAGTTTGGC AACGTTGTT CCAATGCTG AGGATCTG GTCTACCT CGTCTTGG TATGGTTCA TTACGCTCG GTTCCBAAG ATCBAAGCGA
ATCAAGCG TTGCAACAC GGTARCGAG TCCGTAGCAC CACAGTSCA GCAACRAAC ATACCAAGT AAGTCAGGC CAAGGTTGC TAGTTCCGCT

5001 GTTACATGAT CCCCATGTT GTSCAAAAA GCGGTAGCT CTTGCTGTC CCGATCTT TCCGATCGT GTCAAGTA AGTGGCCG AGTGTATCA CTCATGGTTA
CAATGTACTA GGGGTACTA CAGTTTTT GCGCATCGA GGAAGCCAG AGCTCTCAT TCAACCGCG TCACAAATAGT GAGTACCAAT

5101 TGGCAGCAT GCATATTTCT CTTACTGTC TGCATCTGT AGATGCTT TCTGTGCTG GTGAGTACT AACCAAGTCA TTCTGAGAT AGTGTATGCG
ACCGTCTGA CGTATTAAGA GAATGACAGT ACGTAGGCA TTCTAGAAA AGACACTGAC CACTCATGAG TTGTTTCAAGT AAGACTCTTA TCACATACG

5201 GCAACGAGT TGCTTTGOC CCGGCTCAAC ACGGATAT ACCGCGCAC ATAGCAGAC TTAAAGTG CTCATCATTTG GAAACGTTT TCCGGGCGA
CGCTGGCTCA ACAGAACCG GCGGAGTTG TGGCTATTA TGGCGGCTG TATGCTCTG AATTTTAC GAGTAGTAAC CTTTTCAG AAGCCCCGCT

FIG. 3-5
P2H7.chim6.8

```

5301 AAACCTCTCAA GGATCTTACC GCTGTTGAGA TCCAGTTTCGA TGTAAACCCAC TCGTGACACC AACTGATCTT CAGCATCTTT TACTTTCACC AGCGTTTCTG
TTTGAGAGTT CCTAGAATGG CGACAACCTCT AGGTCAAGCT ACATTGGGTG AGCAGGTGGG TTGACTAGAA GTGCTAGAAA ATGAAAGTGG TCGCAAGAC

5401 GGTGAGCATA AACAGGAAGG CAAATGCGG CAAATGCGG AATAAGGGG ACACGGAAT GTTGAATACT CATACTCTTC CTTTTCAT ATTATTGAAG
CCACTCGTTT TTGTCCTTCC GTTTTACGGC GTTTTTCCTC TTATTCCCGC TGTGCTTTA CCACTTATGA GTATGAGAAG GAAAAAGTTA TAATAACTTC

5501 CATTATCAG GGTATTGTC TCATGAGCGG ATACATATTT GAATGTATTT AGAAAAATAA ACAATAGGG GTTCCGCGCA CATTCCCCG AAAAGTGCCA
GTAAATAGTC CCAATAACAG AGTACTCGCC TATGTATAAA CTTACATAAA TCTTTTATT TGTATTCCC CAAGGCGCGT GTAAAGGGGC TTTCACGGT

5601 CCTGACGTCT. AAGAAACCAT TATTATCATG. ACATTAACT ATAAAAATAG GCGTATCACG AGGCCCTTTC GTCTTCAA
GGACTGCAGA TTCTTTGGTA ATAATAGTAC TGTAAATTGA TATTTTATC CGCATAGTGC TCGGGGAAAG CAGAAATT

```

FIG. 4 - plasmid pDR1

TTCGAGCTCGCCCCGACATTGATTATTGACTAGTTATTAATAGTAATCAATTACGGGGTCA
 TTAGTTCATAGCCCATATATGGAGTTCGCGTTACATAACTTACGGTAAATGGCCCCGCT
 GGCTGACCGCCCAACGACCCCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTA
 ACGCCAATAGGGACTTTCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCCAC
 TTGGCAGTACATCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGT
 AAATGGCCCCGCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTTGGCAG
 TACATCTACGTATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACATCAAT
 GGGCGTGGATAGCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCCCATTTGACGTCAAT
 GGGAGTTTGTGTTTGGCACCAAAATCAACGGGACTTTCCAAAATGTCGTAACAACTCCGCC
 CCATTGACGCAAAATGGGCGGTAGGCGGTGACGGTGGGAGGTCTATATAAGCAGAGCTCGT
 TTAGTGAACCGTCAGATCGCCTGGAGACGCCATCCACGCTGTTTTGACCTCCATAGAAGA
 CACCGGGACCGATCCAGCCTCCGCGGCCGGGAACGGTGCATTGGAACGCGGATTCCCCGT
 GCCAAGAGTGACGTAAGTACCGCCTATAGAGTCTATAGGCCACCCCCCTGGCTTCGTTA
 GAACGCGGCTACAATTAATACATAACCTTATGTATCATAACATACGATTAGGTGACAC
 TATAGAATAACATCCACTTTGCCTTTCTCTCCACAGGTGTCCACTCCCAGGTCCAACCTGC
 ACCTCGGTTCTATCGATTGAATTCCACCATGGGATGGTCATGTATCATCTTTTCTAGT
 AGCAACTGCAACTGGAGTACATTGAGATATCCAGATGACCCAGTCCCCGAGCTCCCTGTC
 CGCCTCTGTGGGCGATAGGGTCACCATCACCTGCCGTGCCAGTCAGGACATCCGTAATTA
 TTTGAAGTGGTATCAACAGAAACCAGGAAAAGCTCCGAACTACTGATTTACTATACCTC
 CCGCCTGGAGTCTGGAGTCCCTTCTCGCTTCTCTGGTTCTGGTTCTGGGACGGATTACAC
 TCTGACCATCAGTAGTCTGCAACCGGAGGACTTCGCAACTTATTACTGTCAGCAAGGTAA
 TACTCTGCCGTGGACGTTCCGGACAGGGCACCAAGGTGGAGATCAAACGAACTGTGGCTGC
 ACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACCTGCCTCTGT
 TGTGTGCCTGCTGAATAACTTCTATCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAA
 CGCCCTCCAATCGGGTAACCTCCAGGAGAGTGTACAGAGCAGGACAGCAAGGACAGCAC
 CTACAGCCTCAGCAGCACCCCTGAAGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTA
 CGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGG
 AGAGTGTAAAGCTTGGCCGCCATGGCCCAACTTGTATTATGTCAGCTTATAATGGTTACAA
 ATAAAGCAATAGCATCACAAATTTACAAATAAAGCATTTTTTTCACTGCATTCTAGTTG
 TGGTTTGTCCAAACTCATCAATGTATCTTATCATGTCTGGATCGATCGGGAATTAATTG
 GCGCAGCACCATGGCCTGAAATAACCTCTGAAAGAGGAACCTGGTTAGGTACCTTCTGAG
 GCGGAAAGAACCAGCTGTGGAATGTGTGTCAGTTAGGGTGTGGAAAGTCCCAGGCTCCC
 CAGCAGGCAGAAGTATGCAAAGCATGCATCTCAATTAGTCAGCAACCAGGTGTGGAAAGT
 CCCAGGCTCCCAGCAGGCAGAAGTATGCAAAGCATGCATCTCAATTAGTCAGCAACCA
 TAGTCCCGCCCCTAACCTCCGCCATCCCGCCCCTAACCTCCGCCAGTTCGGCCCCATTCTC
 CGCCCCATGGCTGACTAATTTTTTTTATTTATGTCAGAGGCCGAGGCCGCTCGGCCCTCTG
 AGCTATTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCCTAGGCTTTTGCAAAAAGCTGT
 TAACAGCTTGGCACTGGCCGTGTTTTTACAACGTCGTGACTGGGAAAACCTGGCGTTAC
 CCAACTTAATCGCCTTGACAGCACATCCCCCTTCGCCAGCTGGCGTAATAGCGAAGAGGC
 CCGCACCGATCGCCCTTCCCAACAGTTGCGTAGCCTGAATGGCGAATGGCGCCTGATGCG
 GTATTTTCTCCTTACGCATCTGTGCGGTATTTACACCGCATACGTCAAAGCAACCATAG
 TACGCGCCCTGTAGCGGCGCATTAAGCGCGGCGGGTGTGGTGGTTACGCGCAGCGTGACC
 GCTACACTTGCCAGCGCCCTAGCGCCCGCTCCTTTGCTTTCTTCCCTTCTTCTCGCC
 ACGTTCGCGCGGCTTTCCCGTCAAGCTCTAAATCGGGGGCTCCCTTTAGGGTTCCGATTT
 AGTGCTTTACGGCACCTCGACCCCAAAAACCTTGATTGGGTGATGGTTACGTAAGTGGG
 CCATCGCCCTGATAGACGTTTTTCGCCCTTTGACGTTGGAGTCCACGTTCTTTAATAGT
 GGACTCTTGTTCCAAACCTGGAACAACACTCAACCTATCTCGGGCTATTCTTTTGATTTA
 TAAGGGATTTTGGCGATTTTGGCCCTATTGGTTAAAAAATGAGCTGATTTAAACAAAATTT
 AACGCGAATTTTAAACAAAATATTAAAGTTTACAATTTTATGGTGCATCTCAGTACAATC
 TGCTCTGATGCCGCATAGTTAAGCCAACTCCGCTATCGCTACGTGACTGGGTGATGGCTG
 CGCCCCGACACCCGCCAACACCCGCTGACGCGCCCTGACGGGCTTGTCTGCTCCCGCAT

FIG. 4 - cont'd

CCGCTTACAGACAAGCTGTGACCGTCTCCGGGAGCTGCATGTGTGTCAGAGGTTTTCACCGT
 CATCACCGAAACGCGCGAGGCAGTATTCTTGAAGACGAAAGGGCCTCGTGATACGCCTAT
 TTTTATAGGTTAATGTCATGATAATAATGGTTTCTTAGACGTCAGGTGGCACTTTTCGGG
 GAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGC
 TCATGAGACAATAACCCGTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTA
 TTCAACATTTCCGTGTGCGCCCTTATTCCTTTTTTTCGGGCATTTTGCCTTCCTGTTTTTG
 CTCACCCAGAAACGCTGGTGAAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGG
 GTTACATCGAAGCTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTTCGCCCCGAAGAAC
 GTTTTCCAATGATGAGCACTTTTAAAGTTCGTCTATGTGGCGCGGTATTATCCCGTGATG
 ACGCCGGGCAAGAGCAACTCGGTGCGCGCATACACTATTCTCAGAATGACTTGGTTGAGT
 ACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTG
 CTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGAC
 CGAAGGAGCTAACCGCTTTTTTGCAACAACATGGGGGATCATGTAACGCGCTTGATCGTT
 GGGAAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCAGCAG
 CAATGGCAACAACGTTGCGCAAACTATTAAGTGGCGAACTACTTACTCTAGCTTCCCGGC
 AACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACCTCTGCGCTCGGCCC
 TTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTA
 TCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGG
 GGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGA
 TTAAGCATTGGTAAGTGTGAGACCAAGTTTACTCATATATACTTTAGATTGATTTAAAC
 TTCATTTTTTAATTTAAAAGGATCTAGGTGAAGATCCTTTTTTGATAATCTCATGACCAAAA
 TCCCTTAACGTGAGTTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGAT
 CTTCTTGAGATCCTTTTTTCTGCGCGTAATCTGCTGCTTGCAACAAAAAACACCGC
 TACCAGCGGTGGTTTGTGTTGCCGGATCAAGAGCTACCAACTCTTTTCCGAAGGTAAC TG
 GCTTCAGCAGAGCGCAGATACCAATACTGTCTTCTAGTGTAGCCGTAGTTAGGCCACC
 ACTTCAAGAACTCTGTAGCACCGCTACATAACCTCGCTCTGCTAATCCTGTTACCAAGTGG
 CTGCTGCCAGTGGCGATAAGTCTGTCTTACCAGGTTGGACTCAAGACGATAGTTACCGG
 ATAAGGCGCAGCGGTGCGGCTGAACGCGGGGTTTCGTGCACACAGCCAGCTTGGAGCGAA
 CGACCTACACCGAACTGAGATACCTACAGCGTGAGCATTGAGAAAAGCGCCACGCTTCCCG
 AAGGGAGAAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGA
 GGGAGCTTCCAGGGGGAACGCCGTGGTATCTTTATAGTCCTGTGCGGGTTTCGCCACCTCT
 GACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGCGGAGCCTATGGAAAAACGCCA
 GCAACGCGGCCTTTTACGGTTCCGCGCTTTTGCTGGCCTTTTGCTCACATGTTCTTTC
 CTGCGTTATCCCTGATTCTGTGGATAACCGTATTACCGCCTTTGAGTGAGCTGATACCG
 CTCGCCGACGCCGAACGACCGAGCGCAGCGAGTCAGTGAGCGAGGAAGCGGAAGAGCGCC
 CAATACGCAAACCGCCTCTCCCGCGCGTTGGCCGATTCAATTAATCCAGCTGGCACGACA
 GGTTCCTCCGACTGGAAAGCGGGCAGTGAGCGCAACGCAATTAATGTGAGTTACCTCACTC
 ATTAGGCACCCAGGCTTTACACTTTATGCTTCCGGCTCGTATGTTGTGTGGAATTGTGA
 GCGGATAACAATTTACACACAGGAAACAGCTATGACCATGATTACGAATTAA

FIG. 5 - plasmid pDR2

ATTCGAGCTCGCCCGACATTGATTATTGACTAGTTATTAATAGTAATCAATTACGGGGTCT
 ATTAGTTTCATAGCCCATATATGGAGTTCGCGGTTACATAACTTACGGTAAATGGCCCGCC
 TGGCTGACCGCCCAACGACCCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGT
 AACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCA
 CTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGG
 TAAATGGCCCGCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCA
 GTACATCTACGTATTAGTCATCGCTATTACCATGGTGATGCGGTTTGGCAGTACATCAA
 TGGGCGTGGATAGCGGTTTGAATCACGGGGATTTCGAAGTCTCCACCCCATTGACGTCAA
 TGGGAGTTTGTGTTGGCACCAAAATCAACGGGACTTTCGAAAATGTCGTAACAACCTCCGC
 CCCATTGACGCAATGGGCGGTAGGCGTGACGGTGGGAGGTCTATATAAGCAGAGCTCG
 TTTAGTGAACCGTCAGATCGCCTGGAGACGCCATCCACGCTGTTTGGACCTCCATAGAAG
 ACACCGGGACCGATCCAGCCTCCGCGGCCGGGAACGGTGCATTGGAACGCGGATTCCCCG
 TGCCAAGAGTGACGTAAGTACCGCTATAGAGTCTATAGGCCACCCCCCTTGGCTTCGTT
 AGAACGCGGCTACAATTAATACATAACCTTATGTATCATACACATACGATTTAGGTGACA
 CTATAGAATAACATCCACTTTGCTTCTCTCCACAGGTGTCCACTCCCAGGTCCAACCTG
 CACCTCGGTTCTATCGATTGAATTCACCATGGGATGGTGCATGTATCATCCTTTTTCTAG
 TAGCAACTGCAACTGGAGTACATTGAGAGTTGAGCTGGTGGAGTCTGGCGGTGGCCTGG
 TGCAGCCAGGGGGCTCACTCCGTTTGTCTGTGCAGCTTCTGGCTACTCCTTTACCGGCT
 AACTATGAAGTGGGTGCGTCAGGCCCCAGGTAAGGGCCTGGAATGGGTGCACTGATTA
 ATCCTTATAAAGGTGTTACTACCTATGCCGATAGCGTCAAGGGCCGTTTCACTATAAGCG
 TAGATAAATCCAAAAACACAGCCTACCTGCAATGAACAGCCTGCGTGCTGAGGACACTG
 CCGTCTATTATTGTGCTAGAAGCGGATACCTACGGCGATAGCGACTGGTATTTTGACGTCT
 GGGGTCAAGGAACCTGGTCAACGCTCTCCTCGGCCTCCACCAAGGGCCCATCGTCTTCC
 CCCTGGCACCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCA
 AGGACTACTTCCCCGAACCGGTGACGGTGTGCTGGAACCTCAGGCGCCCTGACCAGCGCG
 TGCACACCTTCCCGGCTGTCTACAGTCTCAGGACTCTACTCCCTCAGCAGCGTGGTGA
 CTGTGCCCTCTAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCA
 GCAACACCAAGGTGGACAAGAAAGTTGAGCCCAAATCTTGTGACAAAACCTCACACATGCC
 CACCGTGCCAGCACCTGAACCTCTGGGGGACCGTCAGTCTTCTCTTCCCCCAAAAC
 CCAAGGACACCTCATGATCTCCCGGACCCCTGAGGTACATGCGTGGTGGTGGACGTGA
 GCCACGAAGACCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATG
 CCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAAGCTCTCA
 CCGTCTTGACACAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAG
 CCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAGCCAAAGGGCAGCCCCGAGAACCCAC
 AGGTGTACACCTGCCCCCATCCCGGGAAGAGATGACCAAGAACCAGGTGACCTGACCT
 GCCTGGTCAAAGGCTTCTATCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGC
 CGGAGAACAACTACAAGACCACGCCTCCCGTGTGGACTCCGACGGCTCCTTCTTCTCT
 ACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGTCCG
 TGATGCTAGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGT
 AATGAGTGCGACGGCCCTAGAGTGCACCTGCAGAAGCTTGGCCGCCATGGCCCAACTTGT
 TTATTGCAGCTTATAATGGTTACAAATAAAGCAATAGCATCACAAATTTACAAATAAAG
 CATTTTTTCACTGCATTCTAGTTGTGGTTTGTCCAACTCATCAATGTATCTTATCATG
 TCTGGATCGATCGGGAATTAATTCGGCGCAGCACCATGGCCTGAAATAACCTCTGAAAGA
 GGAACCTTGGTTAGGTACCTTCTGAGGCGGAAAGAACCATCTGTGGAATGTGTGTCAGTTA
 GGGTGTGGAAAGTCCCAGGCTCCCCAGCAGGCAGAAGTATGCAAAGCATGCATCTCAAT
 TAGTCAGCAACCAAGGTGTGGAAAGTCCCCAGGCTCCCCAGCAGGCAGAAGTATGCAAAGC
 ATGCATCTCAATTAGTCAGCAACCATAGTCCCGCCCCTAACCTCCGCCCATCCCGCCCCTA
 ACTCCGCCCAGTTCCGCCCATTTCTCCGCCCATGGCTGACTAATTTTTTTTATTTATGCA
 GAGGCCGAGGCCGCTCGGCTCTGAGCTATTCCAGAAGTAGTGAGGAGGCTTTTTTTGGA
 GGCTTAGGCTTTTGCAAAAAGCTGTAAACAGCTTGGCACTGGCCGTCGTTTTTACAACGTC
 GTGACTGGGAAAACCTGGCGTTACCCAACCTAATCGCCTTGCAGCACATCCCCCTTCG

FIG. 5 Cont.'d

CCAGTTGGCGTAATAGCGAAGAGGCCCGCACCGATCGCCCTTCCCAACAGTTGCGTAGCC
 TGAATGGCGAATGGCGCCTGATGCGGTATTTTCTCCTTACGCATCTGTGCGGTATTTTAC
 ACCGCATACGTCAAAGCAACCATAGTACGCGCCCTGTAGCGGCGCATTAAAGCGCGGCGGG
 TGTGGTGGTTACGCGCAGCGTGACCGCTACACTTGCCAGCGCCCTAGCGCCGCTCCTTT
 CGCTTTCTCCCTTCCCTTCTCGCCACGTTCCGCGGCTTTCCCGTCAAGCTCTAAATCG
 GGGGCTCCCTTTAGGGTTCCGATTTAGTGCTTTACGGCACCTCGACCCCAAAAACTTGA
 TTTGGGTGATGGTTCACGTAGTGGGCCATCGCCCTGATAGACGGTTTTTTCGCCCTTTGAC
 GTTGGAGTCCACGTTCTTTAATAGTGGACTCTTGTTCAAACTGGAACAACACTCAACCC
 TATCTCGGGCTATTCTTTTATTATTAAGGGATTTTGCCTGATTTTCGGCTATTGGTTAA
 AAATGAGCTGATTTAACAAAAATTTAACGCGAATTTTAACAAAATATTAACGTTTACAAT
 TTTATGGTGCACTCTCAGTACAATCTGCTCTGATGCCGCATAGTTAAGCCAACCTCCGCTA
 TCGCTACGTGACTGGGTCTAGGCTGCGCCCCGACACCCGCCAACACCCGCTGACGCGCCC
 TGACGGGCTTGTCTGCTCCCGGCATCCGCTTACAGACAAGCTGTGACCGTCTCCGGGAGC
 TGCATGTGTGAGAGTTTTCACCGTCATCACCGAAACGCGCGAGGCAGTATTCTTGAAGA
 CGAAAGGGCCTCGTGATACGCCTATTTTTATAGGTTAATGTGATGATAATAATGGTTTCT
 TAGACGTGAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTGTTTATTTTTT
 TAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCGTATAAATGCTTCAATAA
 TATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTGCGCCCTATTCCCTTTTTT
 GCGGCATTTTGCCTTCTGTGTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAGATGCT
 GAAGATCAGTTGGGTGACGAGTGGGTACATCGAAGTGGATCTCAACAGCGGTAAAGATC
 CTTGAGAGTTTTCGCCCCGAAGAAGCTTTTCCAATGATGAGCACTTTTAAAGTCTGCTA
 TGTGGCGCGGTATTATCCCGTGATGACGCGGGAAGAGCAACTCGGTGCGCGCATACAC
 TATTCTCAGAATGACTTGGTTGAGTACTACCGAGTCACAGAAAAGCATCTTACGGATGGC
 ATGACAGTAAGAGAATTATGCACTGCTGCCATAACCATGAGTGATAAAGTGGCGCAAC
 TTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGG
 GATCATGTAAGTACGCTTGTGCTGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGAC
 GAGCGTGACACCACGATGCCAGCAGCAATGGCAACAACGTTGCGCAAACTATTAAGTGGC
 GAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTT
 GCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTTATTGCTGATAAATCTGGA
 GCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCC
 CGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAG
 ATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAAGTGTGACCAAGTTTACTCA
 TATATACTTTAGATTGATTTAAAACCTTCATTTTAAATTTAAAAGGATCTAGGTGAAGATC
 CTTTTTGATAATCTCATGACCAAAATCCCTTAACGTGAGTTTTCGTTCCACTGAGCGTCA
 GACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGC
 TGCTTGCAAACAAAAAACCACCGCTACCAGCGGTGGTTTGTGTTGCCGGATCAAGAGCTA
 CCAACTCTTTTTCCGAAGGTAAGTGGCTTCAGCAGAGCGCAGATACCAAATACTGTCTT
 CTAGTGTAGCCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCTC
 GCTCTGCTAATCCTGTTACCAAGTGGCTGCTGCCAGTGGCGATAAGTGTGCTTACCGGG
 TTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGTGGGCTGAACGGGGGGTTCCG
 TGCACACAGCCAGCTTGGAGCGAAGCAGCTACACCGAACTGAGATACCTACAGCGTGAG
 CATTGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGGC
 AGGGTCGGAACAGGAGAGCGCAGAGGGAGCTTCCAGGGGAAACGCTTGGTATCTTTAT
 AGTCTGTGCGGTTTTCGCCACCTCTGACTTGAGCGTGCATTTTTGTGATGCTCGTCAGGG
 GGGCGGAGCCTATGGAAAAACGCCAGCAACGCGGCTTTTTACGGTTCTGCGCTTTTGC
 TGGCCTTTTGTCTCATGTTCTTTTCTGCGTTATCCCTGATTCTGTGGATAACCGTATT
 ACCGCTTTTGTGAGTGGCTGATACCGCTCGCCGCGAGCCGAACGACCGAGCGCAGCGAGTCA
 GTGAGCGAGGAAGCGGAAGAGCGCCCAATACGCAAAACCGCTCTCCCCGCGCTTGGCCG
 ATTCAATTAATCCAACTGGCAGCAGAGTTTCCCGACTGGAAAGCGGGCAGTGAGCGCAAC
 GCAATTAATGTGAGTTACCTCACTCATTAGGCACCCAGGCTTTACACTTTATGCTTCCG
 GCTCGTATGTTGTGGAATTGTGAGCGGATAACAATTTACACAGGAAACAGCTATGAC
 CATGATTACGAATTA

FIG. 6

hu2H7.v16 L chain [232 aa]

MGWSCIIILFLVATATGVHSDIQMTQSPSSLSASVGDRVTTTCRASSSVSYMHWYQQKPGK
APKPLIYAPSNLASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQWSFNPPTFGQGT
KVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQES
VTEQDSKDSSTYSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

FIG. 7

hu2H7.v16 H chain [471 aa]

MGWSCIILFLVATATGVHSEVQLVESGGGLVQPGGSLRLSCAASGYTFTSYNMHWVRQAP
GKGLEWVGAIYPGNGDTSYNQKFKGRFTISVDKSKNTLYLQMNSLRAEDTAVYYCARVVY
YSNSYWYFDVWGQGTLLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTV
SWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKKVE
PKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFN
WYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTI
SKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPP
VLDSGDGSFFLYSKLTVDKSRWQQGNVFCFSVMHEALHNHYTQKSLSLSPGK

FIG. 8

hu2H7.v31_H chain [471 aa]

MGWSCIIILFLVATATGVHSEVQLVESGGGLVQPGGSLRLSCAASGYTFTSYNMHWVRQAP
GKGLEWVGAIYPNGDTSYNQKFGRFTISVDKSKNTLYLQMNSLRAEDTAVYYCARVVY
YSNSYWYFDVWGQGTLLTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTV
SWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVE
PKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFN
WYVDGVEVHNAKTKPREEQYNATYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIAATI
SKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPP
VLDSGDSFFLYSKLTVDKSRWQQGNVFSQSVMHREALHNHYTQKSLSLSPGK

FIG. 9




FIG. 10




FIG. 11




FIG. 12




FIG. 13
Apoptotic Activity: Annexin V Staining




FIG. 14

Apoptotic Activity: Annexin V and Propidium Iodide Double-Staining




FIG. 15

Apoptotic Activity: Live Unstained Cells




FIG. 16




FIG. 17




FIG. 18




FIG. 19

```

1  ATGACAACAC CCAGAAATTC AGTAAATGGG ACTTTCCAG
   METThrThrPro ArgAsnSer ValAsnGly ThrPheProA
41  CAGAGCCAAT GAAAGGCCCT ATTGCTATGC AACCTGGTCC
   laGluProMET LysGlyPro IleAlaMETGln ProGlyPr
61  AAAACCACTC CTCAGGAGGA TGTCTTCACT GGTGGGTCCC
   oLysProLeu LeuArgArgMET SerSerLeu ValGlyPro
121  ACGCAAAGCT TCTTCATGAG GGAATCTAAG GCTTTGGGGG
   ThrGlnSerPhe PheMETArg GluSerLys AlaLeuGlyA
161  CTGTCCAGAT TATGAATGGG CTCTTCCACA TTGCCCTGGG
   laValGlnIle METAsnGly LeuPheHisIle AlaLeuGl
201  GGGTCTTCTG ATGATCCCAG CAGGGATCTA TGCACCCATC
   yGlyLeuLeu METileProAla GlyIleTyr AlaProIle
241  TGTGTGACTG TGTGGTACCC TCTGTGGGGA GGCATTATGT
   CysValThrVal TrpTyrPro LeuTrpGly GlyIleMETT
281  ATATTATTTC CGGATCACTC CTGGCAGCAA CGGAGAAAAA
   yrIleIleSer GlySerLeu LeuAlaAlaThr GluLysAs
321  CTCCAGGAAG TGTITGGTCA AAGGAAAAAT GATAATGAAT
   nSerArgLys CysLeuValLys GlyLysMET IleMETAsn
361  TCATTGAGCC TCTTTGCTGC CATTTCGGA ATGATTCTTT
   SerLeuSerLeu PheAlaAla IleSerGly METileLeuS
401  CAATCATGGA CATACTTAAT ATTAAATTT CCCATTTTTT
   erIleMETAsp IleLeuAsn IleLysIleSer HisPheLe
441  AAAAATGGAG AGTCTGAATT TTATCAGAGT TCACACACCA
   uLysMETGlu SerLeuAsnPhe IleArgVal HisThrPro
481  TATATTAACA TATACACTG TGAACCAGCT AATCCCTCTG
   TyrIleAsnIle TyrAsnCys GluProAla AsnProSerG
521  AGAAAACTC TCCATCTACT CAATACTGTT ACAGCATACA
   luLysAsnSer ProSerThr GlnTyrCysTyr SerIleGl
561  ATCTCTGTTT CTGGGCATTT TGTCACTGAT GCTGATCTTT
   nSerLeuPhe LeuGlyIleLeu SerValMET LeuIlePhe
601  GCCTTCTTCC AGGAACITGT AATAGCTGGC ATCGTTGAGA
   AlaPhePheGln GluLeuVal IleAlaGly IleValGluA
641  ATGAATGGAG AAGAACATGC TCCAGACCCA AATCTAGCGT
   snGluTrpArg ArgThrCys SerArgProLys SerSerVa
681  AGTTCTCTTG TCAGCTGAAG AAAAAAAGA ACAAGTCATT
   lValLeuLeu SerAlaGluGlu LysLysGlu GlnValIle
721  GAAATAAAAG AAGAAGTGGT TGGGCTAACT GAAACATCTT
   GluIleLysGlu GluValVal GlyLeuThr GluThrSers
761  CCCAACCAAA GAATGAAGAA GCCATTGAAA TTATTCCAAT
   erGlnProLys AsnGluGlu AlaIleGluIle IleProIl
801  CCAAGAAGAG GAAGAAGAAG AAACAGAGAC AAACTTTCCA
   eGlnGluGlu GluGluGluGlu ThrGluThr AsnPhePro
841  GAACCTCCCC AAGATCAGGA ATCTTCACCA ATAGAAAATG
   GluProProGln AspGlnGlu SerSerPro IleGluAsnA
881  ACAGCTCTCC T.
      spSerSerPro

```

FIG. 20

MTTPRNSVNGTFPAEPMKGPIAMQPGPKPLLRMSSLVGPTQSFFMR
S F
ESKALGAVQIMNGLFHLALGGLLMIPAGIYAPICVTVWYPLWGGIMYII
SGSLLAATEKNSRKCLVKGKMIMNSLSLFAAISGMILSIMDILNIKISH
FLKMESLNFIRVHTPYINIYNCEPANPSEKNSPSTQYCYSIQSLFLGILS
A
VMLIFAFFQELVIAGIVENEWRRTCSPKSSVLLSAEEKKEQVIEIKE
K NI T
EVVGLTETSSQPKNEEAIEIPIQEEEEETETNFPPEPPQDQESSPIENDS
D
SP

FIG. 21






Fig. 22

FIG. 23

SV40.PD.hu2H7.H16.SV.L16
8.277 kb





EUROPEAN SEARCH REPORT

 Application Number
EP 17 16 7520

DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)
A	WO 01/13945 A1 (BIOCRYSTAL LTD) 1 March 2001 (2001-03-01) * claims 1-22; example 4 *	1-11	INV. C07K16/00 A61K39/395 C12N15/63
A,P	WO 03/068821 A (IMMUNOMEDICS, INC) 21 August 2003 (2003-08-21) * page 10, line 4 - line 13 * * claims 7,8 * * page 35, line 12 - page 36, line 13 * * page 45, line 3 - line 23 * * page 49, paragraph 4 *	1-11	
A	WO 00/09160 A (IDEC PHARMACEUTICALS CORPORATION) 24 February 2000 (2000-02-24) * page 4, line 9 - line 14 * * page 9, line 8 - page 10, line 7 *	1-11	
A	WO 00/76542 A (CONSIGLIO NAZIONALE DELLE RICERCHE; GOLAY, JOSEE; INTRONA, MARTINO; RA) 21 December 2000 (2000-12-21) * claims 1-3 *	1-11	
A,D	IDUSOGIE E E ET AL: "Engineered antibodies with increased activity to recruit complement", JOURNAL OF IMMUNOLOGY, vol. 166, no. 4, 15 February 2001 (2001-02-15), pages 2571-2575, XP002298345, ISSN: 0022-1767 * figure 2 *	1-11	TECHNICAL FIELDS SEARCHED (IPC) C07K A61K C12N
The present search report has been drawn up for all claims			
Place of search Munich		Date of completion of the search 15 September 2017	Examiner Lewis, Birgit
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	

EPO FORM 1503 03.82 (P04/C01)



EUROPEAN SEARCH REPORT

Application Number
EP 17 16 7520

DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)
A	TEDDER T F: "ISOLATION AND STRUCTURE OF A CDNA ENCODING THE B1 (CD20) CELL-SURFACE ANTIGEN OF HUMAN B LYMPHOCYTES", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 85, no. 1, January 1988 (1988-01), pages 208-212, XP002016361, ISSN: 0027-8424 * figure 3 *	1-11	TECHNICAL FIELDS SEARCHED (IPC)
A	WO 02/22212 A (IDEC PHARMACEUTICALS CORPORATION) 21 March 2002 (2002-03-21) * page 49; example 1 *	1-11	
T	LUDWIG KAPPOS: "Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial", LANCET, vol. 19, no. 378, 1 November 2011 (2011-11-01), pages 1779-1787, XP055406865, * the whole document *		
T	WO 2005/117978 A2 (GENENTECH INC [US]; FROHNA PAUL A [US]) 15 December 2005 (2005-12-15)		
The present search report has been drawn up for all claims			
Place of search Munich		Date of completion of the search 15 September 2017	Examiner Lewis, Birgit
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	

EPO FORM 1503 03.82 (P04C01)

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 17 16 7520

5

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

15-09-2017

10

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
WO 0113945	A1	01-03-2001	AU	6929100 A		19-03-2001
			US	2005079174 A1		14-04-2005
			WO	0113945 A1		01-03-2001

WO 03068821	A	21-08-2003	AU	2003208415 A1		04-09-2003
			AU	2009202613 A1		16-07-2009
			AU	2011253536 A1		08-12-2011
			CA	2476166 A1		21-08-2003
			CN	1662557 A		31-08-2005
			CN	101914158 A		15-12-2010
			EP	1519959 A2		06-04-2005
			EP	2295468 A1		16-03-2011
			HK	1074052 A1		04-07-2014
			IL	204847 A		31-10-2012
			IL	204848 A		31-10-2012
			JP	4498746 B2		07-07-2010
			JP	4790831 B2		12-10-2011
			JP	2006500904 A		12-01-2006
			JP	2009291197 A		17-12-2009
			KR	20040086383 A		08-10-2004
			US	2003219433 A1		27-11-2003
			US	2007020259 A1		25-01-2007
			US	2009155253 A1		18-06-2009
			US	2012034185 A1		09-02-2012
			WO	03068821 A2		21-08-2003

WO 0009160	A	24-02-2000	AT	414536 T		15-12-2008
			AU	767965 B2		27-11-2003
			AU	2004200806 A1		25-03-2004
			AU	2008207357 A1		04-09-2008
			BR	9913645 A		25-09-2001
			CA	2340091 A1		24-02-2000
			CN	1320044 A		31-10-2001
			CN	1689644 A		02-11-2005
			CN	1689645 A		02-11-2005
			CN	1689646 A		02-11-2005
			CN	101695574 A		21-04-2010
			CY	1108906 T1		02-07-2014
			CY	1113600 T1		22-06-2016
			CZ	20010526 A3		13-11-2002
			DK	1112084 T3		16-03-2009
			DK	1974747 T3		17-09-2012
			EA	200100224 A1		27-08-2001
			EP	1112084 A1		04-07-2001
			EP	1946775 A2		23-07-2008
			EP	1974747 A1		01-10-2008

15

20

25

30

35

40

45

50

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

55

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 17 16 7520

5

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

15-09-2017

10

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
		EP 2260866 A1	15-12-2010
		EP 2263693 A1	22-12-2010
		EP 2275136 A1	19-01-2011
		EP 2990054 A1	02-03-2016
15		ES 2317702 T3	16-04-2009
		ES 2388893 T3	19-10-2012
		HK 1083444 A1	08-05-2009
		HK 1083449 A1	11-06-2010
		HK 1122511 A1	18-01-2013
20		HU 0103484 A2	28-01-2002
		IL 141349 A	28-06-2012
		JP 2002522511 A	23-07-2002
		JP 2009173686 A	06-08-2009
		JP 2010265318 A	25-11-2010
		JP 2013227352 A	07-11-2013
25		JP 2015098486 A	28-05-2015
		JP 2017128615 A	27-07-2017
		KR 20080038453 A	06-05-2008
		KR 20090014243 A	06-02-2009
		KR 20090115895 A	09-11-2009
30		KR 20110022097 A	04-03-2011
		MX PA01001530 A	24-04-2002
		MY 136203 A	29-08-2008
		NO 20010699 A	10-04-2001
		NZ 528199 A	24-06-2005
		NZ 573838 A	28-01-2011
35		PL 346046 A1	14-01-2002
		PT 1112084 E	20-02-2009
		PT 1974747 E	05-09-2012
		TW I242444 B	01-11-2005
		TW I322014 B	21-03-2010
40		TW 200846021 A	01-12-2008
		TW 201106974 A	01-03-2011
		US 6455043 B1	24-09-2002
		US 2003026804 A1	06-02-2003
		US 2003206903 A1	06-11-2003
		US 2008038261 A1	14-02-2008
45		US 2012251534 A1	04-10-2012
		US 2012251535 A1	04-10-2012
		US 2012258101 A1	11-10-2012
		US 2012258102 A1	11-10-2012
		US 2013273039 A1	17-10-2013
		US 2014056887 A1	27-02-2014
50		US 2015183882 A1	02-07-2015
		US 2016333106 A1	17-11-2016
		US 2017037140 A1	09-02-2017

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

55

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 17 16 7520

5

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

15-09-2017

10

15

20

25

30

35

40

45

50

55

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
		WO 0009160 A1	24-02-2000
		ZA 200101157 B	10-07-2002
WO 0076542 A	21-12-2000	AU 774206 B2	17-06-2004
		CA 2376288 A1	21-12-2000
		CN 1355712 A	26-06-2002
		CZ 20014450 A3	17-04-2002
		DE 60033030 T2	31-05-2007
		DK 1185299 T3	21-05-2007
		EE 200100667 A	17-02-2003
		EP 1185299 A1	13-03-2002
		ES 2278616 T3	16-08-2007
		HK 1043549 A1	01-09-2006
		HU 0201600 A2	28-08-2002
		IS 6195 A	10-12-2001
		IT MI991299 A1	11-12-2000
		JP 2003501482 A	14-01-2003
		KR 20020026455 A	10-04-2002
		NO 20016035 A	11-02-2002
		NZ 515992 A	30-01-2004
		PL 352860 A1	08-09-2003
		PT 1185299 E	30-03-2007
		SK 18132001 A3	09-05-2002
		TR 200103581 T2	21-08-2002
		US 2007014785 A1	18-01-2007
		WO 0076542 A1	21-12-2000
		ZA 200110004 B	26-02-2003
WO 0222212 A	21-03-2002	CA 2422076 A1	21-03-2002
		CN 1592645 A	09-03-2005
		JP 2004508420 A	18-03-2004
		KR 20040023565 A	18-03-2004
		MX PA03002262 A	15-10-2003
		NO 20031218 A	19-05-2003
		US 2002058029 A1	16-05-2002
		US 2006275284 A1	07-12-2006
		US 2007003544 A1	04-01-2007
		WO 0222212 A2	21-03-2002
WO 2005117978 A2	15-12-2005	AR 049200 A1	05-07-2006
		AU 2005249566 A1	15-12-2005
		BR PI0510915 A	13-11-2007
		CA 2566979 A1	15-12-2005
		CN 1993143 A	04-07-2007
		CN 102512675 A	27-06-2012
		CN 106075435 A	09-11-2016

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 17 16 7520

5

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on

The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

15-09-2017

10

15

20

25

30

35

40

45

50

55

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
		EP 1753455 A2	21-02-2007
		EP 3130349 A1	15-02-2017
		IL 179139 A	31-05-2012
		IL 219285 A	28-05-2014
		JP 2008501712 A	24-01-2008
		KR 20070029733 A	14-03-2007
		KR 20130099228 A	05-09-2013
		KR 20150092374 A	12-08-2015
		NZ 604082 A	26-09-2014
		RU 2384345 C2	20-03-2010
		SG 183012 A1	30-08-2012
		SV 2006002132 A	20-04-2006
		TW 1433682 B	11-04-2014
		TW 201422238 A	16-06-2014
		US 2006051345 A1	09-03-2006
		US 2010233121 A1	16-09-2010
		US 2012199516 A1	09-08-2012
		WO 2005117978 A2	15-12-2005
		ZA 200610158 B	30-07-2008

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- US 5736137 A, Anderson [0004]
- US 5776456 A [0004]
- US 4816567 A [0034] [0039] [0072] [0082] [0083]
- US 5500362 A [0042]
- US 5821337 A [0042] [0093]
- WO 0042072 A, Presta [0044]
- US 6194551 B1 [0047]
- WO 9951642 A [0047]
- US 5545806 A [0087]
- US 5569825 A [0087]
- US 5591669 A [0087]
- US 5545807 A [0087]
- WO 9717852 A [0087]
- US 5565332 A [0088]
- US 5573905 A [0088]
- US 5567610 A [0089]
- US 5229275 A [0089]
- US 5869046 A [0091]
- WO 9316185 A [0091]
- US 5571894 A [0091]
- US 5587458 A [0091]
- US 5641870 A [0091]
- WO 9616673 A [0093]
- US 5837234 A [0093]
- WO 9802463 A [0093]
- WO 9308829 A [0094]
- WO 9404690 A [0096]
- US 5731168 A [0097]
- US 4676980 A [0098]
- WO 9100360 A [0098]
- WO 92200373 A [0098]
- EP 03089 A [0098]
- US 5739277 A [0117]
- WO 9013646 A [0125]
- US 4965199 A [0132]
- EP 73657 A [0138]
- US 4419446 A [0140]
- US 4601978 A [0140]
- WO 9411026 A [0142] [0164]
- DD 266710 [0143]
- US 5648237 A, Carter [0144]
- US 5789199 A, Joly [0144]
- US 5840523 A, Simmons [0144]
- EP 183070 A [0145]
- EP 244234 A [0145]
- US 4767704 A [0150]
- US 4657866 A [0150]
- US 4927762 A [0150]
- US 4560655 A [0150]
- US 5122469 A [0150]
- WO 9003430 A [0150]
- WO 8700195 A [0150]
- US RE30985 E [0150]
- US 3896111 A [0156]
- US 4151042 A [0156]
- US 4137230 A [0156]
- US 4248870 A [0156]
- US 4256746 A [0156]
- US 4260608 A [0156]
- US 4265814 A [0156]
- US 4294757 A [0156]
- US 4307016 A [0156]
- US 4308268 A [0156]
- US 4308269 A [0156]
- US 4309428 A [0156]
- US 4313946 A [0156]
- US 4315929 A [0156]
- US 4317821 A [0156]
- US 4322348 A [0156]
- US 4331598 A [0156]
- US 4361650 A [0156]
- US 4364866 A [0156]
- US 4424219 A [0156]
- US 4450254 A [0156]
- US 4362663 A [0156]
- US 4371533 A [0156]
- US 5208020 A [0157] [0158] [0164]
- US 5416064 A [0157]
- EP 0425235 B1 [0157] [0158]
- US 5712374 A [0161]
- US 5714586 A [0161]
- US 5739116 A [0161]
- US 5767285 A [0161]
- US 5770701 A [0161]
- US 5770710 A [0161]
- US 5773001 A [0161]
- US 5877296 A [0161]
- US 4665077 A [0192]
- US 4120649 A [0192]
- WO 9008187 A [0192]
- US 5114721 A [0192]
- WO 9011294 A [0192]
- WO 9101133 A [0192]
- EP 340109 A [0192]
- WO 9856418 A [0198]
- US 6171586 B [0198]
- WO 9704801 A [0198]
- US 3773919 A [0203]

- US 5846818 A [0209]

- US 6204023 B [0209]

Non-patent literature cited in the description

- VALENTINE et al. *J. Biol. Chem.*, 1989, vol. 264 (19), 11282-11287 [0003] [0029]
- EINFELD et al. *EMBO J.*, 1988, vol. 7 (3), 711-717 [0003]
- ANDERSON et al. *Blood*, 1984, vol. 63 (6), 1424-1433 [0003]
- TEDDER et al. *J. Immunol.*, 1985, vol. 135 (2), 973-979 [0003]
- TEDDER et al. *Cell. Biochem.*, 1990, vol. 14D, 195 [0003]
- REFF et al. *Blood*, 1994, vol. 83 (2), 435-445 [0004]
- MILLER, R.A. et al. Monoclonal antibody therapeutic trials in seven patients with T-cell lymphoma. *Blood*, 1983, vol. 62, 988-995 [0005]
- SCHROFF, R.W. et al. Human anti-murine immunoglobulin response in patients receiving monoclonal antibody therapy. *Cancer Res.*, 1985, vol. 45, 879-885 [0005]
- NEUBERGER et al. *Nature (Lond.)*, 1985, vol. 314, 268-270 [0005]
- JONES et al. *Nature (Lond.)*, 1986, vol. 321, 522-525 [0005]
- RIECHMAN et al. *Nature (Lond.)*, 1988, vol. 332, 323-327 [0005]
- KABAT et al. Sequences of Immunological Interest. Public Health Service, National Institutes of Health, 1991 [0028]
- SHALABY et al. *J. Exp. Med.*, 1992, vol. 175, 217-225 [0028] [0100]
- CLARK ; LEDBETTER. *Adv. Can. Res.*, 1989, vol. 52, 81-149 [0029]
- KOHLER et al. *Nature*, 1975, vol. 256, 495 [0034] [0072]
- CLACKSON et al. *Nature*, 1991, vol. 352, 624-628 [0034] [0081] [0088]
- MARKS et al. *J. Mol. Biol.*, 1991, vol. 222, 581-597 [0034] [0088]
- KABAT et al. Sequences of Proteins of Immunological Interest. Public Health Service, National Institutes of Health, 1991 [0036] [0037]
- CHOTHIA ; LESK. *J. Mol. Biol.*, 1987, vol. 196, 901-917 [0037]
- MORRISON et al. *Proc. Natl. Acad. Sci. USA*, 1984, vol. 81, 6851-6855 [0039]
- JONES et al. *Nature*, 1986, vol. 321, 522-525 [0040] [0083]
- REICHMANN et al. *Nature*, 1988, vol. 332, 323-329 [0040]
- PRESTA. *Curr. Op. Struct. Biol.*, 1992, vol. 2, 593-596 [0040]
- RAVETCH ; KINET. *Annu. Rev. Immunol.*, 1991, vol. 9, 457-92 [0042] [0043]
- CLYNES et al. *PNAS (USA)*, 1998, vol. 95, 652-656 [0042]
- DAËRON. *Annu. Rev. Immunol.*, 1997, vol. 15, 203-234 [0043]
- CAPEL et al. *Immunomethods*, 1994, vol. 4, 25-34 [0043]
- HAAS et al. *J. Lab. Clin. Med.*, 1995, vol. 126, 330-41 [0043]
- GUYER et al. *J. Immunol.*, 1976, vol. 117, 587 [0043]
- KIM et al. *J. Immunol.*, 1994, vol. 24, 249 [0043]
- SHIELDS et al. *J. Biol. Chem.*, 2001, vol. 9 (2), 6591-6604 [0044]
- GAZZANO-SANTORO et al. *J. Immunol. Methods*, 1996, vol. 202, 163 [0046]
- IDUSOGIE et al. *J. Immunol.*, 2000, vol. 164, 4178-4184 [0047] [0232]
- LEHRNBECHER et al. *Blood*, 1999, vol. 94, 4220 [0048]
- GODING. Monoclonal Antibodies: Principles and Practice. Academic Press, 1986, 59-103 [0073] [0078]
- KOZBOR. *J. Immunol.*, 1984, vol. 133, 3001 [0075]
- BRODEUR et al. Monoclonal Antibody Production Techniques and Applications. Marcel Dekker, Inc, 1987, 51-63 [0075]
- MUNSON et al. *Anal. Biochem.*, 1980, vol. 107, 220 [0077]
- SKERRA et al. *Curr. Opinion in Immunol.*, 1993, vol. 5, 256-262 [0080]
- PLUCKTHUN. *Immunol. Revs.*, 1992, vol. 130, 151-188 [0080]
- MCCAFFERTY et al. *Nature*, 1990, vol. 348, 552-554 [0081]
- MARKS et al. *J. Mol. Biol.*, 1991, vol. 222, 581-597 [0081]
- MARKS et al. *BioTechnology*, 1992, vol. 10, 779-783 [0081]
- WATERHOUSE et al. *Nuc. Acids. Res.*, 1993, vol. 21, 2265-2266 [0081]
- MORRISON et al. *Proc. Natl. Acad. Sci. USA*, 1984, vol. 81, 6851 [0082]
- REICHMANN et al. *Nature*, 1988, vol. 332, 323-327 [0083]
- VERHOEYEN et al. *Science*, 1988, vol. 239, 1534-1536 [0083]
- SIMS et al. *J. Immunol.*, 1993, vol. 151, 2296 [0084]
- CHOTHIA et al. *J. Mol. Biol.*, 1987, vol. 196, 901 [0084]
- CARTER et al. *Proc. Natl. Acad. Sci. USA*, 1992, vol. 89, 4285 [0084] [0210]
- PRESTA et al. *J. Immunol.*, 1993, vol. 151, 2623 [0084]

- **JAKOBOVITS et al.** *Proc. Natl. Acad. Sci. USA*, 1993, vol. 90, 2551 [0087]
- **JAKOBOVITS et al.** *Nature*, 1993, vol. 362, 255-258 [0087]
- **BRUGGEMANN et al.** *Year in Immuno.*, 1993, vol. 7, 33 [0087]
- **MCCAFFERTY et al.** *Nature*, 1990, vol. 348, 552-553 [0088]
- **JOHNSON, KEVIN S. ; CHISWELL, DAVID J.** *Current Opinion in Structural Biology*, 1993, vol. 3, 564-571 [0088]
- **GRIFFITH et al.** *EMBO J.*, 1993, vol. 12, 725-734 [0088]
- **MORIMOTO et al.** *Journal of Biochemical and Biophysical Methods*, 1992, vol. 24, 107-117 [0091]
- **BRENNAN et al.** *Science*, 1985, vol. 229, 81 [0091] [0099]
- **CARTER et al.** *BiolTechnology*, 1992, vol. 10, 163-167 [0091] [0151]
- Antibody Engineering [0091]
- **MILLSTEIN et al.** *Nature*, 1983, vol. 305, 537-539 [0094]
- **TRAUNECKER et al.** *EMBO J.*, 1991, vol. 10, 3655-3659 [0094]
- **SURESH et al.** *Methods in Enzymology*, 1986, vol. 121, 210 [0096]
- **KOSTELNY et al.** *J. Immunol.*, 1992, vol. 148 (5), 1547-1553 [0101]
- **HOLLINGER et al.** *Proc. Natl. Acad. Sci. USA*, 1993, vol. 90, 6444-6448 [0101]
- **GRUBER et al.** *J. Immunol.*, 1994, vol. 152, 5368 [0101]
- **TUTT et al.** *J. Immunol.*, 1991, vol. 147, 60 [0102]
- **CUNNINGHAM ; WELLS.** *Science*, 1989, vol. 244, 1081-1085 [0105] [0221]
- **CARON et al.** *J. Exp Med.*, 1992, vol. 176, 1191-1195 [0116]
- **SHOPES, B.** *J. Immunol.*, 1992, vol. 148, 2918-2922 [0116]
- **WOLFF et al.** *Cancer Research*, 1993, vol. 53, 2560-2565 [0116]
- **STEVENSON et al.** *Anti-Cancer Drug Design*, 1989, vol. 3, 219-230 [0116]
- Remington's Pharmaceutical Sciences. 1980 [0118] [0202]
- Antibodies, A Laboratory Manual. Cold Spring Harbor Laboratory, 1988 [0122]
- **STINCHCOMB et al.** *Nature*, 1979, vol. 282, 39 [0133]
- **JONES.** *Genetics*, 1977, vol. 85, 12 [0133]
- **K. LACTIS ; VAN DEN BERG.** *BiolTechnology*, 1990, vol. 8, 135 [0134]
- **FLEER et al.** *BiolTechnology*, 1991, vol. 9, 968-975 [0134]
- **REYES et al.** *Nature*, 1982, vol. 297, 598-601 [0140]
- **YANIV.** *Nature*, 1982, vol. 297, 17-18 [0141]
- **GRAHAM et al.** *J. Gen Virol.*, 1977, vol. 36, 59 [0148]
- **URLAUB et al.** *Proc. Natl. Acad. Sci. USA*, 1980, vol. 77, 4216 [0148]
- **MATHER.** *Biol. Reprod.*, 1980, vol. 23, 243-251 [0148]
- **MATHER et al.** *Annals N.Y. Acad. Sci.*, 1982, vol. 383, 44-68 [0148]
- **HAM et al.** *Meth. Enz.*, 1979, vol. 58, 44 [0150]
- **BARNES et al.** *Anal. Biochem.*, 1980, vol. 102, 255 [0150]
- **LINDMARK et al.** *J. Immunol. Meth.*, 1983, vol. 62, 1-13 [0152]
- **GUSS et al.** *EMBO J.*, 1986, vol. 5, 1567-1575 [0152]
- **LIU et al.** *Proc. Natl. Acad. Sci. USA*, 1996, vol. 93, 8618-8623 [0157]
- **CHARI et al.** *Cancer Research*, 1992, vol. 52, 127-131 [0157] [0158] [0164]
- **CARLSSON et al.** *Biochem. J.*, 1978, vol. 173, 723-737 [0159]
- **HINMAN et al.** *Cancer Research*, 1993, vol. 53, 3336-3342 [0161]
- **LODE et al.** *Cancer Research*, 1998, vol. 58, 2925-2928 [0161]
- **FRAKER et al.** *Biochem. Biophys. Res. Commun.*, 1978, vol. 80, 49-57 [0163]
- **CHATAL.** Monoclonal Antibodies in Immunoscintigraphy. CRC Press, 1989 [0163]
- **VITETTA et al.** *Science*, 1987, vol. 238, 1098 [0164]
- **CANELLOS GP ; LISTER, TA ; SKLAR JL.** The Lymphomas. W.B.Saunders Company, 1998 [0173]
- Clinical Manifestations, Staging and Treatment of Non-Hodgkin's Lymphoma. **VAN BESIEENK ; CABANILLAS, F et al.** Hematology, Basic Principles and Practice. Churchill Livingstone, 2000, 1293-1338 [0173]
- Chronic Lymphocytic Leukemia. **RAI, K ; PATEL, D et al.** Hematology , Basic Principles and Practice. Churchill Livingstone, 2000, 1350-1362 [0173]
- **BRYAN GESCUK ; JOHN DAVIS.** Novel therapeutic agent for systemic lupus erythematosus. *Current Opinion in Rheumatology*, 2002, vol. 14, 515-521 [0179]
- **OFFNER et al.** *Science*, 1991, vol. 251, 430-432 [0192]
- Guidelines for the management of rheumatoid arthritis. *Arthritis & Rheumatism*, February 2002, vol. 46 (2), 328-346 [0193]
- Remington's Pharmaceutical Sciences. 1980 [0197]
- **KABAT et al.** Sequences of proteins of immunological interest. Public Health Service, National Institutes of Health, 1991 [0209]
- **KUNKEL.** *Proc. Natl. Acad. Sci.*, 1985, vol. 82, 488-492 [0209]
- **CUNNINGHAM et al.** *Science*, 1989, vol. 243, 1330-1336 [0210]
- **CHANG et al.** *Gene*, 1987, vol. 55, 189-196 [0210]
- **CARTER et al.** *Proc. Natl. Acad. Sci. USA*, 1992, vol. 89, 4285-4289 [0214]

- **GORMAN et al.** *DNA Prot. Eng. Tech.*, 1990, vol. 2, 3-10 [0218]
- **GRAHAM et al.** *J. Gen. Virol.*, 1977, vol. 36, 59-74 [0218]
- **IDUSOGIE et al.** *J. Immunol.*, 2001, vol. 166, 2571-2575 [0225] [0232]
- **SHIELDS et al.** *J. Biol. Chem.*, 2001, vol. 276, 6591-6604 [0225] [0234]
- **PRESTA et al.** *Biochem. Soc. Trans.*, 2002, vol. 30, 487-490 [0225]
- **LEFRANC ; LEFRANC.** The human IgG subclasses: molecular analysis of structure, function, and regulation. Pergamon Press, 1990, 43-78 [0227]
- **MUNSON ; RODBARD.** *Anal. Biochem.*, 1980, vol. 107, 220-239 [0231]
- **MCPHERSON.** *Comput. Programs Biomed.*, 1983, vol. 17, 107-114 [0231]
- **KOENE et al.** *Blood*, 1997, vol. 90, 1109-1114 [0234]
- **REFF et al.** *Blood*, 1994, vol. 83, 435-445 [0239]
- **SHIELDS et al.** *J. Biol. Chem.*, 2001, vol. 276 (9), 6591-6604 [0249]
- **PAPAC et al.** *Glycobiology*, 1998, vol. 8, 445-454 [0250]
- *Current Protocols in Immunology.* 1994 [0257]
- **SHAN et al.** *Blood*, 1998, vol. 9, 1644-1652 [0261]
- **BYRD et al.** *Blood*, 2002, vol. 99, 1038-43 [0261]
- **PEDERSON et al.** *Blood*, 2002, vol. 99, 1314-19 [0261]
- **GHETIE et al.** *Proc Natl Acad Sci USA*, 1997, vol. 94, 7509-14 [0261]
- **CLYNES et al.** *Nature Medicine*, 2000, vol. 6, 443-446 [0265]
- **J. SAMBROOK et al.** *Molecular Cloning: A Laboratory Manual.* Cold Spring Harbor Laboratory, 1989 [0284]
- *Current Protocols in Molecular Biology.* 1987 [0284]
- *Essential Molecular Biology.* IRL Press, 1991 [0284]
- *Gene Expression Technology.* Academic Press, 1991 [0284]
- *Methods for Cloning and Analysis of Eukaryotic Genes.* Bartlett Publ, 1990 [0284]
- **M. KRIEGLER.** *Gene Transfer and Expression.* Stockton Press, 1990 [0284]
- *Recombinant DNA Methodology II.* Academic Press, 1995 [0284]
- **M. MCPHERSON et al.** *A Practical Approach.* IRL Press at Oxford University Press, 1991 [0284]
- *Oligonucleotide Synthesis.* 1984 [0284]
- *Cell Culture for Biochemists.* Elsevier Science Publishers, 1990 [0284]
- *Gene Transfer Vectors for Mammalian Cells.* 1987 [0284]
- *Mammalian Cell Biotechnology.* 1991 [0284]
- *Animal Cell Culture.* Humana Press, 1990 [0284]
- *Culture of Animal Cells.* Alan R. Liss, 1987 [0284]
- *Flow Cytometry and Sorting.* Wiley-Liss, 1990 [0284]
- **WIRTH M. ; HAUSER H.** *Methods in Enzymology.* Academic Press, Inc, 1993 [0284]
- *Immunochemistry in Practice.* Blackwell Science, 1996 [0284]
- *Techniques in Immunocytochemistry.* Academic Press, 1982 [0284]
- *Handbook of Experimental Immunology* [0284]
- *Current Protocols in Immunology.* 1991 [0284]
- *Immunoassay.* Academic Press, Inc, 1996 [0284]
- **GODING.** *Monoclonal Antibodies: Principles and Practice.* Academic Press, 1986 [0284]
- *Antibodies A laboratory Manual.* Cold Spring Harbor Laboratory, 1988 [0284]
- *Antibody Engineering.* Oxford University Press, 1995 [0284]

摘要

本發明提供人源化和嵌合的抗 CD20 抗體，用於治療 CD20 陽性惡性腫瘤和自身免疫病。